{"bb12f88b5dde53fc22e5e25184c2bfd1f0883ac1": [["Introduction A brief overview on plant lectinsLectins are ubiquitous proteins found in many living organisms in the animal and plant kingdom, such as bacteria, fungi, viruses and algae (Lis & Sharon, 1998) .", [["lectinsLectins", "GENE_OR_GENE_PRODUCT", 39, 53], ["ubiquitous proteins", "PROTEIN", 58, 77], ["plant lectinsLectins", "TREATMENT", 33, 53], ["ubiquitous proteins", "PROBLEM", 58, 77], ["bacteria", "PROBLEM", 150, 158], ["fungi", "PROBLEM", 160, 165], ["viruses", "PROBLEM", 167, 174]]], ["These molecules include all \"proteins and glycoproteins of nonimmune origin containing at least one noncatalytic domain that binds reversibly and specifically to mono or oligosaccharides\".", [["glycoproteins", "PROTEIN", 42, 55], ["noncatalytic domain", "PROTEIN", 100, 119], ["all \"proteins", "PROBLEM", 24, 37], ["nonimmune origin", "PROBLEM", 59, 75]]], ["Lectins can also be called agglutinins or hemagglutinins, since many can agglutinate cells and/or precipitate glycoconjugates through the binding of lectin-carbohydrate complexes, which involves, mainly, hydrogen ligations, although van der Waals and hydrophobic interactions can also occur (Carlini & Grossi-de-Sa, 2002 ; Goldstein, Hughes, Monsigny, Os-glucanase, and glycosidase, lectins are unique plant proteins capable of recognizing and binding glycoconjugates on the outer surface of microorganisms and on the membranes of gastrointestinal insect and herbivore mammal cells, in order to protect plants against phytopathogens, phytophagous insects, and herbivores (Michiels, Van Damme, & Smagghe, 2010; Peumans & Van Damme, 1995a , 1995b Peumans & Van Damme, 1996; Van Damme, 2008) .", [["cells", "ANATOMY", 85, 90], ["outer surface", "ANATOMY", 475, 488], ["membranes", "ANATOMY", 518, 527], ["gastrointestinal insect", "ANATOMY", 531, 554], ["cells", "ANATOMY", 576, 581], ["phytopathogens", "ANATOMY", 618, 632], ["hydrogen", "CHEMICAL", 204, 212], ["carbohydrate", "CHEMICAL", 156, 168], ["hydrogen", "CHEMICAL", 204, 212], ["Lectins", "GENE_OR_GENE_PRODUCT", 0, 7], ["agglutinins", "GENE_OR_GENE_PRODUCT", 27, 38], ["cells", "CELL", 85, 90], ["lectin", "GENE_OR_GENE_PRODUCT", 149, 155], ["hydrogen", "SIMPLE_CHEMICAL", 204, 212], ["Os-glucanase", "SIMPLE_CHEMICAL", 352, 364], ["glycosidase", "GENE_OR_GENE_PRODUCT", 370, 381], ["lectins", "GENE_OR_GENE_PRODUCT", 383, 390], ["outer surface", "CELLULAR_COMPONENT", 475, 488], ["membranes", "CELLULAR_COMPONENT", 518, 527], ["gastrointestinal insect", "CELL", 531, 554], ["herbivore mammal cells", "CELL", 559, 581], ["agglutinins", "PROTEIN", 27, 38], ["hemagglutinins", "PROTEIN", 42, 56], ["agglutinate cells", "CELL_TYPE", 73, 90], ["lectin", "PROTEIN", 149, 155], ["carbohydrate complexes", "PROTEIN", 156, 178], ["gastrointestinal insect and herbivore mammal cells", "CELL_TYPE", 531, 581], ["Van Damme, & Smagghe, 2010; Peumans & Van Damme, 1995a , 1995b Peumans & Van Damme, 1996; Van Damme, 2008)", "SPECIES", 682, 788], ["Lectins", "TREATMENT", 0, 7], ["agglutinins", "PROBLEM", 27, 38], ["hemagglutinins", "TREATMENT", 42, 56], ["many can agglutinate cells", "PROBLEM", 64, 90], ["precipitate glycoconjugates", "PROBLEM", 98, 125], ["hydrogen ligations", "TREATMENT", 204, 222], ["glucanase", "TEST", 355, 364], ["glycosidase", "TEST", 370, 381], ["unique plant proteins", "PROBLEM", 395, 416], ["binding glycoconjugates", "PROBLEM", 444, 467], ["microorganisms", "PROBLEM", 492, 506], ["gastrointestinal insect", "PROBLEM", 531, 554], ["herbivore mammal cells", "TREATMENT", 559, 581], ["phytopathogens", "PROBLEM", 618, 632], ["microorganisms", "OBSERVATION", 492, 506], ["gastrointestinal", "ANATOMY", 531, 547]]], ["Some plant lectin characteristics contribute to their insecticidal property, such as resistance to proteolysis and stability in a wide range of pH, enough to guarantee their passage through the gastrointestinal tract without degradation.", [["gastrointestinal tract", "ANATOMY", 194, 216], ["lectin", "GENE_OR_GENE_PRODUCT", 11, 17], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 194, 216], ["Some plant lectin characteristics", "PROBLEM", 0, 33], ["proteolysis", "PROBLEM", 99, 110], ["a wide range of pH", "PROBLEM", 128, 146], ["lectin", "OBSERVATION", 11, 17], ["stability", "OBSERVATION_MODIFIER", 115, 124], ["gastrointestinal tract", "ANATOMY", 194, 216]]], ["Hence, these proteins would be free to bind glycoconjugates on the outer surface of epithelial cells from the gastrointestinal system, causing changes in cellular morphology, leading to impairment of stomach and intestinal metabolism and absorption process (Vasconcelos & Oliveira, 2004) .", [["outer surface", "ANATOMY", 67, 80], ["epithelial cells", "ANATOMY", 84, 100], ["gastrointestinal system", "ANATOMY", 110, 133], ["cellular", "ANATOMY", 154, 162], ["stomach", "ANATOMY", 200, 207], ["intestinal", "ANATOMY", 212, 222], ["impairment of stomach and intestinal metabolism", "DISEASE", 186, 233], ["outer surface", "CELLULAR_COMPONENT", 67, 80], ["epithelial cells", "CELL", 84, 100], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 110, 133], ["cellular", "CELL", 154, 162], ["stomach", "ORGAN", 200, 207], ["intestinal", "ORGAN", 212, 222], ["epithelial cells", "CELL_TYPE", 84, 100], ["these proteins", "PROBLEM", 7, 21], ["epithelial cells", "PROBLEM", 84, 100], ["changes in cellular morphology", "PROBLEM", 143, 173], ["impairment of stomach and intestinal metabolism", "PROBLEM", 186, 233], ["absorption process", "PROBLEM", 238, 256], ["epithelial cells", "OBSERVATION", 84, 100], ["gastrointestinal system", "ANATOMY", 110, 133], ["cellular morphology", "OBSERVATION", 154, 173], ["stomach", "ANATOMY", 200, 207], ["intestinal", "ANATOMY", 212, 222]]], ["The consumption of raw or partially cooked Phaseolus vulgaris by humans can cause foodborne illness, due to its high lectin content, which is inactivated by adequate cooking (Carlini & Grossi-de-Sa, 2002; Ohno, Naganuma, Ogawa, & Muramoto, 2006; Varki, 1993) .Introduction A brief overview on plant lectinsFortunately, most plant lectins in the human diet do not produce toxic or antinutritional effects, since dietary doses are not high enough.", [["Phaseolus vulgaris", "CHEMICAL", 43, 61], ["foodborne illness", "DISEASE", 82, 99], ["Phaseolus vulgaris", "ORGANISM", 43, 61], ["humans", "ORGANISM", 65, 71], ["lectin", "GENE_OR_GENE_PRODUCT", 117, 123], ["human", "ORGANISM", 345, 350], ["lectin", "PROTEIN", 117, 123], ["Phaseolus vulgaris", "SPECIES", 43, 61], ["humans", "SPECIES", 65, 71], ["human", "SPECIES", 345, 350], ["Phaseolus vulgaris", "SPECIES", 43, 61], ["humans", "SPECIES", 65, 71], ["human", "SPECIES", 345, 350], ["partially cooked Phaseolus vulgaris", "PROBLEM", 26, 61], ["foodborne illness", "PROBLEM", 82, 99], ["its high lectin content", "PROBLEM", 108, 131], ["plant lectins", "TREATMENT", 293, 306], ["dietary doses", "TREATMENT", 411, 424], ["high lectin", "OBSERVATION_MODIFIER", 112, 123]]], ["Moreover, not all lectins are toxic; some can contribute in improving nutrient absorption (Peumans & Van Damme, 1996; Rudiger et al., 2000) .", [["toxic", "PROBLEM", 30, 35], ["toxic", "OBSERVATION_MODIFIER", 30, 35]]], ["The lectins from Glycine max (soybean), Canavalia gladiate (sword bean), and Triticum vulgaris (wheat germ) enhance permeability to nutritional factors, such as isoflavone and calcium ions (Ohno et al., 2006) .Introduction A brief overview on plant lectinsThe reversible and specific binding of lectins to a wide variety of carbohydrates in several kinds of cells can trigger various biological effects, such as antiviral, antifungal, antibacterial, antitumoral, and insecticidal properties, as well as mitogenic lymphocyte stimulation, resulting in benefits to humans (Ingale & Hivrale, 2013) .Introduction A brief overview on plant lectinsBased on this, plant lectins have been targets as tools for broad applications of several scientific interests (Pusztai, Bardocz, & Ewen, 2007) .", [["germ", "ANATOMY", 102, 106], ["cells", "ANATOMY", 358, 363], ["lymphocyte", "ANATOMY", 513, 523], ["isoflavone", "CHEMICAL", 161, 171], ["calcium", "CHEMICAL", 176, 183], ["isoflavone", "CHEMICAL", 161, 171], ["calcium", "CHEMICAL", 176, 183], ["carbohydrates", "CHEMICAL", 324, 337], ["lectins", "GENE_OR_GENE_PRODUCT", 4, 11], ["Glycine max", "ORGANISM", 17, 28], ["soybean", "ORGANISM_SUBDIVISION", 30, 37], ["Canavalia gladiate", "ORGANISM", 40, 58], ["sword bean", "ORGANISM", 60, 70], ["Triticum vulgaris", "ORGANISM", 77, 94], ["wheat germ", "ORGANISM", 96, 106], ["isoflavone", "SIMPLE_CHEMICAL", 161, 171], ["calcium ions", "SIMPLE_CHEMICAL", 176, 188], ["cells", "CELL", 358, 363], ["antitumoral", "CANCER", 450, 461], ["lymphocyte", "CELL", 513, 523], ["humans", "ORGANISM", 562, 568], ["nutritional factors", "PROTEIN", 132, 151], ["Glycine max", "SPECIES", 17, 28], ["soybean", "SPECIES", 30, 37], ["Canavalia gladiate", "SPECIES", 40, 58], ["bean", "SPECIES", 66, 70], ["Triticum vulgaris", "SPECIES", 77, 94], ["wheat", "SPECIES", 96, 101], ["humans", "SPECIES", 562, 568], ["Glycine max", "SPECIES", 17, 28], ["soybean", "SPECIES", 30, 37], ["Canavalia gladiate", "SPECIES", 40, 58], ["sword bean", "SPECIES", 60, 70], ["Triticum vulgaris", "SPECIES", 77, 94], ["humans", "SPECIES", 562, 568], ["The lectins", "TREATMENT", 0, 11], ["Glycine max (soybean)", "TREATMENT", 17, 38], ["Canavalia gladiate (sword bean", "TREATMENT", 40, 70], ["Triticum vulgaris (wheat germ", "TREATMENT", 77, 106], ["nutritional factors", "PROBLEM", 132, 151], ["isoflavone", "TREATMENT", 161, 171], ["calcium ions", "TREATMENT", 176, 188], ["plant lectins", "TREATMENT", 243, 256], ["The reversible and specific binding of lectins", "PROBLEM", 256, 302], ["a wide variety of carbohydrates", "PROBLEM", 306, 337], ["antiviral", "TREATMENT", 412, 421], ["antifungal", "TREATMENT", 423, 433], ["antibacterial", "TREATMENT", 435, 448], ["antitumoral", "TREATMENT", 450, 461], ["insecticidal properties", "TREATMENT", 467, 490], ["mitogenic lymphocyte stimulation", "TREATMENT", 503, 535], ["plant lectins", "TREATMENT", 628, 641], ["Triticum vulgaris", "ANATOMY", 77, 94], ["reversible", "OBSERVATION_MODIFIER", 260, 270]]], ["Since 1888, many plant lectins have been purified and described in detail (Stillmark, 1888) .", [["lectins", "GENE_OR_GENE_PRODUCT", 23, 30], ["lectins", "OBSERVATION_MODIFIER", 23, 30]]], ["Over the last century, studies revealed a very heterogeneous group of proteins with diverse specificities, primary sequences and structural features.", [["studies", "TEST", 23, 30], ["a very heterogeneous group of proteins", "PROBLEM", 40, 78], ["very", "OBSERVATION_MODIFIER", 42, 46], ["heterogeneous", "OBSERVATION_MODIFIER", 47, 60]]], ["Accumulated information allowed the classification of plant lectins into 12 families, based on their evolutionary and sequence relationships, as follows: (i) Agaricus bisporus agglutinin homologs; (ii) Amaranthins; (iii) Class V chitinase homologs; (iv) Cyanovirin family; (v) Euonymus europaeus family; (vi) Galanthus nivalis (GNA)-related family; (vii) Proteins with hevein domains; (viii) Jacalins; (ix) Proteins with legume-lectin domains; (x) LysM domain; (xi) Nictaba family (formally Cucurbitaceae phloem lectins), and (xii) Ricin-B family (Van Damme, 2014; Van Damme, Lannoo, & Peumans, 2008) .Introduction A brief overview on plant lectinsTuberous plants are valuable matrices abundant in lectins, accounting for up to 50% of the total protein content (Shet & Madaiah, 1988; Van Damme, 2008) .", [["Agaricus bisporus agglutinin", "ORGANISM", 158, 186], ["Class V chitinase", "GENE_OR_GENE_PRODUCT", 221, 238], ["Cyanovirin", "GENE_OR_GENE_PRODUCT", 254, 264], ["Euonymus europaeus", "ORGANISM", 277, 295], ["Galanthus nivalis (GNA)-related family", "GENE_OR_GENE_PRODUCT", 309, 347], ["Ricin-B", "GENE_OR_GENE_PRODUCT", 532, 539], ["lectins", "GENE_OR_GENE_PRODUCT", 698, 705], ["agglutinin homologs", "PROTEIN", 176, 195], ["Amaranthins", "PROTEIN", 202, 213], ["Class V chitinase homologs", "PROTEIN", 221, 247], ["Cyanovirin family", "PROTEIN", 254, 271], ["Euonymus europaeus family", "PROTEIN", 277, 302], ["Galanthus nivalis (GNA)-related family; (vii) Proteins", "PROTEIN", 309, 363], ["hevein domains", "PROTEIN", 369, 383], ["Jacalins", "PROTEIN", 392, 400], ["legume-lectin domains", "PROTEIN", 421, 442], ["LysM domain", "PROTEIN", 448, 459], ["Nictaba family", "PROTEIN", 466, 480], ["lectins", "PROTEIN", 698, 705], ["Agaricus bisporus", "SPECIES", 158, 175], ["Euonymus europaeus", "SPECIES", 277, 295], ["Galanthus nivalis", "SPECIES", 309, 326], ["Agaricus bisporus", "SPECIES", 158, 175], ["Euonymus europaeus", "SPECIES", 277, 295], ["Galanthus nivalis", "SPECIES", 309, 326], ["Agaricus bisporus agglutinin homologs", "TREATMENT", 158, 195], ["hevein domains", "PROBLEM", 369, 383], ["legume-lectin domains", "PROBLEM", 421, 442], ["plant lectinsTuberous plants", "TREATMENT", 635, 663]]], ["They are widely cultivated and consumed in tropical and subtropical countries as a staple food, supplying carbohydrate and proteins for human and animals.", [["carbohydrate", "CHEMICAL", 106, 118], ["human", "ORGANISM", 136, 141], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["widely", "OBSERVATION_MODIFIER", 9, 15], ["cultivated", "OBSERVATION", 16, 26]]], ["However, the importance of tuberous plants is not restricted to their nutritive value, as some of them exhibit remarkable pharmaceutical properties due to their lectin content (Chandrasekara & Josheph Kumar, 2016; de Castro, Carneiro, Neshich Dde, & de Paiva, 1992; Monte-Neshich et al., 1995) .The taro plant [Colocasia esculenta (L.)", [["lectin", "GENE_OR_GENE_PRODUCT", 161, 167], ["taro plant", "ORGANISM", 299, 309], ["Colocasia esculenta", "ORGANISM", 311, 330], ["lectin", "PROTEIN", 161, 167], ["Colocasia esculenta", "SPECIES", 311, 330], ["Colocasia esculenta", "SPECIES", 311, 330], ["tuberous plants", "PROBLEM", 27, 42], ["tuberous plants", "OBSERVATION", 27, 42]]], ["Schott]Scientifically named Colocasia esculenta, taro is a tuberous plant classified as monocotyledonous, belonging to the Liliatae class and Araceae family.", [["tuberous plant", "ANATOMY", 59, 73], ["Colocasia esculenta", "ORGANISM", 28, 47], ["Araceae", "GENE_OR_GENE_PRODUCT", 142, 149], ["Colocasia esculenta", "SPECIES", 28, 47], ["Colocasia esculenta", "SPECIES", 28, 47]]], ["Currently, taro crops are widespread through Oceania, Central, and South America, Asia and Africa, the latter being the major producer (Alcantara, Hurtada, & Dizon, 2013) .", [["widespread", "OBSERVATION_MODIFIER", 26, 36], ["Central", "OBSERVATION_MODIFIER", 54, 61]]], ["In Brazil, taro crops are more pronounced in the Central-South region, with Rio de Janeiro, Minas Gerais, and Esp\u00edrito Santo states leading the production (Mesquita, 2002) .", [["taro crops", "OBSERVATION", 11, 21], ["more pronounced", "OBSERVATION_MODIFIER", 26, 41], ["Central", "ANATOMY_MODIFIER", 49, 56], ["South", "ANATOMY_MODIFIER", 57, 62], ["region", "ANATOMY_MODIFIER", 63, 69]]], ["Genetic characterization and relationship studies among taro cultivars in Brazil have focused on the sequence analysis of exons of the plastid genes rbcL and matK loci and the pbsA-trnH intergenic sequence used alone or in combination (Nunes, Del Aguila, Paschoalin, & da Silva, 2014) .", [["taro cultivars", "ORGANISM", 56, 70], ["plastid", "CELLULAR_COMPONENT", 135, 142], ["rbcL", "GENE_OR_GENE_PRODUCT", 149, 153], ["pbsA", "GENE_OR_GENE_PRODUCT", 176, 180], ["exons", "DNA", 122, 127], ["plastid genes", "DNA", 135, 148], ["rbcL", "DNA", 149, 153], ["matK loci", "DNA", 158, 167], ["pbsA", "DNA", 176, 180], ["trnH intergenic sequence", "DNA", 181, 205], ["Genetic characterization", "TEST", 0, 24], ["relationship studies", "TEST", 29, 49], ["the sequence analysis", "TEST", 97, 118], ["the plastid genes rbcL", "TEST", 131, 153], ["matK loci", "TEST", 158, 167], ["the pbsA", "TEST", 172, 180]]], ["Polymorphisms among taro cultivars have been evaluated by using SSR (Simple sequence repeats) polymorphisms analysis in 7 loci (Xuqtem55, Xuqtem73, Xuqtem84, Xuqtem88, Xuqtem91, Xuqtem97, and Xuqtem110) (Nunes et al., 2012) .", [["taro cultivars", "CELL", 20, 34], ["SSR", "DNA", 64, 67], ["Xuqtem97", "DNA", 178, 186], ["Xuqtem110", "DNA", 192, 201], ["Polymorphisms among taro cultivars", "TREATMENT", 0, 34], ["polymorphisms analysis", "TEST", 94, 116]]], ["Both microsatellite markers and matK locus and the noncoding sequence pbsA-trnH contributed to establish the genetic diversity among taro cultivars grown in Brazil.", [["pbsA-trnH", "GENE_OR_GENE_PRODUCT", 70, 79], ["taro cultivars", "CELL", 133, 147], ["microsatellite markers", "DNA", 5, 27], ["matK locus", "DNA", 32, 42], ["noncoding sequence", "DNA", 51, 69], ["pbsA", "DNA", 70, 74], ["trnH", "DNA", 75, 79], ["Both microsatellite markers", "TEST", 0, 27], ["matK locus", "PROBLEM", 32, 42], ["the noncoding sequence pbsA", "TEST", 47, 74], ["trnH", "PROBLEM", 75, 79], ["the genetic diversity", "PROBLEM", 105, 126], ["microsatellite markers", "OBSERVATION", 5, 27], ["matK locus", "OBSERVATION", 32, 42]]], ["The taro cultivar mostly consumed in Rio de Janeiro is the Chinese (Chin\u00eas or Chinezinho) variety (Nunes et al., 2012) .", [["taro cultivar", "CELL", 4, 17]]], ["A voucher specimen was deposited at the RFA Herbarium belonging to the Federal Univ. of Rio de Janeiro [Univ.", [["specimen", "ANATOMY", 10, 18], ["A voucher specimen", "PROBLEM", 0, 18]]], ["Federal do Rio de Janeiro (UFRJ)], Centro de Ci\u00eancias da Sa\u00fade, Departamento de Bot\u00e2nica (Rio de Janeiro, Brazil) under the designation RFA-39.962 (Pereira, Silva, Ver\u00edcimo, Paschoalin, & Teixeira, 2015) .Taro -edible parts and processingEdible taro parts include stems and leaves, although the corms are traditionally the most consumed part of this plant worldwide.", [["stems", "ANATOMY", 264, 269], ["leaves", "ANATOMY", 274, 280], ["stems", "TISSUE", 264, 269], ["leaves", "ORGANISM_SUBDIVISION", 274, 280], ["RFA", "TEST", 136, 139], ["Edible taro parts", "TREATMENT", 238, 255], ["taro", "OBSERVATION", 245, 249], ["stems", "OBSERVATION_MODIFIER", 264, 269], ["leaves", "OBSERVATION_MODIFIER", 274, 280]]], ["Some taro cultivars display high oxalate content, mainly in leaves, that can form nonabsorbable salts with divalent cations, such as Ca 2+ , Fe 2+ , or Mg 2+ , and these oxalate crystals can be deposited in the kidneys, leading to renal failure (Du Thanh et al., 2017) .", [["leaves", "ANATOMY", 60, 66], ["kidneys", "ANATOMY", 211, 218], ["renal", "ANATOMY", 231, 236], ["oxalate", "CHEMICAL", 33, 40], ["Ca", "CHEMICAL", 133, 135], ["Fe", "CHEMICAL", 141, 143], ["Mg", "CHEMICAL", 152, 154], ["oxalate", "CHEMICAL", 170, 177], ["renal failure", "DISEASE", 231, 244], ["oxalate", "CHEMICAL", 33, 40], ["Ca 2+", "CHEMICAL", 133, 138], ["Fe 2+", "CHEMICAL", 141, 146], ["Mg 2+", "CHEMICAL", 152, 157], ["oxalate", "CHEMICAL", 170, 177], ["oxalate", "SIMPLE_CHEMICAL", 33, 40], ["nonabsorbable salts", "SIMPLE_CHEMICAL", 82, 101], ["cations", "SIMPLE_CHEMICAL", 116, 123], ["Ca 2+", "SIMPLE_CHEMICAL", 133, 138], ["Fe 2+", "SIMPLE_CHEMICAL", 141, 146], ["Mg 2+", "SIMPLE_CHEMICAL", 152, 157], ["oxalate crystals", "SIMPLE_CHEMICAL", 170, 186], ["kidneys", "ORGAN", 211, 218], ["renal", "ORGAN", 231, 236], ["Some taro cultivars", "PROBLEM", 0, 19], ["high oxalate content", "PROBLEM", 28, 48], ["divalent cations", "TREATMENT", 107, 123], ["Ca", "TEST", 133, 135], ["Fe", "TEST", 141, 143], ["Mg", "TREATMENT", 152, 154], ["these oxalate crystals", "TREATMENT", 164, 186], ["renal failure", "PROBLEM", 231, 244], ["high", "OBSERVATION_MODIFIER", 28, 32], ["oxalate content", "OBSERVATION", 33, 48], ["kidneys", "ANATOMY", 211, 218], ["renal", "ANATOMY", 231, 236], ["failure", "OBSERVATION", 237, 244]]], ["The insoluble oxalates, especially needle like calcium oxalate crystalraphides-may cause irritation, and swelling of mouth and throat.", [["mouth", "ANATOMY", 117, 122], ["throat", "ANATOMY", 127, 133], ["calcium", "CHEMICAL", 47, 54], ["swelling of mouth and throat", "DISEASE", 105, 133], ["oxalates", "CHEMICAL", 14, 22], ["calcium oxalate", "CHEMICAL", 47, 62], ["oxalates", "SIMPLE_CHEMICAL", 14, 22], ["calcium oxalate crystalraphides", "SIMPLE_CHEMICAL", 47, 78], ["mouth", "ORGANISM_SUBDIVISION", 117, 122], ["throat", "ORGANISM_SUBDIVISION", 127, 133], ["The insoluble oxalates", "TREATMENT", 0, 22], ["calcium oxalate crystalraphides", "TREATMENT", 47, 78], ["irritation", "PROBLEM", 89, 99], ["swelling of mouth and throat", "PROBLEM", 105, 133], ["may cause", "UNCERTAINTY", 79, 88], ["irritation", "OBSERVATION", 89, 99], ["swelling", "OBSERVATION", 105, 113], ["mouth", "ANATOMY", 117, 122], ["throat", "ANATOMY", 127, 133]]], ["Thermal treatments, such as boiling or cooking taro (corm, stems, or leaves) can remove oxalates, by converting the salts into soluble phases (Kumoro, Putri, Budiyati, & Retnowati, 2014) .Taro -edible parts and processingTaro corm storage for long periods is directly affected by the high moisture content present in this plant portion.", [["stems", "ANATOMY", 59, 64], ["leaves", "ANATOMY", 69, 75], ["taro", "CHEMICAL", 47, 51], ["oxalates", "CHEMICAL", 88, 96], ["oxalates", "CHEMICAL", 88, 96], ["oxalates", "SIMPLE_CHEMICAL", 88, 96], ["Thermal treatments", "TREATMENT", 0, 18], ["oxalates", "TREATMENT", 88, 96], ["Taro -edible parts", "TREATMENT", 188, 206], ["processingTaro corm storage", "TREATMENT", 211, 238], ["the high moisture content", "PROBLEM", 280, 305], ["Taro corm", "OBSERVATION", 221, 230], ["high", "OBSERVATION_MODIFIER", 284, 288], ["moisture content", "OBSERVATION", 289, 305]]], ["Corms can be steamed, fried, baked or processed into flour.", [["flour", "ORGANISM_SUBDIVISION", 53, 58]]], ["Taro flour composition is comparable to other vegetable and grain flours, such as potato, corn and soybean, exhibiting high ash concentrations and crude fiber content in a low-fat product, making taro flour an adequate substitute for currently available flours.", [["vegetable", "ANATOMY", 46, 55], ["grain flours", "ANATOMY", 60, 72], ["vegetable", "ORGANISM_SUBDIVISION", 46, 55], ["grain flours", "ORGANISM_SUBSTANCE", 60, 72], ["potato", "ORGANISM_SUBDIVISION", 82, 88], ["corn", "ORGANISM_SUBDIVISION", 90, 94], ["soybean", "ORGANISM_SUBDIVISION", 99, 106], ["potato", "SPECIES", 82, 88], ["corn", "SPECIES", 90, 94], ["soybean", "SPECIES", 99, 106], ["potato", "SPECIES", 82, 88], ["corn", "SPECIES", 90, 94], ["soybean", "SPECIES", 99, 106], ["Taro flour composition", "TREATMENT", 0, 22], ["soybean", "TREATMENT", 99, 106], ["high ash concentrations", "PROBLEM", 119, 142], ["crude fiber content", "PROBLEM", 147, 166], ["a low-fat product", "TREATMENT", 170, 187], ["taro flour", "TREATMENT", 196, 206]]], ["Substitutions or combinations with wheat could be an economic alternative for developing countries that depend on wheat imports, but present appropriate climate and soil conditions for taro cultivation.", [["taro", "CHEMICAL", 185, 189], ["wheat", "SPECIES", 35, 40], ["wheat", "SPECIES", 114, 119], ["wheat", "SPECIES", 35, 40], ["wheat", "SPECIES", 114, 119], ["Substitutions", "TREATMENT", 0, 13], ["taro cultivation", "TREATMENT", 185, 201]]], ["Moreover, supplementation of wheat-derived products with taro flour could improve nutritional food quality, since wheat is poor in essential amino acids.", [["taro flour", "CHEMICAL", 57, 67], ["amino acids", "CHEMICAL", 141, 152], ["amino acids", "CHEMICAL", 141, 152], ["wheat", "ORGANISM", 29, 34], ["amino acids", "AMINO_ACID", 141, 152], ["wheat", "SPECIES", 29, 34], ["wheat", "SPECIES", 114, 119], ["wheat", "SPECIES", 29, 34], ["wheat", "SPECIES", 114, 119], ["wheat-derived products", "TREATMENT", 29, 51], ["taro flour", "TREATMENT", 57, 67], ["essential amino acids", "TREATMENT", 131, 152], ["amino acids", "OBSERVATION", 141, 152]]], ["Taro flour may be used in many preparations, such as cookies, noodle, paste, bread and infant formulations, reaching not only regular consumers, but also those that display dietary restrictions, such as gluten intolerance or food allergenic disorders (Kaur, Kaushal, & Sandhu, 2013; Kaushal et al., 2013; Noorfarahzilah, Lee, Sharifudin, MohdFadzelly, & Hasmadi, 2014) .Taro -edible parts and processingTarin, potential immunomodulator lectin . . .Taro -edible parts and processingTaro flour in combination with wheat flour has been reported for the preparation of breads with similar or better functional characteristics than breads prepared exclusively with wheat flour (Ammar, Hegazy, & Bedeir, 2009; Emmanuel, Osuchukwu, & Oshiele, 2010; Noorfarahzilah et al., 2014) .", [["gluten intolerance", "DISEASE", 203, 221], ["allergenic disorders", "DISEASE", 230, 250], ["Tarin", "CHEMICAL", 403, 408], ["Taro flour", "CHEMICAL", 481, 491], ["wheat flour", "CHEMICAL", 512, 523], ["bread", "ORGANISM_SUBDIVISION", 77, 82], ["Tarin", "SIMPLE_CHEMICAL", 403, 408], ["Taro flour", "ORGANISM", 481, 491], ["wheat", "ORGANISM", 512, 517], ["breads", "ORGANISM_SUBDIVISION", 565, 571], ["wheat", "SPECIES", 512, 517], ["wheat", "SPECIES", 660, 665], ["wheat", "SPECIES", 512, 517], ["wheat", "SPECIES", 660, 665], ["Taro flour", "TREATMENT", 0, 10], ["gluten intolerance", "PROBLEM", 203, 221], ["food allergenic disorders", "PROBLEM", 225, 250], ["potential immunomodulator lectin", "TREATMENT", 410, 442], ["Taro -edible parts", "TREATMENT", 448, 466], ["processingTaro flour", "TREATMENT", 471, 491], ["wheat flour", "TREATMENT", 512, 523], ["potential", "UNCERTAINTY", 410, 419], ["immunomodulator lectin", "OBSERVATION", 420, 442]]], ["Emmanuel et al. (2010) demonstrated that the incorporation of up to 10% of taro flour in the production of wheat/taro bread in its composition minimally affected the pasting properties responsible for conferring food characteristics and, hence, acceptability.", [["taro flour", "CHEMICAL", 75, 85], ["taro flour", "ORGANISM", 75, 85], ["wheat", "ORGANISM", 107, 112], ["taro bread", "ORGANISM", 113, 123], ["wheat", "SPECIES", 107, 112], ["wheat", "SPECIES", 107, 112], ["taro flour", "TREATMENT", 75, 85], ["wheat/taro bread", "TREATMENT", 107, 123]]], ["Taro flour incorporation produced comparable values for bulk density and swelling capacity (unblanched flour), improvement of gelling ability and, although it caused a decrease in water and oil absorption capacity, this was not enough to interfere in the sensorial characteristics of the final product.", [["oil", "ANATOMY", 190, 193], ["Taro flour", "CHEMICAL", 0, 10], ["swelling", "DISEASE", 73, 81], ["water", "SIMPLE_CHEMICAL", 180, 185], ["oil", "SIMPLE_CHEMICAL", 190, 193], ["bulk density", "PROBLEM", 56, 68], ["swelling capacity", "PROBLEM", 73, 90], ["a decrease in water and oil absorption capacity", "PROBLEM", 166, 213], ["density", "OBSERVATION", 61, 68], ["swelling", "OBSERVATION", 73, 81], ["decrease", "OBSERVATION_MODIFIER", 168, 176]]], ["Similarly, Ammar et al. (2009) reported that the incorporation of taro flour in wheat bread preserved its organoleptic and rheological properties when concentrations did not exceed 10% substitution.", [["taro flour", "CHEMICAL", 66, 76], ["taro flour", "ORGANISM", 66, 76], ["wheat", "ORGANISM", 80, 85], ["bread", "ORGANISM_SUBDIVISION", 86, 91], ["wheat", "SPECIES", 80, 85], ["wheat", "SPECIES", 80, 85], ["taro flour", "TREATMENT", 66, 76]]], ["Moreover, the combination of taro/wheat flour in bread formulations increases the amounts of ash, crude fibers and carbohydrates of the final product (Ammar et al., 2009) .Taro -edible parts and processingPoi.", [["fibers", "ANATOMY", 104, 110], ["taro/wheat flour", "CHEMICAL", 29, 45], ["carbohydrates", "CHEMICAL", 115, 128], ["taro", "SIMPLE_CHEMICAL", 29, 33], ["wheat flour", "ORGANISM", 34, 45], ["bread", "ORGANISM_SUBDIVISION", 49, 54], ["ash", "SIMPLE_CHEMICAL", 93, 96], ["wheat", "SPECIES", 34, 39], ["wheat", "SPECIES", 34, 39], ["taro/wheat flour", "TREATMENT", 29, 45], ["bread formulations", "TREATMENT", 49, 67]]], ["Another interesting formulation prepared from taro corms is called \"poi,\" a common probiotic dish in Hawaii, where taro is considered a sacred food Poi is a starchy paste prepared by cooking and crushing the corms, followed by the addition of water and allowing the wet mixture to spontaneously be fermented by yeast and bacteria (mainly Lactobacillus sp and Lactococcus sp) (Huang, Lam, Nakayama, & Lin, 1994) .", [["taro", "CHEMICAL", 115, 119], ["Poi", "CHEMICAL", 148, 151], ["Lactobacillus sp", "ORGANISM", 338, 354], ["Lactococcus sp", "ORGANISM", 359, 373], ["yeast", "SPECIES", 311, 316], ["Lactobacillus", "SPECIES", 338, 351], ["Lactococcus sp", "SPECIES", 359, 373], ["yeast", "SPECIES", 311, 316], ["Lactobacillus sp and Lactococcus sp)", "SPECIES", 338, 374], ["a starchy paste", "TREATMENT", 155, 170], ["water", "TREATMENT", 243, 248], ["the wet mixture", "PROBLEM", 262, 277], ["yeast", "PROBLEM", 311, 316], ["bacteria", "PROBLEM", 321, 329], ["Lactobacillus sp", "TREATMENT", 338, 354], ["Lam", "ANATOMY", 383, 386]]], ["Poi can be allowed to reach a sour stage, where lactic acid and acetic acid accumulate, after the utilization of simple sugars by the microbial consortium.", [["lactic acid", "CHEMICAL", 48, 59], ["acetic acid", "CHEMICAL", 64, 75], ["lactic acid", "CHEMICAL", 48, 59], ["acetic acid", "CHEMICAL", 64, 75], ["sugars", "CHEMICAL", 120, 126], ["Poi", "SIMPLE_CHEMICAL", 0, 3], ["lactic acid", "SIMPLE_CHEMICAL", 48, 59], ["acetic acid", "SIMPLE_CHEMICAL", 64, 75], ["lactic acid", "TEST", 48, 59], ["acetic acid accumulate", "PROBLEM", 64, 86], ["simple sugars", "TEST", 113, 126]]], ["The nutritional composition of poi is quite similar to that of taro corms, but carbohydrate decreases and secondary metabolites comprise a probiotic food that could be used in medical nutrition therapy.", [["carbohydrate", "CHEMICAL", 79, 91], ["carbohydrate", "SIMPLE_CHEMICAL", 79, 91], ["poi", "PROBLEM", 31, 34], ["carbohydrate decreases", "PROBLEM", 79, 101], ["secondary metabolites", "PROBLEM", 106, 127], ["a probiotic food", "TREATMENT", 137, 153], ["medical nutrition therapy", "TREATMENT", 176, 201], ["nutritional composition", "OBSERVATION_MODIFIER", 4, 27]]], ["During the early 1950s, poi was used in Hawaiian hospitals to successfully ameliorate infant food allergies and failure-to-thrive (Brown & Valiere, 2004) .", [["food allergies", "DISEASE", 93, 107], ["failure-to-thrive", "DISEASE", 112, 129], ["infant", "SPECIES", 86, 92], ["infant food allergies", "PROBLEM", 86, 107], ["failure-to-thrive", "PROBLEM", 112, 129]]], ["Studies on poi are scarce, but 1 study analyzed the effect of poi extracts in an in vitro assay concerning the proliferation of rat YYT colorectal cancer cells (Brown, Reitzenstein, Liu, & Jadus, 2005) .", [["extracts", "ANATOMY", 66, 74], ["YYT colorectal cancer cells", "ANATOMY", 132, 159], ["colorectal cancer", "DISEASE", 136, 153], ["poi extracts", "ORGANISM_SUBSTANCE", 62, 74], ["rat", "ORGANISM", 128, 131], ["YYT colorectal cancer cells", "CELL", 132, 159], ["rat YYT colorectal cancer cells", "CELL_TYPE", 128, 159], ["rat", "SPECIES", 128, 131], ["rat", "SPECIES", 128, 131], ["1 study", "TEST", 31, 38], ["poi extracts", "PROBLEM", 62, 74], ["an in vitro assay", "TEST", 78, 95], ["colorectal cancer cells", "PROBLEM", 136, 159]]], ["Poi partially inhibited the proliferation of colorectal cancer cells in a dose-dependent manner, reaching maximum inhibition at 25%.", [["colorectal cancer cells", "ANATOMY", 45, 68], ["colorectal cancer", "DISEASE", 45, 62], ["Poi", "SIMPLE_CHEMICAL", 0, 3], ["colorectal cancer cells", "CELL", 45, 68], ["colorectal cancer cells", "CELL_TYPE", 45, 68], ["Poi", "PROBLEM", 0, 3], ["colorectal cancer cells", "PROBLEM", 45, 68], ["proliferation", "OBSERVATION_MODIFIER", 28, 41], ["colorectal cancer cells", "OBSERVATION", 45, 68]]], ["Further studies revealed that poi extract induced cancer cell apoptosis in vitro and was also able to stimulate hematopoietic cells from normal mouse spleen, especially T cells.Taro nutrientsTaro corms provide multiple nutrients, such as carbohydrates, proteins, vitamins (thiamine, riboflavin, niacin, vitamins A and C), minerals (potassium, calcium, sodium, phosphorus, and iron) and fibers Subhash, Sarla, & Jaybardhan, 2012; Temesgen & Retta, 2015) .", [["poi extract", "ANATOMY", 30, 41], ["cancer cell", "ANATOMY", 50, 61], ["hematopoietic cells", "ANATOMY", 112, 131], ["spleen", "ANATOMY", 150, 156], ["T cells", "ANATOMY", 169, 176], ["poi extract", "CHEMICAL", 30, 41], ["cancer", "DISEASE", 50, 56], ["thiamine", "CHEMICAL", 273, 281], ["riboflavin", "CHEMICAL", 283, 293], ["niacin", "CHEMICAL", 295, 301], ["vitamins A and C", "CHEMICAL", 303, 319], ["potassium", "CHEMICAL", 332, 341], ["calcium", "CHEMICAL", 343, 350], ["sodium, phosphorus", "CHEMICAL", 352, 370], ["iron", "CHEMICAL", 376, 380], ["carbohydrates", "CHEMICAL", 238, 251], ["thiamine", "CHEMICAL", 273, 281], ["riboflavin", "CHEMICAL", 283, 293], ["niacin", "CHEMICAL", 295, 301], ["vitamins A and C", "CHEMICAL", 303, 319], ["potassium", "CHEMICAL", 332, 341], ["calcium", "CHEMICAL", 343, 350], ["sodium", "CHEMICAL", 352, 358], ["phosphorus", "CHEMICAL", 360, 370], ["iron", "CHEMICAL", 376, 380], ["cancer cell", "CELL", 50, 61], ["hematopoietic cells", "CELL", 112, 131], ["mouse", "ORGANISM", 144, 149], ["spleen", "ORGAN", 150, 156], ["T cells", "CELL", 169, 176], ["vitamins", "SIMPLE_CHEMICAL", 263, 271], ["thiamine", "SIMPLE_CHEMICAL", 273, 281], ["riboflavin", "SIMPLE_CHEMICAL", 283, 293], ["niacin", "SIMPLE_CHEMICAL", 295, 301], ["vitamins A", "SIMPLE_CHEMICAL", 303, 313], ["C", "SIMPLE_CHEMICAL", 318, 319], ["minerals", "SIMPLE_CHEMICAL", 322, 330], ["potassium", "SIMPLE_CHEMICAL", 332, 341], ["calcium", "SIMPLE_CHEMICAL", 343, 350], ["sodium", "SIMPLE_CHEMICAL", 352, 358], ["phosphorus", "SIMPLE_CHEMICAL", 360, 370], ["iron", "SIMPLE_CHEMICAL", 376, 380], ["hematopoietic cells", "CELL_TYPE", 112, 131], ["T cells", "CELL_TYPE", 169, 176], ["mouse", "SPECIES", 144, 149], ["mouse", "SPECIES", 144, 149], ["Further studies", "TEST", 0, 15], ["poi extract", "PROBLEM", 30, 41], ["cancer cell apoptosis", "PROBLEM", 50, 71], ["multiple nutrients", "TREATMENT", 210, 228], ["carbohydrates, proteins", "TREATMENT", 238, 261], ["vitamins", "TREATMENT", 263, 271], ["thiamine", "TREATMENT", 273, 281], ["riboflavin", "TREATMENT", 283, 293], ["niacin", "TREATMENT", 295, 301], ["vitamins A and C)", "TREATMENT", 303, 320], ["minerals", "TREATMENT", 322, 330], ["potassium", "TREATMENT", 332, 341], ["calcium", "TREATMENT", 343, 350], ["sodium", "TREATMENT", 352, 358], ["phosphorus", "TREATMENT", 360, 370], ["iron", "TREATMENT", 376, 380], ["cancer cell apoptosis", "OBSERVATION", 50, 71], ["hematopoietic cells", "OBSERVATION", 112, 131], ["normal mouse", "OBSERVATION", 137, 149], ["spleen", "ANATOMY", 150, 156]]], ["This staple crop offers mainly high quality, gluten-free carbohydrates (29% on a fresh weight bases), composed of small and resistant starch granules, which accounts for a controlled glucose release and absorption, making taro carbohydrates highly digestible and an important adjuvant candidate to reduce the risk of obesity, diabetes, heart disease and certain types of cancers .Taro nutrientsTaro leaves and stems provide the same nutrients found in the corms but in different amounts.", [["starch granules", "ANATOMY", 134, 149], ["heart", "ANATOMY", 336, 341], ["cancers", "ANATOMY", 371, 378], ["leaves", "ANATOMY", 399, 405], ["stems", "ANATOMY", 410, 415], ["glucose", "CHEMICAL", 183, 190], ["obesity", "DISEASE", 317, 324], ["diabetes", "DISEASE", 326, 334], ["heart disease", "DISEASE", 336, 349], ["cancers", "DISEASE", 371, 378], ["carbohydrates", "CHEMICAL", 57, 70], ["glucose", "CHEMICAL", 183, 190], ["carbohydrates", "CHEMICAL", 227, 240], ["carbohydrates", "SIMPLE_CHEMICAL", 57, 70], ["starch", "SIMPLE_CHEMICAL", 134, 140], ["granules", "ORGANISM_SUBSTANCE", 141, 149], ["glucose", "SIMPLE_CHEMICAL", 183, 190], ["taro carbohydrates", "SIMPLE_CHEMICAL", 222, 240], ["heart", "ORGAN", 336, 341], ["cancers", "CANCER", 371, 378], ["Taro leaves", "ORGANISM", 394, 405], ["stems", "ORGAN", 410, 415], ["This staple crop", "TREATMENT", 0, 16], ["a fresh weight bases", "TREATMENT", 79, 99], ["small and resistant starch granules", "PROBLEM", 114, 149], ["a controlled glucose release", "TREATMENT", 170, 198], ["obesity", "PROBLEM", 317, 324], ["diabetes", "PROBLEM", 326, 334], ["heart disease", "PROBLEM", 336, 349], ["cancers", "PROBLEM", 371, 378], ["high", "OBSERVATION_MODIFIER", 31, 35], ["small", "OBSERVATION_MODIFIER", 114, 119], ["resistant", "OBSERVATION_MODIFIER", 124, 133], ["starch granules", "OBSERVATION", 134, 149], ["obesity", "OBSERVATION", 317, 324], ["heart", "ANATOMY", 336, 341], ["disease", "OBSERVATION", 342, 349], ["cancers", "OBSERVATION", 371, 378]]], ["Except for thiamine and carbohydrate content, taro leaves exhibit higher levels of all the other nutrients.", [["leaves", "ANATOMY", 51, 57], ["thiamine", "CHEMICAL", 11, 19], ["thiamine", "CHEMICAL", 11, 19], ["carbohydrate", "CHEMICAL", 24, 36], ["thiamine", "SIMPLE_CHEMICAL", 11, 19], ["carbohydrate", "SIMPLE_CHEMICAL", 24, 36], ["taro leaves", "ORGANISM", 46, 57], ["thiamine", "TREATMENT", 11, 19], ["carbohydrate content", "TREATMENT", 24, 44]]], ["On the other hand, the stems are poor in these nutrients compared to the corms, offering higher contents only for calcium, iron and vitamin A, while the other nutrients are mostly found in smaller amounts .Taro nutrientsCorm proteins.", [["calcium", "CHEMICAL", 114, 121], ["iron", "CHEMICAL", 123, 127], ["vitamin A", "CHEMICAL", 132, 141], ["calcium", "CHEMICAL", 114, 121], ["iron", "CHEMICAL", 123, 127], ["vitamin A", "CHEMICAL", 132, 141], ["calcium", "SIMPLE_CHEMICAL", 114, 121], ["iron", "SIMPLE_CHEMICAL", 123, 127], ["vitamin A", "SIMPLE_CHEMICAL", 132, 141], ["Corm proteins", "PROTEIN", 220, 233], ["calcium", "TREATMENT", 114, 121], ["iron", "TREATMENT", 123, 127], ["vitamin A", "TREATMENT", 132, 141], ["stems", "ANATOMY", 23, 28], ["poor", "OBSERVATION", 33, 37]]], ["As a gluten-free food, the consumption of taro corms may be a healthier alternative carbohydrate source, avoiding food allergy reactions and related disorders.", [["allergy reactions", "DISEASE", 119, 136], ["carbohydrate", "CHEMICAL", 84, 96], ["food allergy reactions", "PROBLEM", 114, 136], ["related disorders", "PROBLEM", 141, 158]]], ["Taro corm also provides significant amount of soluble and nonsoluble dietary fibers, which may optimize intestinal transit and possibly reduce the risk of colorectal cancer (Alcantara et al., 2013; Lim, 2015; Prajapati, Kalariya, Umbarkar, Parmar, & Sheth, 2011) .", [["fibers", "ANATOMY", 77, 83], ["intestinal", "ANATOMY", 104, 114], ["colorectal cancer", "ANATOMY", 155, 172], ["colorectal cancer", "DISEASE", 155, 172], ["intestinal", "ORGAN", 104, 114], ["colorectal cancer", "CANCER", 155, 172], ["soluble and nonsoluble dietary fibers", "TREATMENT", 46, 83], ["intestinal transit", "PROBLEM", 104, 122], ["colorectal cancer", "PROBLEM", 155, 172], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["amount", "OBSERVATION_MODIFIER", 36, 42], ["colorectal", "ANATOMY", 155, 165], ["cancer", "OBSERVATION", 166, 172]]], ["The lower protein content (1.4% to 3.0% on a fresh weight basis) of taro corms contributes to their hypoallergenicity.", [["taro corms", "ANATOMY", 68, 78], ["hypoallergenicity", "DISEASE", 100, 117], ["The lower protein content", "TEST", 0, 25], ["a fresh weight basis", "TREATMENT", 43, 63], ["their hypoallergenicity", "PROBLEM", 94, 117], ["lower", "ANATOMY_MODIFIER", 4, 9], ["protein content", "OBSERVATION", 10, 25], ["taro corms", "OBSERVATION", 68, 78], ["hypoallergenicity", "OBSERVATION", 100, 117]]], ["Moreover, taro corms are a low-fat and high calorie crop (Maga, 1992; Temesgen & Retta, 2015) .Taro nutrientsThe polypeptide composition of taro corm extracts can change slightly among distinct cultivars, as demonstrated by electrophoresis analyses (Carneiro, Rodrigues, De Castro, Da Silva, & Coutinho, 1990; Hirai, Sato, & Takayanagi, 1989) .", [["taro corms", "ANATOMY", 10, 20], ["extracts", "ANATOMY", 150, 158], ["fat", "TISSUE", 31, 34], ["taro corm extracts", "ORGANISM_SUBSTANCE", 140, 158], ["The polypeptide composition of taro corm extracts", "TREATMENT", 109, 158], ["slightly among distinct cultivars", "PROBLEM", 170, 203], ["electrophoresis analyses", "TEST", 224, 248]]], ["The aqueous extracts prepared from taro corms are mainly composed of four major proteins, classified as albumins (A1 and A2) and globulins (G1 and G2) (Carneiro et al., 1990; Hirai, Nakamura, Imai, & Sato, 1993; Monte-Neshich et al., 1995) .", [["aqueous extracts", "ANATOMY", 4, 20], ["aqueous extracts", "ORGANISM_SUBSTANCE", 4, 20], ["taro corms", "CELL", 35, 45], ["albumins", "GENE_OR_GENE_PRODUCT", 104, 112], ["A1", "GENE_OR_GENE_PRODUCT", 114, 116], ["A2", "GENE_OR_GENE_PRODUCT", 121, 123], ["globulins", "GENE_OR_GENE_PRODUCT", 129, 138], ["albumins", "PROTEIN", 104, 112], ["A1", "PROTEIN", 114, 116], ["A2", "PROTEIN", 121, 123], ["globulins", "PROTEIN", 129, 138], ["albumins", "TEST", 104, 112], ["globulins", "TEST", 129, 138]]], ["Globulins (G1 and G2) are the most abundant, accounting for 80% of total soluble proteins, and are well-characterized in C. esculenta corms .", [["Globulins", "GENE_OR_GENE_PRODUCT", 0, 9], ["C. esculenta", "ORGANISM", 121, 133], ["corms", "ORGANISM", 134, 139], ["soluble proteins", "PROTEIN", 73, 89], ["C. esculenta", "SPECIES", 121, 133], ["C. esculenta", "SPECIES", 121, 133], ["Globulins", "TEST", 0, 9], ["total soluble proteins", "TEST", 67, 89], ["most abundant", "OBSERVATION_MODIFIER", 30, 43], ["esculenta corms", "OBSERVATION", 124, 139]]], ["On the other hand, little information is available about the identification of albumins or their biological properties.", [["albumins", "GENE_OR_GENE_PRODUCT", 79, 87], ["albumins", "PROTEIN", 79, 87]]], ["A1 Albumin is not always found in the aqueous extract, perhaps due to cultivar differences, extraction procedures or corm maturation stage (de Castro et al., 1992) .", [["aqueous extract", "ANATOMY", 38, 53], ["Albumin", "GENE_OR_GENE_PRODUCT", 3, 10], ["aqueous extract", "ORGANISM_SUBSTANCE", 38, 53], ["A1 Albumin", "TEST", 0, 10], ["cultivar differences", "PROBLEM", 70, 90], ["extraction procedures", "TREATMENT", 92, 113], ["corm maturation stage", "PROBLEM", 117, 138], ["Albumin", "OBSERVATION", 3, 10], ["not always", "UNCERTAINTY", 14, 24]]], ["The aqueous extract prepared by our research group did not show the presence of the A1 albumin in any of the two extraction procedures applied ( Figure 1A and B) (Pereira et al., 2014 (Pereira et al., , 2015 .", [["aqueous extract", "ANATOMY", 4, 19], ["aqueous extract", "ORGANISM_SUBSTANCE", 4, 19], ["A1 albumin", "GENE_OR_GENE_PRODUCT", 84, 94], ["A1 albumin", "PROTEIN", 84, 94], ["the A1 albumin", "TREATMENT", 80, 94], ["the two extraction procedures", "TREATMENT", 105, 134]]], ["The A1 albumin has been purified and characterized, revealing that it accounts for 11% of total soluble proteins and that its expression decreases along corm development (Carneiro et al., 1990) .", [["A1 albumin", "GENE_OR_GENE_PRODUCT", 4, 14], ["A1 albumin", "PROTEIN", 4, 14], ["soluble proteins", "PROTEIN", 96, 112], ["The A1 albumin", "TEST", 0, 14], ["total soluble proteins", "TREATMENT", 90, 112], ["expression", "OBSERVATION_MODIFIER", 126, 136], ["decreases", "OBSERVATION_MODIFIER", 137, 146]]], ["This protein, termed colocasin, is composed of six 8.3 kDa homogeneous monomers, which are held together to form a 50 kDa hexamer with an isoelectric point (pI) ranging from 5.3 to 6.1.", [["colocasin", "GENE_OR_GENE_PRODUCT", 21, 30], ["colocasin", "PROTEIN", 21, 30], ["8.3 kDa homogeneous monomers", "PROTEIN", 51, 79], ["50 kDa hexamer", "PROTEIN", 115, 129], ["This protein", "TEST", 0, 12], ["six 8.3 kDa homogeneous monomers", "TREATMENT", 47, 79], ["an isoelectric point", "TEST", 135, 155]]], ["A2 albumin exhibits an apparent molecular mass of about 55 to 60 kDa,with pI varying from 5.5 to 6.0.", [["albumin", "GENE_OR_GENE_PRODUCT", 3, 10], ["A2 albumin", "PROTEIN", 0, 10], ["A2 albumin", "TEST", 0, 10], ["an apparent molecular mass", "PROBLEM", 20, 46], ["pI", "TEST", 74, 76], ["apparent", "OBSERVATION_MODIFIER", 23, 31], ["molecular", "OBSERVATION_MODIFIER", 32, 41], ["mass", "OBSERVATION", 42, 46], ["55 to 60 kDa", "OBSERVATION_MODIFIER", 56, 68], ["varying", "OBSERVATION_MODIFIER", 77, 84]]], ["This albumin accumulates in the first two stages of corm development, decreasing in the last 3 stages (de Castro et al., 1992) .Taro nutrientsG2 Globulins are composed of two polypeptide bands of about 24 kDa (G2a) and 22 kDa (G2b), with pI of 7.5.", [["corm", "ANATOMY", 52, 56], ["albumin", "GENE_OR_GENE_PRODUCT", 5, 12], ["corm", "CANCER", 52, 56], ["albumin", "PROTEIN", 5, 12], ["G2 Globulins", "PROTEIN", 142, 154], ["polypeptide bands", "PROTEIN", 175, 192], ["G2a", "PROTEIN", 210, 213], ["22 kDa", "PROTEIN", 219, 225], ["G2b", "PROTEIN", 227, 230], ["This albumin", "TEST", 0, 12], ["G2 Globulins", "TREATMENT", 142, 154], ["two polypeptide bands", "PROBLEM", 171, 192], ["pI", "TEST", 238, 240], ["corm", "OBSERVATION_MODIFIER", 52, 56], ["development", "OBSERVATION_MODIFIER", 57, 68], ["decreasing", "OBSERVATION_MODIFIER", 70, 80]]], ["These globulins account for approximately 40% of total soluble proteins and have a native molecular mass of 50 kDa, indicating that they occur as a heterodimer (de Castro et al., 1992; Hirai et al., 1993; Monte-Neshich et al., 1995; Shewry, 2003) .", [["globulins", "GENE_OR_GENE_PRODUCT", 6, 15], ["globulins", "PROTEIN", 6, 15], ["soluble proteins", "PROTEIN", 55, 71], ["These globulins", "TEST", 0, 15], ["total soluble proteins", "TEST", 49, 71], ["a native molecular mass", "PROBLEM", 81, 104], ["globulins", "OBSERVATION", 6, 15], ["mass", "OBSERVATION", 100, 104], ["50 kDa", "OBSERVATION_MODIFIER", 108, 114]]], ["Additionally, de Castro et al. (1992) found that there is no amino acid homology among the N-terminal chains of the two globulin families (G1 and G2), indicating that they might be encoded by distinct genes.", [["amino acid", "CHEMICAL", 61, 71], ["amino acid", "CHEMICAL", 61, 71], ["N", "CHEMICAL", 91, 92], ["amino acid", "AMINO_ACID", 61, 71], ["globulin", "GENE_OR_GENE_PRODUCT", 120, 128], ["N-terminal chains", "PROTEIN", 91, 108], ["globulin families", "PROTEIN", 120, 137], ["G2", "PROTEIN", 146, 148], ["amino acid homology", "PROBLEM", 61, 80], ["no", "UNCERTAINTY", 58, 60]]], ["The amino acid sequencing of the G2 polypeptide indicates that it is homologous to the trypsin inhibitor family members found in soybeans, winged beans, sweet potato and barley (Hirai et al., 1993) .Taro nutrientsThe G1 globulin, which accounts for 40% of total soluble proteins, was identified as a lectin, named tarin, from C. esculenta (Van Damme et al., 1995) .", [["beans", "ANATOMY", 146, 151], ["amino acid", "CHEMICAL", 4, 14], ["G1 globulin", "CHEMICAL", 217, 228], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["trypsin", "GENE_OR_GENE_PRODUCT", 87, 94], ["soybeans", "ORGANISM_SUBDIVISION", 129, 137], ["beans", "ORGANISM_SUBDIVISION", 146, 151], ["sweet potato", "ORGANISM", 153, 165], ["barley", "ORGANISM_SUBDIVISION", 170, 176], ["G1 globulin", "GENE_OR_GENE_PRODUCT", 217, 228], ["lectin", "GENE_OR_GENE_PRODUCT", 300, 306], ["tarin", "GENE_OR_GENE_PRODUCT", 314, 319], ["C. esculenta", "ORGANISM", 326, 338], ["G2 polypeptide", "PROTEIN", 33, 47], ["trypsin inhibitor family members", "PROTEIN", 87, 119], ["G1 globulin", "PROTEIN", 217, 228], ["soluble proteins", "PROTEIN", 262, 278], ["lectin", "PROTEIN", 300, 306], ["tarin", "PROTEIN", 314, 319], ["soybeans", "SPECIES", 129, 137], ["beans", "SPECIES", 146, 151], ["potato", "SPECIES", 159, 165], ["barley", "SPECIES", 170, 176], ["C. esculenta", "SPECIES", 326, 338], ["soybeans", "SPECIES", 129, 137], ["sweet potato", "SPECIES", 153, 165], ["barley", "SPECIES", 170, 176], ["C. esculenta", "SPECIES", 326, 338], ["The amino acid sequencing", "TEST", 0, 25], ["the G2 polypeptide", "TREATMENT", 29, 47], ["The G1 globulin", "TREATMENT", 213, 228], ["total soluble proteins", "TEST", 256, 278], ["a lectin", "TEST", 298, 306], ["G1 globulin", "OBSERVATION", 217, 228]]], ["This taro lectin exhibits remarkable biological properties, such as in vitro and in vivo antimetastatic and mitogenic activities and in vitro antitumoral, insecticidal and antiviral activities, making tarin a promising candidate as a future biopharmaceutical molecule (Table 1 and Figure 2 , dashed green lines).", [["taro", "CHEMICAL", 5, 9], ["taro lectin", "GENE_OR_GENE_PRODUCT", 5, 16], ["antitumoral", "CANCER", 142, 153], ["tarin", "SIMPLE_CHEMICAL", 201, 206], ["green lines", "CELL", 299, 310], ["taro lectin", "PROTEIN", 5, 16], ["vitro", "TREATMENT", 71, 76], ["vivo antimetastatic", "TREATMENT", 84, 103], ["mitogenic activities", "TREATMENT", 108, 128], ["vitro antitumoral", "TREATMENT", 136, 153], ["antiviral activities", "TREATMENT", 172, 192], ["remarkable", "OBSERVATION_MODIFIER", 26, 36], ["biological properties", "OBSERVATION", 37, 58]]], ["Our research group has successfully purified and fully characterized tarin from C. esculenta using a simple, low-cost and single-step purification technique on an affinity chromatography column (Cibacron Blue 3GA) which released a high purity fraction (>90%) (Pereira et al., 2014 (Pereira et al., , 2015 ( Figure 1A ).Bioactive compounds from taroApart from its nutritional quality, taro consumption goes beyond dietary purposes.", [["Cibacron Blue 3GA", "CHEMICAL", 195, 212], ["taroApart", "CHEMICAL", 344, 353], ["taro", "CHEMICAL", 384, 388], ["tarin", "SIMPLE_CHEMICAL", 69, 74], ["C. esculenta", "ORGANISM", 80, 92], ["Cibacron Blue 3GA", "SIMPLE_CHEMICAL", 195, 212], ["taroApart", "SIMPLE_CHEMICAL", 344, 353], ["taro", "SIMPLE_CHEMICAL", 384, 388], ["C. esculenta", "SPECIES", 80, 92], ["C. esculenta", "SPECIES", 80, 92], ["C. esculenta", "PROBLEM", 80, 92], ["single-step purification technique", "TREATMENT", 122, 156], ["an affinity chromatography column", "TEST", 160, 193]]], ["Since ancient times, taro has been used for medicinal purposes by indigenous populations although some of its applications still require scientific support.", [["taro", "CHEMICAL", 21, 25], ["medicinal purposes", "TREATMENT", 44, 62], ["scientific support", "TREATMENT", 137, 155]]], ["The traditional use of taro comes from popular knowledge, and many parts of the plant (corm, leaf and petiole) are applied for several health disorders such as diabetes mellitus, internal hemorrhages, gastrointestinal diseases, alopecia, body ache, snakebite, anemia, as well as for the stimulation of the immune system in humans (Lim, 2015; Nwauzoma & Dappa, 2013) .", [["leaf", "ANATOMY", 93, 97], ["petiole", "ANATOMY", 102, 109], ["gastrointestinal", "ANATOMY", 201, 217], ["body", "ANATOMY", 238, 242], ["immune system", "ANATOMY", 306, 319], ["diabetes mellitus", "DISEASE", 160, 177], ["internal hemorrhages", "DISEASE", 179, 199], ["gastrointestinal diseases", "DISEASE", 201, 226], ["alopecia", "DISEASE", 228, 236], ["body ache", "DISEASE", 238, 247], ["snakebite", "DISEASE", 249, 258], ["anemia", "DISEASE", 260, 266], ["corm", "ORGANISM_SUBDIVISION", 87, 91], ["leaf", "TISSUE", 93, 97], ["petiole", "ORGAN", 102, 109], ["gastrointestinal", "ORGANISM_SUBDIVISION", 201, 217], ["body", "ORGANISM_SUBDIVISION", 238, 242], ["ache", "ORGANISM_SUBDIVISION", 243, 247], ["humans", "ORGANISM", 323, 329], ["humans", "SPECIES", 323, 329], ["humans", "SPECIES", 323, 329], ["several health disorders", "PROBLEM", 127, 151], ["diabetes mellitus", "PROBLEM", 160, 177], ["internal hemorrhages", "PROBLEM", 179, 199], ["gastrointestinal diseases", "PROBLEM", 201, 226], ["alopecia", "PROBLEM", 228, 236], ["body ache", "PROBLEM", 238, 247], ["snakebite", "PROBLEM", 249, 258], ["anemia", "PROBLEM", 260, 266], ["internal", "OBSERVATION_MODIFIER", 179, 187], ["hemorrhages", "OBSERVATION", 188, 199], ["gastrointestinal", "ANATOMY", 201, 217], ["diseases", "OBSERVATION", 218, 226], ["anemia", "OBSERVATION", 260, 266]]], ["Taro leaf extracts have shown no in vitro toxicity against BHK-21 fibroblast cells, which are found in the pulp, periodontal ligament and gingiva, enabling them to be included as a natural biocide in the formulation of a commercial mouthwash (L'Angelica collutorio -product registered in Italy under the number GTIN/EAN:8017331000069) (Meilena, 2017) .", [["leaf extracts", "ANATOMY", 5, 18], ["BHK-21 fibroblast cells", "ANATOMY", 59, 82], ["pulp", "ANATOMY", 107, 111], ["periodontal ligament", "ANATOMY", 113, 133], ["gingiva", "ANATOMY", 138, 145], ["toxicity", "DISEASE", 42, 50], ["Taro leaf extracts", "ORGANISM_SUBSTANCE", 0, 18], ["BHK-21 fibroblast cells", "CELL", 59, 82], ["pulp", "TISSUE", 107, 111], ["periodontal ligament", "TISSUE", 113, 133], ["gingiva", "ORGAN", 138, 145], ["BHK-21 fibroblast cells", "CELL_LINE", 59, 82], ["BHK-21", "SPECIES", 59, 65], ["Taro leaf extracts", "TEST", 0, 18], ["vitro toxicity", "PROBLEM", 36, 50], ["BHK", "TEST", 59, 62], ["21 fibroblast cells", "PROBLEM", 63, 82], ["a natural biocide", "TREATMENT", 179, 196], ["a commercial mouthwash", "TREATMENT", 219, 241], ["no in", "UNCERTAINTY", 30, 35], ["fibroblast cells", "OBSERVATION", 66, 82], ["pulp", "ANATOMY", 107, 111], ["periodontal ligament", "ANATOMY", 113, 133], ["gingiva", "ANATOMY", 138, 145]]], ["Taro corm powder is marketed worldwide as a food supplement and ingredient.", [["Taro corm powder", "TREATMENT", 0, 16]]], ["The medicinal utilization of taro plant-derivatives supports the presence of pharmacologically active molecules, which is in accordance with scientific reports.", [["taro plant-derivatives", "SIMPLE_CHEMICAL", 29, 51], ["taro plant-derivatives", "TREATMENT", 29, 51], ["pharmacologically active molecules", "PROBLEM", 77, 111], ["pharmacologically", "OBSERVATION_MODIFIER", 77, 94], ["active", "OBSERVATION_MODIFIER", 95, 101], ["molecules", "OBSERVATION", 102, 111]]], ["A wide variety of bioactive compounds can be extracted from taro, including organic acids, phenolic compounds, anthocyanins, tannins, sterols, phytocystatin, alkaloids, saponins, terpenes, and bioactive proteins (Ferreres et al., 2012; Lim, 2015; Reyad-ul-Ferdous et al., 2015) .", [["taro", "CHEMICAL", 60, 64], ["phenolic compounds, anthocyanins, tannins, sterols, phytocystatin, alkaloids, saponins, terpenes", "CHEMICAL", 91, 187], ["phenolic", "CHEMICAL", 91, 99], ["anthocyanins", "CHEMICAL", 111, 123], ["tannins", "CHEMICAL", 125, 132], ["sterols", "CHEMICAL", 134, 141], ["phytocystatin", "CHEMICAL", 143, 156], ["saponins", "CHEMICAL", 169, 177], ["terpenes", "CHEMICAL", 179, 187], ["taro", "SIMPLE_CHEMICAL", 60, 64], ["organic acids", "SIMPLE_CHEMICAL", 76, 89], ["phenolic compounds", "SIMPLE_CHEMICAL", 91, 109], ["anthocyanins", "SIMPLE_CHEMICAL", 111, 123], ["tannins", "SIMPLE_CHEMICAL", 125, 132], ["sterols", "SIMPLE_CHEMICAL", 134, 141], ["phytocystatin", "SIMPLE_CHEMICAL", 143, 156], ["alkaloids", "SIMPLE_CHEMICAL", 158, 167], ["saponins", "SIMPLE_CHEMICAL", 169, 177], ["terpenes", "SIMPLE_CHEMICAL", 179, 187], ["A wide variety of bioactive compounds", "PROBLEM", 0, 37], ["organic acids", "TEST", 76, 89], ["phenolic compounds", "TEST", 91, 109], ["anthocyanins", "TREATMENT", 111, 123], ["alkaloids", "TREATMENT", 158, 167], ["saponins", "TREATMENT", 169, 177], ["terpenes", "TREATMENT", 179, 187], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14], ["bioactive compounds", "OBSERVATION", 18, 37]]], ["Such a set of bioactive molecules exhibits interesting pharmacological properties, based on in vitro and/or in vivo experiments in mice, consistent with some of their popular uses.", [["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135]]], ["Taro corm and leaf extracts have been reported as antitumoral/antimetastatic (Brown et al., 2005; Kundu et al., 2012) , antihyperlipidemic/antihypercholesterolemic (Sakano et al., 2005) , anxiolytic (Kalariya, Parmar, & Sheth, 2010) , wound healing (Gon\u00e7alves et al., 2013) , antimelanogenic (Kim, Moon, Kim, & Lee, 2010) , anti-inflammatory (Biren, Nayak, Bhatt, Jalalpure, & Seth, 2007) , probiotic (Brown & Valiere, 2004) , antihypertensive (Vasant et al., 2012) , antidiabetic (Eleazu, Iroaganachi, & Eleazu, 2013; Kumawat, Chaudhari, Wani, Deshmukh, & Patil, 2010; H. M. Li, Hwang, Kang, Hong, & Lim, 2014) , antioxidant (Lee, Wee, Yong, & Syamsumir, 2011) , hepatoprotective (Chinonyelum, Uwadiegwu, Nwachukwu, & Emmanuel, 2015; Patil & Ageely, 2011) , antimicrobial (Dhanraj, Kadam, Patil, & Mane, 2013) , anthelmintic (Kubde, Khadabadi, Farooqui, & Deore, 2010) , mitogenic (Pereira et al., 2014 (Pereira et al., , 2015 Tulin & Ecleo, 2007) , hypolipidemic (Boban, Nambisan, & Sudhakaran, 2006) , insecticidal (Rajashekar, Tonsing, Shantibala, & Manjunath, 2016) and antiviral (Keyaerts et al., 2007) .", [["leaf extracts", "ANATOMY", 14, 27], ["wound", "ANATOMY", 235, 240], ["leaf extracts", "ORGANISM_SUBSTANCE", 14, 27], ["antitumoral", "CANCER", 50, 61], ["wound", "PATHOLOGICAL_FORMATION", 235, 240], ["Eleazu", "SIMPLE_CHEMICAL", 482, 488], ["antitumoral/antimetastatic", "TREATMENT", 50, 76], ["antihyperlipidemic", "TREATMENT", 120, 138], ["antihypercholesterolemic", "TREATMENT", 139, 163], ["anxiolytic", "TREATMENT", 188, 198], ["wound healing", "PROBLEM", 235, 248], ["anti-inflammatory", "TEST", 324, 341], ["Biren", "TEST", 343, 348], ["Nayak", "TEST", 350, 355], ["Bhatt", "TEST", 357, 362], ["Jalalpure", "TEST", 364, 373], ["antihypertensive", "TREATMENT", 427, 443], ["antidiabetic", "TREATMENT", 468, 480], ["hypolipidemic", "TEST", 951, 964], ["Nambisan", "TREATMENT", 973, 981], ["antiviral", "TREATMENT", 1075, 1084], ["leaf", "ANATOMY", 14, 18], ["wound", "ANATOMY", 235, 240], ["healing", "OBSERVATION", 241, 248]]], ["The biological properties attributed to taro corm extracts, the focus of this review, is displayed in Figure 2 (gray circles) alongside the activities reported for the lectin from taro corms, tarin (dashed green lines).Bioactive compounds from taroTarin -physicochemical and structural characterization.", [["extracts", "ANATOMY", 50, 58], ["taroTarin", "CHEMICAL", 244, 253], ["lectin", "GENE_OR_GENE_PRODUCT", 168, 174], ["tarin", "SIMPLE_CHEMICAL", 192, 197], ["green lines", "CELL", 206, 217], ["taroTarin", "SIMPLE_CHEMICAL", 244, 253], ["lectin", "PROTEIN", 168, 174], ["tarin (dashed green lines", "CELL_LINE", 192, 217], ["structural characterization", "TEST", 275, 302]]], ["Due to its structural and functional similarities with Galanthus nivalis agglutinin, tarin was included within the GNA-related lectins family, previously termed the monocot mannose-binding family.", [["mannose", "CHEMICAL", 173, 180], ["Galanthus nivalis agglutinin", "ORGANISM", 55, 83], ["tarin", "GENE_OR_GENE_PRODUCT", 85, 90], ["lectins", "GENE_OR_GENE_PRODUCT", 127, 134], ["Galanthus nivalis agglutinin", "PROTEIN", 55, 83], ["GNA", "PROTEIN", 115, 118], ["lectins family", "PROTEIN", 127, 141], ["monocot mannose-binding family", "PROTEIN", 165, 195], ["Galanthus nivalis", "SPECIES", 55, 72], ["Galanthus nivalis", "SPECIES", 55, 72], ["Galanthus nivalis agglutinin", "TREATMENT", 55, 83]]], ["The monomers that compose these lectins originate from single-or two-domain protomers.", [["lectins", "GENE_OR_GENE_PRODUCT", 32, 39], ["lectins", "PROTEIN", 32, 39], ["single-or two-domain protomers", "PROTEIN", 55, 85], ["two-domain protomers", "TREATMENT", 65, 85]]], ["In the former group, one protomer generates 1 monomer with exclusive specificity towards mannose, while each two-domain protomer releases two monomers with complex glycan specificity.", [["mannose", "CHEMICAL", 89, 96], ["mannose", "CHEMICAL", 89, 96], ["mannose", "SIMPLE_CHEMICAL", 89, 96]]], ["Each monomer originally possesses up to 3 functional binding sites (subdomains I, II, and III), characterized by the consensus sequence QxDxNxVxY, which exclusively binds mannose/oligomannose, in single-domain lectins, and more complex glycans, including high-mannose and complex N-glycans, in two-domain lectins.", [["oligomannose", "CHEMICAL", 179, 191], ["mannose", "CHEMICAL", 171, 178], ["oligomannose", "CHEMICAL", 179, 191], ["mannose", "CHEMICAL", 260, 267], ["QxDxNxVxY", "SIMPLE_CHEMICAL", 136, 145], ["mannose", "SIMPLE_CHEMICAL", 171, 178], ["oligomannose", "SIMPLE_CHEMICAL", 179, 191], ["mannose", "SIMPLE_CHEMICAL", 260, 267], ["functional binding sites", "PROTEIN", 42, 66], ["subdomains I, II, and III", "PROTEIN", 68, 93], ["QxDxNxVxY", "PROTEIN", 136, 145], ["oligomannose", "PROTEIN", 179, 191], ["single-domain lectins", "PROTEIN", 196, 217], ["complex N-glycans", "PROTEIN", 272, 289], ["two-domain lectins", "PROTEIN", 294, 312], ["the consensus sequence QxDxNxVxY", "TEST", 113, 145], ["single-domain lectins", "TEST", 196, 217], ["high-mannose", "TREATMENT", 255, 267], ["complex N-glycans", "TREATMENT", 272, 289]]], ["The amino acid composition within carbohydrate binding sites for mannose/oligomannosides in single-domain lectins is highly conserved.", [["amino acid", "CHEMICAL", 4, 14], ["mannose", "CHEMICAL", 65, 72], ["oligomannosides", "CHEMICAL", 73, 88], ["amino acid", "CHEMICAL", 4, 14], ["carbohydrate", "CHEMICAL", 34, 46], ["mannose", "CHEMICAL", 65, 72], ["amino acid", "AMINO_ACID", 4, 14], ["mannose", "AMINO_ACID", 65, 72], ["carbohydrate binding sites", "PROTEIN", 34, 60], ["oligomannosides", "PROTEIN", 73, 88], ["single-domain lectins", "PROTEIN", 92, 113], ["The amino acid composition", "TREATMENT", 0, 26], ["carbohydrate binding sites", "TREATMENT", 34, 60], ["mannose/oligomannosides", "TREATMENT", 65, 88], ["single-domain lectins", "TREATMENT", 92, 113]]], ["On the other hand, two-domain lectins exhibit a less conserved amino acid composition in the subdomain regions.", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "AMINO_ACID", 63, 73], ["subdomain regions", "PROTEIN", 93, 110], ["a less conserved amino acid composition in the subdomain regions", "PROBLEM", 46, 110], ["amino acid composition", "OBSERVATION", 63, 85], ["subdomain", "ANATOMY_MODIFIER", 93, 102], ["regions", "ANATOMY_MODIFIER", 103, 110]]], ["This group evolved from their single-domain counterparts by inter-domain sequence divergence, generating nonidentical subdomains with a wider and dual specificity towards more complex and longer glycan chains .", [["glycan chains", "PROTEIN", 195, 208], ["inter-domain sequence divergence", "TEST", 60, 92], ["a wider and dual specificity towards more complex and longer glycan chains", "PROBLEM", 134, 208], ["subdomains", "OBSERVATION_MODIFIER", 118, 128], ["wider", "OBSERVATION_MODIFIER", 136, 141], ["glycan chains", "OBSERVATION", 195, 208]]], ["Tarin, the two-domain GNA-related lectin from taro corms, is encoded by the tar1 gene, as a 27 to 28 kDa protomer containing the signal peptide and the linker sequence located between the monomer A and B sequences.", [["Tarin", "GENE_OR_GENE_PRODUCT", 0, 5], ["GNA-related lectin", "GENE_OR_GENE_PRODUCT", 22, 40], ["taro", "GENE_OR_GENE_PRODUCT", 46, 50], ["tar1", "GENE_OR_GENE_PRODUCT", 76, 80], ["B", "GENE_OR_GENE_PRODUCT", 202, 203], ["Tarin", "PROTEIN", 0, 5], ["-domain GNA", "PROTEIN", 14, 25], ["lectin", "PROTEIN", 34, 40], ["taro corms", "PROTEIN", 46, 56], ["tar1 gene", "DNA", 76, 85], ["27 to 28 kDa protomer", "PROTEIN", 92, 113], ["linker sequence", "PROTEIN", 152, 167], ["monomer A and B sequences", "DNA", 188, 213], ["Tarin", "TREATMENT", 0, 5], ["the signal peptide", "TEST", 125, 143], ["the linker sequence", "TEST", 148, 167], ["lectin", "ANATOMY_MODIFIER", 34, 40], ["taro corms", "OBSERVATION", 46, 56]]], ["The signal peptide and linker are removed after posttranslational processing, giving rise to monomer A, with 11.9 kDa, and monomer B, with 12.6 kDa.", [["monomer B", "GENE_OR_GENE_PRODUCT", 123, 132], ["monomer A", "PROTEIN", 93, 102], ["11.9 kDa", "PROTEIN", 109, 117], ["monomer B", "PROTEIN", 123, 132], ["The signal peptide and linker", "TREATMENT", 0, 29], ["posttranslational processing", "PROBLEM", 48, 76], ["linker", "OBSERVATION_MODIFIER", 23, 29], ["12.6 kDa", "OBSERVATION_MODIFIER", 139, 147]]], ["Both monomers are arranged as heterodimers, held together by noncovalent binding, where monomer A is at the N-terminal and monomer B, at the C-terminal (Bezerra et al., 1995; Hirai et al., 1993; Pereira et al., 2015) .", [["N", "CHEMICAL", 108, 109], ["heterodimers", "PROTEIN", 30, 42], ["monomer A", "PROTEIN", 88, 97], ["N-terminal", "PROTEIN", 108, 118], ["monomer B", "PROTEIN", 123, 132], ["monomers", "OBSERVATION", 5, 13]]], ["The heterodimers oligomerize as a heterotetramer, originating the functional structure of tarin, with 47 kDa (Figure 3 ).", [["tarin", "GENE_OR_GENE_PRODUCT", 90, 95], ["heterodimers", "PROTEIN", 4, 16], ["heterotetramer", "PROTEIN", 34, 48], ["tarin", "PROTEIN", 90, 95], ["47 kDa", "PROTEIN", 102, 108], ["The heterodimers oligomerize", "TREATMENT", 0, 28], ["a heterotetramer", "TREATMENT", 32, 48], ["functional", "OBSERVATION_MODIFIER", 66, 76], ["structure", "OBSERVATION_MODIFIER", 77, 86], ["47 kDa", "OBSERVATION_MODIFIER", 102, 108]]], ["The tarin purification performed by our group produced a heterogeneous mixture of, at least, 10 tarin isoforms with similar apparent molecular mass (\u00df12 kDa), but distinct pI ranging from 5.5 to 9.5 and carbohydrate content of 2% to 3% (Pereira et al., 2015) . de Castro et al. (1992) have sequenced the N-terminal of the 4 major tarin isoforms, classifying them as G1a, G1b, G1c, and G1d.", [["carbohydrate", "CHEMICAL", 203, 215], ["N", "CHEMICAL", 304, 305], ["tarin", "GENE_OR_GENE_PRODUCT", 330, 335], ["G1a", "GENE_OR_GENE_PRODUCT", 366, 369], ["G1b", "GENE_OR_GENE_PRODUCT", 371, 374], ["G1c", "GENE_OR_GENE_PRODUCT", 376, 379], ["tarin isoforms", "PROTEIN", 96, 110], ["N-terminal", "PROTEIN", 304, 314], ["4 major tarin isoforms", "PROTEIN", 322, 344], ["G1a", "PROTEIN", 366, 369], ["G1b", "PROTEIN", 371, 374], ["G1c", "PROTEIN", 376, 379], ["G1d", "PROTEIN", 385, 388], ["The tarin purification", "TREATMENT", 0, 22], ["similar apparent molecular mass", "PROBLEM", 116, 147], ["distinct pI", "TEST", 163, 174], ["carbohydrate content", "TEST", 203, 223], ["heterogeneous", "OBSERVATION_MODIFIER", 57, 70], ["molecular", "OBSERVATION_MODIFIER", 133, 142], ["mass", "OBSERVATION", 143, 147], ["distinct", "OBSERVATION_MODIFIER", 163, 171], ["pI", "OBSERVATION_MODIFIER", 172, 174], ["ranging", "OBSERVATION_MODIFIER", 175, 182]]], ["G1a and G1c share 88% identity in amino acid sequence while, G1b and G1d share 96%.", [["amino acid", "CHEMICAL", 34, 44], ["amino acid", "CHEMICAL", 34, 44], ["G1a", "GENE_OR_GENE_PRODUCT", 0, 3], ["G1c", "GENE_OR_GENE_PRODUCT", 8, 11], ["amino acid", "AMINO_ACID", 34, 44], ["G1a", "PROTEIN", 0, 3], ["G1c", "PROTEIN", 8, 11], ["G1b", "PROTEIN", 61, 64], ["G1d", "PROTEIN", 69, 72], ["G1a", "TEST", 0, 3], ["G1c", "TEST", 8, 11], ["amino acid sequence", "TEST", 34, 53], ["G1b", "TEST", 61, 64], ["G1d", "TEST", 69, 72]]], ["The subgroups G1a/c and G1b/d are found at C-terminal and N-terminal, respectively, of the protomer and share 25% identity among the subgroups.Bioactive compounds from taroThe heterogeneity in the lectin purified by our research group was evidenced during the deduction of primary sequence from tarin high-resolution electron density data, where two amino acids, R and Q, share the position 203 at the monomer B, each with 50% occupancy (Figure 3 ) .", [["taro", "CHEMICAL", 168, 172], ["amino acids", "CHEMICAL", 350, 361], ["C", "CHEMICAL", 43, 44], ["N", "CHEMICAL", 58, 59], ["amino acids", "CHEMICAL", 350, 361], ["c", "GENE_OR_GENE_PRODUCT", 18, 19], ["G1b", "GENE_OR_GENE_PRODUCT", 24, 27], ["lectin", "GENE_OR_GENE_PRODUCT", 197, 203], ["amino acids", "AMINO_ACID", 350, 361], ["G1a", "PROTEIN", 14, 17], ["G1b", "PROTEIN", 24, 27], ["C-terminal and N-terminal", "DNA", 43, 68], ["lectin", "PROTEIN", 197, 203], ["R", "PROTEIN", 363, 364], ["Q", "PROTEIN", 369, 370], ["position 203", "PROTEIN", 382, 394], ["monomer B", "PROTEIN", 402, 411], ["The subgroups G1a/c", "TEST", 0, 19], ["G1b", "TEST", 24, 27], ["primary sequence", "TEST", 273, 289], ["two amino acids", "TEST", 346, 361], ["terminal", "ANATOMY_MODIFIER", 45, 53], ["terminal", "ANATOMY_MODIFIER", 60, 68], ["heterogeneity", "OBSERVATION_MODIFIER", 176, 189]]], ["Additionally, a comparison between the 6 available primary sequences of C. esculenta lectin (A5HMM7, R9RL27, Q43418, Q39487, 5J76 A, and 5J76 B, 5D5G A and 5D5G B) revealed that, although they share many similarities, they are not identical, supporting the heterogeneous mixture data found in the purified tarin fraction by our group and other authors (Figure 4) .", [["C. esculenta", "ORGANISM", 72, 84], ["lectin", "ORGANISM", 85, 91], ["C. esculenta lectin", "PROTEIN", 72, 91], ["A5HMM7", "PROTEIN", 93, 99], ["R9RL27", "PROTEIN", 101, 107], ["Q43418", "PROTEIN", 109, 115], ["Q39487", "PROTEIN", 117, 123], ["5J76 A", "PROTEIN", 125, 131], ["5J76 B", "PROTEIN", 137, 143], ["5D5G A", "PROTEIN", 145, 151], ["5D5G B", "PROTEIN", 156, 162], ["C. esculenta", "SPECIES", 72, 84], ["C. esculenta", "SPECIES", 72, 84], ["C. esculenta lectin", "TEST", 72, 91], ["the heterogeneous mixture data", "PROBLEM", 253, 283], ["heterogeneous", "OBSERVATION_MODIFIER", 257, 270]]], ["Except for the last sequence identified by Q43418, the lectin purified by our group is highly identical to the other ones, reaching from 88% to 94% identity, filling the criteria to consider them as distinct isoforms of the same lectin.", [["lectin", "GENE_OR_GENE_PRODUCT", 55, 61], ["lectin", "GENE_OR_GENE_PRODUCT", 229, 235], ["lectin", "PROTEIN", 55, 61], ["lectin", "PROTEIN", 229, 235], ["the last sequence", "TEST", 11, 28]]], ["In fact, evidence indicates that tar1 is a multigene family, which also occurs within other members of the GNA-related lectins as already discussed by our group (Pereira et al., 2015) .Bioactive compounds from taroAs a typical GNA-related lectin, tarin monomers A and B assume the \u03b2-prism II fold of three antiparallel \u03b2-sheets formed by 4 \u03b2-strands each.", [["taro", "CHEMICAL", 210, 214], ["tar1", "GENE_OR_GENE_PRODUCT", 33, 37], ["GNA-related lectins", "GENE_OR_GENE_PRODUCT", 107, 126], ["lectin", "GENE_OR_GENE_PRODUCT", 239, 245], ["tarin", "GENE_OR_GENE_PRODUCT", 247, 252], ["\u03b2-prism II", "GENE_OR_GENE_PRODUCT", 281, 291], ["tar1", "DNA", 33, 37], ["GNA", "PROTEIN", 107, 110], ["lectins", "PROTEIN", 119, 126], ["GNA", "PROTEIN", 227, 230], ["lectin", "PROTEIN", 239, 245], ["tarin monomers A", "PROTEIN", 247, 263], ["B", "PROTEIN", 268, 269], ["\u03b2-prism II", "PROTEIN", 281, 291], ["\u03b2", "PROTEIN", 340, 341]]], ["Both monomers exhibit a hydrophobic core and a disulfide bond contributing to the \u03b2-prism stability.", [["disulfide", "CHEMICAL", 47, 56], ["\u03b2-prism", "SIMPLE_CHEMICAL", 82, 89], ["a hydrophobic core", "PROBLEM", 22, 40], ["a disulfide bond", "TREATMENT", 45, 61], ["monomers", "OBSERVATION", 5, 13], ["hydrophobic core", "OBSERVATION_MODIFIER", 24, 40]]], ["Monomers A (11.9 kDa) and B (12.6 kDa) are held together as a heterodimer by a C-terminal exchange.", [["C", "CHEMICAL", 79, 80], ["B", "PROTEIN", 26, 27], ["heterodimer", "PROTEIN", 62, 73], ["kDa", "TEST", 17, 20], ["B", "TEST", 26, 27], ["a C-terminal exchange", "TREATMENT", 77, 98], ["terminal exchange", "OBSERVATION", 81, 98]]], ["At the C-terminal region, the fourth \u03b2-strand in monomer A molds the \u03b2-sheet in monomer B and vice-versa, characterizing the C-terminal exchanges and stabilizing the heterodimer 2 [A+B].", [["C", "CHEMICAL", 7, 8], ["C", "CHEMICAL", 125, 126], ["C-terminal region", "DNA", 7, 24], ["fourth \u03b2-strand", "PROTEIN", 30, 45], ["\u03b2-sheet", "PROTEIN", 69, 76], ["monomer B", "PROTEIN", 80, 89], ["heterodimer 2", "PROTEIN", 166, 179], ["A+B", "PROTEIN", 181, 184], ["the C-terminal exchanges", "PROBLEM", 121, 145], ["terminal", "ANATOMY_MODIFIER", 9, 17], ["region", "ANATOMY_MODIFIER", 18, 24]]], ["Four monomers (2 heterodimers or 2 [A+B]) oligomerize, giving rise to the tarin native structure, a stable 47 kDa heterotetramer capable of recovering or maintaining its functionality after being exposed to a wide range of pH, from 1 to 11, and high temperatures (Pereira et al., 2015 Vajravijayan, Pletnev, Pletnev, Nandhagopal, & Gunasekaran, 2016) .", [["heterodimers", "PROTEIN", 17, 29], ["tarin native structure", "PROTEIN", 74, 96], ["47 kDa heterotetramer", "PROTEIN", 107, 128], ["Four monomers (2 heterodimers", "TREATMENT", 0, 29], ["oligomerize", "PROBLEM", 42, 53], ["high temperatures", "PROBLEM", 245, 262], ["stable", "OBSERVATION_MODIFIER", 100, 106]]], ["Tarin exhibits one functional binding site per monomer and, consequently, a total of four binding sites in each tetramer.", [["Tarin", "CHEMICAL", 0, 5], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["Tarin", "PROTEIN", 0, 5], ["binding sites", "PROTEIN", 90, 103], ["one", "OBSERVATION_MODIFIER", 15, 18], ["functional binding", "OBSERVATION", 19, 37], ["monomer", "OBSERVATION_MODIFIER", 47, 54]]], ["Since both binding sites (A and B) are not identical, tarin C 2018 Institute of Food Technologists \u00ae Vol.", [["binding sites", "DNA", 11, 24]]], ["Comparison between tarin sequences, available at Natural Center for Biotechnology Information (NCBI) protein data bank https://www.ncbi.nlm.nih.gov/protein/?term=Colocasia+esculenta+lectin, and tarin purified by our group (Pereira et al.) .", [["tarin sequences", "DNA", 19, 34]]], ["Similarities in amino acid sequences are presented in color gradient as follows: dark blue = >80%, light blue >60%, lighter blue >40% and white <40%.The overall identity percentage is represented in the left side of the figure. can bind a wide variety of ligands, including high-mannose and complex N-glycans, which are commonly found in animals.", [["amino acid", "CHEMICAL", 16, 26], ["amino acid", "CHEMICAL", 16, 26], ["mannose", "CHEMICAL", 279, 286], ["amino acid", "AMINO_ACID", 16, 26], ["mannose", "SIMPLE_CHEMICAL", 279, 286], ["N-glycans", "GENE_OR_GENE_PRODUCT", 299, 308], ["amino acid sequences", "TEST", 16, 36], ["color gradient", "TEST", 54, 68], ["dark blue", "TEST", 81, 90], ["light blue", "TEST", 99, 109], ["lighter blue", "TEST", 116, 128], ["high-mannose and complex N-glycans", "PROBLEM", 274, 308], ["amino acid", "OBSERVATION", 16, 26], ["color gradient", "OBSERVATION", 54, 68], ["overall", "OBSERVATION_MODIFIER", 153, 160], ["identity", "OBSERVATION_MODIFIER", 161, 169], ["percentage", "OBSERVATION_MODIFIER", 170, 180], ["left", "ANATOMY_MODIFIER", 203, 207], ["figure", "OBSERVATION", 220, 226]]], ["A closer analysis of tarin binding sites able to complexed to trimannose [Man\u03b1(1,3)Man\u03b1(1,6)Man] revealed that tarin can exhibit different affinities to the same ligand .", [["trimannose", "CHEMICAL", 62, 72], ["Man\u03b1", "CHEMICAL", 74, 78], ["tarin", "CHEMICAL", 111, 116], ["trimannose", "CHEMICAL", 62, 72], ["Man\u03b1(1,3)Man\u03b1(1,6)Man", "CHEMICAL", 74, 95], ["tarin", "CHEMICAL", 111, 116], ["tarin", "GENE_OR_GENE_PRODUCT", 21, 26], ["trimannose", "SIMPLE_CHEMICAL", 62, 72], ["Man\u03b1(1,3)Man\u03b1(1,6)Man", "SIMPLE_CHEMICAL", 74, 95], ["tarin", "SIMPLE_CHEMICAL", 111, 116], ["tarin binding sites", "DNA", 21, 40], ["A closer analysis", "TEST", 0, 17], ["tarin binding sites", "PROBLEM", 21, 40], ["trimannose", "TEST", 62, 72], ["Man\u03b1", "TEST", 74, 78], ["Man\u03b1", "TEST", 83, 87]]], ["Moreover, the interaction with the ligand is not restricted to the conserved domain QxDxNxVxY shared by GNA lectins (Figure 4) .", [["QxDxNxVxY", "GENE_OR_GENE_PRODUCT", 84, 93], ["GNA lectins", "GENE_OR_GENE_PRODUCT", 104, 115], ["QxDxNxVxY", "PROTEIN", 84, 93], ["GNA lectins", "PROTEIN", 104, 115]]], ["Very close to the consensus sequence, comes a sequence of three (NGN) and five (GGKYG) amino acids in monomers A and B, respectively, which forms a loop that connects the \u03b2-strands three and four of two \u03b2-sheets (Figure 4) .", [["amino acids", "CHEMICAL", 87, 98], ["amino acids", "CHEMICAL", 87, 98], ["amino acids", "AMINO_ACID", 87, 98], ["consensus sequence", "DNA", 18, 36], ["NGN", "PROTEIN", 65, 68], ["B", "PROTEIN", 117, 118], ["\u03b2-strands", "PROTEIN", 171, 180], ["\u03b2-sheets", "PROTEIN", 203, 211], ["the consensus sequence", "TEST", 14, 36], ["five (GGKYG) amino acids", "TREATMENT", 74, 98]]], ["The loop sequence takes part in the trimannose interaction, particularly 1,6-terminal mannose, creating an extended binding site area, allowing the protein to accommodate more complex and longer glycan chains .", [["trimannose", "CHEMICAL", 36, 46], ["1,6-terminal mannose", "CHEMICAL", 73, 93], ["trimannose", "CHEMICAL", 36, 46], ["mannose", "CHEMICAL", 86, 93], ["trimannose", "SIMPLE_CHEMICAL", 36, 46], ["1,6-terminal mannose", "SIMPLE_CHEMICAL", 73, 93], ["1,6-terminal mannose", "PROTEIN", 73, 93], ["glycan chains", "PROTEIN", 195, 208], ["The loop sequence", "TREATMENT", 0, 17], ["an extended binding site area", "PROBLEM", 104, 133], ["more complex and longer glycan chains", "PROBLEM", 171, 208], ["loop", "OBSERVATION_MODIFIER", 4, 8]]], ["In fact, tarin binds preferentially complex N-glycans over high mannoses .", [["N", "CHEMICAL", 44, 45], ["tarin", "SIMPLE_CHEMICAL", 9, 14], ["tarin", "PROTEIN", 9, 14]]], ["With a longer loop, monomer B allows a closer binding with the ligand, establishing a superior number of interactions with the trimannose compared to monomer A. A careful comparison of the loop sequence in tarin with the 10 \u03b2-prism II lectins showed that these amino acids are limited by a conserved tyrosine (Y) and tryptophan (W), preserved in all the 11 lectins.", [["trimannose", "CHEMICAL", 127, 137], ["amino acids", "CHEMICAL", 261, 272], ["tyrosine", "CHEMICAL", 300, 308], ["tryptophan", "CHEMICAL", 317, 327], ["trimannose", "CHEMICAL", 127, 137], ["amino acids", "CHEMICAL", 261, 272], ["tyrosine", "CHEMICAL", 300, 308], ["tryptophan", "CHEMICAL", 317, 327], ["trimannose", "SIMPLE_CHEMICAL", 127, 137], ["tarin", "SIMPLE_CHEMICAL", 206, 211], ["amino acids", "AMINO_ACID", 261, 272], ["tyrosine", "AMINO_ACID", 300, 308], ["tryptophan", "AMINO_ACID", 317, 327], ["monomer B", "PROTEIN", 20, 29], ["loop sequence", "PROTEIN", 189, 202], ["\u03b2", "PROTEIN", 224, 225], ["prism II lectins", "PROTEIN", 226, 242], ["a longer loop", "TREATMENT", 5, 18], ["the loop sequence", "TEST", 185, 202], ["prism II lectins", "TEST", 226, 242], ["these amino acids", "TEST", 255, 272], ["tryptophan (W)", "TREATMENT", 317, 331]]], ["The number and amino acid composition in the region between Y and W is highly variable, ranging from three to six amino acids, suggesting an important role of these residues on lectins-fine specificity.", [["amino acid", "CHEMICAL", 15, 25], ["amino acids", "CHEMICAL", 114, 125], ["amino acid", "CHEMICAL", 15, 25], ["amino acids", "CHEMICAL", 114, 125], ["amino acid", "AMINO_ACID", 15, 25], ["amino acids", "AMINO_ACID", 114, 125], ["lectins", "GENE_OR_GENE_PRODUCT", 177, 184], ["lectins", "PROTEIN", 177, 184], ["The number and amino acid composition", "TREATMENT", 0, 37], ["six amino acids", "TEST", 110, 125], ["amino acid", "OBSERVATION", 15, 25], ["region", "ANATOMY_MODIFIER", 45, 51], ["variable", "OBSERVATION_MODIFIER", 78, 86]]], ["The loop conformation also contributes to tarin specificity, since it assumes a flat conformation expanding the surface area contact, which is two amino acids longer in the monomer B. In classical mannose-binding lectins like concanavalin A and the GNA family, the loop does not assume a flat conformation but it folds like a pocket, sandwiching the ligand and limiting their binding to less complex glycans with short chains, such as trimannose .", [["surface area", "ANATOMY", 112, 124], ["amino acids", "CHEMICAL", 147, 158], ["trimannose", "CHEMICAL", 435, 445], ["amino acids", "CHEMICAL", 147, 158], ["mannose", "CHEMICAL", 197, 204], ["trimannose", "CHEMICAL", 435, 445], ["tarin", "SIMPLE_CHEMICAL", 42, 47], ["amino acids", "AMINO_ACID", 147, 158], ["mannose-binding lectins", "GENE_OR_GENE_PRODUCT", 197, 220], ["concanavalin A", "GENE_OR_GENE_PRODUCT", 226, 240], ["trimannose", "SIMPLE_CHEMICAL", 435, 445], ["classical mannose-binding lectins", "PROTEIN", 187, 220], ["concanavalin A", "PROTEIN", 226, 240], ["GNA family", "PROTEIN", 249, 259], ["The loop conformation", "PROBLEM", 0, 21], ["a flat conformation", "PROBLEM", 78, 97], ["two amino acids", "TREATMENT", 143, 158], ["a flat conformation", "PROBLEM", 286, 305], ["a pocket", "PROBLEM", 324, 332], ["loop conformation", "OBSERVATION", 4, 21], ["flat", "OBSERVATION_MODIFIER", 80, 84], ["surface", "OBSERVATION_MODIFIER", 112, 119], ["area", "OBSERVATION_MODIFIER", 120, 124], ["pocket", "OBSERVATION", 326, 332], ["short chains", "OBSERVATION_MODIFIER", 413, 425]]], ["Some particularities exclusively found in tarin structure were evidenced by our research group .", [["Some particularities", "PROBLEM", 0, 20]]], ["Tarin crystallized as a unique octamer due to the dimerization of monomers A from two tetramers, forming a circle of eight monomers into the asymmetric unit.", [["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["Tarin", "PROTEIN", 0, 5], ["monomers A", "PROTEIN", 66, 76], ["tetramers", "PROTEIN", 86, 95], ["a unique octamer", "TREATMENT", 22, 38], ["asymmetric", "OBSERVATION_MODIFIER", 141, 151]]], ["Four hydrogen bonds and two salt bridges were found in the interface, which we believe to be a crystallographic artifact.", [["hydrogen", "CHEMICAL", 5, 13], ["salt bridges", "SIMPLE_CHEMICAL", 28, 40], ["Four hydrogen bonds", "TREATMENT", 0, 19], ["two salt bridges", "TREATMENT", 24, 40], ["a crystallographic artifact", "PROBLEM", 93, 120], ["hydrogen bonds", "OBSERVATION", 5, 19], ["two", "OBSERVATION_MODIFIER", 24, 27], ["salt bridges", "OBSERVATION", 28, 40], ["crystallographic artifact", "OBSERVATION", 95, 120]]], ["Similarly, tarin structure bound to trimannose also oligomerizes as an octamer, but now, two octamers were found into the asymmetric unit.", [["trimannose", "CHEMICAL", 36, 46], ["trimannose", "CHEMICAL", 36, 46], ["trimannose", "SIMPLE_CHEMICAL", 36, 46], ["tarin structure", "PROTEIN", 11, 26], ["trimannose", "PROTEIN", 36, 46], ["octamer", "DNA", 71, 78], ["octamers", "PROTEIN", 93, 101], ["asymmetric", "OBSERVATION_MODIFIER", 122, 132]]], ["Although not relevant to the biological activity of tarin, the octamer formation contributes to trimannose binding to monomer A, sandwiching the ligand with the participation of amino acids from the adjacent monomer A and giving rise to a highly stable octamer organization (unpublished data).Tarin-biological and therapeutic propertiesIt is well known that GNA-related lectins are important molecules with broad therapeutic applications.", [["tarin", "CHEMICAL", 52, 57], ["trimannose", "CHEMICAL", 96, 106], ["amino acids", "CHEMICAL", 178, 189], ["tarin", "CHEMICAL", 52, 57], ["trimannose", "CHEMICAL", 96, 106], ["amino acids", "CHEMICAL", 178, 189], ["tarin", "SIMPLE_CHEMICAL", 52, 57], ["trimannose", "SIMPLE_CHEMICAL", 96, 106], ["monomer A", "SIMPLE_CHEMICAL", 118, 127], ["amino acids", "AMINO_ACID", 178, 189], ["GNA-related lectins", "GENE_OR_GENE_PRODUCT", 358, 377], ["octamer", "DNA", 63, 70], ["adjacent monomer A", "PROTEIN", 199, 217], ["the octamer formation", "PROBLEM", 59, 80], ["trimannose binding", "PROBLEM", 96, 114], ["amino acids", "TREATMENT", 178, 189], ["Tarin-biological", "TREATMENT", 293, 309], ["therapeutic properties", "TREATMENT", 314, 336], ["GNA-related lectins", "PROBLEM", 358, 377], ["broad therapeutic applications", "TREATMENT", 407, 437], ["stable", "OBSERVATION_MODIFIER", 246, 252], ["therapeutic properties", "OBSERVATION_MODIFIER", 314, 336]]], ["The lectins belonging to the GNA family are especially known for their antitumoral, antiviral and biocide activities, among others, no less important, biological activities (C.-y.", [["GNA", "GENE_OR_GENE_PRODUCT", 29, 32], ["antitumoral", "CANCER", 71, 82], ["lectins", "PROTEIN", 4, 11], ["GNA family", "PROTEIN", 29, 39], ["antiviral and biocide activities", "TREATMENT", 84, 116]]], ["Li, Meng, Liu, & Bao, 2009; Van Damme, 2008; Wu & Bao, 2013) .", [["Li", "CHEMICAL", 0, 2]]], ["The bioactivities of lectins are strictly related to their glycan specificity, which were evidenced by the glycan array screening for tarin ligand profiling (Pereira et al., 2015) .", [["lectins", "GENE_OR_GENE_PRODUCT", 21, 28], ["the glycan array screening", "TEST", 103, 129]]], ["Tarin exhibits specificity towards glycan chains that make part of many cell surface antigens including cancer cells, viruses, insect cells and also hematopoietic cells, providing the molecular basis that might explain its broad bioactivities (Table 1) .", [["cell surface", "ANATOMY", 72, 84], ["cancer cells", "ANATOMY", 104, 116], ["cells", "ANATOMY", 134, 139], ["hematopoietic cells", "ANATOMY", 149, 168], ["Tarin", "CHEMICAL", 0, 5], ["cancer", "DISEASE", 104, 110], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 72, 76], ["cancer cells", "CELL", 104, 116], ["insect cells", "CELL", 127, 139], ["hematopoietic cells", "CELL", 149, 168], ["glycan chains", "PROTEIN", 35, 48], ["cell surface antigens", "PROTEIN", 72, 93], ["cancer cells", "CELL_TYPE", 104, 116], ["insect cells", "CELL_TYPE", 127, 139], ["hematopoietic cells", "CELL_TYPE", 149, 168], ["glycan chains", "PROBLEM", 35, 48], ["many cell surface antigens", "PROBLEM", 67, 93], ["cancer cells", "PROBLEM", 104, 116], ["viruses", "PROBLEM", 118, 125], ["insect cells", "PROBLEM", 127, 139], ["hematopoietic cells", "PROBLEM", 149, 168], ["cancer cells", "OBSERVATION", 104, 116], ["insect cells", "OBSERVATION", 127, 139], ["hematopoietic cells", "OBSERVATION", 149, 168]]], ["Distinct protein purification procedures adopted by researchers have evidenced tarin's multiple bioactivities (Table 1) .Tarin-biological and therapeutic propertiesBiocide activity.", [["tarin", "SIMPLE_CHEMICAL", 79, 84], ["Biocide", "SIMPLE_CHEMICAL", 164, 171], ["Distinct protein purification procedures", "TREATMENT", 0, 40], ["protein", "OBSERVATION", 9, 16], ["purification procedures", "OBSERVATION", 17, 40]]], ["Most plant lectins bind foreign glycans, typical constituents of insect, microorganism and vertebrate membranes, making these molecules an essential part of the defense mechanism of plants ( Van Damme, 2008) .", [["membranes", "ANATOMY", 102, 111], ["vertebrate membranes", "CELLULAR_COMPONENT", 91, 111], ["microorganism and vertebrate membranes", "PROBLEM", 73, 111], ["lectins bind", "OBSERVATION_MODIFIER", 11, 23], ["foreign glycans", "OBSERVATION", 24, 39], ["vertebrate membranes", "OBSERVATION", 91, 111]]], ["N-glycans classified as paucimannose (trimannosides) and high-mannose representatives of over 90% of these glycan group to which tarin is able to bind (Pereira et al., 2015; Walski, De Schutter, Van Damme, & Smagghe, 2017) .", [["paucimannose", "CHEMICAL", 24, 36], ["trimannosides", "CHEMICAL", 38, 51], ["paucimannose", "CHEMICAL", 24, 36], ["trimannosides", "CHEMICAL", 38, 51], ["mannose", "CHEMICAL", 62, 69], ["N-glycans", "GENE_OR_GENE_PRODUCT", 0, 9], ["paucimannose", "SIMPLE_CHEMICAL", 24, 36], ["trimannosides", "SIMPLE_CHEMICAL", 38, 51], ["tarin", "SIMPLE_CHEMICAL", 129, 134], ["trimannosides", "TEST", 38, 51]]], ["This binding specificity can be extended to the other lectins from the GNA-related family, which exhibit high insecticidal activity due to their high specificity towards complex and high-mannose N-glycans, the main ligands abundantly found along the intestinal tract of insects and superior animals.", [["intestinal tract", "ANATOMY", 250, 266], ["mannose", "CHEMICAL", 187, 194], ["intestinal tract", "ORGANISM_SUBDIVISION", 250, 266], ["GNA-related family", "PROTEIN", 71, 89], ["high insecticidal activity", "PROBLEM", 105, 131], ["intestinal tract", "ANATOMY", 250, 266]]], ["The insecticidal effects exerted by lectin molecules are of great importance in the development of tools to promote crop protection against pests (Macedo, Oliveira, & Oliveira, 2015) .", [["lectin molecules", "GENE_OR_GENE_PRODUCT", 36, 52], ["lectin molecules", "PROTEIN", 36, 52]]], ["The bio pesticide activity of tarin has been extensively reported in the literature (Table 1) and endorsed by our group (Pereira et al., 2015) .", [["tarin", "CHEMICAL", 30, 35], ["tarin", "CHEMICAL", 30, 35], ["tarin", "SIMPLE_CHEMICAL", 30, 35]]], ["We have demonstrated that tarin displays ligand-specificity toward highmannose N-glycans number 477 [Man\u03b11-6(Man\u03b11-3)Man\u03b21-4GlcNAc\u03b21-4(Fuc\u03b11-6)GlcNAc\u03b2] and number 49 [Man\u03b11-3(Man\u03b11-6)Man\u03b21-4GlcNAc\u03b21-4GlcNAc\u03b2], found in insect and nematode cell membranes (Pereira et al., 2015; Walski et al., 2017) .", [["cell membranes", "ANATOMY", 239, 253], ["tarin", "CHEMICAL", 26, 31], ["tarin", "SIMPLE_CHEMICAL", 26, 31], ["highmannose", "SIMPLE_CHEMICAL", 67, 78], ["Man\u03b21-4GlcNAc\u03b21-4", "GENE_OR_GENE_PRODUCT", 117, 134], ["Fuc\u03b11-6)GlcNAc\u03b2", "GENE_OR_GENE_PRODUCT", 135, 150], ["Man\u03b11-3", "GENE_OR_GENE_PRODUCT", 167, 174], ["Man\u03b11-6)Man\u03b21-4GlcNAc\u03b21-4GlcNAc\u03b2", "GENE_OR_GENE_PRODUCT", 175, 207], ["nematode cell", "CELL", 230, 243], ["membranes", "CELLULAR_COMPONENT", 244, 253], ["Man\u03b21", "PROTEIN", 117, 122], ["4GlcNAc\u03b21", "PROTEIN", 123, 132], ["GlcNAc\u03b2", "PROTEIN", 143, 150], ["Man\u03b21", "PROTEIN", 183, 188], ["4GlcNAc\u03b21", "PROTEIN", 189, 198], ["4GlcNAc\u03b2", "DNA", 199, 207], ["ligand", "TEST", 41, 47], ["highmannose", "TEST", 67, 78], ["Man\u03b11", "TEST", 101, 106], ["Man\u03b1", "TEST", 109, 113], ["Man\u03b21", "TEST", 117, 122], ["4GlcNAc\u03b21", "TEST", 123, 132], ["Fuc\u03b1", "TEST", 135, 139], ["GlcNAc\u03b2", "TEST", 143, 150], ["number", "TEST", 156, 162], ["Man\u03b11", "TEST", 167, 172], ["Man\u03b11", "TEST", 175, 180], ["Man\u03b21", "TEST", 183, 188], ["4GlcNAc\u03b21", "TEST", 189, 198], ["NAc\u03b2", "TEST", 203, 207], ["nematode cell membranes", "OBSERVATION", 230, 253]]], ["Further studies are required to confirm the participation of such glycans on tarin insecticidal properties.", [["tarin", "GENE_OR_GENE_PRODUCT", 77, 82], ["Further studies", "TEST", 0, 15], ["tarin insecticidal properties", "TREATMENT", 77, 106]]], ["Das, Roy, Hess, and Das (2013) and Roy, Gupta, Hess, Das, and Das (2014) , Roy, Banerjee, Majumder, and Das (2002) described the insecticidal activity of tarin against the hemipteran sucking pest red cotton bug (Dysdercus koenigii/cingulatus), cowpea aphid (Aphis craccivora), cotton aphid (Aphis gossypii), white fly (Bemisia tabaci), and mustard aphid (Liphaphis erysimi).", [["tarin", "CHEMICAL", 154, 159], ["tarin", "CHEMICAL", 154, 159], ["tarin", "SIMPLE_CHEMICAL", 154, 159], ["Dysdercus koenigii/cingulatus", "ORGANISM", 212, 241], ["cowpea aphid", "ORGANISM", 244, 256], ["Aphis craccivora", "ORGANISM", 258, 274], ["cotton aphid", "ORGANISM", 277, 289], ["Aphis gossypii", "ORGANISM", 291, 305], ["white fly", "ORGANISM", 308, 317], ["Bemisia tabaci", "ORGANISM", 319, 333], ["mustard aphid", "ORGANISM", 340, 353], ["Liphaphis erysimi", "ORGANISM", 355, 372], ["cotton", "SPECIES", 200, 206], ["Dysdercus koenigii", "SPECIES", 212, 230], ["cingulatus", "SPECIES", 231, 241], ["cowpea", "SPECIES", 244, 250], ["Aphis craccivora", "SPECIES", 258, 274], ["cotton", "SPECIES", 277, 283], ["Aphis gossypii", "SPECIES", 291, 305], ["fly", "SPECIES", 314, 317], ["Bemisia tabaci", "SPECIES", 319, 333], ["mustard", "SPECIES", 340, 347], ["Liphaphis erysimi", "SPECIES", 355, 372], ["red cotton bug", "SPECIES", 196, 210], ["Dysdercus koenigii/cingulatus", "SPECIES", 212, 241], ["cowpea aphid", "SPECIES", 244, 256], ["Aphis craccivora", "SPECIES", 258, 274], ["cotton aphid", "SPECIES", 277, 289], ["Aphis gossypii", "SPECIES", 291, 305], ["white fly", "SPECIES", 308, 317], ["Bemisia tabaci", "SPECIES", 319, 333], ["mustard aphid", "SPECIES", 340, 353], ["Liphaphis erysimi", "SPECIES", 355, 372], ["cotton aphid", "PROBLEM", 277, 289], ["white fly (Bemisia tabaci", "PROBLEM", 308, 333], ["mustard aphid", "PROBLEM", 340, 353], ["mustard aphid", "OBSERVATION", 340, 353]]], ["Tarin, when included in insect diets, can affect insect pupation and emergence and, when in high concentrations, can be lethal to several agricultural pests (Table 1) .", [["Tarin", "CHEMICAL", 0, 5], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["Tarin", "TREATMENT", 0, 5]]], ["Interestingly, the toxic effects of tarin on Dysdercus koenigii/cingulatus were shown to be transferred to the next generation, where nymphs presented almost 50% reduced size/weight and different colors (Roy et al., 2002) .", [["tarin", "CHEMICAL", 36, 41], ["tarin", "CHEMICAL", 36, 41], ["tarin", "SIMPLE_CHEMICAL", 36, 41], ["Dysdercus koenigii/cingulatus", "ORGANISM", 45, 74], ["Dysdercus koenigii", "SPECIES", 45, 63], ["cingulatus", "SPECIES", 64, 74], ["Dysdercus koenigii/cingulatus", "SPECIES", 45, 74], ["Dysdercus koenigii", "TREATMENT", 45, 63], ["toxic", "OBSERVATION_MODIFIER", 19, 24], ["size", "OBSERVATION_MODIFIER", 170, 174]]], ["Studies on tarin-treated B. cucurbitae larvae have demonstrated that lectin was able to induce the insect detoxification system, by increasing esterase and phosphatase activities, as well as the antioxidant defense system by increasing superoxide dismutase (SOD), catalase (CAT) and glutathione-S-transferase (GST) activities (Thakur et al., 2013) .Tarin-biological and therapeutic propertiesThe insecticidal activity of tarin has been elucidated (Roy & Das, 2015; Roy et al., 2014) .", [["tarin", "CHEMICAL", 11, 16], ["superoxide", "CHEMICAL", 236, 246], ["glutathione", "CHEMICAL", 283, 294], ["tarin", "CHEMICAL", 421, 426], ["superoxide", "CHEMICAL", 236, 246], ["glutathione", "CHEMICAL", 283, 294], ["S", "CHEMICAL", 295, 296], ["tarin", "CHEMICAL", 421, 426], ["tarin", "SIMPLE_CHEMICAL", 11, 16], ["B. cucurbitae larvae", "ORGANISM", 25, 45], ["lectin", "GENE_OR_GENE_PRODUCT", 69, 75], ["esterase", "SIMPLE_CHEMICAL", 143, 151], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 236, 256], ["SOD", "SIMPLE_CHEMICAL", 258, 261], ["catalase", "SIMPLE_CHEMICAL", 264, 272], ["CAT", "SIMPLE_CHEMICAL", 274, 277], ["glutathione-S-transferase", "GENE_OR_GENE_PRODUCT", 283, 308], ["GST", "GENE_OR_GENE_PRODUCT", 310, 313], ["tarin", "SIMPLE_CHEMICAL", 421, 426], ["lectin", "PROTEIN", 69, 75], ["esterase", "PROTEIN", 143, 151], ["phosphatase", "PROTEIN", 156, 167], ["superoxide dismutase", "PROTEIN", 236, 256], ["SOD", "PROTEIN", 258, 261], ["catalase", "PROTEIN", 264, 272], ["CAT", "PROTEIN", 274, 277], ["glutathione-S-transferase", "PROTEIN", 283, 308], ["GST", "PROTEIN", 310, 313], ["B. cucurbitae", "SPECIES", 25, 38], ["B. cucurbitae", "SPECIES", 25, 38], ["Studies", "TEST", 0, 7], ["tarin", "TREATMENT", 11, 16], ["increasing esterase and phosphatase activities", "PROBLEM", 132, 178], ["the antioxidant defense system", "TREATMENT", 191, 221], ["increasing superoxide dismutase (SOD)", "TREATMENT", 225, 262], ["catalase (CAT)", "TEST", 264, 278], ["glutathione", "TEST", 283, 294], ["Tarin", "TREATMENT", 349, 354], ["therapeutic properties", "TREATMENT", 370, 392], ["therapeutic properties", "OBSERVATION_MODIFIER", 370, 392], ["insecticidal", "OBSERVATION_MODIFIER", 396, 408], ["activity", "OBSERVATION_MODIFIER", 409, 417]]], ["Tarin is able to bind to the glycan chains on the surface of midgut epithelial cells of Dysdercus koenigii/cingulatus, reaching the hemolymph and ovary, resulting in the aforementioned entomotoxic effects (Roy & Das, 2015) .", [["surface", "ANATOMY", 50, 57], ["midgut epithelial cells", "ANATOMY", 61, 84], ["cingulatus", "ANATOMY", 107, 117], ["hemolymph", "ANATOMY", 132, 141], ["ovary", "ANATOMY", 146, 151], ["Tarin", "GENE_OR_GENE_PRODUCT", 0, 5], ["surface", "CELLULAR_COMPONENT", 50, 57], ["midgut epithelial cells", "CELL", 61, 84], ["Dysdercus koenigii/cingulatus", "ORGANISM", 88, 117], ["hemolymph", "ORGANISM_SUBSTANCE", 132, 141], ["ovary", "ORGAN", 146, 151], ["Tarin", "PROTEIN", 0, 5], ["glycan chains", "PROTEIN", 29, 42], ["midgut epithelial cells", "CELL_TYPE", 61, 84], ["Dysdercus koenigii", "SPECIES", 88, 106], ["Dysdercus koenigii/cingulatus", "SPECIES", 88, 117], ["Tarin", "TREATMENT", 0, 5], ["cingulatus", "TREATMENT", 107, 117], ["midgut", "ANATOMY", 61, 67], ["epithelial cells", "OBSERVATION", 68, 84], ["hemolymph", "ANATOMY", 132, 141], ["ovary", "ANATOMY", 146, 151]]], ["The putative binding partners have been identified: ATP synthase, which is directly involved in the insect growth, loss of fecundity, development and midgut morphology.", [["midgut", "ANATOMY", 150, 156], ["ATP", "CHEMICAL", 52, 55], ["loss of fecundity", "DISEASE", 115, 132], ["ATP", "CHEMICAL", 52, 55], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 52, 64], ["midgut", "ORGAN", 150, 156], ["ATP synthase", "PROTEIN", 52, 64], ["ATP synthase", "TEST", 52, 64], ["loss of fecundity", "PROBLEM", 115, 132], ["midgut morphology", "OBSERVATION_MODIFIER", 150, 167]]], ["Another target for tarin was the cytochrome P450, involved in the detoxification of insecticide molecules causing failure in the insecticide resistance mechanism and making insects vulnerable when its activity decreases in the presence of lectin.", [["tarin", "GENE_OR_GENE_PRODUCT", 19, 24], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 33, 48], ["lectin", "GENE_OR_GENE_PRODUCT", 239, 245], ["cytochrome P450", "PROTEIN", 33, 48], ["lectin", "PROTEIN", 239, 245], ["the cytochrome P450", "TREATMENT", 29, 48], ["insecticide molecules", "PROBLEM", 84, 105], ["failure in the insecticide resistance mechanism", "PROBLEM", 114, 161], ["insecticide resistance", "OBSERVATION", 129, 151]]], ["Additional findings came from studies with Bemisia tabaci and Liphaphis erysimi where some specific tarin binding partners were confirmed and others were revealed in each species (Roy et al., 2014) .", [["Bemisia tabaci", "ORGANISM", 43, 57], ["Liphaphis erysimi", "ORGANISM", 62, 79], ["tarin", "GENE_OR_GENE_PRODUCT", 100, 105], ["Bemisia tabaci", "SPECIES", 43, 57], ["Liphaphis erysimi", "SPECIES", 62, 79], ["Bemisia tabaci", "SPECIES", 43, 57], ["Liphaphis erysimi", "SPECIES", 62, 79], ["Bemisia tabaci", "PROBLEM", 43, 57], ["Liphaphis erysimi", "PROBLEM", 62, 79]]], ["In B. tabaci, tarin binds to ATP synthase and sarcoplasmic endoplasmic reticulum type Ca 2+ ATPase while in L. erysimi, tarin partners are the previously mentioned ATP synthase, but heat shock protein 70 and clathrin heavy chain assemble protein were also included, explaining insect growth and reproduction impairment and mortality enhancement.", [["sarcoplasmic endoplasmic reticulum", "ANATOMY", 46, 80], ["ATP", "CHEMICAL", 29, 32], ["Ca", "CHEMICAL", 86, 88], ["ATP", "CHEMICAL", 164, 167], ["reproduction impairment", "DISEASE", 295, 318], ["ATP", "CHEMICAL", 29, 32], ["Ca 2+", "CHEMICAL", 86, 91], ["ATP", "CHEMICAL", 164, 167], ["B. tabaci", "ORGANISM", 3, 12], ["tarin", "GENE_OR_GENE_PRODUCT", 14, 19], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 29, 41], ["sarcoplasmic endoplasmic reticulum type Ca 2+ ATPase", "GENE_OR_GENE_PRODUCT", 46, 98], ["L. erysimi", "ORGANISM", 108, 118], ["tarin", "GENE_OR_GENE_PRODUCT", 120, 125], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 164, 176], ["heat shock protein 70", "GENE_OR_GENE_PRODUCT", 182, 203], ["clathrin heavy chain", "GENE_OR_GENE_PRODUCT", 208, 228], ["tarin", "PROTEIN", 14, 19], ["ATP synthase", "PROTEIN", 29, 41], ["sarcoplasmic endoplasmic reticulum type Ca 2+ ATPase", "PROTEIN", 46, 98], ["ATP synthase", "PROTEIN", 164, 176], ["heat shock protein 70", "PROTEIN", 182, 203], ["clathrin heavy chain", "PROTEIN", 208, 228], ["B. tabaci", "SPECIES", 3, 12], ["L. erysimi", "SPECIES", 108, 118], ["B. tabaci", "SPECIES", 3, 12], ["L. erysimi", "SPECIES", 108, 118], ["ATP synthase", "TEST", 29, 41], ["sarcoplasmic endoplasmic reticulum type Ca", "TEST", 46, 88], ["ATPase", "PROBLEM", 92, 98], ["ATP synthase", "TEST", 164, 176], ["heat shock protein", "TEST", 182, 200], ["clathrin heavy chain assemble protein", "PROBLEM", 208, 245], ["insect growth", "PROBLEM", 277, 290], ["reproduction impairment", "PROBLEM", 295, 318], ["mortality enhancement", "PROBLEM", 323, 344]]], ["Leal-Bertioli et al. (2003) demonstrated the potential application of tarin for pest management using plant engineering techniques.", [["tarin", "CHEMICAL", 70, 75], ["tarin", "SIMPLE_CHEMICAL", 70, 75], ["tarin", "TREATMENT", 70, 75], ["pest management", "TREATMENT", 80, 95], ["plant engineering techniques", "TREATMENT", 102, 130]]], ["Genetically modified tobacco able to express tarin promoted plant protection against Spodoptera frugiperda larvae and Pseudomonas syringae pv. tomato, which cause severe crop losses.", [["tarin", "CHEMICAL", 45, 50], ["Spodoptera frugiperda larvae", "DISEASE", 85, 113], ["tobacco", "ORGANISM", 21, 28], ["tarin", "GENE_OR_GENE_PRODUCT", 45, 50], ["Spodoptera frugiperda", "ORGANISM", 85, 106], ["larvae", "ORGANISM", 107, 113], ["Pseudomonas syringae", "ORGANISM", 118, 138], ["pv.", "ORGANISM", 139, 142], ["tomato", "ORGANISM", 143, 149], ["tobacco", "SPECIES", 21, 28], ["Spodoptera frugiperda", "SPECIES", 85, 106], ["Pseudomonas syringae pv.", "SPECIES", 118, 142], ["tomato", "SPECIES", 143, 149], ["tobacco", "SPECIES", 21, 28], ["Spodoptera frugiperda", "SPECIES", 85, 106], ["Pseudomonas syringae pv.", "SPECIES", 118, 142], ["tomato", "SPECIES", 143, 149], ["plant protection", "TREATMENT", 60, 76], ["Spodoptera frugiperda larvae", "TREATMENT", 85, 113], ["Pseudomonas syringae pv.", "PROBLEM", 118, 142], ["severe crop losses", "PROBLEM", 163, 181], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["crop losses", "OBSERVATION", 170, 181]]], ["S. frugiperda is a natural predator of a variety of crops, including maize, rice, sorghum, cotton, peanut, soybean and pastures, while P. syringae pv. tomato affects tomato, crucifers and tobacco plantations.", [["maize, rice, sorghum, cotton, peanut, soybean and pastures", "CHEMICAL", 69, 127], ["S. frugiperda", "ORGANISM", 0, 13], ["maize", "ORGANISM_SUBDIVISION", 69, 74], ["rice", "ORGANISM_SUBDIVISION", 76, 80], ["sorghum", "ORGANISM_SUBDIVISION", 82, 89], ["cotton", "ORGANISM_SUBDIVISION", 91, 97], ["peanut", "ORGANISM_SUBDIVISION", 99, 105], ["soybean", "ORGANISM_SUBDIVISION", 107, 114], ["P. syringae pv", "ORGANISM", 135, 149], ["tomato", "ORGANISM", 151, 157], ["tomato", "ORGANISM_SUBDIVISION", 166, 172], ["tobacco", "ORGANISM", 188, 195], ["S. frugiperda", "SPECIES", 0, 13], ["maize", "SPECIES", 69, 74], ["rice", "SPECIES", 76, 80], ["sorghum", "SPECIES", 82, 89], ["cotton", "SPECIES", 91, 97], ["peanut", "SPECIES", 99, 105], ["soybean", "SPECIES", 107, 114], ["P. syringae", "SPECIES", 135, 146], ["tomato", "SPECIES", 151, 157], ["tomato", "SPECIES", 166, 172], ["tobacco", "SPECIES", 188, 195], ["S. frugiperda", "SPECIES", 0, 13], ["maize", "SPECIES", 69, 74], ["rice", "SPECIES", 76, 80], ["sorghum", "SPECIES", 82, 89], ["cotton", "SPECIES", 91, 97], ["soybean", "SPECIES", 107, 114], ["P. syringae", "SPECIES", 135, 146], ["tomato", "SPECIES", 151, 157], ["tomato", "SPECIES", 166, 172], ["tobacco", "SPECIES", 188, 195], ["tobacco plantations", "OBSERVATION", 188, 207]]], ["Tarinengineered plants challenged by these insect infections were able to reduce the survival, average weight, accumulated mass and pupation of S. frugiperda larvae and inhibit the growth of P. syringae pv. tomato.", [["insect infections", "DISEASE", 43, 60], ["insect", "ORGANISM", 43, 49], ["S. frugiperda", "ORGANISM", 144, 157], ["larvae", "ORGANISM", 158, 164], ["P. syringae", "ORGANISM", 191, 202], ["pv.", "ORGANISM", 203, 206], ["tomato", "ORGANISM", 207, 213], ["S. frugiperda", "SPECIES", 144, 157], ["P. syringae pv.", "SPECIES", 191, 206], ["tomato", "SPECIES", 207, 213], ["S. frugiperda", "SPECIES", 144, 157], ["P. syringae pv.", "SPECIES", 191, 206], ["tomato", "SPECIES", 207, 213], ["Tarinengineered plants", "TREATMENT", 0, 22], ["these insect infections", "PROBLEM", 37, 60], ["accumulated mass", "PROBLEM", 111, 127], ["S. frugiperda larvae", "PROBLEM", 144, 164], ["P. syringae pv.", "PROBLEM", 191, 206], ["mass", "OBSERVATION", 123, 127], ["frugiperda larvae", "OBSERVATION", 147, 164]]], ["Antiviral effects.", [["Antiviral effects", "TREATMENT", 0, 17]]], ["Although antiviral activity is widespread among plant lectins, the majority displaying this bioactivity are found within the GNA-related family members, due to their ability to bind complex and high mannose N-glycans, usually found on the viral envelope (Akkouh et al., 2015; Wu & Bao, 2013) .", [["mannose", "CHEMICAL", 199, 206], ["GNA-related family members", "PROTEIN", 125, 151], ["mannose N-glycans", "PROTEIN", 199, 216], ["high mannose N-glycans", "PROBLEM", 194, 216], ["antiviral activity", "OBSERVATION", 9, 27], ["lectins", "OBSERVATION_MODIFIER", 54, 61]]], ["Keyaerts et al. (2007) screened the in vitro antiviral activity of 33 plant lectins, including tarin, against severe acute respiratory syndrome (SARS CoV, Frankfurt 1 strain) and feline infectious peritonitis virus (FIPV, strain 79-1146).", [["tarin", "CHEMICAL", 95, 100], ["acute respiratory syndrome", "DISEASE", 117, 143], ["SARS", "DISEASE", 145, 149], ["feline infectious peritonitis", "DISEASE", 179, 208], ["79-1146", "CHEMICAL", 229, 236], ["tarin", "SIMPLE_CHEMICAL", 95, 100], ["feline infectious peritonitis virus", "ORGANISM", 179, 214], ["feline infectious peritonitis virus", "SPECIES", 179, 214], ["severe acute respiratory syndrome (SARS CoV", "SPECIES", 110, 153], ["feline infectious peritonitis virus", "SPECIES", 179, 214], ["FIPV", "SPECIES", 216, 220], ["tarin", "TREATMENT", 95, 100], ["severe acute respiratory syndrome", "PROBLEM", 110, 143], ["SARS CoV", "PROBLEM", 145, 153], ["Frankfurt 1 strain)", "PROBLEM", 155, 174], ["feline infectious peritonitis virus", "PROBLEM", 179, 214], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["respiratory syndrome", "OBSERVATION", 123, 143], ["infectious", "OBSERVATION_MODIFIER", 186, 196], ["peritonitis", "OBSERVATION", 197, 208]]], ["SARS-CoV affects humans, causing a severe infection in the lower respiratory tract, and its discovery boosted the finding of other human coronaviruses (HCoV-NL63 and HCoV-HKU1).", [["lower respiratory tract", "ANATOMY", 59, 82], ["SARS", "DISEASE", 0, 4], ["infection in the lower respiratory tract", "DISEASE", 42, 82], ["SARS-CoV", "ORGANISM", 0, 8], ["humans", "ORGANISM", 17, 23], ["lower", "ORGANISM_SUBDIVISION", 59, 64], ["respiratory tract", "ORGANISM_SUBDIVISION", 65, 82], ["human", "ORGANISM", 131, 136], ["coronaviruses", "ORGANISM", 137, 150], ["HCoV-NL63", "CELL", 152, 161], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 166, 175], ["HCoV", "PROTEIN", 166, 170], ["HKU1", "PROTEIN", 171, 175], ["humans", "SPECIES", 17, 23], ["human", "SPECIES", 131, 136], ["SARS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 17, 23], ["human coronaviruses", "SPECIES", 131, 150], ["SARS", "PROBLEM", 0, 4], ["a severe infection in the lower respiratory tract", "PROBLEM", 33, 82], ["other human coronaviruses", "PROBLEM", 125, 150], ["HCoV", "TEST", 152, 156], ["CoV affects", "OBSERVATION_MODIFIER", 5, 16], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["infection", "OBSERVATION", 42, 51], ["lower", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82]]], ["FIPV is responsible for chronic peritonitis in cats, a rare and fatal disease with no clinically effective treatment.Tarin-biological and therapeutic propertiesThe in vitro screening results revealed that the antiviral activity was dependent on lectin specificity.", [["FIPV", "CHEMICAL", 0, 4], ["peritonitis", "DISEASE", 32, 43], ["FIPV", "SIMPLE_CHEMICAL", 0, 4], ["cats", "ORGANISM", 47, 51], ["lectin", "GENE_OR_GENE_PRODUCT", 245, 251], ["lectin", "PROTEIN", 245, 251], ["cats", "SPECIES", 47, 51], ["FIPV", "SPECIES", 0, 4], ["FIPV", "PROBLEM", 0, 4], ["chronic peritonitis in cats", "PROBLEM", 24, 51], ["a rare and fatal disease", "PROBLEM", 53, 77], ["therapeutic properties", "TREATMENT", 138, 160], ["The in vitro screening", "TEST", 160, 182], ["the antiviral activity", "PROBLEM", 205, 227], ["lectin specificity", "TEST", 245, 263], ["responsible for", "UNCERTAINTY", 8, 23], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["peritonitis", "OBSERVATION", 32, 43], ["fatal", "OBSERVATION_MODIFIER", 64, 69], ["disease", "OBSERVATION", 70, 77], ["no", "UNCERTAINTY", 83, 85], ["therapeutic properties", "OBSERVATION_MODIFIER", 138, 160], ["antiviral activity", "OBSERVATION", 209, 227]]], ["A high correlation Tarin, potential immunomodulator lectin . . . between the antiviral activity against both viruses and lectins from the GNA family was evidenced by the study, confirming the statement above.", [["lectins", "GENE_OR_GENE_PRODUCT", 121, 128], ["Tarin", "PROTEIN", 19, 24], ["immunomodulator lectin", "PROTEIN", 36, 58], ["lectins", "PROTEIN", 121, 128], ["GNA family", "PROTEIN", 138, 148], ["potential immunomodulator lectin", "TREATMENT", 26, 58], ["the antiviral activity", "TREATMENT", 73, 95], ["the study", "TEST", 166, 175], ["immunomodulator lectin", "OBSERVATION", 36, 58], ["viruses", "OBSERVATION", 109, 116]]], ["Tarin reached 50% effectiveness against SARS-CoV at a concentration >60 \u03bcg/mL, and against FIPV at 2.5 \u00b1 0.6 \u03bcg/mL (Table 1) .", [["Tarin", "CHEMICAL", 0, 5], ["SARS", "DISEASE", 40, 44], ["FIPV", "CHEMICAL", 91, 95], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["FIPV", "SIMPLE_CHEMICAL", 91, 95], ["SARS-CoV", "SPECIES", 40, 48], ["FIPV", "SPECIES", 91, 95], ["Tarin", "TREATMENT", 0, 5], ["SARS", "PROBLEM", 40, 44], ["FIPV", "TREATMENT", 91, 95]]], ["To study the virucidal mechanism, the GNA-related lectin Hippeastrum hybrid agglutinin (HHA) was chosen as a representative agent to perform virus adsorption and entry assays.", [["HHA", "CHEMICAL", 88, 91], ["lectin", "ORGANISM", 50, 56], ["Hippeastrum hybrid agglutinin", "SIMPLE_CHEMICAL", 57, 86], ["HHA", "SIMPLE_CHEMICAL", 88, 91], ["GNA", "PROTEIN", 38, 41], ["lectin", "PROTEIN", 50, 56], ["HHA", "PROTEIN", 88, 91], ["the GNA", "TEST", 34, 41], ["virus adsorption", "TREATMENT", 141, 157], ["entry assays", "TEST", 162, 174]]], ["Virus entry and release from the target cells were inhibited by HHA, which may interact with specific surface glycoproteins that are directly involved in the mechanism of infection.", [["cells", "ANATOMY", 40, 45], ["surface", "ANATOMY", 102, 109], ["HHA", "CHEMICAL", 64, 67], ["infection", "DISEASE", 171, 180], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 40, 45], ["HHA", "SIMPLE_CHEMICAL", 64, 67], ["target cells", "CELL_TYPE", 33, 45], ["surface glycoproteins", "PROTEIN", 102, 123], ["Virus entry", "PROBLEM", 0, 11], ["specific surface glycoproteins", "TREATMENT", 93, 123], ["infection", "PROBLEM", 171, 180], ["target cells", "OBSERVATION", 33, 45], ["infection", "OBSERVATION", 171, 180]]], ["SRAS-CoV entry into cells is mediated by the ACE2 receptor, a protein glycosylated by the addition of high-mannose and complex Nglycans to some of the 12 candidate sites (Krokhin et al., 2003) .Tarin-biological and therapeutic propertiesThere is no experimental evidence for tarin anti-HIV activity, although the anti-HIV effectiveness of many GNA-related lectins has been well-documented (Wu & Bao, 2013) .", [["cells", "ANATOMY", 20, 25], ["mannose", "CHEMICAL", 107, 114], ["SRAS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["cells", "CELL", 20, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["mannose", "SIMPLE_CHEMICAL", 107, 114], ["Nglycans", "GENE_OR_GENE_PRODUCT", 127, 135], ["tarin", "GENE_OR_GENE_PRODUCT", 275, 280], ["anti-HIV", "CANCER", 313, 321], ["SRAS", "PROTEIN", 0, 4], ["ACE2 receptor", "PROTEIN", 45, 58], ["high-mannose", "PROTEIN", 102, 114], ["complex Nglycans", "PROTEIN", 119, 135], ["SRAS", "TEST", 0, 4], ["a protein glycosylated", "TREATMENT", 60, 82], ["high-mannose", "TREATMENT", 102, 114], ["complex Nglycans", "TREATMENT", 119, 135], ["Tarin", "TREATMENT", 194, 199], ["therapeutic properties", "TREATMENT", 215, 237], ["tarin anti-HIV activity", "TREATMENT", 275, 298], ["the anti-HIV effectiveness", "TREATMENT", 309, 335], ["many GNA-related lectins", "PROBLEM", 339, 363], ["therapeutic properties", "OBSERVATION_MODIFIER", 215, 237], ["no experimental evidence for", "UNCERTAINTY", 246, 274], ["tarin", "OBSERVATION_MODIFIER", 275, 280], ["anti-HIV activity", "OBSERVATION", 281, 298]]], ["However, tarin has been reported to specifically bind 2 glycan chains (numbers 212 and 213) present in the gp120 glycoprotein found on the surface of HIV-1, which could impair its attachment to the target cells (Pereira et al., 2015) .Tarin-biological and therapeutic propertiesImmunomodulator potential.", [["surface", "ANATOMY", 139, 146], ["cells", "ANATOMY", 205, 210], ["tarin", "CHEMICAL", 9, 14], ["tarin", "GENE_OR_GENE_PRODUCT", 9, 14], ["gp120 glycoprotein", "GENE_OR_GENE_PRODUCT", 107, 125], ["surface", "CELLULAR_COMPONENT", 139, 146], ["HIV-1", "ORGANISM", 150, 155], ["cells", "CELL", 205, 210], ["tarin", "PROTEIN", 9, 14], ["gp120 glycoprotein", "PROTEIN", 107, 125], ["target cells", "CELL_TYPE", 198, 210], ["HIV-1", "SPECIES", 150, 155], ["HIV-1", "SPECIES", 150, 155], ["the gp120 glycoprotein", "TEST", 103, 125], ["HIV", "PROBLEM", 150, 153], ["Tarin", "TREATMENT", 235, 240]]], ["According to Kumar, Manjunath, Thaminzhmani, Kiran, and Brahmaiah (2012) , tarin seems to fill the requisites to consider this lectin an immunomodulatory candidate, since it exhibits the ability to act on immunological components of both innate or adaptive immunity, promoting stimulation, suppression or modulation.", [["lectin", "GENE_OR_GENE_PRODUCT", 127, 133], ["lectin", "PROTEIN", 127, 133], ["Kiran", "TREATMENT", 45, 50], ["immunological components", "TREATMENT", 205, 229], ["adaptive immunity", "TREATMENT", 248, 265], ["promoting stimulation", "TREATMENT", 267, 288]]], ["In general, plant lectins can interact with hematopoietic cells by binding to their surface carbohydrates (Daoudi, Abdel-Satter, & Aarab, 2013; Shanmugham et al., 2006) .", [["hematopoietic cells", "ANATOMY", 44, 63], ["surface", "ANATOMY", 84, 91], ["carbohydrates", "CHEMICAL", 92, 105], ["hematopoietic cells", "CELL", 44, 63], ["hematopoietic cells", "CELL_TYPE", 44, 63], ["hematopoietic cells", "TREATMENT", 44, 63]]], ["Tarin specifically binds with high affinity to glycan chains, found in hematopoietic progenitor cells and peripheral neutrophils, as revealed by studies on tarin binding specificity (Pereira et al., 2015) .", [["hematopoietic progenitor cells", "ANATOMY", 71, 101], ["peripheral neutrophils", "ANATOMY", 106, 128], ["Tarin", "CHEMICAL", 0, 5], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["hematopoietic progenitor cells", "CELL", 71, 101], ["peripheral neutrophils", "CELL", 106, 128], ["tarin", "SIMPLE_CHEMICAL", 156, 161], ["Tarin", "PROTEIN", 0, 5], ["glycan chains", "PROTEIN", 47, 60], ["hematopoietic progenitor cells", "CELL_TYPE", 71, 101], ["peripheral neutrophils", "CELL_TYPE", 106, 128], ["high affinity to glycan chains", "PROBLEM", 30, 60], ["peripheral neutrophils", "TEST", 106, 128], ["high affinity", "OBSERVATION_MODIFIER", 30, 43], ["hematopoietic progenitor cells", "OBSERVATION", 71, 101], ["peripheral", "ANATOMY_MODIFIER", 106, 116], ["neutrophils", "ANATOMY", 117, 128]]], ["Tarin binds to glycans 358 and 465, also known as the CD173/H2 and CD174/Lewis Y antigens, which are highly expressed in CD34+ progenitor cells and peripheral neutrophils, suggesting their participation in tarin activity (Cao, Merling, Karsten, & Schwartz-Albiez, 2001; Dettke, P\u00e1lfi, & Loibner, 2000; Pereira et al., 2015) .Tarin-biological and therapeutic propertiesTwo research groups independently reported the effects of tarin on immune system components (Chan, Wong, & Ng, 2010; Pereira et al., 2014) .", [["CD34+ progenitor cells", "ANATOMY", 121, 143], ["peripheral neutrophils", "ANATOMY", 148, 170], ["immune system", "ANATOMY", 435, 448], ["tarin", "CHEMICAL", 426, 431], ["tarin", "CHEMICAL", 426, 431], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["CD173", "GENE_OR_GENE_PRODUCT", 54, 59], ["H2", "GENE_OR_GENE_PRODUCT", 60, 62], ["CD174", "GENE_OR_GENE_PRODUCT", 67, 72], ["Lewis Y antigens", "GENE_OR_GENE_PRODUCT", 73, 89], ["CD34", "GENE_OR_GENE_PRODUCT", 121, 125], ["peripheral neutrophils", "CELL", 148, 170], ["tarin", "GENE_OR_GENE_PRODUCT", 206, 211], ["tarin", "SIMPLE_CHEMICAL", 426, 431], ["Tarin", "PROTEIN", 0, 5], ["CD173", "PROTEIN", 54, 59], ["H2", "PROTEIN", 60, 62], ["CD174", "PROTEIN", 67, 72], ["Lewis Y antigens", "PROTEIN", 73, 89], ["CD34+ progenitor cells", "CELL_TYPE", 121, 143], ["peripheral neutrophils", "CELL_TYPE", 148, 170], ["glycans", "TEST", 15, 22], ["the CD173/H2", "TEST", 50, 62], ["Lewis Y antigens", "TEST", 73, 89], ["peripheral neutrophils", "TEST", 148, 170], ["Tarin", "TREATMENT", 325, 330], ["therapeutic properties", "TREATMENT", 346, 368], ["progenitor cells", "OBSERVATION", 127, 143], ["peripheral neutrophils", "OBSERVATION", 148, 170], ["therapeutic properties", "OBSERVATION_MODIFIER", 346, 368]]], ["Tarin is able to stimulate splenocyte proliferation in vitro with a maximum response at 0.698 \u03bcM (Chan et al., 2010) (Table 1 ).", [["splenocyte", "ANATOMY", 27, 37], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["splenocyte", "CELL", 27, 37], ["splenocyte", "CELL_TYPE", 27, 37], ["Tarin", "TREATMENT", 0, 5], ["splenocyte proliferation", "OBSERVATION", 27, 51]]], ["In a further investigation of the RNAm expression of these cells, the transcriptional activation of pro-inflammatory cytokine genes, such as interleukin-1\u03b2 (IL-1\u03b2), interleukin-2 (IL-2), interferon-\u03b3 (INF-\u03b3 ), and tumor necrosis factor-\u03b1 (TNF-\u03b1) was observed.", [["cells", "ANATOMY", 59, 64], ["tumor necrosis", "DISEASE", 214, 228], ["RNAm", "GENE_OR_GENE_PRODUCT", 34, 38], ["cells", "CELL", 59, 64], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 141, 155], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 165, 178], ["IL-2", "GENE_OR_GENE_PRODUCT", 180, 184], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 187, 199], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 201, 206], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 214, 237], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 239, 244], ["RNAm", "PROTEIN", 34, 38], ["pro-inflammatory cytokine genes", "DNA", 100, 131], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 141, 162], ["interferon-\u03b3", "PROTEIN", 187, 199], ["INF-\u03b3", "PROTEIN", 201, 206], ["tumor necrosis factor-\u03b1", "PROTEIN", 214, 237], ["TNF", "PROTEIN", 239, 242], ["these cells", "PROBLEM", 53, 64], ["pro-inflammatory cytokine genes", "PROBLEM", 100, 131], ["interleukin", "TEST", 141, 152], ["IL", "TEST", 157, 159], ["interleukin", "TEST", 165, 176], ["interferon", "TREATMENT", 187, 197], ["tumor necrosis factor", "PROBLEM", 214, 235], ["TNF", "TEST", 239, 242], ["pro-inflammatory cytokine genes", "OBSERVATION", 100, 131], ["tumor necrosis", "OBSERVATION", 214, 228]]], ["Cytokines are essential molecules in cancer treatments.", [["cancer", "ANATOMY", 37, 43], ["cancer", "DISEASE", 37, 43], ["cancer", "CANCER", 37, 43], ["Cytokines", "PROTEIN", 0, 9], ["Cytokines", "PROBLEM", 0, 9], ["cancer treatments", "TREATMENT", 37, 54], ["essential", "OBSERVATION_MODIFIER", 14, 23], ["molecules", "OBSERVATION_MODIFIER", 24, 33], ["cancer", "OBSERVATION", 37, 43]]], ["Animal and clinical trial studies should to be conducted to investigate if tarin may trigger cytokine release, bringing health benefits.", [["tarin", "CHEMICAL", 75, 80], ["tarin", "SIMPLE_CHEMICAL", 75, 80], ["cytokine", "PROTEIN", 93, 101], ["clinical trial studies", "TEST", 11, 33]]], ["The expression of the aforementioned cytokines may be useful to help hosts fight against infection by stimulating innate or adaptive responses.", [["infection", "DISEASE", 89, 98], ["cytokines", "PROTEIN", 37, 46], ["infection", "PROBLEM", 89, 98]]], ["Interleukin-2 is involved in the proliferation and activation of T and B lymphocytes and NK cells in humans.", [["T", "ANATOMY", 65, 66], ["B lymphocytes", "ANATOMY", 71, 84], ["NK cells", "ANATOMY", 89, 97], ["Interleukin-2", "GENE_OR_GENE_PRODUCT", 0, 13], ["T", "CELL", 65, 66], ["B lymphocytes", "CELL", 71, 84], ["NK cells", "CELL", 89, 97], ["humans", "ORGANISM", 101, 107], ["Interleukin-2", "PROTEIN", 0, 13], ["T and B lymphocytes", "CELL_TYPE", 65, 84], ["NK cells", "CELL_TYPE", 89, 97], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 101, 107], ["Interleukin", "TEST", 0, 11], ["lymphocytes", "ANATOMY", 73, 84], ["NK cells", "OBSERVATION", 89, 97]]], ["Interferon-\u03b3 activates macrophages and B-lymphocytes, promotes the differentiation of T cells to TH1 and enhances the expression of MHC-I and -II.", [["macrophages", "ANATOMY", 23, 34], ["B-lymphocytes", "ANATOMY", 39, 52], ["T cells", "ANATOMY", 86, 93], ["Interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 12], ["macrophages", "CELL", 23, 34], ["B-lymphocytes", "CELL", 39, 52], ["T cells", "CELL", 86, 93], ["TH1", "GENE_OR_GENE_PRODUCT", 97, 100], ["MHC-I", "GENE_OR_GENE_PRODUCT", 132, 137], ["-II", "GENE_OR_GENE_PRODUCT", 142, 145], ["Interferon-\u03b3", "PROTEIN", 0, 12], ["macrophages", "CELL_TYPE", 23, 34], ["B-lymphocytes", "CELL_TYPE", 39, 52], ["T cells", "CELL_TYPE", 86, 93], ["MHC-I and -II", "PROTEIN", 132, 145], ["Interferon", "TREATMENT", 0, 10], ["lymphocytes", "ANATOMY", 41, 52]]], ["Interleukin-1\u03b2 and TNF-\u03b1 participate in inflammatory responses through the activation of endothelial cells.", [["endothelial cells", "ANATOMY", 89, 106], ["Interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 14], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 19, 24], ["endothelial cells", "CELL", 89, 106], ["Interleukin-1\u03b2", "PROTEIN", 0, 14], ["TNF-\u03b1", "PROTEIN", 19, 24], ["endothelial cells", "CELL_TYPE", 89, 106], ["Interleukin", "TEST", 0, 11], ["TNF", "TEST", 19, 22], ["inflammatory responses", "PROBLEM", 40, 62], ["endothelial cells", "TREATMENT", 89, 106], ["inflammatory", "OBSERVATION", 40, 52], ["endothelial cells", "OBSERVATION", 89, 106]]], ["Additionally, TNF-\u03b1 can also activate neutrophils, the main phagocytic cells involved in the first line of defense against infection (Abbas, Lichtman, & Pillai, 2014) .Tarin-biological and therapeutic propertiesOur research group evaluated the effects of tarin on hematopoietic cells (Corr\u00eaa et al., 2017; Pereira et al., 2014) .", [["neutrophils", "ANATOMY", 38, 49], ["phagocytic cells", "ANATOMY", 60, 76], ["hematopoietic cells", "ANATOMY", 264, 283], ["infection", "DISEASE", 123, 132], ["tarin", "CHEMICAL", 255, 260], ["tarin", "CHEMICAL", 255, 260], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 14, 19], ["neutrophils", "CELL", 38, 49], ["phagocytic cells", "CELL", 60, 76], ["tarin", "SIMPLE_CHEMICAL", 255, 260], ["hematopoietic cells", "CELL", 264, 283], ["TNF", "PROTEIN", 14, 17], ["-\u03b1", "PROTEIN", 17, 19], ["neutrophils", "CELL_TYPE", 38, 49], ["phagocytic cells", "CELL_TYPE", 60, 76], ["hematopoietic cells", "CELL_TYPE", 264, 283], ["TNF", "TEST", 14, 17], ["neutrophils", "TEST", 38, 49], ["infection", "PROBLEM", 123, 132], ["Abbas", "TEST", 134, 139], ["Lichtman", "TEST", 141, 149], ["therapeutic properties", "TREATMENT", 189, 211], ["main", "OBSERVATION_MODIFIER", 55, 59], ["phagocytic cells", "OBSERVATION", 60, 76], ["infection", "OBSERVATION", 123, 132], ["therapeutic properties", "OBSERVATION_MODIFIER", 189, 211], ["hematopoietic cells", "OBSERVATION", 264, 283]]], ["Mouse splenocyte cells were cultivated in the presence of increasing tarin concentrations, revealing a dose-dependent proliferation curve with a maximum proliferation rate at 2.5 \u03bcg/mL.", [["splenocyte cells", "ANATOMY", 6, 22], ["tarin", "CHEMICAL", 69, 74], ["tarin", "CHEMICAL", 69, 74], ["Mouse", "ORGANISM", 0, 5], ["splenocyte cells", "CELL", 6, 22], ["tarin", "SIMPLE_CHEMICAL", 69, 74], ["Mouse splenocyte cells", "CELL_LINE", 0, 22], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse splenocyte cells", "PROBLEM", 0, 22], ["increasing tarin concentrations", "PROBLEM", 58, 89], ["dependent proliferation curve", "PROBLEM", 108, 137], ["a maximum proliferation rate", "TEST", 143, 171], ["splenocyte cells", "OBSERVATION", 6, 22], ["increasing", "OBSERVATION_MODIFIER", 58, 68], ["tarin concentrations", "OBSERVATION", 69, 89], ["dependent", "OBSERVATION_MODIFIER", 108, 117], ["proliferation", "OBSERVATION_MODIFIER", 118, 131], ["curve", "OBSERVATION_MODIFIER", 132, 137], ["maximum", "OBSERVATION_MODIFIER", 145, 152], ["proliferation", "OBSERVATION_MODIFIER", 153, 166]]], ["Additionally, the intraperitoneal administration of 100 \u03bcg of tarin promoted a 3.3-fold increase in the number of total splenocytes and B lymphocytes 5 days after treatment (Table 1) .", [["intraperitoneal", "ANATOMY", 18, 33], ["splenocytes", "ANATOMY", 120, 131], ["B lymphocytes", "ANATOMY", 136, 149], ["tarin", "CHEMICAL", 62, 67], ["tarin", "CHEMICAL", 62, 67], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 33], ["tarin", "SIMPLE_CHEMICAL", 62, 67], ["splenocytes", "CELL", 120, 131], ["B lymphocytes", "CELL", 136, 149], ["splenocytes", "CELL_TYPE", 120, 131], ["B lymphocytes", "CELL_TYPE", 136, 149], ["the intraperitoneal administration", "TREATMENT", 14, 48], ["tarin", "TREATMENT", 62, 67], ["a 3.3-fold increase", "PROBLEM", 77, 96], ["total splenocytes and B lymphocytes", "TREATMENT", 114, 149], ["intraperitoneal", "ANATOMY", 18, 33], ["3.3-fold", "OBSERVATION_MODIFIER", 79, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["splenocytes", "ANATOMY", 120, 131], ["lymphocytes", "ANATOMY", 138, 149]]], ["Previous studies with taro corm extracts have indicated that tarin may also interfere in the B cell population in the bone marrow, causing a decrease in the number of mature (B220+ IgM+) and immature (B220+ IgM\u2212) B lymphocytes, while at the same time increasing B220+ cell numbers in the spleen (Pereira et al., 2014 (Pereira et al., , 2015 .", [["extracts", "ANATOMY", 32, 40], ["B cell", "ANATOMY", 93, 99], ["bone marrow", "ANATOMY", 118, 129], ["B220+ IgM+)", "ANATOMY", 175, 186], ["B220+ IgM\u2212) B lymphocytes", "ANATOMY", 201, 226], ["B220+ cell", "ANATOMY", 262, 272], ["spleen", "ANATOMY", 288, 294], ["tarin", "CHEMICAL", 61, 66], ["extracts", "ORGANISM_SUBSTANCE", 32, 40], ["tarin", "SIMPLE_CHEMICAL", 61, 66], ["B cell", "CELL", 93, 99], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 118, 129], ["B220", "GENE_OR_GENE_PRODUCT", 175, 179], ["IgM", "GENE_OR_GENE_PRODUCT", 181, 184], ["B220", "GENE_OR_GENE_PRODUCT", 201, 205], ["B220", "GENE_OR_GENE_PRODUCT", 262, 266], ["spleen", "ORGAN", 288, 294], ["B cell population", "CELL_TYPE", 93, 110], ["B220", "PROTEIN", 175, 179], ["IgM", "PROTEIN", 181, 184], ["immature (B220+ IgM\u2212) B lymphocytes", "CELL_TYPE", 191, 226], ["B220", "PROTEIN", 262, 266], ["Previous studies", "TEST", 0, 16], ["taro corm extracts", "TEST", 22, 40], ["the B cell population in the bone marrow", "PROBLEM", 89, 129], ["a decrease", "PROBLEM", 139, 149], ["IgM", "TEST", 181, 184], ["lymphocytes", "TEST", 215, 226], ["B cell population", "OBSERVATION", 93, 110], ["bone marrow", "ANATOMY", 118, 129], ["decrease", "OBSERVATION_MODIFIER", 141, 149], ["number", "OBSERVATION_MODIFIER", 157, 163], ["mature", "OBSERVATION_MODIFIER", 167, 173], ["lymphocytes", "ANATOMY", 215, 226], ["B220+ cell numbers", "OBSERVATION", 262, 280], ["spleen", "ANATOMY", 288, 294]]], ["These results suggest that hematopoietic cells may be directly stimulated in the spleen or stimulated to migrate from the bone marrow to peripheral organs to fill the demand caused by tarin administration, as indicated in Figure 5 .Tarin-biological and therapeutic propertiesIn a recent study by our group, long-term mouse bone-marrow cell in culture was stimulated by tarin, promoting repopulation with Gr-1+ granulocytes (Corr\u00eaa et al., 2017) .", [["hematopoietic cells", "ANATOMY", 27, 46], ["spleen", "ANATOMY", 81, 87], ["bone marrow", "ANATOMY", 122, 133], ["peripheral organs", "ANATOMY", 137, 154], ["bone-marrow cell", "ANATOMY", 323, 339], ["Gr-1+ granulocytes", "ANATOMY", 404, 422], ["tarin", "CHEMICAL", 184, 189], ["hematopoietic cells", "CELL", 27, 46], ["spleen", "ORGAN", 81, 87], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 122, 133], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 137, 154], ["tarin", "SIMPLE_CHEMICAL", 184, 189], ["mouse", "ORGANISM", 317, 322], ["bone-marrow cell", "CELL", 323, 339], ["tarin", "SIMPLE_CHEMICAL", 369, 374], ["Gr-1", "GENE_OR_GENE_PRODUCT", 404, 408], ["hematopoietic cells", "CELL_TYPE", 27, 46], ["long-term mouse bone-marrow cell", "CELL_LINE", 307, 339], ["granulocytes", "CELL_TYPE", 410, 422], ["mouse", "SPECIES", 317, 322], ["mouse", "SPECIES", 317, 322], ["hematopoietic cells", "PROBLEM", 27, 46], ["Tarin", "TREATMENT", 232, 237], ["therapeutic properties", "TREATMENT", 253, 275], ["a recent study", "TEST", 278, 292], ["long-term mouse bone", "TREATMENT", 307, 327], ["culture", "TEST", 343, 350], ["Gr", "TEST", 404, 406], ["hematopoietic cells", "OBSERVATION", 27, 46], ["spleen", "ANATOMY", 81, 87], ["bone", "ANATOMY", 122, 126], ["therapeutic properties", "OBSERVATION_MODIFIER", 253, 275], ["bone", "ANATOMY", 323, 327], ["marrow cell", "OBSERVATION", 328, 339]]], ["Since tarin binds with high affinity to the CD173/H2 and CD174/LewisY antigens present in CD34+ progenitor cells, these results strongly suggest that tarin could be capable of maintaining progenitor cells in vitro.", [["CD34+ progenitor cells", "ANATOMY", 90, 112], ["progenitor cells", "ANATOMY", 188, 204], ["tarin", "CHEMICAL", 150, 155], ["tarin", "GENE_OR_GENE_PRODUCT", 6, 11], ["CD173", "GENE_OR_GENE_PRODUCT", 44, 49], ["H2", "GENE_OR_GENE_PRODUCT", 50, 52], ["CD174", "GENE_OR_GENE_PRODUCT", 57, 62], ["LewisY antigens", "GENE_OR_GENE_PRODUCT", 63, 78], ["CD34", "GENE_OR_GENE_PRODUCT", 90, 94], ["tarin", "SIMPLE_CHEMICAL", 150, 155], ["progenitor cells", "CELL", 188, 204], ["tarin", "PROTEIN", 6, 11], ["CD173", "PROTEIN", 44, 49], ["H2", "PROTEIN", 50, 52], ["CD174", "PROTEIN", 57, 62], ["LewisY antigens", "PROTEIN", 63, 78], ["CD34+ progenitor cells", "CELL_TYPE", 90, 112], ["progenitor cells", "CELL_TYPE", 188, 204], ["high affinity", "PROBLEM", 23, 36], ["the CD173/H2", "TEST", 40, 52], ["CD174", "TEST", 57, 62], ["LewisY antigens", "PROBLEM", 63, 78], ["high affinity", "OBSERVATION_MODIFIER", 23, 36], ["progenitor cells", "OBSERVATION", 96, 112], ["progenitor cells", "OBSERVATION", 188, 204]]], ["In vivo studies indicated that the intraperitoneal administration of 200 \u03bcg of tarin in immunossupressed mice significantly minimized leukopenia induced by cyclophosphamide (CY) at 300 mg/kg.", [["intraperitoneal", "ANATOMY", 35, 50], ["tarin", "CHEMICAL", 79, 84], ["leukopenia", "DISEASE", 134, 144], ["cyclophosphamide", "CHEMICAL", 156, 172], ["CY", "CHEMICAL", 174, 176], ["tarin", "CHEMICAL", 79, 84], ["cyclophosphamide", "CHEMICAL", 156, 172], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 50], ["tarin", "SIMPLE_CHEMICAL", 79, 84], ["mice", "ORGANISM", 105, 109], ["cyclophosphamide", "SIMPLE_CHEMICAL", 156, 172], ["CY", "SIMPLE_CHEMICAL", 174, 176], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["vivo studies", "TEST", 3, 15], ["the intraperitoneal administration", "TREATMENT", 31, 65], ["tarin", "TREATMENT", 79, 84], ["leukopenia", "PROBLEM", 134, 144], ["cyclophosphamide (CY", "TREATMENT", 156, 176], ["intraperitoneal", "ANATOMY", 35, 50]]], ["Moreover, tarin administration also protected erythrocyte lineage cells from death by reducing the number of micronucleated cells, an indicative of CY cytotoxic effects.Tarin-biological and therapeutic propertiesTarin activity may possibly be explored as a potential immunomodulator to boost the immunological system in order to reverse immunosuppressive effects.", [["erythrocyte lineage cells", "ANATOMY", 46, 71], ["micronucleated cells", "ANATOMY", 109, 129], ["tarin", "CHEMICAL", 10, 15], ["death", "DISEASE", 77, 82], ["CY", "CHEMICAL", 148, 150], ["tarin", "SIMPLE_CHEMICAL", 10, 15], ["erythrocyte lineage cells", "CELL", 46, 71], ["micronucleated cells", "CELL", 109, 129], ["CY", "SIMPLE_CHEMICAL", 148, 150], ["Tarin", "GENE_OR_GENE_PRODUCT", 212, 217], ["erythrocyte lineage cells", "CELL_TYPE", 46, 71], ["micronucleated cells", "CELL_TYPE", 109, 129], ["tarin administration", "TREATMENT", 10, 30], ["erythrocyte lineage cells", "PROBLEM", 46, 71], ["death", "PROBLEM", 77, 82], ["micronucleated cells", "PROBLEM", 109, 129], ["CY cytotoxic effects", "PROBLEM", 148, 168], ["Tarin-biological", "TREATMENT", 169, 185], ["therapeutic properties", "TREATMENT", 190, 212], ["a potential immunomodulator", "TREATMENT", 255, 282], ["the immunological system", "TREATMENT", 292, 316], ["immunosuppressive effects", "TREATMENT", 337, 362], ["lineage cells", "OBSERVATION", 58, 71], ["micronucleated cells", "OBSERVATION", 109, 129], ["indicative of", "UNCERTAINTY", 134, 147], ["cytotoxic effects", "OBSERVATION", 151, 168], ["therapeutic properties", "OBSERVATION_MODIFIER", 190, 212]]], ["By stimulating the host-immune system, the organism could not only be able to reestablish its immunological status, but may be prepared to fight against microbial infections.Tarin-biological and therapeutic propertiesAnticancer activity.", [["microbial infections", "DISEASE", 153, 173], ["Anticancer", "CANCER", 217, 227], ["microbial infections", "PROBLEM", 153, 173], ["therapeutic propertiesAnticancer activity", "TREATMENT", 195, 236], ["therapeutic properties", "OBSERVATION_MODIFIER", 195, 217], ["Anticancer activity", "OBSERVATION", 217, 236]]], ["The study carried out by Chan et al. (2010) was the first to evaluate the in vitro antitumoral effects of purified tarin against hepatoma HepG2 cells, demonstrating that, although in a weak manner, tarin inhibited the proliferation of these tumoral cells.", [["hepatoma HepG2 cells", "ANATOMY", 129, 149], ["tumoral cells", "ANATOMY", 241, 254], ["tarin", "CHEMICAL", 115, 120], ["tarin", "CHEMICAL", 198, 203], ["tarin", "CHEMICAL", 198, 203], ["antitumoral", "CANCER", 83, 94], ["tarin", "SIMPLE_CHEMICAL", 115, 120], ["hepatoma HepG2 cells", "CELL", 129, 149], ["tarin", "SIMPLE_CHEMICAL", 198, 203], ["tumoral cells", "CELL", 241, 254], ["hepatoma HepG2 cells", "CELL_LINE", 129, 149], ["tumoral cells", "CELL_TYPE", 241, 254], ["The study", "TEST", 0, 9], ["hepatoma HepG2 cells", "PROBLEM", 129, 149], ["a weak manner", "PROBLEM", 183, 196], ["the proliferation of these tumoral cells", "PROBLEM", 214, 254], ["proliferation", "OBSERVATION_MODIFIER", 218, 231], ["tumoral cells", "OBSERVATION", 241, 254]]], ["When cells were cultivated in 22.3 \u03bcM tarin, 64.5% of initial cells were still viable after 24 hr and 74.8% after 48 hr.", [["cells", "ANATOMY", 5, 10], ["cells", "ANATOMY", 62, 67], ["cells", "CELL", 5, 10], ["cells", "CELL", 62, 67]]], ["As mentioned previously, tarin was able to induce in vitro cytokine release, including interleukin-1\u03b2 (IL-1\u03b2), IL-2, tumor necrosis factor-\u03b1 (TNF-\u03b1), and interferon-\u03b3 (INF-\u03b3 ), which are currently being used for cancer treatments (except for IL-1\u03b2), to stimulate the immune response against tumor cells (Dranoff, 2004; Vacchelli et al., 2016) .", [["cancer", "ANATOMY", 212, 218], ["tumor cells", "ANATOMY", 291, 302], ["necrosis", "DISEASE", 123, 131], ["cancer", "DISEASE", 212, 218], ["tumor", "DISEASE", 291, 296], ["tarin", "SIMPLE_CHEMICAL", 25, 30], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 87, 101], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-2", "GENE_OR_GENE_PRODUCT", 111, 115], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 117, 140], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 154, 166], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 168, 173], ["cancer", "CANCER", 212, 218], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 242, 247], ["tumor cells", "CELL", 291, 302], ["cytokine", "PROTEIN", 59, 67], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 87, 108], ["tumor necrosis factor-\u03b1", "PROTEIN", 117, 140], ["TNF", "PROTEIN", 142, 145], ["\u03b1", "PROTEIN", 146, 147], ["interferon-\u03b3", "PROTEIN", 154, 166], ["INF-\u03b3", "PROTEIN", 168, 173], ["IL-1\u03b2", "PROTEIN", 242, 247], ["tumor cells", "CELL_TYPE", 291, 302], ["vitro cytokine release", "TEST", 53, 75], ["interleukin", "TEST", 87, 98], ["IL", "TEST", 103, 105], ["IL", "TEST", 111, 113], ["tumor necrosis factor", "TEST", 117, 138], ["TNF", "TEST", 142, 145], ["interferon", "TREATMENT", 154, 164], ["cancer treatments", "TREATMENT", 212, 229], ["IL", "TREATMENT", 242, 244], ["tumor cells", "PROBLEM", 291, 302], ["tumor", "ANATOMY", 117, 122], ["necrosis", "OBSERVATION", 123, 131]]], ["However, further studies need to be conducted to investigate if tarin would be able to induce cytokine release in vivo and if those molecules could interfere in the antitumoral and antimetastatic responses ( Figure 5) .", [["antitumoral", "ANATOMY", 165, 176], ["tarin", "SIMPLE_CHEMICAL", 64, 69], ["antitumoral", "CANCER", 165, 176], ["cytokine", "PROTEIN", 94, 102], ["further studies", "TEST", 9, 24]]], ["Kundu et al. (2012) described the isolation of a protein, later identified as tarin, which was suggested to be the antimetastatic active principle of taro corm extracts.", [["extracts", "ANATOMY", 160, 168], ["tarin", "GENE_OR_GENE_PRODUCT", 78, 83], ["taro corm extracts", "ORGANISM_SUBSTANCE", 150, 168], ["a protein", "PROBLEM", 47, 56]]], ["A murine cell breast cancer lineage 66.1, highly metastatic and easily able to colonize lung and heart tissue was used in that study.", [["cell breast cancer lineage 66.1", "ANATOMY", 9, 40], ["lung", "ANATOMY", 88, 92], ["heart tissue", "ANATOMY", 97, 109], ["breast cancer", "DISEASE", 14, 27], ["murine", "ORGANISM", 2, 8], ["cell breast cancer lineage 66.1", "CELL", 9, 40], ["lung", "ORGAN", 88, 92], ["heart tissue", "TISSUE", 97, 109], ["murine cell breast cancer lineage 66.1", "CELL_LINE", 2, 40], ["murine", "SPECIES", 2, 8], ["A murine cell breast cancer", "PROBLEM", 0, 27], ["highly metastatic", "PROBLEM", 42, 59], ["that study", "TEST", 122, 132], ["murine cell", "OBSERVATION", 2, 13], ["breast", "ANATOMY", 14, 20], ["cancer", "OBSERVATION", 21, 27], ["metastatic", "OBSERVATION", 49, 59], ["lung", "ANATOMY", 88, 92], ["heart", "ANATOMY", 97, 102], ["tissue", "OBSERVATION", 103, 109]]], ["According to the aforementioned study, tarin exhibited a modest antiproliferative effect, being able to reduce up to 35% of the 66.1 cell lineage proliferation in vitro.", [["cell", "ANATOMY", 133, 137], ["tarin", "CHEMICAL", 39, 44], ["tarin", "CHEMICAL", 39, 44], ["tarin", "SIMPLE_CHEMICAL", 39, 44], ["cell lineage", "CELL", 133, 145], ["the aforementioned study", "TEST", 13, 37], ["a modest antiproliferative effect", "PROBLEM", 55, 88], ["66.1 cell", "OBSERVATION", 128, 137], ["lineage proliferation", "OBSERVATION", 138, 159]]], ["On the other hand, when syngeneic BALB/cByJ mice were treated with tarin prior to and after the injection of 66.1 cells, lung colonization was significantly reduced and no heart colonization was observed.", [["cells", "ANATOMY", 114, 119], ["lung", "ANATOMY", 121, 125], ["heart", "ANATOMY", 172, 177], ["syngeneic BALB/cByJ mice", "ORGANISM", 24, 48], ["cells", "CELL", 114, 119], ["lung", "ORGAN", 121, 125], ["heart", "ORGAN", 172, 177], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["syngeneic BALB/cByJ mice", "TREATMENT", 24, 48], ["tarin", "TREATMENT", 67, 72], ["lung colonization", "PROBLEM", 121, 138], ["heart colonization", "PROBLEM", 172, 190], ["lung", "ANATOMY", 121, 125], ["colonization", "OBSERVATION", 126, 138], ["no", "UNCERTAINTY", 169, 171], ["heart", "ANATOMY", 172, 177], ["colonization", "OBSERVATION", 178, 190]]], ["Studies on taro corm extract mechanisms indicated that the antimetastatic activity could be induced by the down-regulation of cyclooxygenase (COX)-1 and -2 and subsequent inhibition of prostaglandins E2 (PGE2) synthesis, which are associated to tumor aggressiveness (Kundu et al., 2012) .", [["tumor", "ANATOMY", 245, 250], ["prostaglandins E2", "CHEMICAL", 185, 202], ["PGE2", "CHEMICAL", 204, 208], ["tumor", "DISEASE", 245, 250], ["aggressiveness", "DISEASE", 251, 265], ["prostaglandins E2", "CHEMICAL", 185, 202], ["PGE2", "CHEMICAL", 204, 208], ["cyclooxygenase (COX)-1", "GENE_OR_GENE_PRODUCT", 126, 148], ["-2", "GENE_OR_GENE_PRODUCT", 153, 155], ["prostaglandins E2", "SIMPLE_CHEMICAL", 185, 202], ["PGE2", "SIMPLE_CHEMICAL", 204, 208], ["tumor", "CANCER", 245, 250], ["cyclooxygenase (COX)-1 and -2", "PROTEIN", 126, 155], ["taro corm extract mechanisms", "TEST", 11, 39], ["the antimetastatic activity", "PROBLEM", 55, 82], ["cyclooxygenase (COX", "TREATMENT", 126, 145], ["prostaglandins E2 (PGE2) synthesis", "TREATMENT", 185, 219], ["tumor aggressiveness", "PROBLEM", 245, 265], ["tumor", "OBSERVATION", 245, 250]]], ["COX inhibitors, especially COX-2 is highly expressed in certain pathological conditions and has been extensively used in clinical trials to treat breast, lung, prostate and colon cancer cells, since it is strongly associated to decreases in tumor proliferation, growth and migration and blockage of the inhibition of antitumoral responses as a result of the suppression of dendritic cells, natural killer cells and T cells by PGE2 (Liu, Qu, & Yan, 2015) .Tarin-biological and therapeutic propertiesOur research group demonstrated that tarin binding specificity to cell membrane glycans could explain its anticancer properties.", [["breast", "ANATOMY", 146, 152], ["lung", "ANATOMY", 154, 158], ["prostate", "ANATOMY", 160, 168], ["colon cancer cells", "ANATOMY", 173, 191], ["tumor", "ANATOMY", 241, 246], ["antitumoral", "ANATOMY", 317, 328], ["dendritic cells", "ANATOMY", 373, 388], ["natural killer cells", "ANATOMY", 390, 410], ["T cells", "ANATOMY", 415, 422], ["cell membrane", "ANATOMY", 564, 577], ["anticancer", "ANATOMY", 604, 614], ["breast, lung, prostate and colon cancer", "DISEASE", 146, 185], ["tumor", "DISEASE", 241, 246], ["PGE2", "CHEMICAL", 426, 430], ["tarin", "CHEMICAL", 535, 540], ["PGE2", "CHEMICAL", 426, 430], ["tarin", "CHEMICAL", 535, 540], ["COX", "GENE_OR_GENE_PRODUCT", 0, 3], ["COX-2", "GENE_OR_GENE_PRODUCT", 27, 32], ["breast", "ORGANISM_SUBDIVISION", 146, 152], ["lung", "ORGAN", 154, 158], ["prostate", "CELL", 160, 168], ["colon cancer cells", "CELL", 173, 191], ["tumor", "CANCER", 241, 246], ["antitumoral", "CANCER", 317, 328], ["dendritic cells", "CELL", 373, 388], ["natural killer cells", "CELL", 390, 410], ["T cells", "CELL", 415, 422], ["PGE2", "SIMPLE_CHEMICAL", 426, 430], ["tarin", "SIMPLE_CHEMICAL", 535, 540], ["cell", "CELL", 564, 568], ["anticancer", "CANCER", 604, 614], ["COX", "PROTEIN", 0, 3], ["COX-2", "PROTEIN", 27, 32], ["colon cancer cells", "CELL_TYPE", 173, 191], ["dendritic cells", "CELL_TYPE", 373, 388], ["natural killer cells", "CELL_TYPE", 390, 410], ["T cells", "CELL_TYPE", 415, 422], ["COX inhibitors", "PROBLEM", 0, 14], ["COX", "TEST", 27, 30], ["breast, lung, prostate and colon cancer cells", "PROBLEM", 146, 191], ["tumor proliferation", "PROBLEM", 241, 260], ["migration", "PROBLEM", 273, 282], ["blockage of the inhibition of antitumoral responses", "PROBLEM", 287, 338], ["dendritic cells", "PROBLEM", 373, 388], ["Tarin", "TREATMENT", 455, 460], ["therapeutic properties", "TREATMENT", 476, 498], ["cell membrane glycans", "TREATMENT", 564, 585], ["breast", "ANATOMY", 146, 152], ["lung", "ANATOMY", 154, 158], ["prostate", "ANATOMY", 160, 168], ["colon", "ANATOMY", 173, 178], ["cancer", "OBSERVATION", 179, 185], ["strongly associated to", "UNCERTAINTY", 205, 227], ["decreases", "OBSERVATION_MODIFIER", 228, 237], ["tumor", "OBSERVATION", 241, 246], ["proliferation", "OBSERVATION_MODIFIER", 247, 260], ["growth", "OBSERVATION_MODIFIER", 262, 268], ["migration", "OBSERVATION_MODIFIER", 273, 282], ["dendritic cells", "OBSERVATION", 373, 388], ["natural killer cells", "OBSERVATION", 390, 410], ["therapeutic properties", "OBSERVATION_MODIFIER", 476, 498], ["anticancer properties", "OBSERVATION", 604, 625]]], ["Tarin specifically binds the high mannose N-glycan 49 [Man\u03b11-3(Man\u03b11-6)Man\u03b21-4GlcNAc\u03b21-4GlcNAc\u03b2], which is commonly found in human cancer tissue but not in healthy ones (Zipser, Bello-DeOcampo, Diestel, Tai, & Schmitz, 2012) .", [["cancer tissue", "ANATOMY", 131, 144], ["cancer", "DISEASE", 131, 137], ["mannose", "CHEMICAL", 34, 41], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["Man\u03b11-3", "GENE_OR_GENE_PRODUCT", 55, 62], ["Man\u03b11-6)Man\u03b21-4GlcNAc\u03b21-4GlcNAc\u03b2", "GENE_OR_GENE_PRODUCT", 63, 95], ["human", "ORGANISM", 125, 130], ["cancer tissue", "TISSUE", 131, 144], ["Tarin", "PROTEIN", 0, 5], ["high mannose N-glycan 49", "PROTEIN", 29, 53], ["Man\u03b11", "PROTEIN", 55, 60], ["Man\u03b11", "PROTEIN", 63, 68], ["Man\u03b21", "PROTEIN", 71, 76], ["4GlcNAc\u03b21", "PROTEIN", 77, 86], ["NAc\u03b2", "PROTEIN", 91, 95], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["glycan", "TEST", 44, 50], ["Man\u03b11", "TEST", 55, 60], ["human cancer tissue", "PROBLEM", 125, 144], ["cancer", "OBSERVATION", 131, 137]]], ["Additionally, the complex N-glycan 465 exhibits the terminal equivalent to the LeY antigen (Lewis Y/CD174 -Fuc\u03b11-2Gal\u03b21-4[Fuc\u03b11-3]GlcNAc\u03b21-), a cell marker specifically associated to cancer.", [["cell", "ANATOMY", 144, 148], ["cancer", "ANATOMY", 183, 189], ["N-glycan 465", "CHEMICAL", 26, 38], ["cancer", "DISEASE", 183, 189], ["Glc", "CHEMICAL", 130, 133], ["LeY antigen", "GENE_OR_GENE_PRODUCT", 79, 90], ["2Gal\u03b21-4", "GENE_OR_GENE_PRODUCT", 113, 121], ["Fuc\u03b11-3]GlcNAc\u03b21", "GENE_OR_GENE_PRODUCT", 122, 138], ["cell", "CELL", 144, 148], ["cancer", "CANCER", 183, 189], ["complex N-glycan 465", "PROTEIN", 18, 38], ["LeY antigen", "PROTEIN", 79, 90], ["CD174", "PROTEIN", 100, 105], ["Fuc\u03b11", "PROTEIN", 107, 112], ["2Gal\u03b21", "PROTEIN", 113, 119], ["Fuc\u03b11", "PROTEIN", 122, 127], ["GlcNAc\u03b21", "PROTEIN", 130, 138], ["the complex N-glycan", "TREATMENT", 14, 34], ["CD174", "TEST", 100, 105], ["Fuc\u03b1", "TEST", 107, 111], ["Fuc\u03b11", "TEST", 122, 127], ["GlcNAc\u03b21", "TEST", 130, 138], ["a cell marker", "TEST", 142, 155], ["cancer", "PROBLEM", 183, 189], ["cancer", "OBSERVATION", 183, 189]]], ["The LeY antigen is up-regulated in a variety of cancer cells derived from colon, stomach, ovary, breast, pancreas, prostate, and lung (Dube & Bertozzi, 2005) .", [["cancer cells", "ANATOMY", 48, 60], ["colon", "ANATOMY", 74, 79], ["stomach", "ANATOMY", 81, 88], ["ovary", "ANATOMY", 90, 95], ["breast", "ANATOMY", 97, 103], ["pancreas", "ANATOMY", 105, 113], ["prostate", "ANATOMY", 115, 123], ["lung", "ANATOMY", 129, 133], ["cancer", "DISEASE", 48, 54], ["LeY antigen", "GENE_OR_GENE_PRODUCT", 4, 15], ["cancer cells", "CELL", 48, 60], ["colon", "ORGAN", 74, 79], ["stomach", "ORGAN", 81, 88], ["ovary", "ORGAN", 90, 95], ["breast", "ORGAN", 97, 103], ["pancreas", "ORGAN", 105, 113], ["prostate", "ORGAN", 115, 123], ["lung", "ORGAN", 129, 133], ["LeY antigen", "PROTEIN", 4, 15], ["cancer cells", "CELL_TYPE", 48, 60], ["The LeY antigen", "TEST", 0, 15], ["cancer cells", "PROBLEM", 48, 60], ["colon, stomach, ovary, breast, pancreas, prostate, and lung", "PROBLEM", 74, 133], ["cancer cells", "OBSERVATION", 48, 60], ["colon", "ANATOMY", 74, 79], ["stomach", "ANATOMY", 81, 88], ["ovary", "ANATOMY", 90, 95], ["breast", "ANATOMY", 97, 103], ["pancreas", "ANATOMY", 105, 113], ["prostate", "ANATOMY", 115, 123], ["lung", "ANATOMY", 129, 133]]], ["Although it was not proved to be an effect caused exclusively by tarin, taro corm extract exhibits partial antiproliferative activity against rat YYT colon cancer cells, breast cancer cells (MCF-7, MDA-MB-231, T47D, and MDA-MB-435) and prostate cancer cells (DU145, LNCaP, and PC3) (Brown et al., 2005; Kundu et al., 2012) .", [["YYT colon cancer cells", "ANATOMY", 146, 168], ["breast cancer cells", "ANATOMY", 170, 189], ["MCF-7", "ANATOMY", 191, 196], ["MDA-MB-231", "ANATOMY", 198, 208], ["T47D", "ANATOMY", 210, 214], ["MDA-MB-435)", "ANATOMY", 220, 231], ["prostate cancer cells", "ANATOMY", 236, 257], ["DU145", "ANATOMY", 259, 264], ["LNCaP", "ANATOMY", 266, 271], ["PC3", "ANATOMY", 277, 280], ["tarin", "CHEMICAL", 65, 70], ["taro corm extract", "CHEMICAL", 72, 89], ["colon cancer", "DISEASE", 150, 162], ["breast cancer", "DISEASE", 170, 183], ["prostate cancer", "DISEASE", 236, 251], ["tarin", "CHEMICAL", 65, 70], ["tarin", "SIMPLE_CHEMICAL", 65, 70], ["rat", "ORGANISM", 142, 145], ["YYT colon cancer cells", "CELL", 146, 168], ["breast cancer cells", "CELL", 170, 189], ["MCF-7", "CELL", 191, 196], ["MDA-MB-231", "CELL", 198, 208], ["T47D", "CELL", 210, 214], ["MDA-MB-435)", "CELL", 220, 231], ["prostate cancer cells", "CELL", 236, 257], ["DU145", "CELL", 259, 264], ["LNCaP", "CELL", 266, 271], ["PC3", "CELL", 277, 280], ["rat YYT colon cancer cells", "CELL_LINE", 142, 168], ["breast cancer cells", "CELL_TYPE", 170, 189], ["MCF-7", "CELL_LINE", 191, 196], ["MDA-MB-231", "CELL_LINE", 198, 208], ["T47D", "CELL_LINE", 210, 214], ["MDA-MB-435", "CELL_LINE", 220, 230], ["prostate cancer cells", "CELL_TYPE", 236, 257], ["DU145", "CELL_LINE", 259, 264], ["LNCaP", "CELL_LINE", 266, 271], ["PC3", "CELL_LINE", 277, 280], ["rat", "SPECIES", 142, 145], ["rat", "SPECIES", 142, 145], ["partial antiproliferative activity against rat YYT colon cancer cells", "PROBLEM", 99, 168], ["breast cancer cells", "PROBLEM", 170, 189], ["MCF", "TEST", 191, 194], ["MDA-MB", "TEST", 198, 204], ["T47D", "TEST", 210, 214], ["MDA", "TEST", 220, 223], ["MB", "TEST", 224, 226], ["prostate cancer cells", "PROBLEM", 236, 257], ["DU145", "TEST", 259, 264], ["LNCaP", "TEST", 266, 271], ["PC3", "TEST", 277, 280], ["partial", "OBSERVATION_MODIFIER", 99, 106], ["antiproliferative activity", "OBSERVATION", 107, 133], ["colon", "ANATOMY", 150, 155], ["cancer", "OBSERVATION", 156, 162], ["breast", "ANATOMY", 170, 176], ["cancer", "OBSERVATION", 177, 183], ["T47D", "ANATOMY", 210, 214], ["prostate", "ANATOMY", 236, 244], ["cancer cells", "OBSERVATION", 245, 257]]], ["17, 2018 r Comprehensive Reviews in Food Science and Food Safety 887 able to bind H2 antigen (CD173 -Fuc\u03b11-2Gal\u03b21-4GlcNAc\u03b21-), present at the glycan 358 expressed in the leukemia cells lineages KG1 and KG1a (pro-myeloid cells) and TF1 (pre-erithroblastoid cells) (Cao et al., 2001) .", [["leukemia cells", "ANATOMY", 170, 184], ["KG1", "ANATOMY", 194, 197], ["KG1a", "ANATOMY", 202, 206], ["pro-myeloid cells", "ANATOMY", 208, 225], ["TF1", "ANATOMY", 231, 234], ["pre-erithroblastoid cells", "ANATOMY", 236, 261], ["leukemia", "DISEASE", 170, 178], ["H2 antigen", "GENE_OR_GENE_PRODUCT", 82, 92], ["CD173 -Fuc\u03b11-2Gal\u03b21-4GlcNAc\u03b21", "GENE_OR_GENE_PRODUCT", 94, 123], ["leukemia cells", "CELL", 170, 184], ["KG1", "CELL", 194, 197], ["KG1a", "CELL", 202, 206], ["pro-myeloid cells", "CELL", 208, 225], ["TF1", "CELL", 231, 234], ["pre-erithroblastoid cells", "CELL", 236, 261], ["H2 antigen", "PROTEIN", 82, 92], ["CD173", "PROTEIN", 94, 99], ["Fuc\u03b11", "PROTEIN", 101, 106], ["2Gal\u03b21", "PROTEIN", 107, 113], ["4GlcNAc\u03b21", "PROTEIN", 114, 123], ["glycan 358", "PROTEIN", 142, 152], ["leukemia cells lineages", "CELL_TYPE", 170, 193], ["KG1", "CELL_LINE", 194, 197], ["KG1a", "CELL_LINE", 202, 206], ["pro-myeloid cells", "CELL_TYPE", 208, 225], ["TF1", "CELL_LINE", 231, 234], ["pre-erithroblastoid cells", "CELL_TYPE", 236, 261], ["H2 antigen", "TEST", 82, 92], ["CD173", "TEST", 94, 99], ["Fuc\u03b11", "TEST", 101, 106], ["the leukemia cells", "TEST", 166, 184], ["KG1", "TEST", 194, 197], ["KG1a (pro-myeloid cells", "TEST", 202, 225], ["TF1 (pre-erithroblastoid cells", "TREATMENT", 231, 261], ["leukemia cells", "OBSERVATION", 170, 184], ["KG1a", "ANATOMY", 202, 206], ["myeloid cells", "OBSERVATION", 212, 225]]], ["The CA-125 antigen, which characterizes ovary cancer cells, is also a target for tarin binding (Wong et al., 2003) .", [["ovary cancer cells", "ANATOMY", 40, 58], ["ovary cancer", "DISEASE", 40, 52], ["CA-125 antigen", "GENE_OR_GENE_PRODUCT", 4, 18], ["ovary cancer cells", "CELL", 40, 58], ["CA-125 antigen", "PROTEIN", 4, 18], ["ovary cancer cells", "CELL_TYPE", 40, 58], ["The CA-125 antigen", "TEST", 0, 18], ["ovary cancer cells", "PROBLEM", 40, 58], ["ovary", "ANATOMY", 40, 45], ["cancer cells", "OBSERVATION", 46, 58]]], ["Taken together, these data are indicative of the possible broad spectrum of action of tarin anticancer effects.", [["anticancer", "ANATOMY", 92, 102], ["tarin", "CHEMICAL", 86, 91], ["tarin", "CHEMICAL", 86, 91], ["tarin", "SIMPLE_CHEMICAL", 86, 91], ["anticancer", "CANCER", 92, 102], ["these data", "TEST", 16, 26], ["tarin anticancer effects", "TREATMENT", 86, 110]]], ["The aqueous extract from taro corms and the active principle, tarin, have been patented as a natural product for controlling cancer metastasis, to be administered in combination with chemotherapy (Fulton & Kundu, 2014) .Tarin-biological and therapeutic propertiesBased on the in vitro and in vivo characteristics of tarin, we suggest a molecular model that unites its possible prophylactic and therapeutic actions on hematopoietic or cancer cells, which could boost murine responses ( Figure 5 ).", [["aqueous extract", "ANATOMY", 4, 19], ["cancer", "ANATOMY", 125, 131], ["hematopoietic", "ANATOMY", 417, 430], ["cancer cells", "ANATOMY", 434, 446], ["tarin", "CHEMICAL", 62, 67], ["cancer metastasis", "DISEASE", 125, 142], ["hematopoietic or cancer", "DISEASE", 417, 440], ["tarin", "CHEMICAL", 316, 321], ["aqueous extract", "ORGANISM_SUBSTANCE", 4, 19], ["taro corms", "CELL", 25, 35], ["tarin", "SIMPLE_CHEMICAL", 62, 67], ["cancer", "CANCER", 125, 131], ["tarin", "SIMPLE_CHEMICAL", 316, 321], ["hematopoietic", "CELL", 417, 430], ["cancer cells", "CELL", 434, 446], ["murine", "ORGANISM", 466, 472], ["hematopoietic or cancer cells", "CELL_TYPE", 417, 446], ["murine", "SPECIES", 466, 472], ["a natural product", "TREATMENT", 91, 108], ["controlling cancer metastasis", "PROBLEM", 113, 142], ["chemotherapy", "TREATMENT", 183, 195], ["Tarin", "TREATMENT", 220, 225], ["therapeutic properties", "TREATMENT", 241, 263], ["prophylactic and therapeutic actions", "TREATMENT", 377, 413], ["hematopoietic or cancer cells", "PROBLEM", 417, 446], ["taro corms", "OBSERVATION", 25, 35], ["active", "OBSERVATION_MODIFIER", 44, 50], ["principle", "OBSERVATION", 51, 60], ["metastasis", "OBSERVATION", 132, 142], ["therapeutic properties", "OBSERVATION_MODIFIER", 241, 263]]], ["When administered to mice, tarin may act directly on hematopoietic progenitor cells (possibly CD34+) in the bone marrow, protecting them against immunosuppressant cytotoxicity.", [["hematopoietic progenitor cells", "ANATOMY", 53, 83], ["CD34+", "ANATOMY", 94, 99], ["bone marrow", "ANATOMY", 108, 119], ["tarin", "CHEMICAL", 27, 32], ["mice", "ORGANISM", 21, 25], ["tarin", "GENE_OR_GENE_PRODUCT", 27, 32], ["hematopoietic progenitor cells", "CELL", 53, 83], ["CD34", "GENE_OR_GENE_PRODUCT", 94, 98], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 108, 119], ["hematopoietic progenitor cells", "CELL_TYPE", 53, 83], ["CD34", "PROTEIN", 94, 98], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["hematopoietic progenitor cells", "TREATMENT", 53, 83], ["CD34", "TEST", 94, 98], ["the bone marrow", "TREATMENT", 104, 119], ["immunosuppressant cytotoxicity", "TREATMENT", 145, 175], ["bone marrow", "ANATOMY", 108, 119]]], ["This protection could allow tarin-treated immunosuppressed mice to maintain a higher pool of progenitor cells, which could aid mice in recovering faster from immunosuppression.", [["progenitor cells", "ANATOMY", 93, 109], ["tarin", "CHEMICAL", 28, 33], ["tarin", "CHEMICAL", 28, 33], ["tarin", "SIMPLE_CHEMICAL", 28, 33], ["mice", "ORGANISM", 59, 63], ["progenitor cells", "CELL", 93, 109], ["mice", "ORGANISM", 127, 131], ["progenitor cells", "CELL_TYPE", 93, 109], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 127, 131], ["This protection", "TREATMENT", 0, 15], ["immunosuppressed mice", "TREATMENT", 42, 63], ["a higher pool of progenitor cells", "TREATMENT", 76, 109], ["immunosuppression", "TREATMENT", 158, 175], ["progenitor cells", "OBSERVATION", 93, 109]]], ["The effects of tarin on the bone marrow may be reflected by increases in the number and activation of total peripheral leukocytes, especially neutrophils (Gr1+).", [["bone marrow", "ANATOMY", 28, 39], ["peripheral leukocytes", "ANATOMY", 108, 129], ["neutrophils", "ANATOMY", 142, 153], ["tarin", "CHEMICAL", 15, 20], ["tarin", "CHEMICAL", 15, 20], ["tarin", "SIMPLE_CHEMICAL", 15, 20], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 28, 39], ["peripheral leukocytes", "CELL", 108, 129], ["neutrophils", "CELL", 142, 153], ["Gr1", "GENE_OR_GENE_PRODUCT", 155, 158], ["total peripheral leukocytes", "CELL_TYPE", 102, 129], ["neutrophils", "CELL_TYPE", 142, 153], ["Gr1", "CELL_TYPE", 155, 158], ["total peripheral leukocytes", "PROBLEM", 102, 129], ["neutrophils", "TEST", 142, 153], ["tarin", "OBSERVATION_MODIFIER", 15, 20], ["bone", "ANATOMY", 28, 32], ["marrow", "OBSERVATION", 33, 39], ["may be", "UNCERTAINTY", 40, 46], ["increases", "OBSERVATION_MODIFIER", 60, 69], ["number", "OBSERVATION_MODIFIER", 77, 83], ["total", "OBSERVATION_MODIFIER", 102, 107], ["peripheral", "ANATOMY_MODIFIER", 108, 118], ["leukocytes", "ANATOMY", 119, 129]]], ["Additionally, tarin inoculation in mice enhances the number of total B lymphocytes (B220+ cells) in the spleen, concomitantly with the decrease in the number of both mature (B220+IgM+) and immature (B220+IgM\u2212) B lymphocytes in the bone marrow.", [["B lymphocytes", "ANATOMY", 69, 82], ["B220+ cells", "ANATOMY", 84, 95], ["spleen", "ANATOMY", 104, 110], ["B lymphocytes", "ANATOMY", 210, 223], ["bone marrow", "ANATOMY", 231, 242], ["tarin", "CHEMICAL", 14, 19], ["tarin", "GENE_OR_GENE_PRODUCT", 14, 19], ["mice", "ORGANISM", 35, 39], ["B lymphocytes", "CELL", 69, 82], ["B220+ cells", "CELL", 84, 95], ["spleen", "ORGAN", 104, 110], ["B220", "GENE_OR_GENE_PRODUCT", 174, 178], ["IgM", "GENE_OR_GENE_PRODUCT", 179, 182], ["B220", "GENE_OR_GENE_PRODUCT", 199, 203], ["B lymphocytes", "CELL", 210, 223], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 231, 242], ["B lymphocytes", "CELL_TYPE", 69, 82], ["B220+ cells", "CELL_TYPE", 84, 95], ["B220", "PROTEIN", 174, 178], ["IgM", "PROTEIN", 179, 182], ["B220", "PROTEIN", 199, 203], ["IgM", "PROTEIN", 204, 207], ["B lymphocytes", "CELL_TYPE", 210, 223], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["total B lymphocytes", "TEST", 63, 82], ["IgM", "TEST", 179, 182], ["B lymphocytes in the bone marrow", "PROBLEM", 210, 242], ["tarin", "OBSERVATION_MODIFIER", 14, 19], ["inoculation", "OBSERVATION_MODIFIER", 20, 31], ["lymphocytes", "ANATOMY", 71, 82], ["spleen", "ANATOMY", 104, 110], ["decrease", "OBSERVATION_MODIFIER", 135, 143], ["lymphocytes", "OBSERVATION", 212, 223], ["bone marrow", "ANATOMY", 231, 242]]], ["In this case, we suggest that the number of total B cells may be enhanced in the spleen as a result of direct tarin action on splenocytes, activating and stimulating their proliferation.", [["B cells", "ANATOMY", 50, 57], ["spleen", "ANATOMY", 81, 87], ["splenocytes", "ANATOMY", 126, 137], ["B cells", "CELL", 50, 57], ["spleen", "ORGAN", 81, 87], ["tarin", "GENE_OR_GENE_PRODUCT", 110, 115], ["splenocytes", "CELL", 126, 137], ["total B cells", "CELL_TYPE", 44, 57], ["splenocytes", "CELL_TYPE", 126, 137], ["total B cells", "TREATMENT", 44, 57], ["splenocytes", "TREATMENT", 126, 137], ["spleen", "ANATOMY", 81, 87]]], ["Another alternative would be the migration of mature and immature B cells from the bone marrow to the spleen.", [["B cells", "ANATOMY", 66, 73], ["bone marrow", "ANATOMY", 83, 94], ["spleen", "ANATOMY", 102, 108], ["B cells", "CELL", 66, 73], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 83, 94], ["spleen", "ORGAN", 102, 108], ["mature and immature B cells", "CELL_TYPE", 46, 73], ["migration", "OBSERVATION_MODIFIER", 33, 42], ["mature", "OBSERVATION_MODIFIER", 46, 52], ["immature B cells", "OBSERVATION", 57, 73], ["bone marrow", "ANATOMY", 83, 94], ["spleen", "ANATOMY", 102, 108]]], ["Cytokine release (IL-2, IL1-\u03b2, TNF-\u03b1, and INF-\u03b3 ), which could stimulate innate or adaptive responses, may also be triggered by tarin inoculation in mice through leukocyte activation.", [["leukocyte", "ANATOMY", 162, 171], ["tarin", "CHEMICAL", 128, 133], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-2", "GENE_OR_GENE_PRODUCT", 18, 22], ["IL1-\u03b2", "GENE_OR_GENE_PRODUCT", 24, 29], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 31, 36], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 42, 47], ["tarin", "SIMPLE_CHEMICAL", 128, 133], ["mice", "ORGANISM", 149, 153], ["leukocyte", "CELL", 162, 171], ["Cytokine", "PROTEIN", 0, 8], ["IL1", "PROTEIN", 24, 27], ["\u03b2", "PROTEIN", 28, 29], ["TNF", "PROTEIN", 31, 34], ["INF-\u03b3", "PROTEIN", 42, 47], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 149, 153], ["Cytokine release", "TEST", 0, 16], ["IL", "TEST", 18, 20], ["IL1", "TEST", 24, 27], ["TNF", "TEST", 31, 34], ["leukocyte activation", "TEST", 162, 182]]], ["All the effects observed in the bone marrow, peripheral cells and spleen, could be explained by the tarin ability to specifically bind to carbohydrates found on hematopoietic cell surfaces, including glycans 465 and 358.", [["bone marrow", "ANATOMY", 32, 43], ["peripheral cells", "ANATOMY", 45, 61], ["spleen", "ANATOMY", 66, 72], ["hematopoietic cell surfaces", "ANATOMY", 161, 188], ["carbohydrates", "CHEMICAL", 138, 151], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 32, 43], ["peripheral cells", "CELL", 45, 61], ["spleen", "ORGAN", 66, 72], ["tarin", "GENE_OR_GENE_PRODUCT", 100, 105], ["hematopoietic cell", "CELL", 161, 179], ["peripheral cells", "CELL_TYPE", 45, 61], ["carbohydrates", "TEST", 138, 151], ["hematopoietic cell surfaces", "TEST", 161, 188], ["glycans", "TEST", 200, 207], ["bone marrow", "ANATOMY", 32, 43], ["peripheral", "ANATOMY_MODIFIER", 45, 55], ["cells", "ANATOMY", 56, 61], ["spleen", "ANATOMY", 66, 72], ["hematopoietic cell surfaces", "OBSERVATION", 161, 188]]], ["Cytokine release was reported only in vitro, while mature and immature B lymphocyte effects were reported in vivo following taro corm extract administration.", [["B lymphocyte", "ANATOMY", 71, 83], ["extract", "ANATOMY", 134, 141], ["taro corm extract", "CHEMICAL", 124, 141], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["B lymphocyte", "CELL", 71, 83], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine release", "TREATMENT", 0, 16], ["immature B lymphocyte effects", "PROBLEM", 62, 91], ["taro corm extract administration", "TREATMENT", 124, 156], ["immature B lymphocyte effects", "OBSERVATION", 62, 91]]], ["Further studies are required to confirm in vivo cytokine release, to attribute the effects on B lymphocytes to tarin and to study the benefits they could bring to mice responses ( Figure 5 , left-hand panel).Tarin-biological and therapeutic propertiesThe antitumoral and antimetastatic effects exerted in vivo by tarin could also be explained by its binding to a variety of cell ligands, including glycans 213, 49, 465, and 358, which could be responsible for down-regulation of COX-1 and -2 mRNA expression and the subsequent decrease in prostaglandin E2 (PGE2) levels.", [["B lymphocytes", "ANATOMY", 94, 107], ["left-hand", "ANATOMY", 191, 200], ["cell", "ANATOMY", 374, 378], ["tarin", "CHEMICAL", 313, 318], ["prostaglandin E2", "CHEMICAL", 539, 555], ["PGE2", "CHEMICAL", 557, 561], ["tarin", "CHEMICAL", 313, 318], ["prostaglandin E2", "CHEMICAL", 539, 555], ["PGE2", "CHEMICAL", 557, 561], ["B lymphocytes", "CELL", 94, 107], ["tarin", "GENE_OR_GENE_PRODUCT", 111, 116], ["mice", "ORGANISM", 163, 167], ["antitumoral", "CANCER", 255, 266], ["tarin", "SIMPLE_CHEMICAL", 313, 318], ["cell", "CELL", 374, 378], ["COX-1", "GENE_OR_GENE_PRODUCT", 479, 484], ["-2", "GENE_OR_GENE_PRODUCT", 489, 491], ["prostaglandin E2", "SIMPLE_CHEMICAL", 539, 555], ["PGE2", "SIMPLE_CHEMICAL", 557, 561], ["cytokine", "PROTEIN", 48, 56], ["B lymphocytes", "CELL_TYPE", 94, 107], ["COX", "PROTEIN", 479, 482], ["PGE2", "PROTEIN", 557, 561], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 163, 167], ["Further studies", "TEST", 0, 15], ["vivo cytokine release", "TREATMENT", 43, 64], ["B lymphocytes to tarin", "TREATMENT", 94, 116], ["Figure", "TEST", 180, 186], ["Tarin-biological", "TREATMENT", 208, 224], ["therapeutic properties", "TREATMENT", 229, 251], ["The antitumoral and antimetastatic effects", "TREATMENT", 251, 293], ["glycans", "TEST", 398, 405], ["COX", "TEST", 479, 482], ["the subsequent decrease in prostaglandin E2 (PGE2) levels", "TEST", 512, 569], ["therapeutic properties", "OBSERVATION_MODIFIER", 229, 251], ["antitumoral", "OBSERVATION_MODIFIER", 255, 266], ["antimetastatic", "OBSERVATION", 271, 285], ["cell ligands", "OBSERVATION", 374, 386], ["decrease", "OBSERVATION_MODIFIER", 527, 535]]], ["As a result, tumor proliferation, growth, and migration may be reduced.", [["tumor", "ANATOMY", 13, 18], ["tumor", "DISEASE", 13, 18], ["tumor", "CANCER", 13, 18], ["tumor proliferation", "PROBLEM", 13, 32], ["tumor proliferation", "OBSERVATION", 13, 32], ["growth", "OBSERVATION_MODIFIER", 34, 40], ["reduced", "OBSERVATION_MODIFIER", 63, 70]]], ["Additionally, the inhibition of antitumoral immune responses, as a result of the suppression of dendritic cells (DCs), T cells and natural killer cells (NKs) by PGE2, may also be reduced ( Figure 5, right-hand panel) .Tarin-biological and therapeutic propertiesFurther studies should be performed to investigate the participation of the aforementioned glycans, as well as in vivo tarin effectiveness.ConclusionTaro (Colocasia esculenta), a tuberous medicinal plant is a rich source of tarin, a GNA-related lectin.", [["dendritic cells", "ANATOMY", 96, 111], ["DCs", "ANATOMY", 113, 116], ["T cells", "ANATOMY", 119, 126], ["natural killer cells", "ANATOMY", 131, 151], ["NKs", "ANATOMY", 153, 156], ["right-hand", "ANATOMY", 199, 209], ["PGE2", "CHEMICAL", 161, 165], ["PGE2", "CHEMICAL", 161, 165], ["antitumoral", "CANCER", 32, 43], ["dendritic cells", "CELL", 96, 111], ["DCs", "CELL", 113, 116], ["T cells", "CELL", 119, 126], ["natural killer cells", "CELL", 131, 151], ["NKs", "CELL", 153, 156], ["PGE2", "SIMPLE_CHEMICAL", 161, 165], ["tarin", "SIMPLE_CHEMICAL", 380, 385], ["Colocasia esculenta", "ORGANISM", 416, 435], ["tarin", "SIMPLE_CHEMICAL", 485, 490], ["GNA", "GENE_OR_GENE_PRODUCT", 494, 497], ["lectin", "GENE_OR_GENE_PRODUCT", 506, 512], ["dendritic cells", "CELL_TYPE", 96, 111], ["DCs", "CELL_TYPE", 113, 116], ["T cells", "CELL_TYPE", 119, 126], ["natural killer cells", "CELL_TYPE", 131, 151], ["NKs", "CELL_TYPE", 153, 156], ["tarin", "PROTEIN", 485, 490], ["lectin", "PROTEIN", 506, 512], ["Colocasia esculenta", "SPECIES", 416, 435], ["Colocasia esculenta", "SPECIES", 416, 435], ["dendritic cells", "PROBLEM", 96, 111], ["natural killer cells", "TREATMENT", 131, 151], ["PGE2", "TEST", 161, 165], ["Figure", "TEST", 189, 195], ["Further studies", "TEST", 261, 276], ["ConclusionTaro (Colocasia esculenta", "PROBLEM", 400, 435], ["a tuberous medicinal plant", "PROBLEM", 438, 464], ["a GNA-related lectin", "PROBLEM", 492, 512], ["dendritic cells", "OBSERVATION", 96, 111], ["natural killer cells", "OBSERVATION", 131, 151], ["tuberous", "OBSERVATION_MODIFIER", 440, 448], ["medicinal plant", "OBSERVATION", 449, 464]]], ["Highly pure (>90%) and stable tarin samples (200 to 300 mg) can be obtained from 100 g of taro corms through a simple, low-cost and single-step purifica-tion procedure.", [["samples", "ANATOMY", 36, 43], ["tarin", "CHEMICAL", 30, 35], ["tarin samples", "CANCER", 30, 43], ["stable tarin samples", "TREATMENT", 23, 43], ["single-step purifica-tion procedure", "TREATMENT", 132, 167]]], ["Many of the traditional uses of taro as a medicinal plant have been scientifically corroborated.", [["taro", "CHEMICAL", 32, 36], ["taro", "SIMPLE_CHEMICAL", 32, 36], ["taro", "TREATMENT", 32, 36], ["a medicinal plant", "TREATMENT", 40, 57]]], ["Tarin applications for pest management using plant engineering techniques, as well as a functional additive in food should be considered.", [["Tarin applications", "TREATMENT", 0, 18], ["pest management", "TREATMENT", 23, 38], ["plant engineering techniques", "TREATMENT", 45, 73], ["a functional additive in food", "TREATMENT", 86, 115]]], ["Similar to the members of the GNA-related family, tarin is a noteworthy molecule due to its promising antiviral, antitumoral and insecticidal activities and potential as an immunomodulator molecule.", [["tarin", "CHEMICAL", 50, 55], ["GNA", "GENE_OR_GENE_PRODUCT", 30, 33], ["tarin", "GENE_OR_GENE_PRODUCT", 50, 55], ["antitumoral", "CANCER", 113, 124], ["GNA", "PROTEIN", 30, 33], ["tarin", "PROTEIN", 50, 55], ["an immunomodulator molecule", "PROBLEM", 170, 197], ["immunomodulator molecule", "OBSERVATION", 173, 197]]], ["Natural or manufactured food fortified by tarin could contribute to health maintenance and human well-being.", [["tarin", "CHEMICAL", 42, 47], ["tarin", "SIMPLE_CHEMICAL", 42, 47], ["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96]]], ["Tarin activity can be explored as a putative immunomodulatory by bringing new evidence regarding potential boosting of the immunological system in order to partially reverse immunosuppressive effects.", [["Tarin", "GENE_OR_GENE_PRODUCT", 0, 5], ["the immunological system", "TREATMENT", 119, 143], ["immunosuppressive", "OBSERVATION", 174, 191]]], ["Immunosupressive states may take advantage of tarin effects on hematopoietic and progenitor cells.", [["hematopoietic", "ANATOMY", 63, 76], ["progenitor cells", "ANATOMY", 81, 97], ["tarin", "SIMPLE_CHEMICAL", 46, 51], ["hematopoietic", "CELL", 63, 76], ["progenitor cells", "CELL", 81, 97], ["hematopoietic and progenitor cells", "CELL_TYPE", 63, 97], ["tarin effects", "TREATMENT", 46, 59], ["hematopoietic and progenitor cells", "TREATMENT", 63, 97], ["progenitor cells", "OBSERVATION", 81, 97]]], ["Tarin may also be part of future cancer therapeutics, since it may interact directly with cancer cells to inhibit tumor proliferation and the migration of malignant cells.", [["cancer", "ANATOMY", 33, 39], ["cancer cells", "ANATOMY", 90, 102], ["tumor", "ANATOMY", 114, 119], ["malignant cells", "ANATOMY", 155, 170], ["Tarin", "CHEMICAL", 0, 5], ["cancer", "DISEASE", 33, 39], ["cancer", "DISEASE", 90, 96], ["tumor", "DISEASE", 114, 119], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["cancer", "CANCER", 33, 39], ["cancer cells", "CELL", 90, 102], ["tumor", "CANCER", 114, 119], ["malignant cells", "CELL", 155, 170], ["cancer cells", "CELL_TYPE", 90, 102], ["malignant cells", "CELL_TYPE", 155, 170], ["future cancer therapeutics", "TREATMENT", 26, 52], ["cancer cells", "PROBLEM", 90, 102], ["tumor proliferation", "PROBLEM", 114, 133], ["malignant cells", "PROBLEM", 155, 170], ["cancer", "OBSERVATION", 33, 39], ["tumor", "OBSERVATION", 114, 119], ["migration", "OBSERVATION_MODIFIER", 142, 151], ["malignant cells", "OBSERVATION", 155, 170]]], ["Tarin, in its purified form described herein, could be a promising adjuvant in chemotherapeutic treatment if animal and clinical trials support its effectiveness with no serious side effects to human cells associated with the protein preparation.", [["cells", "ANATOMY", 200, 205], ["Tarin", "CHEMICAL", 0, 5], ["Tarin", "SIMPLE_CHEMICAL", 0, 5], ["human", "ORGANISM", 194, 199], ["cells", "CELL", 200, 205], ["human cells", "CELL_TYPE", 194, 205], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["a promising adjuvant", "TREATMENT", 55, 75], ["chemotherapeutic treatment", "TREATMENT", 79, 105], ["serious side effects to human cells", "PROBLEM", 170, 205], ["the protein preparation", "TREATMENT", 222, 245]]]], "bcfe0344b0bc4a32e78efcdb525728b9127547ea": [["IntroductionN ormality is our natural nest, stability our beloved home and certainty our paramount aspiration.", [["our paramount aspiration", "PROBLEM", 85, 109], ["aspiration", "OBSERVATION", 99, 109]]], ["Business people ask for risk, but properly controlled.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["As Alvin Weinberg put it:'Science deals with regularity; art deals with singularity' (Weinberg, 1985) .IntroductionAlas, from time to time, some big storm, disaster or 'situation' rears its ugly head to disturb, for a moment, the so-called 'normal' world.", [["head", "ORGANISM_SUBDIVISION", 195, 199]]], ["A dominant tendency is just to ignore such improper outbreaks, and to concentrate on the 'normal' game plans.Yet, some bold thinkers -philosophers, doctors, strategists, lawyers, mathematicians and economist -have always been captivated by such strange quirks of 'nature' and history.", [["A dominant tendency", "PROBLEM", 0, 19], ["dominant", "OBSERVATION_MODIFIER", 2, 10], ["tendency", "OBSERVATION", 11, 19]]], ["And dubious too: those studying such disturbances were incapable of providing a clear definition of their elusive 'object'.And probably blasphemous into the bargain: you do not question the gods nor the laws of nature and science.", [["such disturbances", "PROBLEM", 32, 49]]], ["In a sense, the very idea of a 'theory' of crisis appeared and still appears as a contradiction in terms, both inconsistent and suspect (B\u00e9jin & Morin, 1976) .IntroductionHowever, in addition to isolated thinkers who dared to explore such fields of experience, others succeeded in developing real schools of thought and even 'best practices' for such ordeals.", [["crisis", "PROBLEM", 43, 49]]], ["The 1960s and 1970s witnessed the remarkable development of sociological studies devoted to communities confronted with natural disasters (Quarantelli & Dynes, 1977) and studies of international crises were prolific (Hermann, 1972; Allison, 1971) .", [["sociological studies", "TEST", 60, 80]]], ["A profusion of severe turbulences were examinedinternational shocks, factory explosions, product tampering, prison protests, urban riots, football stadium tragedies, train or plane hijackings, specific financial crises, etc. Case studies multiplied and sustained efforts were made to consolidate theoretical perspectives and models (Rosenthal, Charles, 't Hart, 1989; Lagadec, 1993) .", [["turbulences", "DISEASE", 22, 33], ["A profusion of severe turbulences", "PROBLEM", 0, 33], ["specific financial crises", "PROBLEM", 193, 218], ["Case studies", "TEST", 225, 237], ["profusion", "OBSERVATION_MODIFIER", 2, 11], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["turbulences", "OBSERVATION", 22, 33]]], ["Yet a lingering plea was made to consolidate, beyond mere case studies, some better 'theory' of crisis.IntroductionThen came the turn of the millennium, with a host of new challenges to address.", [["crisis", "PROBLEM", 96, 102]]], ["It was patently clear that new kind of crises had to be considered, that a broad new ocean of complexity and 'inconceivability' had yet to be explored:'What we learn about the development and management of past crises may have limited value for improving the management of tomorrow's crises' (Rosenthal, Boin, & Comfort, 2001, vii) .IntroductionTen years later, such a warning appears more urgent than ever.", [["crises", "PROBLEM", 39, 45], ["past crises", "PROBLEM", 206, 217]]], ["Climate change and environmental issues, increasingly risk-prone vital networks, massive terrorist threats, huge increases in the cost of disasters due to global coupling and just-in-time production methods, global civil unrest, financial and economic meltdowns show that we have to deal, not with something more, but with something else (Boin & Lagadec, 2000) .", [["Climate change and environmental issues", "PROBLEM", 0, 39], ["massive terrorist threats", "PROBLEM", 81, 106], ["global coupling", "PROBLEM", 155, 170], ["huge", "OBSERVATION_MODIFIER", 108, 112], ["increases", "OBSERVATION_MODIFIER", 113, 122]]], ["In response, the concept of mega crisis has been put forward and is now trying to get its head around a whole set of questions and theoretical challenges (Helsloot, Boin, Jacobs, & Comfort, 2012) .IntroductionBut scale is certainly not the most difficult factor of rupture.", [["head", "ANATOMY", 90, 94], ["rupture", "DISEASE", 265, 272], ["head", "ORGANISM_SUBDIVISION", 90, 94], ["mega crisis", "PROBLEM", 28, 39], ["rupture", "PROBLEM", 265, 272], ["mega crisis", "OBSERVATION", 28, 39], ["rupture", "OBSERVATION", 265, 272]]], ["Crises appear to have taken on an entirely new dimension: they are no longer isolated accidents capable of threatening large subsystems -the core of our theoretical fabric of crisis theory in use.", [["accidents", "DISEASE", 86, 95], ["Crises", "PROBLEM", 0, 6], ["no", "UNCERTAINTY", 67, 69]]], ["They have increasingly become opportunistic expressions of global turbulences impacting our social fabrics, while at the same time our bedrocks are losing their firmness of footing by being exposed to violent liquefaction processes.", [["global turbulences", "PROBLEM", 59, 77], ["violent liquefaction processes", "PROBLEM", 201, 231], ["opportunistic", "OBSERVATION_MODIFIER", 30, 43], ["global", "OBSERVATION_MODIFIER", 59, 65], ["turbulences", "OBSERVATION", 66, 77], ["social fabrics", "OBSERVATION", 92, 106]]], ["All the various isolated currents of vulnerability seem to be meshing to produce a global volatile, chaotic, incomprehensible theatre of operations.IntroductionA quarter of a century after the blossoming of crisis studies, the need for a decisive breakthrough appears crucial in the present world, where crisis is no longer the marginal exception but the core engine.IntroductionHence, tough questions arise.", [["crisis studies", "TEST", 207, 221], ["a decisive breakthrough", "PROBLEM", 236, 259], ["global", "OBSERVATION_MODIFIER", 83, 89], ["volatile", "OBSERVATION_MODIFIER", 90, 98], ["no longer", "UNCERTAINTY", 314, 323]]], ["If not, Kouzmin's perspective must be taken on board -'Crisis Management in Crisis' (Kouzmin, 2008) .What can be put forward at the theoretical level to ensure that analytical tools are able to grasp present realities -which are no longer those of last century?", [["Kouzmin's perspective", "TREATMENT", 8, 29]]], ["This does not mean that we throw all known practices overboard, but that we must open new windows, to shed new light upon challenges poorly addressed by existing theories.IntroductionThe aim of this contribution is to try to tackle this formidable theoretical and managerial challenge.", [["managerial challenge", "TREATMENT", 264, 284]]], ["Finally, we will look at how this original framework can lay the theoretical basis for effective crisis management.IntroductionClearly, this contribution will not settle all the problems or clarify all the theoretical questions.", [["effective crisis management", "TREATMENT", 87, 114]]], ["It will take many years to build a satisfying theory and to forge new practices for the new world of crises.Terra incognitaIndeed, our field of experience is witnessing too many upheavals to leave our visions, hypotheses and tools unquestioned, and these same visions, hypotheses and tools have to be reforged if we still want to be in a position to grasp and deal with the realities that are now shaping and overwhelming our history.Another theatre of operations: 'There is no box anymore'It is common to reject any idea of novelty, especially in the disaster and crisis area -'Nothing new under the sun'.", [["crises", "PROBLEM", 101, 107], ["crisis area", "PROBLEM", 565, 576]]], ["It is traditional to recall the cataclysmic events that have marked history or prehistory (without referring to myths like the Deluge) from the extinction of the dinosaurs by a meteorite, the end of the Minoan civilization due to a volcanic eruption, the Black Death (1347-1352) which decimated Europe, the Laki eruption (1783) and its contribution to the French Revolution, up to the Great Flu (1918) which killed more human beings than the Great War, the 1929 crisis, and so on and so forth.", [["eruption", "DISEASE", 241, 249], ["Death", "DISEASE", 261, 266], ["human", "ORGANISM", 420, 425], ["human", "SPECIES", 420, 425], ["human", "SPECIES", 420, 425], ["the Minoan civilization", "TREATMENT", 199, 222], ["a volcanic eruption", "PROBLEM", 230, 249], ["the Laki eruption", "PROBLEM", 303, 320], ["volcanic eruption", "OBSERVATION", 232, 249]]], ["Not forgetting 'near misses' such as the Cuban missile crisis (1962), when the future of mankind was in the balance only to be saved from the brink by the intelligence of a few -or, according to the latest analyses by Robert McNamara (Morris, 2003 ) -by sheer luck.Another theatre of operations: 'There is no box anymore'theories developed in the last decades of the previous century, has commonly been rejected.", [["no", "UNCERTAINTY", 306, 308], ["rejected", "OBSERVATION", 403, 411]]], ["Beyond immediate 'facts' -from Katrina to Fukushima, from the global financial and economic meltdown to global outbursts of civil unrest -we need to clarify structural factors that change the whole territory of crises, and call for a decisive upgrade of crisis theory.Another theatre of operations: 'There is no box anymore'\u2022 From large-scale to off-scale: major events are not new, but they have got denser, and appear to affect greater numbers, even entire continents and the entire planet, threatening millions, hundred of millions -because of blackouts, pandemics, economic upheavals and social implosions.", [["blackouts", "DISEASE", 547, 556], ["pandemics", "DISEASE", 558, 567], ["structural factors", "PROBLEM", 157, 175], ["crises", "PROBLEM", 211, 217], ["blackouts", "PROBLEM", 547, 556], ["pandemics", "PROBLEM", 558, 567], ["no", "UNCERTAINTY", 309, 311]]], ["Multiplication and concomitance of such mega shocks lead to situations where the means are overwhelmed, where everyone or almost, is under the threat.Another theatre of operations: 'There is no box anymore'\u2022 From complexity to the unreadable: everything can be qualified as complex, but such events as Hurricane Katrina (2005) have shown how today mega shocks can trigger tremors that are impossible to categorize and map.", [["tremors", "DISEASE", 372, 379], ["such mega shocks", "TREATMENT", 35, 51], ["tremors", "PROBLEM", 372, 379], ["map", "TEST", 418, 421], ["no", "UNCERTAINTY", 191, 193]]], ["The case of Hurricane Irene (2011) striking the east side of the American continent is a warning sign: it is impossible to know in advance the potential multiple-head strikes and disruption dynamics -airports, stock exchange, vital networks, military capacities, etc. -of such mega shocks.The field of the complex event gives way to the totally elusive global situation.Another theatre of operations: 'There is no box anymore'\u2022 From tightly-coupled to total interdependence: much has been said, in the 20th century, on critical infrastructures and coupled interdependent systems (Perrow, 1984 (Perrow, , 2007 .", [["head", "ANATOMY", 162, 166], ["head", "ORGANISM_SUBDIVISION", 162, 166], ["multiple-head strikes", "PROBLEM", 153, 174], ["disruption dynamics", "PROBLEM", 179, 198], ["such mega shocks", "TREATMENT", 272, 288], ["head", "ANATOMY", 162, 166], ["mega shocks", "OBSERVATION", 277, 288], ["no", "UNCERTAINTY", 411, 413]]], ["We are now switching to another picture: there is no longer a mere chain of interactions, but 'piles' of activities, 'biologically' entangled and intertwined.", [["no longer", "UNCERTAINTY", 50, 59]]], ["Hence, shocks trigger swells that swallow up 'totalities', beyond the idea of incremental transmission.", [["shocks trigger swells", "PROBLEM", 7, 28]]], ["Reverberation dynamics are unfolding, not only on the ground and from one place to another, but from one network to another, one hub to another, one underlying fabric to another -locally, nationally and globally.This was a characteristic of Fukushima (2011): the plant, the adjacent territory, the province, the nation and the world (with the partial loss of key electronic components, becoming more severe after the additional flooding inThailand).We have clearly switched from complex problems to something else.Another theatre of operations: 'There is no box anymore'\u2022 From high speed to instantaneity: case studies in the 20th century had always underlined the speed factor, especially when it dealt with media coverage.", [["Reverberation dynamics", "PROBLEM", 0, 22], ["the partial loss of key electronic components", "PROBLEM", 339, 384], ["the additional flooding inThailand", "TREATMENT", 413, 447], ["case studies", "TEST", 606, 618], ["media coverage", "TREATMENT", 709, 723], ["fabric", "OBSERVATION", 160, 166], ["territory", "OBSERVATION_MODIFIER", 283, 292], ["no", "UNCERTAINTY", 555, 557]]], ["We are now switching to something else and with a qualitative leap: in 2003, the SARS virus travelled from Hong Kong to Toronto within a few hours, and the capital city of Ontario was deep in crisis before the World Health Organization sounded the worldwide alert; in 2010, Wall Street witnessed the 'disappearance' of 700 billion US $ in just 7 milliseconds.", [["SARS", "DISEASE", 81, 85], ["SARS virus", "SPECIES", 81, 91], ["the SARS virus", "PROBLEM", 77, 91]]], ["More radical still: electronic media coverage is now totally in real time, globally.", [["electronic media coverage", "TREATMENT", 20, 45], ["radical", "OBSERVATION_MODIFIER", 5, 12]]], ["During the top secret operation against Bin Laden, the news of the attack was already on Twitter as the core strategic group was following the assault from the West Wing war room; during the shootings in Liege (Belgium, 14 December 2011), one tweet said that the gunman was in police uniform: and one sees the crowd fleeing from the police, the police not being aware of that item of news.Another theatre of operations: 'There is no box anymore'\u2022 From local events to in-depth dislocation: this is the most decisive watershed.", [["dislocation", "DISEASE", 477, 488], ["no", "UNCERTAINTY", 430, 432], ["dislocation", "OBSERVATION", 477, 488]]], ["In addition, such a strike occurred within a closed field, naturally robust and stable.", [["a strike", "PROBLEM", 18, 26], ["strike", "OBSERVATION", 20, 26], ["stable", "OBSERVATION_MODIFIER", 80, 86]]], ["Studies tried to explain how the event could affect a large territory, step by step, and how the environment could finally absorb the shocks coming from the initial 'Ground Zero'.", [["Studies", "TEST", 0, 7], ["large", "OBSERVATION_MODIFIER", 54, 59], ["territory", "OBSERVATION", 60, 69]]], ["Now, due to global interdependences, shockwaves are finding a milieu favourable to instant chain effects without 'watertight compartments'.As Arjen Boins underlines: 'The modern crisis does not confine itself to a particular policy area (say health or energy); it jumps from one field to the other, unearthing issues and recombining them into unforeseen mega-threats' (Boin, 2004, p.", [["global interdependences", "PROBLEM", 12, 35], ["shockwaves", "PROBLEM", 37, 47], ["The modern crisis", "PROBLEM", 167, 184], ["global", "OBSERVATION_MODIFIER", 12, 18], ["interdependences", "OBSERVATION", 19, 35], ["chain effects", "OBSERVATION", 91, 104]]], ["166) .Another theatre of operations: 'There is no box anymore'Moreover, fundamental fabrics (environment, economy, culture, etc.) are often in a state of preliquefaction, already very fragile.The slightest quiver can develop into extreme tremors.The event itself does not unfold in an absorbent milieu, but in a resonance chamber.", [["tremors", "DISEASE", 238, 245], ["culture", "TEST", 115, 122], ["preliquefaction", "PROBLEM", 154, 169], ["very fragile", "PROBLEM", 179, 191], ["extreme tremors", "PROBLEM", 230, 245], ["a resonance chamber", "TREATMENT", 310, 329], ["no", "UNCERTAINTY", 47, 49], ["fragile", "OBSERVATION", 184, 191], ["extreme", "OBSERVATION_MODIFIER", 230, 237], ["tremors", "OBSERVATION", 238, 245], ["absorbent milieu", "OBSERVATION", 285, 301]]], ["This milieu is prone to triggering rogue waves through the combination-recombination of single shocks.", [["single shocks", "TREATMENT", 88, 101]]], ["Hence, it becomes quasi impossible to trace an event on a graph, along predefined lines.", [["a graph", "TEST", 56, 63]]], ["The paradigm has shifted.", [["shifted", "OBSERVATION_MODIFIER", 17, 24]]], ["We are just now witnessing the conflagration triggered in the Arab world by a film posted on Internet: a low cost weapon of mass dislocation.Another theatre of operations: 'There is no box anymore'\u2022 From uncertainty to ignorance: there is no such thing as a risk or a crisis without uncertainty, but we are now driven into 'voids' of understanding and action that epitomize a loss of fundamental reference points.", [["dislocation", "DISEASE", 129, 140], ["a film", "TEST", 76, 82], ["mass dislocation", "PROBLEM", 124, 140], ["a crisis", "PROBLEM", 266, 274], ["a loss of fundamental reference points", "PROBLEM", 374, 412], ["mass dislocation", "OBSERVATION", 124, 140], ["no", "UNCERTAINTY", 182, 184], ["no", "UNCERTAINTY", 239, 241]]], ["Instantaneity, absorption of large parts of realities until then isolated, abundance of reverberations, rogue wave multiplication, loss of fundamental anchors and bedrocks . . . all this casts us adrift far beyond our familiar theatres of operations, be they intellectual or managerial.", [["Instantaneity", "TREATMENT", 0, 13], ["rogue wave multiplication", "PROBLEM", 104, 129], ["loss of fundamental anchors", "PROBLEM", 131, 158], ["large", "OBSERVATION_MODIFIER", 29, 34]]], ["The challenge is no longer to grasp uncertainty at the margins of a strong core of knowledge.", [["no longer", "UNCERTAINTY", 17, 26]]], ["One is instantly confronted with the unknown, with territories where cardinal hypotheses no longer have purchase.Another theatre of operations: 'There is no box anymore'Indeed, one could argue that not one recent event adequately translates such a model.", [["no longer", "UNCERTAINTY", 89, 98]]], ["However, it is easy to plead when considering Fukushima -economic and social dislocation, the environmental and energetic challenges, etc. -that the picture sketched above is beginning to emerge.Another theatre of operations: 'There is no box anymore'The concept of 'wicked problems', introduced by Rittel and Webber as early as 1973 is probably the most appropriate one to translate such realities (Rittel & Webber, 1973) .", [["dislocation", "DISEASE", 77, 88], ["Fukushima -economic and social dislocation", "PROBLEM", 46, 88], ["social dislocation", "OBSERVATION", 70, 88]]], ["When proposed, it applied to a few difficult issues; it now appears useful and even necessary to grasping the vast majority of our challenges in the crisis field.The basic idea is that the bulk of our conceptual and operational toolbox is designed to deal with tame problems: those that can be precisely defined, whose causes can be specified, that can be resolved by gathering additional data, by breaking them down into smaller problems, and by applying specific remedial techniques (Camillus, 2008) .", [["a few difficult issues", "PROBLEM", 29, 51], ["tame problems", "PROBLEM", 261, 274]]], ["In the conventional line of thinking, crisis issues do not trigger intractable societal discussion.Another theatre of operations: 'There is no box anymore'Wicked issues do not fall into any of these 'normal' niches, which are essential to us.There is no consensus on the definition of the problem-the very idea of a 'definition' is even irrelevant.", [["crisis issues", "PROBLEM", 38, 51], ["no", "UNCERTAINTY", 251, 253]]], ["The search for solutions never stops, there is no ultimate test of a solution since any response generates unexpected consequences, and each implemented solution has consequences that cannot be undone.", [["a solution", "TREATMENT", 67, 77]]], ["Rittel and Webber put it bluntly: 'the classic paradigm of science and engineering -the paradigm that has underlain modern professionalism -is not applicable to the problems of open societal systems' (Rittel & Webber, 1973, p.", [["open societal systems", "TREATMENT", 177, 198]]], ["Judgment becomes crucial.", [["crucial", "OBSERVATION_MODIFIER", 17, 24]]], ["Fundamental values also become part of the problem, and elusive when called upon to ground a given analysis, decision or implementation.", [["Fundamental values", "TEST", 0, 18]]], ["The probabilistic approach becomes ineffective.", [["ineffective", "OBSERVATION_MODIFIER", 35, 46]]], ["Every single move triggers possible global mutations within the system and within its global context, trial and error strategies are no longer appropriate: every move is a one off move.Another theatre of operations: 'There is no box anymore'These are indeed the core characteristics of mega crises, qualitatively different from 'traditional' eventfocused crises.The starting point can no longer be the event -the crisis field must clearly depart from the emergency domain, which has been the original niche of crisis analyses and practices.", [["global mutations within the system", "PROBLEM", 36, 70], ["mega crises", "PROBLEM", 286, 297], ["'traditional' eventfocused crises", "PROBLEM", 328, 361], ["mega crises", "OBSERVATION", 286, 297], ["no longer", "UNCERTAINTY", 385, 394]]], ["The structural issue must be the global dynamics of dislocation.We are no longer dealing with specific crises, but with crisis stages where everything is linked and mutating.", [["dislocation", "DISEASE", 52, 63], ["dislocation", "PROBLEM", 52, 63], ["specific crises", "PROBLEM", 94, 109], ["crisis stages", "PROBLEM", 120, 133], ["dislocation", "OBSERVATION", 52, 63], ["no longer", "UNCERTAINTY", 71, 80]]], ["Dynamics are not so much mechanical chain reaction effects as engulfing global vortices.", [["mechanical chain reaction effects", "PROBLEM", 25, 58], ["engulfing", "OBSERVATION_MODIFIER", 62, 71], ["global vortices", "OBSERVATION", 72, 87]]], ["Hence, we could put forward a tentative definition of the mega crisis as -the embedded engine of an overly complex world that evolves and mutates through global dynamics whose texture is made up of unstable webs of ongoing, major dislocations.", [["dislocations", "DISEASE", 230, 242], ["the mega crisis", "PROBLEM", 54, 69], ["major dislocations", "PROBLEM", 224, 242], ["mega crisis", "OBSERVATION", 58, 69], ["unstable", "OBSERVATION_MODIFIER", 198, 206], ["webs", "OBSERVATION", 207, 211], ["major", "OBSERVATION_MODIFIER", 224, 229], ["dislocations", "OBSERVATION", 230, 242]]], ["The current reality, on all fronts, opens a new landscape: As Mike Granatt puts it: 'There is no box anymore' (Granatt, 2011) .The need to revisit our theoretical frameworkOutstanding constant features have marked our reflections on the notion of crisis since the end of the 1970s: the vigorous calling for the absolute necessity of a solid theorization so that crisis study could be recognized as a genuine science; frustration due to the extreme difficulty encountered in satisfying conventional demands to secure a grading of academic excellence; hesitation between the addition of case studies, giving way to ever more data, but poor additive knowledge and an extraordinarily difficult theorization, impossible indeed within the usual and normative codes.The whole leading to a contrasted situation made up of undeniable advances in the building of a reference body and in case-study publication, but with repeated calls for a better theorization capable of observing the canons of a noble discipline, well recognized by the scientific world.", [["body", "ANATOMY", 865, 869], ["body", "ORGANISM_SUBDIVISION", 865, 869], ["crisis", "PROBLEM", 247, 253], ["a solid theorization", "TREATMENT", 333, 353], ["crisis study", "TEST", 362, 374], ["the extreme difficulty", "PROBLEM", 436, 458], ["case studies", "TEST", 585, 597], ["an extraordinarily difficult theorization", "PROBLEM", 661, 702], ["marked", "OBSERVATION_MODIFIER", 207, 213]]], ["There is something pathetic in this frantic race.", [["pathetic", "OBSERVATION_MODIFIER", 19, 27]]], ["The demands to be satisfied in order to secure a degree of recognition are in effect essentially incompatible with the substance of the crisis phenomenon and the kind of intelligence it requires.", [["the crisis phenomenon", "PROBLEM", 132, 153], ["crisis phenomenon", "OBSERVATION", 136, 153]]], ["As the issue of crises becomes increasingly more strategic, it is urgent to understand and to establish as a founding principle the fact that crisis studies cannot satisfy the requirements of classical theoretical models.", [["crises", "PROBLEM", 16, 22], ["crisis studies", "TEST", 142, 156]]], ["Crisis studies must not beg for recognition by simply trying to play into paradigms that are not and cannot be theirs; they must open their own fields and routes.", [["Crisis studies", "TEST", 0, 14]]], ["If not, crisis intelligence will exhaust itself, and miss its target by the same token.The need to revisit our theoretical frameworkThis supposes, first and foremost, accepting to break, however painfully, with the past so as to escape the usual pitfalls -and to open new routes.", [["crisis intelligence", "PROBLEM", 8, 27]]], ["Instead of requoting here, the ever mentioned founding texts (Hermann, 1972; B\u00e9jin & Morin, 1976; Rosenthal et al., 1989) , rewriting pages now become classic (Lagadec, 1993, pp. 24-41; Dayton, 2004) , citing the conventional references (the Greek tradition, medicine, economic references, psychology, etc.), or trying to embrace the whole of organization theory literature -we will focus on a critical handful of stumbling blocks that must be decisively revisited.The need to revisit our theoretical framework\u2022 Definition.", [["stumbling blocks", "PROBLEM", 414, 430]]], ["The literature is marked by a ritual: emphatic regret for the lack of 'really scientific' definition of the crisis concept has become a matter of course.", [["the crisis concept", "PROBLEM", 104, 122], ["marked", "OBSERVATION_MODIFIER", 18, 24], ["crisis", "OBSERVATION", 108, 114]]], ["Nothing here is all that new.", [["new", "OBSERVATION_MODIFIER", 25, 28]]], ["However, such accusations and regrets are not false, especially with the growing importance of the mass media, so fond of the little word.", [["the mass media", "PROBLEM", 95, 109], ["mass", "OBSERVATION", 99, 103]]], ["But it is necessary to go beyond these basic condemnations: they tell us more about the limits of our understanding of crises than about the intrinsic limits of the concept itself.The need to revisit our theoretical frameworkThe core of crisis is precisely the fact that an event, a dynamic, does not fit into the conventional references, formats and codes -and moreover, is threatening to destroy those very references, formats and codes.", [["crisis", "PROBLEM", 237, 243], ["crisis", "OBSERVATION", 237, 243]]], ["176) . are right when they underline: 'It is our contention that crisis management deals with problems that are inherently ill-structured. . . .To insist, therefore, on agreement as a precondition for studying ill-structured problems, is to ignore and to deny their basic nature.", [["crisis management", "TREATMENT", 65, 82], ["right", "ANATOMY_MODIFIER", 11, 16]]], ["Even if it is useful to explore, find and use formulations that help to shape and consolidate approaches of the crisis phenomenon, it is necessary to state a preliminary and basic condition:'crisis' will resist any attempt to be 'defined'.", [["formulations", "TREATMENT", 46, 58], ["the crisis phenomenon", "PROBLEM", 108, 129], ["'crisis", "PROBLEM", 190, 197]]], ["Moreover, the underlying principle to be laid down should be that any request for a definitive, clear and univocal definition of the concept should be understood as a cognitive and psychic refusal to genuinely accept and explore crisis territory.The need to revisit our theoretical framework\u2022 Classification.", [["a cognitive and psychic refusal", "PROBLEM", 165, 196]]], ["Crisis literature is marked by constant efforts to deliver typologies (natural, technological, social), segmentations (internal, external, technical, organizational), time scaling (before, during, after), categories (from product defects to international crises, etc.) and myriads of crisis components, in a kind pointillist picture helping to fix at least some part of this elusive reality.", [["Crisis literature", "PROBLEM", 0, 17], ["segmentations (internal, external, technical, organizational)", "PROBLEM", 104, 165], ["categories (from product defects to international crises", "PROBLEM", 205, 261], ["crisis components", "PROBLEM", 284, 301], ["marked", "OBSERVATION_MODIFIER", 21, 27], ["crisis", "OBSERVATION", 284, 290]]], ["All these attempts to characterize the crisis phenomenon are interesting and useful, if only they do not strive to reach an erroneous objective.", [["the crisis phenomenon", "PROBLEM", 35, 56]]], ["In crisis territory, more than in any other,a typology can help to clarify -a little -the theatre of operations, but must not dream of locking it down.", [["operations", "TREATMENT", 101, 111], ["crisis", "OBSERVATION_MODIFIER", 3, 9], ["territory", "OBSERVATION_MODIFIER", 10, 19]]], ["Mutating, elusive realities do not let themselves be taken prisoner.The need to revisit our theoretical frameworkIn essence, crisis is, and will remain, a wild and maverick reality, impossible to understand and grasp within frameworks shaped, built and stamped to contain stable and repeated phenomena.", [["crisis", "PROBLEM", 125, 131], ["crisis", "OBSERVATION", 125, 131], ["stable", "OBSERVATION_MODIFIER", 272, 278]]], ["Crisis studies and theory of crisis management have developed in the wake of risk analysis.", [["Crisis studies", "TEST", 0, 14], ["crisis management", "TREATMENT", 29, 46], ["risk analysis", "TEST", 77, 90]]], ["The conventional view is that crisis develops when risk control has failed, when 'residual risks' have taken their toll.", [["crisis", "PROBLEM", 30, 36]]], ["The good news is that the whole is clearly measured, with probabilities.", [["good", "OBSERVATION_MODIFIER", 4, 8]]], ["And crisis lies in a residual territory, limited in essence.", [["crisis", "PROBLEM", 4, 10], ["crisis", "OBSERVATION", 4, 10], ["residual", "OBSERVATION_MODIFIER", 21, 29], ["territory", "OBSERVATION_MODIFIER", 30, 39]]], ["The new theatre of operations in the risk domain compels us to step outside of this vision of 'residual accidents'.The ingredients of a new vision are pointed up, but with caution, in Bernstein's (1996) 'Remarkable story of risks'.The conquest of the crepuscular territory of risks has been extraordinary throughout the centuries but many 'details' that could have been ignored in the past now rush back to centre stage as we enter a much more complex, turbulent, volatile world.", [["operations", "TREATMENT", 19, 29], ["a new vision", "PROBLEM", 134, 146], ["new", "OBSERVATION_MODIFIER", 4, 7], ["new", "OBSERVATION_MODIFIER", 136, 139], ["crepuscular", "OBSERVATION_MODIFIER", 251, 262], ["territory", "OBSERVATION_MODIFIER", 263, 272], ["extraordinary", "OBSERVATION_MODIFIER", 291, 304], ["more complex", "OBSERVATION_MODIFIER", 439, 451], ["turbulent", "OBSERVATION_MODIFIER", 453, 462], ["volatile world", "OBSERVATION", 464, 478]]], ["The issue is that such difficulties, marginal in a stable, controlled and compartmentalized world, are capable of overwhelming the whole landscape in a globalized, volatile and turbulent world.", [["such difficulties", "PROBLEM", 18, 35], ["marginal", "OBSERVATION_MODIFIER", 37, 45], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["turbulent", "OBSERVATION_MODIFIER", 177, 186]]], ["This is exactly Bernstein's ultimate point: the cosmology of risks, and hence of crises, could mutate since 'Discontinuities, irregularities and volatilities seem to be proliferating rather than diminishing' (p.", [["crises", "PROBLEM", 81, 87], ["irregularities and volatilities", "PROBLEM", 126, 157]]], ["329).The need to revisit our theoretical frameworkIf, as it is the case today, the world is mutating and is now shaped around volatility, discontinuity and nonlinearity, then our whole cosmology based on regularity measurement and modelling appears suddenly outmoded and leaves a huge theoretical void.", [["discontinuity and nonlinearity", "PROBLEM", 138, 168], ["regularity measurement", "TEST", 204, 226], ["nonlinearity", "OBSERVATION_MODIFIER", 156, 168]]], ["How to think, model and handle instability, shifting dynamics and the intrinsically mutating?The all season challenge: overcoming 'normal science', opening routes into the unknownThe Age of the Unthinkable (Cooper Ramo, 2009) demands a radically new science and new theoretical foundations.", [["handle instability", "PROBLEM", 24, 42], ["shifting dynamics", "PROBLEM", 44, 61]]], ["Crisis is a specific 'object', which demands a specific, different, theoretical universe.", [["Crisis", "PROBLEM", 0, 6]]], ["But cognitive habits, academic recognition constraints, the difficulties of any discovery process and probably above all,the great ordeals that accompany any exploration of the unknown -'It was as if the ground had been pulled out from under one, with no firm foundation to be seen anywhere, upon which one could have built' (Einstein,in Kuhn,1962,p.83 ) -tend to lead to 'normal thinking' rather than invention.", [["academic recognition constraints", "PROBLEM", 22, 54], ["any exploration", "TEST", 154, 169], ["no", "UNCERTAINTY", 252, 254], ["firm", "OBSERVATION", 255, 259]]], ["An illuminating example of such recoil has been given in a book recently written on the subject of cataclysmic risks.The author of one of the chapters rightly underlines that, for such off-scale risks, it would be necessary to change our paradigm; but his whole contribution is strictly embedded in 'normal science, normal knowledge'.", [["such recoil", "TREATMENT", 27, 38]]], ["He explains: 'The challenge of existential risks to rationality is that, the catastrophe being so huge, people snap into a different mode of thinking. . . .", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["the catastrophe", "PROBLEM", 73, 88]]], ["114) .The all season challenge: overcoming 'normal science', opening routes into the unknownThe fundamental challenge for academics is to understand and confront the violent negative reaction to any attempt to produce, or even to admit the necessity of, new theoretical ground and practices.", [["the violent negative reaction", "PROBLEM", 162, 191]]], ["And there is a cardinal responsibility in science: understanding the moment when a dominant paradigm, which inspired and structured scientific and operational activity until then, begins to show signs of inadequacy.", [["a dominant paradigm", "PROBLEM", 81, 100]]], ["Such a requirement becomes a failing if evidence accumulates to indicate that the hypotheses, visions and tools of reference no longer fit, while people stubbornly remain -out of habit, myopia or terror of change -within outmoded maps.That scientific demand is all the more extreme in the risk and crisis arena: theoretical fault lines rapidly and inevitably lead to collective tragedies.", [["myopia", "DISEASE", 186, 192], ["people", "ORGANISM", 146, 152], ["fault lines", "CELL", 324, 335], ["theoretical fault lines", "CELL_LINE", 312, 335], ["people", "SPECIES", 146, 152], ["myopia", "PROBLEM", 186, 192], ["theoretical fault lines", "PROBLEM", 312, 335], ["myopia", "OBSERVATION", 186, 192], ["more extreme", "OBSERVATION_MODIFIER", 269, 281], ["fault lines", "OBSERVATION", 324, 335]]], ["The intellectual fault line has been a decisive driver of failures and repeated fiascos in crisis territory.", [["fiascos", "DISEASE", 80, 87], ["The intellectual fault line", "PROBLEM", 0, 27], ["failures", "PROBLEM", 58, 66], ["repeated fiascos in crisis territory", "PROBLEM", 71, 107], ["intellectual", "OBSERVATION_MODIFIER", 4, 16], ["fault line", "OBSERVATION", 17, 27], ["failures", "OBSERVATION", 58, 66], ["crisis", "OBSERVATION_MODIFIER", 91, 97], ["territory", "OBSERVATION_MODIFIER", 98, 107]]], ["5), which imposes its norms and bans is more than reluctant to wander beyond usual closed-in and reassuring frameworks.The usual day-to-day accepted work consists of documenting 'residual ambiguities' (p.", [["residual ambiguities", "OBSERVATION", 179, 199]]], ["The obstacle is all the more unyielding in the crisis field because, precisely, the very prospect of going beyond 'signed and sealed' schemes often triggers an instant and irrepressible need for protection and negationwhich leads to further entrenchment in conventionaloutmoded, yet so comfortable -practices and theories.The all season challenge: overcoming 'normal science', opening routes into the unknownWithin this line of thinking, any questioning of the dominant paradigm is an immediate ordeal for anyone trying to open up the approach.", [["protection", "TREATMENT", 195, 205]]], ["In the words of Hegel (1820): 'The owl of Minerva takes its flight only as the shades of night are gathering'.The all season challenge: overcoming 'normal science', opening routes into the unknownThe issue of the effective relevance of our reference models is however, crucial and must be subject to repeated auditing, all the more rigorous and frequent, given that the stakes are high, and the environments mutating and turbulent.That is precisely the case now as we enter the second decade of the 21st century.The all season challenge: overcoming 'normal science', opening routes into the unknownAs Thomas Kuhn (1962) has underlined, when a current theory encounters more and more difficulties in its attempt to encapsulate reality, the time is ripe for a paradigm shift.This appears to be the case in the crisis world -and in management science globally.", [["turbulent", "OBSERVATION_MODIFIER", 421, 430], ["appears to be", "UNCERTAINTY", 778, 791]]], ["It requires the acceptance of the risk of trial and error, the acceptance of great discomfort.", [["great discomfort", "PROBLEM", 77, 93]]], ["After all, exploration beyond known paradigms is a vertiginous affair.", [["exploration", "TEST", 11, 22], ["a vertiginous affair", "PROBLEM", 49, 69], ["vertiginous affair", "OBSERVATION", 51, 69]]], ["It requires acceptance of denial: it is impossible to convince people of the validity of a new paradigm with the arguments of the previous paradigm; moreover: any paradigm shift will be a source of anxiety, and blunt refusal is the usual initial response.The all season challenge: overcoming 'normal science', opening routes into the unknownThere are numerous new pathways to be explored, tested, rejected or elicited.", [["anxiety", "DISEASE", 198, 205], ["people", "SPECIES", 63, 69], ["anxiety", "PROBLEM", 198, 205], ["blunt refusal", "PROBLEM", 211, 224], ["numerous new pathways", "PROBLEM", 351, 372], ["numerous", "OBSERVATION_MODIFIER", 351, 359], ["new", "OBSERVATION_MODIFIER", 360, 363]]], ["Thus, in the second section we are going to modestly open up a few avenues and propose a number of signposts from the field of fractal geometry.", [["fractal geometry", "OBSERVATION", 127, 143]]], ["It is important to go further, yet with caution.A new paradigm: fractal geometry for crisis theoryFractal geometry, formalized and developed by Benoit Mandelbrot, has shown its importance in areas subject to crisis such as finance, a domain also well known for its great complexity, volatility and discontinuity (Mandelbrot, 1982) .", [["crisis", "PROBLEM", 85, 91], ["fractal geometry", "OBSERVATION", 64, 80], ["Fractal geometry", "OBSERVATION", 98, 114]]], ["It is therefore natural to wonder whether this body of concepts could be used in the field of contemporary crises, which also show these same features.", [["contemporary crises", "PROBLEM", 94, 113]]], ["This line of thought in terms of fractal geometry is not entirely new (Sornette, 2006) , but it is worth giving it a second look as mega crises (Helsloot et al., 2012; Lagadec & Topper, 2012 ) are more than ever becoming the norm.", [["mega crises", "PROBLEM", 132, 143], ["fractal geometry", "OBSERVATION", 33, 49], ["not entirely", "UNCERTAINTY", 53, 65], ["new", "OBSERVATION_MODIFIER", 66, 69]]], ["The first challenge is to master the scientific use of a foreign set of concepts in order to apply them to the field considered here.", [["a foreign set of concepts", "TREATMENT", 55, 80]]], ["The idea is not to propose a 'miraculous key' or a ready-to-use toolbox but rather to initiate new thinking, innovative perspectives for the field of crises, through the understanding of the potentials and limitations of this approach.Importing theories: danger and opportunityWhen one happens upon the need for a paradigm shift in the theory of complex societal phenomena, as is the case today in the theory of contemporary crises, the temptation exists to import apparently attractive, but sometimes illusory, 'theories' from elsewhere -especially from the world of physics and mathematics.", [["toolbox", "TREATMENT", 64, 71], ["crises", "PROBLEM", 150, 156], ["this approach", "TREATMENT", 221, 234], ["a paradigm shift", "TREATMENT", 312, 328], ["contemporary crises", "PROBLEM", 412, 431]]], ["Moreover, such concepts and theories cannot be extended to social sciences simply because they cannot, by definition, be translated from mathematical language to that of the social sciences (Thi\u00e9tart & Forgues, 1995) .Importing theories: danger and opportunityIf such imports are to be made, it is only provided that:Importing theories: danger and opportunity\u2022 The underlying assumptions of the imported theoretical concepts and ideas are effectively understood (beyond the mere attractiveness of the words and images used);Importing theories: danger and opportunity\u2022 The contribution is not put forward as a solution or an explanation to everything, but as a means to open up new avenues that will bring new theoretical perspectives and operational avenues.Importing theories: danger and opportunityIn this paper, we argue that it is possible to develop the new concept of fractal crises and show how the principles it is based upon can be of real help in deepening our understanding of crisis theory and in offering ways -among other new avenues -to renew crisis management theory.Importing theories: danger and opportunityWe will also underline the limits of the proposition: fractal geometry cannot answer all the challenges that contemporary crises bring up and shall not be applied without a careful reflection on its practicability.Keys to complex dynamics and volatilityMandelbrot suggested that the underlying mathematics behind market prices is based on fractals (Mandelbrot, 2005) .", [["fractal crises", "PROBLEM", 874, 888], ["crisis management", "TREATMENT", 1058, 1075], ["contemporary crises", "PROBLEM", 1234, 1253], ["fractal crises", "OBSERVATION", 874, 888]]], ["A fractal can be defined as 'a geometric shape that can be split into parts, each of which is a reducedsize copy of the whole', a property called self-similarity, which itself is a subset of a larger class called invariance principles.Keys to complex dynamics and volatilityHence, fractals and invariance principles are strongly linked.", [["fractal", "OBSERVATION", 2, 9]]], ["Such invariance principles are beloved of physicists and mathematicians, because finding an invariant means finding a key to grasping the way the system is behaving, as this property is intrinsic to the system under study.Keys to complex dynamics and volatilityWhat we will be doing here is not only basing ourselves on invariance principles, but it going beyond Mandelbrot's approach by looking at how complexity can be reframed using fractals, founding our approach on the various scales and the complex dynamics that are at play in a crisis event.Keys to complex dynamics and volatilityThe existence of unchanging properties in market prices was, at first, not given much weight by most statisticians in finance.", [["unchanging", "OBSERVATION_MODIFIER", 606, 616], ["properties", "OBSERVATION_MODIFIER", 617, 627]]], ["But Mandelbrot managed to prove that his way of thinking was more adequate to model the behaviour of the financial markets, especially in times of crisis and high volatility.", [["crisis", "PROBLEM", 147, 153], ["high volatility", "OBSERVATION", 158, 173]]], ["The classical financial model follows a Gaussian distribution, and is therefore blind to extreme events.Keys to complex dynamics and volatilityTo be more precise, the mathematics underlying portfolio theory handles extreme phenomena with benign neglect: it regards large market shifts as too unlikely to matter or as impossible to take into account.Therefore, the theoretical approach in itself does not allow working on extreme phenomena.", [["blind to extreme events", "PROBLEM", 80, 103], ["extreme phenomena", "PROBLEM", 215, 232], ["benign neglect", "PROBLEM", 238, 252], ["the theoretical approach", "TREATMENT", 360, 384], ["extreme phenomena", "PROBLEM", 421, 438], ["more precise", "OBSERVATION_MODIFIER", 149, 161], ["benign", "OBSERVATION_MODIFIER", 238, 244], ["neglect", "OBSERVATION", 245, 252]]], ["If the weather is moderate 95% of the time, can the mariner afford to ignore the possibility of a typhoon?Keys to complex dynamics and volatilityThe introduction of invariance principles by Mandelbrot, thus proving the link between the volatility that can be tracked every day in market prices and massive market crashes, allowed a return of the exceptional to the theoretical field.", [["Mandelbrot", "SIMPLE_CHEMICAL", 190, 200], ["massive market crashes", "PROBLEM", 298, 320], ["moderate", "OBSERVATION_MODIFIER", 18, 26], ["massive", "OBSERVATION_MODIFIER", 298, 305], ["market crashes", "OBSERVATION", 306, 320]]], ["The use of fractal geometry does not come closer to forecasting a price drop or rise on a specific day on the basis of past records, but it provides adequate estimates of the probability of what the market might do and allows one to prepare for the larger scale changes, for extreme events.Keys to complex dynamics and volatilityIn other words, Mandelbrot came up with an approach that allowed bringing the extreme phenomena into the scientific field.", [["extreme events", "PROBLEM", 275, 289], ["an approach", "TREATMENT", 369, 380]]], ["It was no longer necessary to label them as 'exceptional' and leave them aside.They were taken into consideration, and as we are seeing today, 5% of the extraordinary can have more weight than the conventional 95%.", [["no longer", "UNCERTAINTY", 7, 16]]], ["The theoretical leap, not only had relevance, but it became crucial.Keys to complex dynamics and volatilityThe power of this approach and its potential application in crisis theory is to allow us to work in universes of high volatility, with extremes being the norm, multiple domains interacting at high speed, etc. These characteristics are not considered as aberrations on the margins any more, but as an intrinsic dynamic of the identity of the new paradigm.Key parameters and their role in contemporary crisesThe efficient use of fractal geometry to model the extreme events in the stock market is a strong argument for applying it to the world of crises, as it also deals with complex interactions and unpredictable shocks.We, therefore, suggest here a modest contribution, and will try to show how it is possible to build a new path for crisis theory in terms of fractal geometry, and in turn build a new path to crisis management through the search of key parameters that we call 'invariants' as they will prove to be a useful toolkit for grasping a large spectrum of crisis events.", [["this approach", "TREATMENT", 120, 133], ["aberrations on the margins", "PROBLEM", 360, 386], ["fractal geometry", "TREATMENT", 534, 550], ["crises", "PROBLEM", 652, 658], ["unpredictable shocks", "TREATMENT", 707, 727], ["crisis", "PROBLEM", 843, 849], ["crisis management", "TREATMENT", 919, 936], ["crisis events", "PROBLEM", 1075, 1088], ["power", "OBSERVATION_MODIFIER", 111, 116], ["high volatility", "OBSERVATION", 220, 235], ["high speed", "OBSERVATION_MODIFIER", 299, 309], ["not considered", "UNCERTAINTY", 342, 356], ["new", "OBSERVATION_MODIFIER", 448, 451], ["extreme", "OBSERVATION_MODIFIER", 564, 571]]], ["Our new conceptual approach is based on looking for underlying principles that allow a better understanding of global catastrophic events, in the same way that invariants can represent fundamental keys to understanding fractals and volatility.Key parameters and their role in contemporary crisesA number of methods are available for identifying complex realities in terms of fractals.", [["global catastrophic events", "PROBLEM", 111, 137], ["global", "OBSERVATION_MODIFIER", 111, 117], ["catastrophic", "OBSERVATION", 118, 130]]], ["In most cases, fractal theory is described through invariance principles, i.e., considering what is common in universes where crises happen on different scales.", [["crises", "PROBLEM", 126, 132]]], ["Invariants are then the key to analyzing the more important interactions, the potential tipping points, the weak signals that allow one to anticipate possible turbulence, etc.Key parameters and their role in contemporary crisesMany papers have documented how the world has become global or interconnected, but very little exists on a deeper conceptualization of what that implies.The introduction by N. Taleb (2007) of the concept of black swans, i.e., the rare events that have dramatic consequences, was a first step towards making people understand that rare does not mean inexistent and that a rare but destructive event is not to be neglected.Key parameters and their role in contemporary crisesAlthough his point was a very interesting conceptual advancement, it did not in itself imply a rethinking of how the world has changed.", [["people", "ORGANISM", 534, 540], ["people", "SPECIES", 534, 540], ["black swans", "SPECIES", 434, 445], ["the weak signals", "PROBLEM", 104, 120], ["turbulence", "PROBLEM", 159, 169], ["black swans", "PROBLEM", 434, 445], ["destructive event", "PROBLEM", 607, 624], ["turbulence", "OBSERVATION", 159, 169], ["black swans", "OBSERVATION", 434, 445], ["destructive", "OBSERVATION", 607, 618], ["not to be", "UNCERTAINTY", 628, 637]]], ["It was merely remembering people that Gaussian statistics are just an approximation of reality, the tip of the iceberg.", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32], ["tip", "OBSERVATION_MODIFIER", 100, 103], ["iceberg", "OBSERVATION", 111, 118]]], ["A useful approximation, as long as everything is normal, i.e. in the smooth 95%.Key parameters and their role in contemporary crisesA precise definition of a crisis has always been difficult to give.", [["a crisis", "PROBLEM", 156, 164], ["normal", "OBSERVATION", 49, 55], ["smooth", "OBSERVATION_MODIFIER", 69, 75]]], ["Our approach allows us to go beyond classic definitions, by approaching crisis events as the transition from one state of equilibrium to another through a massive disruption.Key parameters and their role in contemporary crisesOur contribution here is a new way of thinking, based on a simple, new, principle: looking for fundamental principles of action and identifying their effects.We aim to show that invariants are a general characteristic of modern crises, a pattern that has been long hidden in the fabric of crises and that those invariants have very observable effects, some of which are already well documented, as we shall see.Key parameters and their role in contemporary crisesThe path we are suggesting is not the only possible one, and although it has some very appealing features, it does suffer numerous limitations that we shall explain in the next section.Key parameters and their role in contemporary crisesOur first steps into this new world imply a new set of tools to characterize crises.", [["a massive disruption", "PROBLEM", 153, 173], ["modern crises", "PROBLEM", 447, 460], ["crises", "PROBLEM", 515, 521], ["crises", "PROBLEM", 1003, 1009], ["massive", "OBSERVATION_MODIFIER", 155, 162], ["disruption", "OBSERVATION", 163, 173]]], ["We will be looking at different features of crises, not limiting ourselves to invariance principles but going beyond that by looking at the intrinsic complexity of crises and its key parameters: global effects, high speed, deep complexity and weak signals.Spatial parameters: the domino effectThe shift from small, localized events to global impact catastrophe has become a common feature of modern crises.This widespread feature is commonly referenced in the literature (K\u00f6rnert, 2003) as the 'domino effect'.", [["crises", "PROBLEM", 44, 50], ["crises", "PROBLEM", 164, 170], ["global effects", "PROBLEM", 195, 209], ["high speed", "PROBLEM", 211, 221], ["deep complexity", "PROBLEM", 223, 238], ["weak signals", "PROBLEM", 243, 255], ["the domino effect", "TREATMENT", 276, 293], ["The shift", "PROBLEM", 293, 302], ["small, localized events", "PROBLEM", 308, 331], ["global impact catastrophe", "PROBLEM", 335, 360], ["modern crises", "PROBLEM", 392, 405], ["crises", "OBSERVATION", 44, 50], ["deep", "ANATOMY_MODIFIER", 223, 227], ["weak signals", "OBSERVATION", 243, 255], ["domino effect", "OBSERVATION", 280, 293], ["shift", "OBSERVATION_MODIFIER", 297, 302], ["small", "OBSERVATION_MODIFIER", 308, 313], ["catastrophe", "OBSERVATION", 349, 360]]], ["Trading is reduced to the millisecond (high-frequency trading), communications from one side of the world to the other are almost instantaneous, etc. In turn, crisis has spread from a short-term event to a long-term impact crisis.", [["crisis", "PROBLEM", 159, 165], ["a long-term impact crisis", "PROBLEM", 204, 229], ["reduced", "OBSERVATION_MODIFIER", 11, 18], ["crisis", "OBSERVATION", 159, 165], ["spread", "OBSERVATION_MODIFIER", 170, 176], ["short-term", "OBSERVATION_MODIFIER", 184, 194], ["long-term impact", "OBSERVATION_MODIFIER", 206, 222], ["crisis", "OBSERVATION", 223, 229]]], ["The observable effect is most commonly known as the 'magnifier effect', for example in finance where microsecond trading (Birraux, 2010) leads to market crashes (the example given earlier of the 6th May 2010 market crash being a perfect illustration of it).Any discrepancy, any error, any rigidity propagates extreme volatility and turbulences to the entire deck of cards.Rank invariance and the aggregation effectThe third feature we are introducing is rank invariance, which is linked to how individuals act one towards the other.", [["crashes", "DISEASE", 153, 160], ["rigidity", "DISEASE", 289, 297], ["Any discrepancy", "PROBLEM", 257, 272], ["any error", "PROBLEM", 274, 283], ["any rigidity", "PROBLEM", 285, 297], ["extreme volatility", "PROBLEM", 309, 327], ["the aggregation effect", "PROBLEM", 392, 414], ["aggregation effect", "OBSERVATION", 396, 414]]], ["It is very similar to the domino effect, but this time it is not places that are affected, but people through their interactions.This invariance explains why modern crises can start by impacting one single individual on one side of the world and turn it into a global changing event.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["modern crises", "PROBLEM", 158, 171], ["domino effect", "OBSERVATION", 26, 39]]], ["The observable consequence of this invariance principle is commonly documented as the 'aggregation effect'.The best recent example of such an effect is Mohamed Bouazizi's self-immolation that led to the Arab spring (Mc Kay, 2011).Blurring and sense-makingThe fourth characteristic at play is sense-making (Weick, 1995) invariance.", [["the 'aggregation effect", "PROBLEM", 82, 105], ["Blurring and sense", "PROBLEM", 230, 248]]], ["Understanding this key prin-ciple allows a better understanding of why, during modern crises, the loss of control affects equally the isolated individual, who does not understand what is happening, and the state leaders, who fail to grasp the magnitude of the ongoing crises, leading to global dislocation.This sense-making invariance is best illustrated (Smallman & Weir, 1999) , by the well-known blur effect, which has been used to explain how absurd decisions were taken not only by common individuals but also by eminent leaders.", [["dislocation", "DISEASE", 294, 305], ["the ongoing crises", "PROBLEM", 256, 274], ["global dislocation", "PROBLEM", 287, 305], ["global", "OBSERVATION_MODIFIER", 287, 293], ["dislocation", "OBSERVATION", 294, 305]]], ["It leads to what we like to call 'information asymmetry', i.e., the loss of information when one goes up or down the decision ladder, which we shall explain more in depth in the next section.Blurring and sense-makingWith this set of rules, we have built a grammar of reading that provides common guidelines for crisis theory, relying on a small number of dimensions (space, time, rank and sense).This classification allows for more powerful tests to establish a generic mapping of crisis and avoids entering immediately into hierarchical classifications, which cannot grasp the power of systemic crises.Blurring and sense-makingMoreover, instead of building a theory designed for the 'normal world' and trying to map it to crisis situations, we immediately built its roots a vision that contains complexity.", [["Blurring and sense", "PROBLEM", 191, 209], ["crisis theory", "PROBLEM", 311, 324], ["powerful tests", "TEST", 432, 446], ["crisis", "PROBLEM", 481, 487], ["systemic crises", "PROBLEM", 587, 602], ["Blurring and sense", "PROBLEM", 603, 621], ["small", "OBSERVATION_MODIFIER", 339, 344], ["complexity", "OBSERVATION_MODIFIER", 796, 806]]], ["It goes far beyond Taleb's principles and the possibility of a black swan.", [["Taleb's principles", "TREATMENT", 19, 37], ["a black swan", "TREATMENT", 61, 73]]], ["Here, we are in a world where normality is not the norm, where the black swan is no longer the outlier and where the search for invariants is especially relevant in a world built from variability and stress.Blurring and sense-makingWe have laid the ground to a new understanding of crisis theory,showing that well-documented phenomena can be linked to a set of simple principles that can trace stability and instability in the context of crisis events, which is already a big step forward.This new conceptualization of crises can bring theoretical foundations to crisis management techniques that are already being implemented and can help to provide a deeper understanding of conceptual and practical problems.Crisis management theoryThe power of the fractal approach is that it allows you to get rid of a linear and stable vision of the world, an approach inconsistent with the field of crisis.As long as it remained in the realm of low scale emergency it was possible to keep our unified approach, where consequences are additive and relatively simple to control.Yet we must go beyond simple adjustment when we enter global, volatile worlds.Building a theoretical body able to capture mega crises in turbulent environmentsFractal theory opens up the possibility of envisioning and navigating multiple, unsettled domains, multiple layers and dynamics.Building a theoretical body able to capture mega crises in turbulent environments1.", [["the black swan", "TREATMENT", 63, 77], ["Blurring and sense", "PROBLEM", 207, 225], ["simple principles", "TREATMENT", 361, 378], ["crisis events", "PROBLEM", 438, 451], ["crises", "PROBLEM", 519, 525], ["crisis management techniques", "TREATMENT", 563, 591], ["conceptual and practical problems", "PROBLEM", 677, 710], ["Crisis management", "TREATMENT", 711, 728], ["crisis", "PROBLEM", 889, 895], ["mega crises", "PROBLEM", 1188, 1199], ["navigating multiple, unsettled domains", "PROBLEM", 1284, 1322], ["mega crises", "PROBLEM", 1397, 1408], ["no longer", "UNCERTAINTY", 81, 90], ["stability", "OBSERVATION_MODIFIER", 394, 403], ["power", "OBSERVATION_MODIFIER", 739, 744], ["stable", "OBSERVATION_MODIFIER", 818, 824], ["turbulent environments", "OBSERVATION", 1203, 1225], ["multiple", "OBSERVATION_MODIFIER", 1324, 1332], ["layers", "OBSERVATION_MODIFIER", 1333, 1339], ["turbulent environments", "OBSERVATION", 1412, 1434]]], ["From a spatial point of view, it becomes possible to work separately on the hyperlocal, local, regional, national, continental and global.We can multiply the fields considered, each with their relevance, specificity and dynamics.We work at the outset, where the vision is plural and where one must be able to operate multiple levers of action at the same time.", [["regional", "OBSERVATION_MODIFIER", 95, 103], ["plural", "OBSERVATION", 272, 278]]], ["One is not limited to a single timeline approach, but is allowed to immediately think of many overlapping timelines that have different dynamics and fundamental building blocks such as contradictions, oppositions, factors of evolution and mutations, that blur the view of actors who have different perspectives.", [["fundamental building blocks", "TREATMENT", 149, 176], ["mutations", "PROBLEM", 239, 248]]], ["From the point of view of 'making sense', one can also escape reductive simplistic visions and make room for multiple subjective 'sense making processes'.Building a theoretical body able to capture mega crises in turbulent environmentsThese are just a few well-known dimensions, but there could be many others: the multiplicity, interaction and volatility of fields and dimensions are basically included in the code of the fractal approach.Building a theoretical body able to capture mega crises in turbulent environmentsLet us work out an example where information is minimal, where there are only weak, wild signals, where there is no warning light, no simple data to analyze and where only vigilance, examination of blind spots and informed assumptions based on fractal crisis theory can give a clue as to what the dynamics at play is really is about.Beyond the classic approaches: top-down or bottom-up, information asymmetry and dealing with complexity in crisis managementFor decades, disaster literature has highlighted the limitations and problems hazards caused by the 'Command and Control' vision, the centralized top-down approach (Rodriguez, Quarantelli, & Dynes, 2006; Drabek, 1986) .", [["mega crises", "PROBLEM", 198, 209], ["mega crises", "PROBLEM", 484, 495], ["examination", "TEST", 704, 715], ["blind spots", "PROBLEM", 719, 730], ["fractal crisis", "PROBLEM", 765, 779], ["crisis management", "TREATMENT", 961, 978], ["turbulent environments", "OBSERVATION", 213, 235], ["few", "OBSERVATION_MODIFIER", 252, 255], ["well-known dimensions", "OBSERVATION_MODIFIER", 256, 277], ["could be", "UNCERTAINTY", 289, 297], ["many", "OBSERVATION_MODIFIER", 298, 302], ["multiplicity", "OBSERVATION_MODIFIER", 315, 327], ["volatility", "OBSERVATION_MODIFIER", 345, 355], ["turbulent environments", "OBSERVATION", 499, 521]]], ["The approach developed here escapes from these dilemmas and conflicts of vision.There is no overriding principle that is able to support a global dynamic in which each component has autonomy, an impulse and a specific variability.", [["these dilemmas", "PROBLEM", 41, 55], ["conflicts of vision", "PROBLEM", 60, 79], ["overriding principle", "PROBLEM", 92, 112], ["no overriding", "UNCERTAINTY", 89, 102]]], ["The specificity of a crisis event is the amount of distortion that a 'piece of information' (in its broad meaning) can suffer: during a crisis event, one piece of information is received differently by the actors (partial transmission, mutation, distortion, etc.) and every single actor interprets it differently based on his local reality and acts differently.", [["a crisis event", "PROBLEM", 19, 33], ["a crisis event", "PROBLEM", 134, 148], ["mutation, distortion", "PROBLEM", 236, 256], ["crisis", "OBSERVATION", 21, 27]]], ["Thus, talking about bottom-up or top-down approaches is largely insufficient because there are multiple realities at play.The situationThe common practice has most often been to centralize the decision-making process and to concentrate on a top-down approach, with the strategic oversight of the highest people in the hierarchy often conflicting with what is happening on the ground.That practice in a crisis situation can be easily understood as a response to the top-down approach needed for our judicial and governance system which needs to have a clear chain of command to attribute responsibilities during and after the crisis.The situationOne of the most disturbing facts during a crisis event is how information, or misinformation, circulates and propagates.", [["people", "ORGANISM", 304, 310], ["people", "SPECIES", 304, 310], ["a top-down approach", "TREATMENT", 239, 258], ["the top-down approach", "TREATMENT", 461, 482], ["our judicial and governance system", "TREATMENT", 494, 528], ["the crisis", "PROBLEM", 621, 631], ["a crisis event", "PROBLEM", 685, 699]]], ["But in reality, while his decisions seem to be properly transmitted, with everyone in the decision chain thinking they have all understood the same thing, they all end up interpreting the decision in different ways, thus leading to incoherent, conflicting and sometimes absurd action.Our understandingFractal crises theory teaches us that crises happen on all scales and that the built-in invariants imply that leaders and decision makers will be impacted by effects just as those who are closer to the situation area.That is to say, taking the decision power away from those closest to the ground, best able to evaluate their needs, and giving it to people far from ground level and supposedly less impacted by the crisis is a fallacy.Our understandingWhat is at play here is the conflict between the way decisions circulate and the way information flows.Our understandingThat is why a full top-down or a full bottom-up approach cannot work.", [["people", "ORGANISM", 651, 657], ["people", "SPECIES", 651, 657], ["crises", "PROBLEM", 339, 345]]], ["It all happens exactly as for a fractal pattern: every time you switch to a different scale, you have the sensation of seeing the same thing, but in reality the resolution has changed and what looks the same is in fact different.Our understandingThe blur effect created by sense-making invariance forbids someone on one step of the decision ladder to communicate freely with someone on another step.", [["a different scale", "TREATMENT", 74, 91], ["blur effect", "OBSERVATION", 250, 261]]], ["The current situation, with the decision process being top-down and the information flow going both ways with losses, is incoherent.This realization means that there is something wrong with the conception of crisis management where decisions can be taken on one end of the decision chain to be put into action by someone else at the other end of the chain.Our understandingWe have decided to call this situation, where no one has access to the full, undistorted deck of cards, information asymmetry.", [["crisis management", "TREATMENT", 208, 225]]], ["It is well known that information is a key to the resolution of any crisis, not only to reduce its impact but also in terms of communication to the public, hence such asymmetry is not a minor problem.In terms of crisis managementWe argue that one must not restrict oneself to a top-down approach and open one's minds to broader perspectives.In terms of crisis managementIn other words, if the top-down approach allows a better distribution of responsibilities for the after-crisis, it completely destroys efforts to limit the impact of the crisis.", [["any crisis", "PROBLEM", 64, 74], ["a minor problem", "PROBLEM", 184, 199], ["crisis management", "TREATMENT", 212, 229], ["a top-down approach", "TREATMENT", 276, 295], ["crisis management", "TREATMENT", 353, 370], ["crisis", "PROBLEM", 474, 480], ["the crisis", "PROBLEM", 536, 546], ["crisis", "OBSERVATION", 212, 218], ["crisis", "OBSERVATION", 353, 359]]], ["Thus, fractal crisis theory pleads for a more pluralistic approach based not only a selective distribution of responsibilities and better trust in the personnel on the ground.In terms of crisis managementThe goal is, therefore, to grasp the information as early as possible, at its point of origin, and to dispatch it to the one closest to it.", [["fractal crisis", "PROBLEM", 6, 20], ["a more pluralistic approach", "TREATMENT", 39, 66], ["crisis management", "TREATMENT", 187, 204], ["fractal crisis", "OBSERVATION", 6, 20], ["crisis", "OBSERVATION", 187, 193]]], ["Thus, the one in charge of dealing with the new information would be the one that has had access to the least disturbed information.In terms of crisis managementDispatching the information would require an 'information over-watch' team.This special group would be in charge of collecting all new information, evaluating its credibility and importance, and delivering it with the appropriate context to the right person on the ladder.", [["person", "SPECIES", 412, 418], ["crisis management", "TREATMENT", 144, 161], ["crisis", "OBSERVATION", 144, 150], ["right", "ANATOMY_MODIFIER", 406, 411]]], ["This organizational innovation would thus reduce the loss of information from bad contextualization or improper priority rating.", [["bad contextualization", "PROBLEM", 78, 99]]], ["Each layer has its own dynamics; none can have a steering role and one needs to step back to understand the complexity of the system.We need people who can master the broad view and act within an intensely connected and susceptible world.In terms of crisis managementThus, the decision shall then be taken by the person who receives the information, whatever his or her position in the current 'normal' decision process.", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["person", "SPECIES", 313, 319], ["crisis management", "TREATMENT", 250, 267], ["layer", "OBSERVATION_MODIFIER", 5, 10], ["crisis", "OBSERVATION", 250, 256]]], ["The goal is not to produce people who can apply pre-planned answers; we need people who expect and embrace the new and the novel.", [["people", "ORGANISM", 27, 33], ["people", "ORGANISM", 77, 83], ["people", "SPECIES", 27, 33], ["people", "SPECIES", 77, 83]]], ["We need people who relish the challenge of creative thinking and action, even in the most inconceivable and rapidly developing contexts.In terms of crisis managementThe concept and method of the Rapid Reflection Force (B\u00e9roux, Guilhou, & Lagadec, 2007; B\u00e9roux, Guilhou, & Lagadec, 2008) has been suggested, developed and tested to help organizations overcome such challenges.", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14], ["crisis management", "TREATMENT", 148, 165], ["crisis", "OBSERVATION", 148, 154]]], ["A specific group of people are asked to clarify the high complexity and volatility of a situation, and to suggest new visions and paths of action enabling the whole system to better navigate the turbulence.Limitations and perspectivesClearly, these new paths into the unknown are still in a very preliminary form.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["turbulence", "OBSERVATION", 195, 205], ["new", "OBSERVATION_MODIFIER", 249, 252]]], ["Every single facet of crisis theory and management should now be revisited within this framework of fractal theory.", [["management", "TREATMENT", 40, 50], ["crisis", "OBSERVATION", 22, 28]]], ["It will take time before we develop more precise specific theories and practical knowledge on all these facets.Limitations and perspectivesIt does not mean that our more conventional approach to crisis management should be forgotten.", [["crisis management", "TREATMENT", 195, 212]]], ["Such perspectives are and will remain a source of very deep and severe discomfort.", [["very deep and severe discomfort", "PROBLEM", 50, 81], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["discomfort", "OBSERVATION", 71, 81]]], ["Our deep seated Cartesian culture is very strong and stronger still in times of crisis, as we tend to immediately reject complexity by calling it 'chaotic'.", [["deep seated Cartesian culture", "CELL_LINE", 4, 33], ["Our deep seated Cartesian culture", "TEST", 0, 33], ["crisis", "PROBLEM", 80, 86], ["deep", "ANATOMY_MODIFIER", 4, 8]]], ["Hence, the idea that we should prepare future leaders to open their minds to such new avenues.Limitations and perspectivesIf we can overcome these obstacles, we will have embarked upon the exploration of unknown lands: it will remain very difficult, but at least we will be on a relevant track.ConclusionThe world of crises is facing extreme upheavals.", [["the exploration", "TEST", 185, 200], ["crises", "PROBLEM", 317, 323]]], ["It is not just an extension of accidental phenomena within a system; we are confronted with extreme turbulence, in global and highly unstructured environments.", [["accidental phenomena", "PROBLEM", 31, 51], ["extreme turbulence", "PROBLEM", 92, 110], ["not just", "UNCERTAINTY", 6, 14], ["accidental phenomena", "OBSERVATION", 31, 51], ["turbulence", "OBSERVATION", 100, 110]]], ["Our crisis management theories and practices were not designed to grasp such 'wicked' environments: they are largely outdated.", [["Our crisis management", "TREATMENT", 0, 21]]], ["The first section of this paper documented this challenging situation -in the field as well as in the theoretical arena.ConclusionIn response, there is a growing need for a theoretical leap -obviously resulting from the conjunction of a diversity of inputs.The objective of this contribution has been to consider the possibilities offered by the fractal geometry as a candidate to help those in charge of navigating in unknown, extremely turbulent environments.The path we suggest is one of many ways that can be taken on the road to crisis management theory and operational crisis management.", [["this challenging situation", "PROBLEM", 43, 69], ["crisis management", "TREATMENT", 534, 551], ["operational crisis management", "TREATMENT", 563, 592], ["turbulent", "OBSERVATION", 438, 447]]], ["The ideas underlying Mandelbrot's mathematical work can be effectively used to better describe modern crises as analogous to fractals, and the underlying invariance principles can be mapped into well-known effects in crisis management.", [["modern crises", "PROBLEM", 95, 108], ["crisis management", "TREATMENT", 217, 234]]], ["Yet beyond Mandelbrot's own work, the crucial advance offered by fractal theory is the possibility to envision, capture and handle very unstable, blurred and hypercomplex states of the world.ConclusionA lot remains to be done to test the feasibility of this approach, to assess what it can bring to the field, and last but not least, to detect the limitations of this line of thought.We are only at the beginning of the intellectual brainstorming required by the age of mega crises.", [["handle very unstable", "PROBLEM", 124, 144], ["blurred", "PROBLEM", 146, 153], ["mega crises", "PROBLEM", 470, 481]]]], "PMC6745792": [["BackgroundPorcine epidemic diarrhea virus (PEDV) is the causative agent of porcine epidemic diarrhea (PED), a highly contagious enteric disease characterized by severe watery diarrhea, vomiting and dehydration leading to enormous economic losses in the swine industry worldwide [1, 2].", [["BackgroundPorcine epidemic diarrhea", "DISEASE", 0, 35], ["porcine epidemic diarrhea", "DISEASE", 75, 100], ["PED", "DISEASE", 102, 105], ["enteric disease", "DISEASE", 128, 143], ["watery diarrhea", "DISEASE", 168, 183], ["vomiting", "DISEASE", 185, 193], ["dehydration", "DISEASE", 198, 209], ["BackgroundPorcine epidemic diarrhea virus", "ORGANISM", 0, 41], ["porcine", "ORGANISM", 75, 82], ["BackgroundPorcine epidemic diarrhea virus", "SPECIES", 0, 41], ["porcine epidemic diarrhea", "SPECIES", 75, 100], ["swine", "SPECIES", 253, 258], ["BackgroundPorcine epidemic diarrhea virus", "SPECIES", 0, 41], ["PEDV", "SPECIES", 43, 47], ["porcine epidemic diarrhea (PED)", "SPECIES", 75, 106], ["swine", "SPECIES", 253, 258], ["BackgroundPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 47], ["porcine epidemic diarrhea", "PROBLEM", 75, 100], ["a highly contagious enteric disease", "PROBLEM", 108, 143], ["severe watery diarrhea", "PROBLEM", 161, 183], ["vomiting", "PROBLEM", 185, 193], ["dehydration", "PROBLEM", 198, 209], ["enormous economic losses", "PROBLEM", 221, 245], ["contagious", "OBSERVATION_MODIFIER", 117, 127], ["enteric disease", "OBSERVATION", 128, 143], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["watery", "OBSERVATION_MODIFIER", 168, 174], ["diarrhea", "OBSERVATION", 175, 183], ["enormous", "OBSERVATION_MODIFIER", 221, 229], ["economic", "OBSERVATION_MODIFIER", 230, 238], ["losses", "OBSERVATION", 239, 245]]], ["After PEDV was first reported in Belgium in 1971 and the United Kingdom in 1978, it then emerged in other European countries over the following several years [3].", [["PEDV", "CHEMICAL", 6, 10], ["PEDV", "SPECIES", 6, 10], ["PEDV", "PROBLEM", 6, 10]]], ["PEDV can infect pigs of all ages and causes high mortality in newborn piglets (mortality rate is nearly 100%); however, PEDV mainly causes slow growth in adult pigs.", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "CHEMICAL", 120, 124], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 16, 20], ["piglets", "ORGANISM", 70, 77], ["pigs", "ORGANISM", 160, 164], ["pigs", "SPECIES", 16, 20], ["piglets", "SPECIES", 70, 77], ["pigs", "SPECIES", 160, 164], ["PEDV", "SPECIES", 0, 4], ["pigs", "SPECIES", 16, 20], ["PEDV", "SPECIES", 120, 124], ["pigs", "SPECIES", 160, 164], ["PEDV", "PROBLEM", 0, 4], ["high mortality", "PROBLEM", 44, 58], ["mortality rate", "TEST", 79, 93], ["PEDV", "PROBLEM", 120, 124], ["slow growth", "PROBLEM", 139, 150], ["high", "OBSERVATION_MODIFIER", 44, 48], ["mortality", "OBSERVATION_MODIFIER", 49, 58], ["slow", "OBSERVATION_MODIFIER", 139, 143], ["growth", "OBSERVATION_MODIFIER", 144, 150]]], ["In December 2010, a newly emerged and high virulent strain of PEDV rapidly spread in China, where it killed over 1,000,000 piglets with a mortality rate in suckling piglets approaching 100% [4, 5].", [["PEDV", "CHEMICAL", 62, 66], ["PEDV", "ORGANISM", 62, 66], ["piglets", "ORGANISM", 123, 130], ["piglets", "ORGANISM", 165, 172], ["piglets", "SPECIES", 123, 130], ["piglets", "SPECIES", 165, 172], ["PEDV", "SPECIES", 62, 66], ["high virulent strain", "PROBLEM", 38, 58], ["PEDV", "PROBLEM", 62, 66]]], ["PEDV was identified as a member of the genus Alphacoronavirus within the family Coronaviridae in the order Nidovirales [6].", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 45, 61], ["PEDV", "PROTEIN", 0, 4], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4]]], ["It is an enveloped, single-stranded, positive-sense RNA virus with a genome approximately 28 kb in length that comprises at least seven open reading frames (ORFs) encoding nonstructural ORF1a, ORF1b and ORF3 proteins and the structural spike (S), envelope (E), membrane (M) and nucleocapsid (N) [7].", [["membrane", "ANATOMY", 261, 269], ["ORF1a", "GENE_OR_GENE_PRODUCT", 186, 191], ["ORF1b", "GENE_OR_GENE_PRODUCT", 193, 198], ["ORF3", "GENE_OR_GENE_PRODUCT", 203, 207], ["membrane", "CELLULAR_COMPONENT", 261, 269], ["open reading frames", "DNA", 136, 155], ["ORFs", "DNA", 157, 161], ["ORF1a", "PROTEIN", 186, 191], ["ORF1b", "PROTEIN", 193, 198], ["ORF3 proteins", "PROTEIN", 203, 216], ["structural spike (S), envelope (E), membrane (M)", "PROTEIN", 225, 273], ["sense RNA virus", "PROBLEM", 46, 61], ["nonstructural ORF1a", "TEST", 172, 191], ["ORF1b", "TEST", 193, 198], ["ORF3 proteins", "TEST", 203, 216], ["the structural spike", "PROBLEM", 221, 241], ["envelope (E), membrane (M) and nucleocapsid (N)", "PROBLEM", 247, 294], ["enveloped", "OBSERVATION_MODIFIER", 9, 18], ["spike", "OBSERVATION_MODIFIER", 236, 241]]], ["One of the four structural proteins, the N protein, which is associated with viral replication, transcription and assembly, is a basic internal phosphoprotein important for inducing cell-mediated immunity in the host [8, 9].", [["cell", "ANATOMY", 182, 186], ["cell", "CELL", 182, 186], ["structural proteins", "PROTEIN", 16, 35], ["N protein", "PROTEIN", 41, 50], ["basic internal phosphoprotein", "PROTEIN", 129, 158], ["the N protein", "TEST", 37, 50], ["viral replication", "PROBLEM", 77, 94], ["a basic internal phosphoprotein", "TREATMENT", 127, 158], ["associated with", "UNCERTAINTY", 61, 76], ["viral replication", "OBSERVATION", 77, 94]]], ["Pigs produce high levels of antibodies against the N protein in the early stages of PEDV infection [6, 8].", [["infection", "DISEASE", 89, 98], ["Pigs", "ORGANISM", 0, 4], ["antibodies", "PROTEIN", 28, 38], ["N protein", "PROTEIN", 51, 60], ["Pigs", "SPECIES", 0, 4], ["PEDV", "SPECIES", 84, 88], ["high levels of antibodies", "PROBLEM", 13, 38], ["the N protein", "PROBLEM", 47, 60], ["PEDV infection", "PROBLEM", 84, 98], ["high levels", "OBSERVATION_MODIFIER", 13, 24], ["early stages", "OBSERVATION_MODIFIER", 68, 80], ["PEDV", "OBSERVATION_MODIFIER", 84, 88], ["infection", "OBSERVATION", 89, 98]]], ["Anti-N protein IgG antibodies were first detected on day 7 post infection, so the PEDV N protein is the best candidate antigen for early diagnosis because this gene is highly conserved [10].BackgroundIn recent decades, a variety of methods to detect PEDV have been developed and reported in numerous studies.", [["infection", "DISEASE", 64, 73], ["PEDV N", "GENE_OR_GENE_PRODUCT", 82, 88], ["PEDV", "SIMPLE_CHEMICAL", 250, 254], ["Anti-N protein IgG antibodies", "PROTEIN", 0, 29], ["PEDV N protein", "PROTEIN", 82, 96], ["PEDV", "PROTEIN", 250, 254], ["PEDV", "SPECIES", 82, 86], ["PEDV", "SPECIES", 250, 254], ["Anti-N protein IgG antibodies", "TEST", 0, 29], ["infection", "PROBLEM", 64, 73], ["the PEDV N protein", "TREATMENT", 78, 96], ["PEDV", "PROBLEM", 250, 254], ["infection", "OBSERVATION", 64, 73]]], ["Since the clinical signs and histological changes in PED and other diarrheal diseases, such as transmissible gastroenteritis (TGE), are similar, they cannot be diagnosed without molecular methods and immunoassays [11, 12].", [["PED", "DISEASE", 53, 56], ["diarrheal diseases", "DISEASE", 67, 85], ["transmissible gastroenteritis", "DISEASE", 95, 124], ["TGE", "DISEASE", 126, 129], ["the clinical signs", "TEST", 6, 24], ["histological changes", "PROBLEM", 29, 49], ["other diarrheal diseases", "PROBLEM", 61, 85], ["transmissible gastroenteritis (TGE)", "PROBLEM", 95, 130], ["immunoassays", "TEST", 200, 212], ["diarrheal diseases", "OBSERVATION", 67, 85], ["transmissible", "OBSERVATION_MODIFIER", 95, 108], ["gastroenteritis", "OBSERVATION", 109, 124]]], ["Conventional PEDV diagnostic methods are based on laboratory tests and include virus isolation, conventional reverse transcription-polymerase chain reaction (RT-PCR) [13, 14], real-time RT-PCR [15\u201317], indirect fluorescent antibody (IFA) assay [18] and enzyme-linked immunosorbent assay (ELISA) [19].", [["indirect fluorescent antibody", "PROTEIN", 202, 231], ["IFA", "PROTEIN", 233, 236], ["laboratory tests", "TEST", 50, 66], ["virus isolation", "TREATMENT", 79, 94], ["conventional reverse transcription", "TEST", 96, 130], ["polymerase chain reaction", "TEST", 131, 156], ["RT-PCR", "TEST", 158, 164], ["PCR", "TEST", 189, 192], ["indirect fluorescent antibody", "TEST", 202, 231], ["IFA", "TEST", 233, 236], ["assay", "TEST", 238, 243], ["enzyme", "TEST", 253, 259], ["immunosorbent assay", "TEST", 267, 286]]], ["Moreover, issues such as false-positive results may arise from cross-contamination between samples or transportation delays [20].", [["samples", "ANATOMY", 91, 98], ["false-positive results", "PROBLEM", 25, 47]]], ["Currently, different types of ELISAs, including indirect [19, 21], competitive and blocking ELISA, have been widely applied to detect PEDV in large-scale blood or feces samples, but these assays are based on the use of PEDV-specific monoclonal or polyclonal antibodies that require more support cost and exhibit low expression yields and high levels of instability [22].BackgroundAntibody-mediated immune detection is a popular approach due to its convenience.", [["blood", "ANATOMY", 154, 159], ["feces samples", "ANATOMY", 163, 176], ["PEDV", "SIMPLE_CHEMICAL", 134, 138], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["feces samples", "ORGANISM_SUBSTANCE", 163, 176], ["PEDV", "SIMPLE_CHEMICAL", 219, 223], ["BackgroundAntibody", "SIMPLE_CHEMICAL", 370, 388], ["PEDV-specific monoclonal or polyclonal antibodies", "PROTEIN", 219, 268], ["PEDV", "SPECIES", 134, 138], ["PEDV", "SPECIES", 219, 223], ["ELISAs", "TEST", 30, 36], ["competitive and blocking ELISA", "PROBLEM", 67, 97], ["PEDV", "PROBLEM", 134, 138], ["feces samples", "TEST", 163, 176], ["these assays", "TEST", 182, 194], ["PEDV", "PROBLEM", 219, 223], ["specific monoclonal or polyclonal antibodies", "PROBLEM", 224, 268], ["low expression yields", "PROBLEM", 312, 333], ["high levels of instability", "PROBLEM", 338, 364], ["BackgroundAntibody", "TEST", 370, 388], ["a popular approach", "TREATMENT", 418, 436]]], ["Nanobodies, also termed the variable domain of heavy-chain only antibody (VHH), were surprising discovered in the sera of camelids, such as llamas, dromedaries, camels, alpaca and vicuna [23, 24].", [["sera", "ANATOMY", 114, 118], ["camelids", "ANATOMY", 122, 130], ["VHH", "GENE_OR_GENE_PRODUCT", 74, 77], ["sera", "ORGANISM_SUBSTANCE", 114, 118], ["llamas", "ORGANISM", 140, 146], ["alpaca", "ORGANISM", 169, 175], ["heavy-chain only antibody", "PROTEIN", 47, 72], ["VHH", "PROTEIN", 74, 77], ["Nanobodies", "TREATMENT", 0, 10], ["heavy", "OBSERVATION_MODIFIER", 47, 52]]], ["Nanobodies are also the smallest antibodies with complete antigen-binding sites [25].", [["antibodies", "PROTEIN", 33, 43], ["Nanobodies", "TREATMENT", 0, 10], ["smallest", "OBSERVATION_MODIFIER", 24, 32]]], ["The single-domain nature of nanobodies due to their lack of light chains confers many special properties not observed in conventional antibodies: including high affinity, thermal stability and high yield in microbial production systems [26, 27].", [["light chains", "PROTEIN", 60, 72], ["antibodies", "PROTEIN", 134, 144], ["light chains", "TREATMENT", 60, 72], ["high affinity", "PROBLEM", 156, 169], ["thermal stability", "PROBLEM", 171, 188], ["high yield in microbial production systems", "PROBLEM", 193, 235], ["high affinity", "OBSERVATION_MODIFIER", 156, 169]]], ["Moreover, because the molecular weights of nanobodies are only approximately 15 kDa and they are associated with concave epitopes, nanobodies might be better adapted to access hidden targets and cryptic sites than antibodies [22].", [["nanobodies", "GENE_OR_GENE_PRODUCT", 43, 53], ["nanobodies", "PROTEIN", 43, 53], ["concave epitopes", "PROTEIN", 113, 129], ["nanobodies", "PROTEIN", 131, 141], ["antibodies", "PROTEIN", 214, 224], ["concave epitopes", "PROBLEM", 113, 129], ["nanobodies", "TREATMENT", 131, 141], ["cryptic sites", "PROBLEM", 195, 208], ["15 kDa", "OBSERVATION_MODIFIER", 77, 83]]], ["Based on these unique features, nanobodies hold great potential as candidates for diverse biomedical applications, such as disease diagnosis and therapeutics [28].BackgroundPEDV-specific nanobodies have not yet been reported; however, we motivated to use phage display technology to obtain the special nanobodies against the N protein of PEDV, and the selected nanobody was applied to develop a blocking ELISA for the rapid, low-cost and sensitive detection of PEDV in serum samples.", [["serum samples", "ANATOMY", 469, 482], ["PEDV", "CHEMICAL", 461, 465], ["PEDV", "GENE_OR_GENE_PRODUCT", 338, 342], ["PEDV", "SIMPLE_CHEMICAL", 461, 465], ["serum samples", "ORGANISM_SUBSTANCE", 469, 482], ["BackgroundPEDV", "PROTEIN", 163, 177], ["N protein", "PROTEIN", 325, 334], ["PEDV", "PROTEIN", 338, 342], ["PEDV", "PROTEIN", 461, 465], ["PEDV", "SPECIES", 461, 465], ["diverse biomedical applications", "TREATMENT", 82, 113], ["BackgroundPEDV", "TEST", 163, 177], ["the special nanobodies", "TREATMENT", 290, 312], ["PEDV", "PROBLEM", 338, 342], ["the selected nanobody", "TREATMENT", 348, 369], ["a blocking ELISA", "TEST", 393, 409], ["PEDV in serum samples", "TEST", 461, 482]]], ["Overall, this detection system will be extremely useful for future PEDV diagnosis.Serum samples ::: Materials and methodsInformation on serum samples used in this study is available in the materials and methods section of an Additional file 1.Camel immunization and library construction ::: Materials and methodsA 4-year-old male Bactrian camel was immunized with recombinant PEDV N protein as described in previous studies with modifications; peripheral blood lymphocytes (PBLs) were then isolated from fresh blood as described in detail in Additional file 1 [28, 29].", [["Serum samples", "ANATOMY", 82, 95], ["serum samples", "ANATOMY", 136, 149], ["peripheral blood lymphocytes", "ANATOMY", 444, 472], ["PBLs", "ANATOMY", 474, 478], ["blood", "ANATOMY", 510, 515], ["Serum samples", "ORGANISM_SUBSTANCE", 82, 95], ["serum samples", "ORGANISM_SUBSTANCE", 136, 149], ["Bactrian", "ORGANISM", 330, 338], ["camel", "ORGANISM", 339, 344], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 376, 390], ["peripheral blood lymphocytes", "CELL", 444, 472], ["PBLs", "CELL", 474, 478], ["blood", "ORGANISM_SUBSTANCE", 510, 515], ["recombinant PEDV N protein", "PROTEIN", 364, 390], ["peripheral blood lymphocytes", "CELL_TYPE", 444, 472], ["PBLs", "CELL_TYPE", 474, 478], ["camel", "SPECIES", 339, 344], ["PEDV", "SPECIES", 67, 71], ["camel", "SPECIES", 339, 344], ["PEDV", "SPECIES", 376, 380], ["this detection system", "TEST", 9, 30], ["future PEDV diagnosis", "TEST", 60, 81], ["Serum samples", "TEST", 82, 95], ["serum samples", "TEST", 136, 149], ["this study", "TEST", 158, 168], ["Materials", "TEST", 291, 300], ["methodsA", "TEST", 305, 313], ["recombinant PEDV N protein", "PROBLEM", 364, 390], ["previous studies", "TEST", 407, 423], ["peripheral blood lymphocytes", "TEST", 444, 472], ["PBLs", "TEST", 474, 478], ["fresh blood", "PROBLEM", 504, 515], ["peripheral", "ANATOMY_MODIFIER", 444, 454], ["blood lymphocytes", "ANATOMY", 455, 472], ["fresh blood", "OBSERVATION", 504, 515]]], ["Total RNA was isolated from PBLs using RNAiso Plus (Takara, Japan) according to the manufacturer\u2019s instructions, and the RNA was then reverse transcribed to cDNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher, USA).", [["PBLs", "ANATOMY", 28, 32], ["PBLs", "CELL", 28, 32], ["PBLs", "CELL_TYPE", 28, 32], ["cDNA", "DNA", 157, 161], ["Total RNA", "PROBLEM", 0, 9], ["RNAiso Plus (Takara", "TREATMENT", 39, 58]]], ["The variable regions of the VHH were amplified by nested PCR using Prime STAR HS DNA polymerase (Takara, Japan) with previously described primers [30, 31].", [["VHH", "GENE_OR_GENE_PRODUCT", 28, 31], ["VHH", "PROTEIN", 28, 31], ["Prime STAR HS DNA polymerase", "PROTEIN", 67, 95], ["the VHH", "PROBLEM", 24, 31], ["nested PCR", "TEST", 50, 60], ["Prime STAR HS DNA polymerase", "TREATMENT", 67, 95], ["variable", "OBSERVATION_MODIFIER", 4, 12], ["VHH", "ANATOMY", 28, 31]]], ["The first PCR products contained a 700 bp fragment amplified with CALL001 and CALL002 primers (Sangon Biotech, China) (Additional file 1: Table S1), and an approximately 400 bp VHH fragment was PCR-amplified with the VHH-FOR and VHH-REV primers containing PstI and NotI sites (Additional file 1: Table S1) and the first purified product used as a template.", [["PstI", "GENE_OR_GENE_PRODUCT", 256, 260], ["NotI", "GENE_OR_GENE_PRODUCT", 265, 269], ["PCR products", "DNA", 10, 22], ["700 bp fragment", "DNA", 35, 50], ["CALL001 and CALL002 primers", "DNA", 66, 93], ["400 bp VHH fragment", "DNA", 170, 189], ["VHH-FOR and VHH-REV primers", "DNA", 217, 244], ["PstI and NotI sites", "DNA", 256, 275], ["The first PCR products", "TREATMENT", 0, 22], ["a 700 bp fragment", "TREATMENT", 33, 50], ["CALL001 and CALL002 primers", "TREATMENT", 66, 93], ["an approximately 400 bp VHH fragment", "TREATMENT", 153, 189], ["PCR", "TEST", 194, 197], ["the VHH", "TEST", 213, 220], ["VHH", "TEST", 229, 232], ["REV primers", "TREATMENT", 233, 244], ["PstI and NotI sites", "TREATMENT", 256, 275], ["the first purified product", "TREATMENT", 310, 336], ["a template", "TREATMENT", 345, 355]]], ["The pCANTAB 5E phagemid vector (GE Healthcare Life Science, USA) and the purified VHH products were digested using the PstI and NotI restriction enzymes (New England Biolabs, NEB) and then ligated at 16 \u00b0C with T4 DNA ligase (New England Biolabs, NEB).", [["VHH", "GENE_OR_GENE_PRODUCT", 82, 85], ["PstI", "GENE_OR_GENE_PRODUCT", 119, 123], ["NotI", "GENE_OR_GENE_PRODUCT", 128, 132], ["Biolabs", "GENE_OR_GENE_PRODUCT", 166, 173], ["NEB", "GENE_OR_GENE_PRODUCT", 175, 178], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["pCANTAB 5E phagemid vector", "DNA", 4, 30], ["purified VHH products", "PROTEIN", 73, 94], ["PstI", "DNA", 119, 123], ["NotI restriction enzymes", "PROTEIN", 128, 152], ["New England Biolabs", "PROTEIN", 154, 173], ["NEB", "PROTEIN", 175, 178], ["T4 DNA ligase", "PROTEIN", 211, 224], ["NEB", "PROTEIN", 247, 250], ["The pCANTAB 5E phagemid vector", "TREATMENT", 0, 30], ["the purified VHH products", "TREATMENT", 69, 94], ["the PstI", "TREATMENT", 115, 123], ["NotI restriction enzymes", "TEST", 128, 152], ["New England Biolabs, NEB", "TREATMENT", 154, 178], ["T4 DNA ligase", "PROBLEM", 211, 224], ["New England Biolabs", "TREATMENT", 226, 245], ["NEB", "TREATMENT", 247, 250]]], ["The ligated material was electroporated into electrocompetent E. coli TG1 cells, and then the transformed cells were cultured on Luria\u2013Bertani (LB) agar plates containing 2% (v/v) glucose and 100 \u03bcg/mL ampicillin at 37 \u00b0C overnight.", [["TG1 cells", "ANATOMY", 70, 79], ["cells", "ANATOMY", 106, 111], ["glucose", "CHEMICAL", 180, 187], ["ampicillin", "CHEMICAL", 202, 212], ["glucose", "CHEMICAL", 180, 187], ["ampicillin", "CHEMICAL", 202, 212], ["E. coli TG1 cells", "CELL", 62, 79], ["cells", "CELL", 106, 111], ["Luria\u2013Bertani", "SIMPLE_CHEMICAL", 129, 142], ["glucose", "SIMPLE_CHEMICAL", 180, 187], ["ampicillin", "SIMPLE_CHEMICAL", 202, 212], ["electrocompetent E. coli TG1 cells", "CELL_LINE", 45, 79], ["transformed cells", "CELL_LINE", 94, 111], ["E. coli", "SPECIES", 62, 69], ["E. coli", "SPECIES", 62, 69], ["The ligated material", "TREATMENT", 0, 20], ["electrocompetent E. coli TG1 cells", "PROBLEM", 45, 79], ["the transformed cells", "PROBLEM", 90, 111], ["Luria\u2013", "TEST", 129, 135], ["agar plates", "TEST", 148, 159], ["glucose", "TEST", 180, 187], ["ampicillin", "TREATMENT", 202, 212], ["coli TG1 cells", "OBSERVATION", 65, 79]]], ["Colonies were scraped and stored in LB containing 15% glycerol at \u2212 80 \u00b0C. The size and diversity of the library were evaluated by calculating the number of colonies and the insertion rate by PCR amplification after gradient dilution, and the positive clones were sequenced.Phage preparation ::: Materials and methodsRecombinant E. coli TG1 containing the pCANTAB 5E-VHH plasmid was inoculated into 2\u00d7 YT medium containing 2% (v/v) glucose and 100 \u03bcg/ml ampicillin with vigorous shaking at 200 r/min and 37 \u00b0C until the optical density at 600 nm (OD600nm) of the bacterial culture reached approximately 0.6.", [["Colonies", "ANATOMY", 0, 8], ["colonies", "ANATOMY", 157, 165], ["glycerol", "CHEMICAL", 54, 62], ["glucose", "CHEMICAL", 432, 439], ["ampicillin", "CHEMICAL", 454, 464], ["glycerol", "CHEMICAL", 54, 62], ["glucose", "CHEMICAL", 432, 439], ["ampicillin", "CHEMICAL", 454, 464], ["Colonies", "CELL", 0, 8], ["glycerol", "SIMPLE_CHEMICAL", 54, 62], ["E. coli", "ORGANISM", 329, 336], ["TG1", "ORGANISM", 337, 340], ["pCANTAB 5E", "GENE_OR_GENE_PRODUCT", 356, 366], ["glucose", "SIMPLE_CHEMICAL", 432, 439], ["ampicillin", "SIMPLE_CHEMICAL", 454, 464], ["pCANTAB 5E-VHH plasmid", "DNA", 356, 378], ["E. coli", "SPECIES", 329, 336], ["E. coli", "SPECIES", 329, 336], ["15% glycerol", "TREATMENT", 50, 62], ["the insertion rate", "TREATMENT", 170, 188], ["PCR amplification", "TEST", 192, 209], ["gradient dilution", "TEST", 216, 233], ["the positive clones", "PROBLEM", 239, 258], ["methodsRecombinant E. coli TG1", "TEST", 310, 340], ["the pCANTAB 5E", "TREATMENT", 352, 366], ["VHH plasmid", "TREATMENT", 367, 378], ["YT medium", "TREATMENT", 402, 411], ["v/v) glucose", "TREATMENT", 427, 439], ["ampicillin", "TREATMENT", 454, 464], ["vigorous shaking", "PROBLEM", 470, 486], ["the bacterial culture", "TEST", 559, 580], ["size", "OBSERVATION_MODIFIER", 79, 83], ["diversity", "OBSERVATION_MODIFIER", 88, 97], ["library", "ANATOMY", 105, 112], ["positive clones", "OBSERVATION", 243, 258]]], ["Then, the M13K07 helper phage was added to TG1 cells, which were incubated for 1 h at 37 \u00b0C without shaking.", [["TG1 cells", "ANATOMY", 43, 52], ["TG1 cells", "CELL", 43, 52], ["M13K07 helper phage", "CELL_LINE", 10, 29], ["TG1 cells", "CELL_LINE", 43, 52], ["the M13K07 helper phage", "TREATMENT", 6, 29], ["shaking", "PROBLEM", 100, 107]]], ["Cells were harvested by centrifugation at 2800\u00d7g for 10 min, and the cells were resuspended and grown overnight in 2 \u00d7 YT medium containing 100 \u03bcg/mL ampicillin and 50 \u03bcg/mL kanamycin.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 69, 74], ["ampicillin", "CHEMICAL", 150, 160], ["kanamycin", "CHEMICAL", 174, 183], ["ampicillin", "CHEMICAL", 150, 160], ["kanamycin", "CHEMICAL", 174, 183], ["Cells", "CELL", 0, 5], ["cells", "CELL", 69, 74], ["ampicillin", "SIMPLE_CHEMICAL", 150, 160], ["kanamycin", "SIMPLE_CHEMICAL", 174, 183], ["ampicillin", "TREATMENT", 150, 160], ["kanamycin", "TREATMENT", 174, 183]]], ["Cell culture was collected by centrifugation at 3800\u00d7g for 30 min at 4 \u00b0C, and the supernatant was mixed with PEG/NaCl.", [["Cell", "ANATOMY", 0, 4], ["supernatant", "ANATOMY", 83, 94], ["PEG/NaCl", "CHEMICAL", 110, 118], ["PEG", "CHEMICAL", 110, 113], ["NaCl", "CHEMICAL", 114, 118], ["Cell", "CELL", 0, 4], ["PEG", "SIMPLE_CHEMICAL", 110, 113], ["Cell culture", "TEST", 0, 12], ["the supernatant", "TREATMENT", 79, 94], ["PEG/NaCl", "TREATMENT", 110, 118]]], ["Phages were precipitated by centrifugation at 12,000\u00d7g for 30 min after 2 h of incubation on ice.", [["ice", "TREATMENT", 93, 96]]], ["Finally, the phage particles were resuspended in 1 mL of phosphate buffered saline (PBS) and then quantified by phage titration.", [["phosphate buffered", "CHEMICAL", 57, 75], ["phosphate", "CHEMICAL", 57, 66], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 57, 82], ["the phage particles", "TREATMENT", 9, 28], ["phosphate buffered saline (PBS", "TREATMENT", 57, 87], ["phage titration", "TREATMENT", 112, 127]]], ["The remaining phages were stored at \u2212 80 \u00b0C for subsequent experiments.Phage titration ::: Materials and methodsOne hundred microliters of phage particles dissolved in PBS was serially diluted tenfold in 2\u00d7 YT medium, and 100 \u00b5l of each suspension containing 10\u22128, 10\u22129 and 10\u221210 cells was added to 100 \u00b5l of TG1 cells and incubated for a half-hour at 37 \u00b0C without shaking.", [["cells", "ANATOMY", 280, 285], ["TG1 cells", "ANATOMY", 309, 318], ["PBS", "SIMPLE_CHEMICAL", 168, 171], ["cells", "CELL", 280, 285], ["TG1 cells", "CELL", 309, 318], ["TG1 cells", "CELL_LINE", 309, 318], ["One hundred microliters of phage particles", "TREATMENT", 112, 154], ["TG1 cells", "TREATMENT", 309, 318], ["shaking", "PROBLEM", 366, 373], ["phage particles", "OBSERVATION_MODIFIER", 139, 154]]], ["Then, the transformed cells were cultured on LB agar plates containing 2% (v/v) glucose and 100 \u03bcg/ml ampicillin at 37 \u00b0C overnight.", [["cells", "ANATOMY", 22, 27], ["glucose", "CHEMICAL", 80, 87], ["ampicillin", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 80, 87], ["ampicillin", "CHEMICAL", 102, 112], ["cells", "CELL", 22, 27], ["glucose", "SIMPLE_CHEMICAL", 80, 87], ["ampicillin", "SIMPLE_CHEMICAL", 102, 112], ["transformed cells", "CELL_LINE", 10, 27], ["LB agar plates", "TEST", 45, 59], ["glucose", "TEST", 80, 87], ["ampicillin", "TREATMENT", 102, 112]]], ["The next day, plates containing approximately 50 to 150 colonies were selected, and the phage was quantified with the following formula: the titer value = number of colonies \u00d7 dilution \u00d7 10.Panning for a special VHH against the PEDV N protein ::: Materials and methodsTo select special nanobodies against the PEDV N protein, three consecutive rounds of bio-panning were performed with the target protein.", [["colonies", "ANATOMY", 56, 64], ["PEDV N", "GENE_OR_GENE_PRODUCT", 309, 315], ["VHH", "PROTEIN", 212, 215], ["PEDV N protein", "PROTEIN", 228, 242], ["PEDV N protein", "PROTEIN", 309, 323], ["target protein", "PROTEIN", 389, 403], ["PEDV", "SPECIES", 309, 313], ["plates", "TREATMENT", 14, 20], ["the titer value", "TEST", 137, 152], ["a special VHH", "TEST", 202, 215], ["bio-panning", "TREATMENT", 353, 364]]], ["A 96-well plate was coated with PEDV N protein (100 \u00b5g/ml) diluted in PBS (100 \u00b5l/well) overnight at 4 \u00b0C, and PBS under the same conditions was used as a control.", [["PEDV N", "CHEMICAL", 32, 38], ["PEDV N protein", "PROTEIN", 32, 46], ["PEDV", "SPECIES", 32, 36], ["A 96-well plate", "TREATMENT", 0, 15], ["PEDV N protein", "TREATMENT", 32, 46], ["PBS", "TREATMENT", 111, 114]]], ["On the next day, the panning plate was blocked with 2.5% (w/v) nonfat dried milk (200 \u00b5l/well) in PBS (MPBS) at 25 \u00b0C for 1 h.", [["milk", "ANATOMY", 76, 80], ["milk", "ORGANISM_SUBSTANCE", 76, 80], ["the panning plate", "TREATMENT", 17, 34], ["w/v) nonfat dried milk", "TREATMENT", 58, 80]]], ["Blocked wells were washed four times with PBST (PBS with 0.05% Tween-20 (v/v)).", [["Tween-20", "CHEMICAL", 63, 71], ["Blocked wells", "PROBLEM", 0, 13], ["PBST", "TEST", 42, 46], ["PBS", "TEST", 48, 51]]], ["Then, the resuspended phage particles, which were diluted in MPBS, were prepared at a concentration of 4.4 \u00d7 1011 pfu/ml and incubated in panning plates (100 \u00b5l/well) for 1 h at 25 \u00b0C. The wells were then washed with PBST ten times and PBS five times.", [["MPBS", "SIMPLE_CHEMICAL", 61, 65], ["the resuspended phage particles", "TREATMENT", 6, 37], ["PBST", "TREATMENT", 217, 221]]], ["The special phage particles were eluted with 100 mM triethylamine (100 \u00b5l/well) (Sigma, USA) for 10 min at 25 \u00b0C and the supernatant was transferred to a 1.5 ml tube, following which 1 M Tris\u2013HCl (pH 7.4) was added to neutralize the solution.", [["supernatant", "ANATOMY", 121, 132], ["triethylamine", "CHEMICAL", 52, 65], ["Tris\u2013HCl", "CHEMICAL", 187, 195], ["triethylamine", "CHEMICAL", 52, 65], ["Tris\u2013HCl", "CHEMICAL", 187, 195], ["triethylamine", "SIMPLE_CHEMICAL", 52, 65], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 187, 195], ["The special phage particles", "TREATMENT", 0, 27], ["100 mM triethylamine", "TREATMENT", 45, 65], ["a 1.5 ml tube", "TREATMENT", 152, 165], ["1 M Tris\u2013HCl (pH", "TREATMENT", 183, 199]]], ["Then, a 20 ml aliquot of fresh exponentially growing E. coli TG1 culture was infected with a 1.5 ml aliquot of eluted phage particles for a half-hour at 37 \u00b0C without shaking, followed by incubation in 80 ml 2\u00d7 YT medium containing 2% (v/v) glucose and 100 \u03bcg/ml ampicillin with vigorous shaking at 200 r/min and 37 \u00b0C until the OD600nm of the bacteria culture reached approximately 0.6.", [["glucose", "CHEMICAL", 241, 248], ["ampicillin", "CHEMICAL", 263, 273], ["glucose", "CHEMICAL", 241, 248], ["ampicillin", "CHEMICAL", 263, 273], ["E. coli", "ORGANISM", 53, 60], ["TG1 culture", "CELL", 61, 72], ["glucose", "SIMPLE_CHEMICAL", 241, 248], ["ampicillin", "SIMPLE_CHEMICAL", 263, 273], ["E. coli TG1 culture", "CELL_LINE", 53, 72], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["E. coli TG1 culture", "TEST", 53, 72], ["a 1.5 ml aliquot of eluted phage particles", "TREATMENT", 91, 133], ["shaking", "PROBLEM", 167, 174], ["YT medium", "TREATMENT", 211, 220], ["v/v) glucose", "TREATMENT", 236, 248], ["ampicillin", "TREATMENT", 263, 273], ["vigorous shaking", "PROBLEM", 279, 295], ["the bacteria culture", "TEST", 340, 360], ["coli TG1", "OBSERVATION", 56, 64]]], ["The M13K07 helper phage was added to the TG1 cells to rescue and enrich the special phage particles by three consecutive rounds of bio-panning with the procedures described above.", [["TG1 cells", "ANATOMY", 41, 50], ["TG1 cells", "CELL", 41, 50], ["M13K07 helper phage", "CELL_LINE", 4, 23], ["TG1 cells", "CELL_LINE", 41, 50], ["The M13K07 helper phage", "TREATMENT", 0, 23], ["the TG1 cells", "TREATMENT", 37, 50], ["the special phage particles", "TREATMENT", 72, 99], ["bio-panning", "TREATMENT", 131, 142], ["the procedures", "TREATMENT", 148, 162]]], ["Enrichment in each round of panning was assessed by phage titration, ELISA and colony PCR.Detecting antigen-specific antibodies by phage ELISA ::: Materials and methodsA total of 98 different colonies were randomly selected from the third round of panning and cultured in 96-well plates containing 100 \u00b5l of LB agar, 2% (v/v) glucose and 100 \u03bcg/mL ampicillin for 8 h at 37 \u00b0C. Then, 20 \u00b5l of each cloned culture was transferred to 1 ml of Terrific Broth (TB) in 24-well plates and incubated with vigorous shaking at a speed of 200 r/min at 37 \u00b0C until the OD600nm of the bacterial cultures reached approximately 0.6.", [["colonies", "ANATOMY", 192, 200], ["glucose", "CHEMICAL", 326, 333], ["ampicillin", "CHEMICAL", 348, 358], ["glucose", "CHEMICAL", 326, 333], ["ampicillin", "CHEMICAL", 348, 358], ["antigen", "GENE_OR_GENE_PRODUCT", 100, 107], ["glucose", "SIMPLE_CHEMICAL", 326, 333], ["ampicillin", "SIMPLE_CHEMICAL", 348, 358], ["antigen-specific antibodies", "PROTEIN", 100, 127], ["phage titration", "TEST", 52, 67], ["ELISA and colony PCR", "TEST", 69, 89], ["Materials", "TEST", 147, 156], ["methodsA", "TEST", 161, 169], ["LB agar", "TEST", 308, 315], ["glucose", "TEST", 326, 333], ["ampicillin", "TREATMENT", 348, 358], ["each cloned culture", "TEST", 392, 411], ["Terrific Broth", "TREATMENT", 439, 453], ["vigorous shaking", "PROBLEM", 496, 512], ["the bacterial cultures", "TEST", 567, 589], ["round", "OBSERVATION_MODIFIER", 19, 24]]], ["Then, 100 \u00b5l of 10 mM isopropyl-\u03b2-d-thiogalactopyranoside (IPTG) was added to the TB to induce VHH antibody expression, and the culture was incubated overnight at 37 \u00b0C. The antibodies were extracted using an osmotic shock protocol and identified by periplasmic extract ELISA (PE-ELISA).Detecting antigen-specific antibodies by phage ELISA ::: Materials and methodsA 96-well plate was coated with PEDV N protein (100 \u00b5g/ml) diluted in PBS (100 \u00b5l/well) overnight at 4 \u00b0C, and PBS under the same conditions was used as a control.", [["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 22, 57], ["IPTG", "CHEMICAL", 59, 63], ["PEDV N", "CHEMICAL", 397, 403], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 22, 57], ["IPTG", "CHEMICAL", 59, 63], ["isopropyl-\u03b2-d-thiogalactopyranoside", "SIMPLE_CHEMICAL", 22, 57], ["IPTG", "SIMPLE_CHEMICAL", 59, 63], ["antigen", "GENE_OR_GENE_PRODUCT", 297, 304], ["VHH antibody", "PROTEIN", 95, 107], ["antibodies", "PROTEIN", 174, 184], ["antigen-specific antibodies", "PROTEIN", 297, 324], ["PEDV N protein", "PROTEIN", 397, 411], ["PEDV", "SPECIES", 397, 401], ["10 mM isopropyl-\u03b2-d-thiogalactopyranoside (IPTG)", "TREATMENT", 16, 64], ["VHH antibody expression", "PROBLEM", 95, 118], ["the culture", "TEST", 124, 135], ["The antibodies", "TEST", 170, 184], ["an osmotic shock protocol", "TREATMENT", 206, 231], ["periplasmic extract ELISA", "TEST", 250, 275], ["Materials", "TEST", 344, 353], ["methodsA", "TEST", 358, 366], ["PEDV N protein", "TREATMENT", 397, 411], ["PBS", "TREATMENT", 476, 479], ["osmotic shock", "OBSERVATION", 209, 222], ["PE", "OBSERVATION", 277, 279]]], ["On the next day, the wells were blocked with 2.5% (w/v) MPBS at 37 \u00b0C for 1 h.", [["MPBS", "CHEMICAL", 56, 60], ["MPBS", "TREATMENT", 56, 60]]], ["Then, 100 \u00b5l of extracted antibodies (diluted 1:1 in MPBS) was added to each well and incubated for 1 h.", [["extracted antibodies", "PROTEIN", 16, 36], ["extracted antibodies", "TREATMENT", 16, 36]]], ["Afterward, 100 \u00b5l of rabbit anti-E-tag polyclonal antibody (diluted 1:2000 in MPBS) was added to each well and incubated at 37 \u00b0C for 1 h.", [["rabbit", "ORGANISM", 21, 27], ["anti-E-tag", "GENE_OR_GENE_PRODUCT", 28, 38], ["rabbit anti-E-tag polyclonal antibody", "PROTEIN", 21, 58], ["diluted 1:2000", "PROTEIN", 60, 74], ["rabbit", "SPECIES", 21, 27], ["rabbit", "SPECIES", 21, 27], ["rabbit anti-E-tag polyclonal antibody", "TREATMENT", 21, 58]]], ["The plate was washed four times with PBST, and then 100 \u00b5l of goat anti-rabbit monoclonal antibody conjugated to HRP (diluted 1:5000 in MPBS) (TransGen Biotech, China) was then added and incubated for 1 h at 37 \u00b0C. After another washing step, 100 \u00b5l of a fresh TMB (400 \u00b5l of 0.6% TMB and 100 \u00b5l of 1% H2O2 in 25 ml citrate buffer, pH 5.5) solution was added to the plate, which was incubated at 37 \u00b0C for 30 min.", [["TMB", "CHEMICAL", 261, 264], ["TMB", "CHEMICAL", 281, 284], ["H2O2", "CHEMICAL", 302, 306], ["citrate", "CHEMICAL", 316, 323], ["TMB", "CHEMICAL", 261, 264], ["TMB", "CHEMICAL", 281, 284], ["H2O2", "CHEMICAL", 302, 306], ["citrate", "CHEMICAL", 316, 323], ["goat", "ORGANISM", 62, 66], ["HRP", "SIMPLE_CHEMICAL", 113, 116], ["TMB", "SIMPLE_CHEMICAL", 261, 264], ["H2O2", "SIMPLE_CHEMICAL", 302, 306], ["citrate", "SIMPLE_CHEMICAL", 316, 323], ["goat anti-rabbit monoclonal antibody", "PROTEIN", 62, 98], ["HRP", "PROTEIN", 113, 116], ["goat", "SPECIES", 62, 66], ["anti-rabbit", "SPECIES", 67, 78], ["goat", "SPECIES", 62, 66], ["anti-rabbit", "SPECIES", 67, 78], ["The plate", "TREATMENT", 0, 9], ["PBST", "TEST", 37, 41], ["goat anti-rabbit monoclonal antibody", "TREATMENT", 62, 98], ["HRP", "TEST", 113, 116], ["a fresh TMB", "TREATMENT", 253, 264], ["1% H2O2", "TREATMENT", 299, 306], ["citrate buffer", "TREATMENT", 316, 330], ["pH", "TEST", 332, 334], ["plate", "OBSERVATION_MODIFIER", 4, 9], ["plate", "ANATOMY", 366, 371]]], ["The reaction was stopped by the addition of 50 \u00b5l of 3 M H2SO4.", [["H2SO4", "CHEMICAL", 57, 62], ["The reaction", "PROBLEM", 0, 12], ["3 M H2SO4", "TREATMENT", 53, 62]]], ["The absorbance at 450 nm was read on a microtiter plate reader (Bio-Rad, USA).", [["The absorbance", "TEST", 0, 14], ["a microtiter plate", "TEST", 37, 55], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["If the absorbance in the antigen-coated well was at least threefold greater than that of the well containing PBS, the colony was regarded as positive and subjected to sequence analysis (Sangon Biotech, China).Detecting the specificity, binding activity and affinity of VHH antibodies ::: Materials and methodsThe specificity and binding activity of PEDV N protein nanobodies were determined by indirect ELISA.", [["colony", "ANATOMY", 118, 124], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 349, 363], ["VHH antibodies", "PROTEIN", 269, 283], ["PEDV N protein nanobodies", "PROTEIN", 349, 374], ["the absorbance in the antigen", "TEST", 3, 32], ["sequence analysis", "TEST", 167, 184], ["The specificity", "TEST", 309, 324], ["PEDV N protein nanobodies", "TREATMENT", 349, 374], ["absorbance", "OBSERVATION_MODIFIER", 7, 17]]], ["Specificity was determined according to the method described above, with the TGEV N protein applied as a control.", [["TGEV", "ORGANISM", 77, 81], ["TGEV N protein", "PROTEIN", 77, 91], ["TGEV", "SPECIES", 77, 81], ["Specificity", "TEST", 0, 11], ["the TGEV N protein", "TREATMENT", 73, 91]]], ["The binding activity was assessed with the same method; in this assay, positive nanobodies and unrelated nanobodies were diluted by multiple factors.Detecting the specificity, binding activity and affinity of VHH antibodies ::: Materials and methodsIn order to verify the affinity of PEDV N antigen binding to the Nbs, we conducted surface plasmon resonance (SPR) analysis using a Biacore 3000 instrument (GE Healthcare Life Science, USA).The experimental procedure is as follows: the purified PEDV N protein (5 \u00b5g/ml) was immobilized onto the flow cell of a CM5 sensor chip (GE Healthcare Life Science, USA) using a standard amine-immobilization kit as specified by the manufacturer (Biacore).", [["cell", "ANATOMY", 549, 553], ["amine", "CHEMICAL", 626, 631], ["amine", "CHEMICAL", 626, 631], ["PEDV N antigen", "GENE_OR_GENE_PRODUCT", 284, 298], ["Nbs", "GENE_OR_GENE_PRODUCT", 314, 317], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 494, 508], ["amine", "SIMPLE_CHEMICAL", 626, 631], ["VHH antibodies", "PROTEIN", 209, 223], ["PEDV N antigen", "PROTEIN", 284, 298], ["Nbs", "PROTEIN", 314, 317], ["PEDV N protein", "PROTEIN", 494, 508], ["PEDV", "SPECIES", 284, 288], ["this assay", "TEST", 59, 69], ["positive nanobodies", "PROBLEM", 71, 90], ["unrelated nanobodies", "TREATMENT", 95, 115], ["PEDV N antigen binding", "PROBLEM", 284, 306], ["surface plasmon resonance", "TEST", 332, 357], ["a Biacore 3000 instrument", "TREATMENT", 379, 404], ["The experimental procedure", "TREATMENT", 439, 465], ["the purified PEDV N protein", "TREATMENT", 481, 508], ["a CM5 sensor chip", "TREATMENT", 557, 574], ["a standard amine-immobilization kit", "TREATMENT", 615, 650], ["binding activity", "OBSERVATION", 4, 20]]], ["The SPR assay was performed using HBS-EP running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P20) on the Biacore 3000 instrument at room temperature.", [["NaCl", "CHEMICAL", 85, 89], ["HEPES", "CHEMICAL", 63, 68], ["NaCl", "CHEMICAL", 85, 89], ["EDTA", "CHEMICAL", 96, 100], ["EDTA", "SIMPLE_CHEMICAL", 96, 100], ["The SPR assay", "TEST", 0, 13], ["HBS", "TEST", 34, 37], ["EP running buffer", "TREATMENT", 38, 55], ["HEPES", "TEST", 63, 68], ["pH", "TEST", 70, 72], ["NaCl", "TEST", 85, 89], ["EDTA", "TEST", 96, 100], ["v/v) surfactant P20", "TREATMENT", 114, 133]]], ["The Nb1, Nb2 and Nb3 of same concentration (3 \u00b5g/ml) were flowed over the chip surface respectively.", [["surface", "ANATOMY", 79, 86], ["Nb2", "CHEMICAL", 9, 12], ["Nb3", "CHEMICAL", 17, 20], ["Nb1", "SIMPLE_CHEMICAL", 4, 7], ["Nb2", "SIMPLE_CHEMICAL", 9, 12], ["Nb3", "SIMPLE_CHEMICAL", 17, 20], ["Nb1", "PROTEIN", 4, 7], ["Nb2", "PROTEIN", 9, 12], ["Nb3", "PROTEIN", 17, 20], ["The Nb1", "TEST", 0, 7], ["Nb2", "TEST", 9, 12]]], ["The chips were regenerated with glycine\u2013HCl buffer (pH 2.0).", [["glycine\u2013HCl", "CHEMICAL", 32, 43], ["glycine", "CHEMICAL", 32, 39], ["HCl", "CHEMICAL", 40, 43], ["glycine\u2013HCl", "SIMPLE_CHEMICAL", 32, 43], ["The chips", "TREATMENT", 0, 9], ["glycine\u2013HCl buffer", "TREATMENT", 32, 50]]], ["The sensorgrams were analyzed using BIA evaluation Software version 4.1.", [["The sensorgrams", "TREATMENT", 0, 15], ["BIA evaluation", "TEST", 36, 50], ["Software version", "TEST", 51, 67]]], ["A nanobody sample exhibiting good specificity, binding activity and affinity was selected for the subsequent experiment.Expression and purification of soluble nanobody ::: Materials and methodsThe gene encoding the PEDV N protein specific nanobody was amplified with the pET21b-VHH-F and pET21b-VHH-R primers (Sangon Biotech, China) containing BamHI and HindIII sites and an Avi-tag (Additional file 1: Table S1) and then cloned into the pET21b expression vector.", [["nanobody sample", "ANATOMY", 2, 17], ["PEDV N", "GENE_OR_GENE_PRODUCT", 215, 221], ["BamHI", "GENE_OR_GENE_PRODUCT", 344, 349], ["HindIII", "GENE_OR_GENE_PRODUCT", 354, 361], ["pET21b", "GENE_OR_GENE_PRODUCT", 438, 444], ["PEDV N protein specific nanobody", "PROTEIN", 215, 247], ["pET21b-VHH-F and pET21b-VHH-R primers", "DNA", 271, 308], ["BamHI and HindIII sites", "DNA", 344, 367], ["Avi-tag", "DNA", 375, 382], ["Additional file 1: Table S1", "DNA", 384, 411], ["pET21b expression vector", "DNA", 438, 462], ["A nanobody sample", "TEST", 0, 17], ["the pET21b", "TEST", 267, 277], ["VHH", "TEST", 278, 281], ["pET21b", "TEST", 288, 294], ["VHH", "TEST", 295, 298], ["R primers", "TREATMENT", 299, 308], ["Sangon Biotech", "TREATMENT", 310, 324], ["BamHI and HindIII sites", "TREATMENT", 344, 367], ["an Avi-tag", "TREATMENT", 372, 382]]], ["The recombinant plasmids were transformed into E. coli BL21(DE3) to express nanobodies.", [["plasmids", "ANATOMY", 16, 24], ["E. coli BL21", "ORGANISM", 47, 59], ["DE3", "GENE_OR_GENE_PRODUCT", 60, 63], ["recombinant plasmids", "DNA", 4, 24], ["E. coli BL21", "SPECIES", 47, 59], ["E. coli BL21", "SPECIES", 47, 59], ["DE3", "SPECIES", 60, 63], ["The recombinant plasmids", "TREATMENT", 0, 24], ["E. coli BL21", "TREATMENT", 47, 59], ["coli BL21", "OBSERVATION", 50, 59]]], ["The cells were grown in LB at 200 r/min and 37 \u00b0C until the OD600nm of the bacterial culture reached approximately 0.6, following which expression was induced using 1 mM IPTG followed by incubation at 200 r/min and 37 \u00b0C for 5 h.", [["cells", "ANATOMY", 4, 9], ["IPTG", "CHEMICAL", 170, 174], ["IPTG", "CHEMICAL", 170, 174], ["cells", "CELL", 4, 9], ["the bacterial culture", "TEST", 71, 92], ["1 mM IPTG", "TREATMENT", 165, 174], ["grown", "OBSERVATION_MODIFIER", 15, 20]]], ["The cells were collected through centrifugation and ultrasonically treated.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9]]], ["The soluble protein was suspended in PBS and purified with Ni-NTA according to the manufacturer\u2019s instructions (GE Healthcare Life Science, USA).", [["Ni-NTA", "CHEMICAL", 59, 65], ["Ni-NTA", "CHEMICAL", 59, 65], ["Ni-NTA", "SIMPLE_CHEMICAL", 59, 65], ["soluble protein", "PROTEIN", 4, 19], ["The soluble protein", "TREATMENT", 0, 19], ["Ni-NTA", "TREATMENT", 59, 65]]], ["The purified soluble protein at a final concentration of 1 mg/ml was biotinylated using biotin ligase (GeneCopoeia, China) according to the manufacturer\u2019s instructions.Cross-reactivity assay ::: Materials and methodsThe specificity of the bio-nanobody was tested by indirect ELISA, and six different viral proteins, (the PEDV N, PEDV S, TGEV N, PRRSV N, PCV Cap and PRV gE proteins) were chosen to test potential cross-reactivity.", [["biotin", "CHEMICAL", 88, 94], ["biotin", "SIMPLE_CHEMICAL", 88, 94], ["bio-nanobody", "CANCER", 239, 251], ["PEDV S", "GENE_OR_GENE_PRODUCT", 329, 335], ["TGEV N", "ORGANISM", 337, 343], ["PRRSV", "ORGANISM", 345, 350], ["PCV Cap", "GENE_OR_GENE_PRODUCT", 354, 361], ["PRV gE", "ORGANISM", 366, 372], ["purified soluble protein", "PROTEIN", 4, 28], ["biotin ligase", "PROTEIN", 88, 101], ["viral proteins", "PROTEIN", 300, 314], ["PEDV N", "PROTEIN", 321, 327], ["PEDV S", "PROTEIN", 329, 335], ["TGEV N", "PROTEIN", 337, 343], ["PRRSV N", "PROTEIN", 345, 352], ["PCV Cap", "PROTEIN", 354, 361], ["PRV gE proteins", "PROTEIN", 366, 381], ["PEDV", "SPECIES", 329, 333], ["TGEV", "SPECIES", 337, 341], ["PRRSV", "SPECIES", 345, 350], ["PRV", "SPECIES", 366, 369], ["The purified soluble protein", "TREATMENT", 0, 28], ["a final concentration", "TREATMENT", 32, 53], ["biotin ligase", "TREATMENT", 88, 101], ["indirect ELISA", "TEST", 266, 280], ["six different viral proteins", "TEST", 286, 314], ["the PEDV N", "TEST", 317, 327], ["PEDV S", "TEST", 329, 335], ["TGEV", "TEST", 337, 341], ["PRRSV N", "TEST", 345, 352], ["PCV Cap", "TEST", 354, 361], ["PRV gE proteins", "TREATMENT", 366, 381]]], ["The same amount of the six proteins were used to coated a 96-well plate and incubated overnight at 4 \u00b0C. After blocking, the biotinylated-nanobody was diluted to different concentrations and incubated with antigen at 37 \u00b0C for 1 h.", [["the six proteins", "TREATMENT", 19, 35], ["blocking", "TREATMENT", 111, 119], ["the biotinylated-nanobody", "TREATMENT", 121, 146], ["amount", "OBSERVATION_MODIFIER", 9, 15]]], ["Then, HRP-conjugated streptavidin (diluted 1:5000 in MPBS) was added and incubated at 37 \u00b0C for 30 min.", [["HRP-conjugated streptavidin", "SIMPLE_CHEMICAL", 6, 33], ["MPBS", "SIMPLE_CHEMICAL", 53, 57], ["HRP", "PROTEIN", 6, 9], ["HRP-conjugated streptavidin", "TREATMENT", 6, 33]]], ["After another washing step, 100 \u00b5l of a fresh TMB solution prepared as described above was added to the plate and incubated at 37 \u00b0C for 15 min.", [["TMB", "CHEMICAL", 46, 49], ["TMB", "SIMPLE_CHEMICAL", 46, 49], ["a fresh TMB solution", "TREATMENT", 38, 58]]], ["The reaction was stopped by the addition of 50 \u00b5l of 3 M H2SO4, and then the absorbance at 450 nm was read on a microtiter plate reader.Procedures of the for streptavidin\u2013biotin amplified blocking ELISA ::: Materials and methodsBiotinylated nanobody blocking ELISA (bELISA) was performed with a streptavidin\u2013biotin amplified system.", [["H2SO4", "CHEMICAL", 57, 62], ["streptavidin\u2013biotin", "CHEMICAL", 158, 177], ["streptavidin\u2013biotin", "SIMPLE_CHEMICAL", 158, 177], ["The reaction", "PROBLEM", 0, 12], ["3 M H2SO4", "TREATMENT", 53, 62], ["a microtiter plate", "TREATMENT", 110, 128], ["Materials", "TREATMENT", 207, 216], ["methodsBiotinylated nanobody blocking ELISA", "TREATMENT", 221, 264], ["a streptavidin\u2013biotin amplified system", "TREATMENT", 293, 331]]], ["To achieve optimal blocking ELISA performance, various experimental conditions were optimized.", [["various experimental conditions", "PROBLEM", 47, 78]]], ["First, a checkboard titration was implemented in indirect ELISA to determine the optimal concentration of the antigen (50 ng/well, 100 ng/well, 200 ng/well, and 400 ng/well) and dilution factor of the corresponding biotinylated nanobody (1:500, 1:1000, 1:2000, 1:4000, 1:6000 and 1:8000).", [["a checkboard titration", "TREATMENT", 7, 29], ["indirect ELISA", "TEST", 49, 63], ["the antigen", "TREATMENT", 106, 117]]], ["If the absorbance of the solution in the antigen-coated well was close to 1.0, the concentration of the corresponding coated antigen and the dilution factor of the biotinylated nanobody were considered optimal.Procedures of the for streptavidin\u2013biotin amplified blocking ELISA ::: Materials and methodsTo carry out bELISA, a 96-well plate was coated with the optimal concentration of PEDV N protein, incubated overnight at 4 \u00b0C and then blocked with 1% BSA at 37 \u00b0C for 1 h.", [["BSA", "CHEMICAL", 453, 456], ["streptavidin\u2013biotin", "CHEMICAL", 232, 251], ["streptavidin\u2013biotin", "SIMPLE_CHEMICAL", 232, 251], ["BSA", "SIMPLE_CHEMICAL", 453, 456], ["coated antigen", "PROTEIN", 118, 132], ["dilution factor", "PROTEIN", 141, 156], ["PEDV N protein", "PROTEIN", 384, 398], ["PEDV", "SPECIES", 384, 388], ["the corresponding coated antigen", "TREATMENT", 100, 132], ["the biotinylated nanobody", "TREATMENT", 160, 185], ["PEDV N protein", "TREATMENT", 384, 398], ["1% BSA", "TREATMENT", 450, 456], ["absorbance", "OBSERVATION_MODIFIER", 7, 17]]], ["The positive and negative sera were serially diluted (1:5, 1:10, 1:20, 1:40) and added to the wells at 37 \u00b0C for different lengths of time (30 min, 60 min, 90 min, 120 min).", [["sera", "ANATOMY", 26, 30], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["Then, the plate was washed four times with PBS\u2019T. Afterward, the biotinylated nanobody was added to the wells and incubated for different lengths of time (30 min, 60 min, 90 min and 120 min).", [["the plate", "TREATMENT", 6, 15], ["the biotinylated nanobody", "TREATMENT", 61, 86]]], ["The plate was washed three times with PBST and then the optimal concentration of HRP-conjugated streptavidin (Thermo Fisher, USA) was added for incubation at 37 \u00b0C for the optimal reaction time (30 min, 60 min, 90 min and 120 min).", [["HRP-conjugated streptavidin", "SIMPLE_CHEMICAL", 81, 108], ["HRP", "PROTEIN", 81, 84], ["The plate", "TREATMENT", 0, 9], ["PBST", "TREATMENT", 38, 42], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["After another washing step, 100 \u00b5l of a fresh TMB solution prepared as described above was added to the plate, which was incubated at 37 \u00b0C for 15 min.", [["TMB", "CHEMICAL", 46, 49], ["TMB", "SIMPLE_CHEMICAL", 46, 49], ["a fresh TMB solution", "TREATMENT", 38, 58]]], ["The reaction was stopped by the addition of 50 \u00b5l of 3 M H2SO4, and then the absorbance at 450 nm was read on a microtiter plate reader.", [["H2SO4", "CHEMICAL", 57, 62], ["The reaction", "PROBLEM", 0, 12], ["3 M H2SO4", "TREATMENT", 53, 62], ["a microtiter plate", "TREATMENT", 110, 128]]], ["If the percentage inhibition (PI) {PI (%) = 100 \u00d7 [1 \u2212 (test serum OD450nm/negative reference serum OD450nm)]} was highest, and the absorbance of the negative serum was closest to 1.0, the experimental conditions were then considered optimal.Blocking ELISA cutoff value ::: Materials and methodsNinety standard PEDV-negative serum samples, that were confirmed PEDV-negative by both RT-PCR and a commercial ELISA kit were used to define the positive\u2013negative cutoff value for blocking ELISA.", [["serum", "ANATOMY", 61, 66], ["serum", "ANATOMY", 94, 99], ["serum", "ANATOMY", 159, 164], ["serum samples", "ANATOMY", 325, 338], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["serum", "ORGANISM_SUBSTANCE", 159, 164], ["PEDV", "ORGANISM", 311, 315], ["serum", "ORGANISM", 325, 330], ["the percentage inhibition", "TEST", 3, 28], ["PI", "TEST", 30, 32], ["PI", "TEST", 35, 37], ["test serum OD450nm", "TEST", 56, 74], ["serum OD450nm", "TEST", 94, 107], ["the absorbance", "TEST", 128, 142], ["serum samples", "TEST", 325, 338], ["PEDV", "TEST", 360, 364], ["PCR", "TEST", 385, 388], ["a commercial ELISA kit", "TEST", 393, 415], ["blocking ELISA", "PROBLEM", 475, 489]]], ["The procedure was based on the method mentioned above.", [["The procedure", "TREATMENT", 0, 13]]], ["The two thresholds cutoff value were defined as the mean PI (%) value (", [["The two thresholds cutoff value", "TEST", 0, 31], ["the mean PI", "TEST", 48, 59]]]], "PMC7172573": [], "c7e8a36b45803936929d22dd92a5a24cdb041722": [["IntroductionWith more than 3 million cases and 200,000 deaths [1] by the end of April 2020, the COVID-19 pandemic has rapidly emerged as a serious global health emergency [2] , testing the ability of health care systems to respond.", [["deaths", "DISEASE", 55, 61]]], ["The burden on health care systems emanates both from the high incidence of COVID-19 and the fact that 20% to 30% of patients experience a moderate-to-severe form of the disease-with multi-organ failure, prolonged periods of morbidity and hospitalization, and high mortality [3] .", [["multi-organ", "ANATOMY", 182, 193], ["multi-organ failure", "DISEASE", 182, 201], ["patients", "ORGANISM", 116, 124], ["multi-organ", "ORGAN", 182, 193], ["patients", "SPECIES", 116, 124], ["COVID", "TEST", 75, 80], ["the disease", "PROBLEM", 165, 176], ["multi-organ failure", "PROBLEM", 182, 201], ["morbidity", "PROBLEM", 224, 233], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["moderate-to-severe", "OBSERVATION_MODIFIER", 138, 156], ["disease", "OBSERVATION", 169, 176], ["multi-organ", "ANATOMY", 182, 193], ["failure", "OBSERVATION", 194, 201]]], ["Moreover, from 5% to 12% of all patients diagnosed with COVID-19 and up to 33% of hospitalized patients require supportive critical care in an intensive care unit (ICU) [3] [4] [5] .", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 95, 103], ["COVID", "TEST", 56, 61]]], ["These estimates indicate that the rate of ICU transfer of hospitalized patients with COVID-19 is significantly higher than the ICU transfer rates of 11% reported for other hospitalized patients [6, 7] .IntroductionFurthermore, the need for ICU care may be even higher in specific high-risk groups with COVID-19, such as older individuals [3] or those with pre-existing comorbidities [8] .", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 185, 193], ["COVID", "TEST", 85, 90], ["ICU care", "TREATMENT", 240, 248], ["pre-existing comorbidities", "PROBLEM", 356, 382]]], ["For example, over 75% of COVID-19 patients admitted to the ICU have one or more pre-existing comorbid conditions [9] .", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["COVID", "TEST", 25, 30], ["pre-existing comorbid conditions", "PROBLEM", 80, 112]]], ["COVID-19 patients admitted to non-ICU units often experience rapid clinical deterioration [13] and, therefore, require frequent clinical assessments.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["rapid clinical deterioration", "PROBLEM", 61, 89], ["frequent clinical assessments", "TEST", 119, 148]]], ["However, with resources stretched thin, frequent assessment is difficult and can increase the risk of exposure among frontline personnel.", [["frequent assessment", "TEST", 40, 59]]], ["To efficiently manage these finite resources and personnel, optimal prioritization of patients and efficient use of hospital resources are necessary.IntroductionICU care may be needed for supportive management of severe COVID-19-associated pneumonia, acute respiratory distress (ARDS), sepsis, cardiomyopathy, arrhythmia, and acute renal failure.", [["respiratory", "ANATOMY", 257, 268], ["renal", "ANATOMY", 332, 337], ["COVID-19", "CHEMICAL", 220, 228], ["pneumonia", "DISEASE", 240, 249], ["acute respiratory distress", "DISEASE", 251, 277], ["ARDS", "DISEASE", 279, 283], ["sepsis", "DISEASE", 286, 292], ["cardiomyopathy", "DISEASE", 294, 308], ["arrhythmia", "DISEASE", 310, 320], ["acute renal failure", "DISEASE", 326, 345], ["patients", "ORGANISM", 86, 94], ["renal", "ORGAN", 332, 337], ["patients", "SPECIES", 86, 94], ["hospital resources", "TREATMENT", 116, 134], ["IntroductionICU care", "TREATMENT", 149, 169], ["supportive management", "TREATMENT", 188, 209], ["severe COVID", "PROBLEM", 213, 225], ["pneumonia", "PROBLEM", 240, 249], ["acute respiratory distress", "PROBLEM", 251, 277], ["ARDS)", "PROBLEM", 279, 284], ["sepsis", "PROBLEM", 286, 292], ["cardiomyopathy", "PROBLEM", 294, 308], ["arrhythmia", "PROBLEM", 310, 320], ["acute renal failure", "PROBLEM", 326, 345], ["pneumonia", "OBSERVATION", 240, 249], ["acute", "OBSERVATION_MODIFIER", 251, 256], ["respiratory distress", "OBSERVATION", 257, 277], ["ARDS", "OBSERVATION", 279, 283], ["sepsis", "OBSERVATION", 286, 292], ["cardiomyopathy", "OBSERVATION", 294, 308], ["arrhythmia", "OBSERVATION", 310, 320], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["renal", "ANATOMY", 332, 337], ["failure", "OBSERVATION", 338, 345]]], ["ICU care also may become necessary to manage prolonged hospitalization-associated complications, such as coagulopathy [14] , secondary infections, gastrointestinal bleeding, and other problems [13] .", [["gastrointestinal", "ANATOMY", 147, 163], ["coagulopathy", "DISEASE", 105, 117], ["infections", "DISEASE", 135, 145], ["gastrointestinal bleeding", "DISEASE", 147, 172], ["gastrointestinal", "ORGANISM_SUBDIVISION", 147, 163], ["ICU care", "TREATMENT", 0, 8], ["associated complications", "PROBLEM", 71, 95], ["coagulopathy", "PROBLEM", 105, 117], ["secondary infections", "PROBLEM", 125, 145], ["gastrointestinal bleeding", "PROBLEM", 147, 172], ["other problems", "PROBLEM", 178, 192], ["complications", "OBSERVATION", 82, 95], ["infections", "OBSERVATION", 135, 145], ["gastrointestinal", "ANATOMY", 147, 163], ["bleeding", "OBSERVATION", 164, 172]]], ["Determining whether an individual's dynamic risk of clinical deterioration warrants an ICU transfer may require analyses of temporal changes in patients' conditions and key indicators of imminent complications of COVID-19.", [["COVID-19", "CHEMICAL", 213, 221], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["clinical deterioration", "PROBLEM", 52, 74], ["temporal changes in patients' conditions", "PROBLEM", 124, 164], ["imminent complications", "PROBLEM", 187, 209], ["COVID", "TEST", 213, 218]]], ["Supervised machine learning approaches may be useful to (a) analyze and interpret patients' clinical and laboratory values and their temporal changes, and (b) quantify their dynamic risk of clinical deterioration and the need for ICU transfer.IntroductionThe primary aim of this study is to develop a novel supervised machine learning classifier for predicting the risk of ICU transfer within the next 24 h for COVID-19 patients using hospital EMR data.", [["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 420, 428], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 420, 428], ["Supervised machine learning approaches", "TREATMENT", 0, 38], ["laboratory values", "TEST", 105, 122], ["clinical deterioration", "PROBLEM", 190, 212], ["ICU transfer", "TREATMENT", 230, 242], ["this study", "TEST", 274, 284], ["hospital EMR data", "TEST", 435, 452]]], ["We applied a random forest (RF) [15] approach, which has proven promising in analyzing complex clinical data of multiple types [15] , has high model generalizability [15] , and can elucidate high-order interactions between variables without compromising predictive accuracy [16] .", [["a random forest (RF) [15] approach", "TREATMENT", 11, 45], ["high model generalizability", "PROBLEM", 138, 165]]], ["We describe the development and validation of such a model, its predictive performance, and the interpretation of our results.Study Cohort and FeaturesThis study was approved by the Mount Sinai Health System Institutional Research Board (IRB protocol number: 18-00581); the need for informed consent was waived.Study Cohort and FeaturesThe study cohort was comprised of patients 18 years or older who had a COVID-19 diagnosis and were admitted to the Mount Sinai Hospital in non-ICU general in-patient beds between 26 February and 18 April 2020.", [["patients", "ORGANISM", 370, 378], ["patient", "ORGANISM", 494, 501], ["patients", "SPECIES", 370, 378], ["patient", "SPECIES", 494, 501], ["This study", "TEST", 151, 161], ["The study", "TEST", 336, 345]]], ["The diagnosis was based on a clinical conclusion of an infectious disease specialist or a positive PCR test (initial or repeat testing).Study Cohort and FeaturesThe following data were retrospectively collected from the Mount Sinai Health System COVID-19 registry, sourced from an EPIC EHR system: demographic information, time-series of the admission-discharge-transfer events, structured and semi-structured clinical assessments, vital signs from nursing flowsheets, and laboratory and electrocardiogram (ECG) results.Sampling StrategyGiven the crisis nature of the pandemic, clinicians caring for this cohort collected data such as vital signs, diagnostic labs, ECGs, and nursing assessments based on clinical judgment and resource availability rather than a standard protocol.", [["a positive PCR test", "PROBLEM", 88, 107], ["repeat testing", "TEST", 120, 134], ["semi-structured clinical assessments", "TEST", 394, 430], ["vital signs", "TEST", 432, 443], ["nursing flowsheets", "TEST", 449, 467], ["electrocardiogram", "TEST", 488, 505], ["ECG", "TEST", 507, 510], ["this cohort collected data", "TEST", 600, 626], ["vital signs", "TEST", 635, 646], ["diagnostic labs", "TEST", 648, 663], ["ECGs", "TEST", 665, 669], ["nursing assessments", "TEST", 675, 694], ["clinical judgment", "TEST", 704, 721], ["a standard protocol", "TREATMENT", 760, 779]]], ["Thus, to create time-series data for each observational variable, we included the three most recent assessments available when the feature vector was created.", [["recent assessments", "TEST", 93, 111]]], ["Feature vectors were created daily during each COVID-19 patient's non-ICU general bed stay until discharge, ICU transfer, or death.", [["death", "DISEASE", 125, 130], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["Feature vectors", "PROBLEM", 0, 15]]], ["Missing values for each variable were imputed by using the median value across the cohort [17] .LabelingThe primary outcome of this study was ICU transfer within 24 h from the time of prediction.", [["Missing values", "PROBLEM", 0, 14], ["this study", "TEST", 127, 137]]], ["Labeling of feature vectors followed the following logic: (1) If the ICU transfer was within 24 h of the feature vector creation, we labeled the feature vector as positive; (2) If the ICU transfer occurred after 24 h from the creation of the feature vector, we labeled the feature vector as negative; (3) If the ICU transfer did not occur during the patients' stay, then all feature vectors for that admission were labeled as negative.", [["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 350, 358]]], ["This process is depicted in Figure 1 .Training, Testing, and Cross-ValidationThe study cohort data were randomly split into a training set used for training the prediction model, and a test set used for testing the model's performance.", [["Testing", "TEST", 48, 55], ["The study cohort data", "TEST", 77, 98], ["a training set", "TREATMENT", 124, 138], ["training the prediction model", "TEST", 148, 177], ["a test set", "TEST", 183, 193], ["testing the model's performance", "TEST", 203, 234]]], ["The training set consisted of 70 percent of the full cohort, and the test cohort consisted of the remaining 30 percent.", [["the test cohort", "TEST", 65, 80]]], ["We randomly split our cohort so that patients were only included in the training or the test set.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["the test set", "TEST", 84, 96]]], ["We performed random under-sampling [18, 19] on the training data set for balancing the majority class (negative label) until both classes were equally balanced.Training, Testing, and Cross-ValidationThe RF model was trained with 10-fold cross-validation.", [["the training data", "TEST", 47, 64], ["Testing", "TEST", 170, 177], ["The RF model", "TEST", 199, 211], ["10-fold cross-validation", "TREATMENT", 229, 253]]], ["The open-source Apache Spark project machine-learning library [20] was used.Feature SelectionThe features included in this study were based on clinical judgments and reports in the COVID-19 literature.", [["this study", "TEST", 118, 128], ["clinical judgments", "TEST", 143, 161], ["the COVID", "TEST", 177, 186]]], ["We included periodic monitoring of vital signs [21] , complete blood count, serum biochemical tests [22] , coagulation profile [14] , and electrocardiogram results [23] as relevant input variables.", [["blood", "ANATOMY", 63, 68], ["serum", "ANATOMY", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["periodic monitoring", "TEST", 12, 31], ["vital signs", "TEST", 35, 46], ["complete blood count", "TEST", 54, 74], ["serum biochemical tests", "TEST", 76, 99], ["coagulation profile", "TEST", 107, 126], ["electrocardiogram", "TEST", 138, 155]]], ["Features were ranked by using the Gini importance [20] .Model TestingThe model performance was evaluated on the test set.", [["the test set", "TEST", 108, 120]]], ["RF model-derived class probabilities [20] were used to predict ICU transfer within 24 h with a default threshold of \u22650.5.", [["a default threshold", "TEST", 93, 112]]], ["Predictions less than the default threshold were categorized as negative.", [["the default threshold", "TEST", 22, 43]]], ["Sensitivity, specificity, accuracy, and area under the receiver operating curve (AUC-ROC), along with 95% CI, were estimated for evaluating the screening tool's performance [24] .", [["Sensitivity", "TEST", 0, 11], ["accuracy", "TEST", 26, 34], ["operating curve", "TEST", 64, 79], ["AUC", "TEST", 81, 84], ["the screening tool", "TEST", 140, 158]]], ["The study cohort yielded 9639 feature vectors, which contained data from each day of non-ICU hospital stay for 1987 unique patients.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["The study", "TEST", 0, 9]]], ["Each individual vector, generated 24 h apart, represented a day of in-patient stay in a non-ICU bed for each patient.", [["patient", "ORGANISM", 70, 77], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 70, 77], ["patient", "SPECIES", 109, 116], ["a non-ICU bed", "TREATMENT", 86, 99]]], ["The split cohort resulted in 5548 and 2386 feature vectors created from the stays of 1168 and 521 patients in the training and test datasets, respectively.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["test datasets", "TEST", 127, 140]]], ["After performing majority-class under-sampling, the final training set consisted of 2008 feature vectors, representing each non-ICU stay of 401 unique patients.", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159]]], ["The median time to ICU transfer from the time of admission was 2.45 days.Cohort CharacteristicsThe study cohort included a higher proportion of women, and about two-thirds of the cohort was between 18 and 65 years old.", [["women", "ORGANISM", 144, 149], ["women", "SPECIES", 144, 149], ["The study", "TEST", 95, 104]]], ["About one-quarter of the patients in the cohort had more than one comorbidity, including COPD, diabetes, hypertension, obesity, or cancer.Features and Model HyperparametersA total of 31 variables (comprising 99 features) had predictive value using the Gini importance metric in training the RF model.", [["cancer", "ANATOMY", 131, 137], ["COPD", "DISEASE", 89, 93], ["diabetes", "DISEASE", 95, 103], ["hypertension", "DISEASE", 105, 117], ["obesity", "DISEASE", 119, 126], ["cancer", "DISEASE", 131, 137], ["patients", "ORGANISM", 25, 33], ["cancer", "CANCER", 131, 137], ["patients", "SPECIES", 25, 33], ["COPD", "PROBLEM", 89, 93], ["diabetes", "PROBLEM", 95, 103], ["hypertension", "PROBLEM", 105, 117], ["obesity", "PROBLEM", 119, 126], ["cancer", "PROBLEM", 131, 137], ["Features", "TEST", 138, 146], ["Model HyperparametersA", "TEST", 151, 173], ["predictive value", "TEST", 225, 241], ["training the RF model", "TREATMENT", 278, 299], ["COPD", "OBSERVATION", 89, 93], ["diabetes", "OBSERVATION", 95, 103], ["hypertension", "OBSERVATION", 105, 117], ["obesity", "OBSERVATION", 119, 126], ["cancer", "OBSERVATION", 131, 137], ["HyperparametersA", "OBSERVATION_MODIFIER", 157, 173], ["total", "OBSERVATION_MODIFIER", 174, 179]]], ["Hyper-parameters used in the final model are provided in Table S1 .Predictors and Their ImportanceThe top 20 predictive variables are summarized in Figure 2 .", [["Hyper-parameters", "PROBLEM", 0, 16]]], ["Model input variables with their respective sources are listed in Table S2 .", [["Model input variables", "PROBLEM", 0, 21]]], ["Our model identified a series of features related to progressive respiratory failure (respiratory rate, oxygen saturation), markers of systemic inflammation (C-reactive protein, white blood cell count), shock (systolic and diastolic blood pressures), renal failure (blood urea nitrogen, anion gap, and serum creatinine), and the pathophysiology of COVID-19 (lymphocyte count).", [["respiratory", "ANATOMY", 65, 76], ["respiratory", "ANATOMY", 86, 97], ["white blood cell", "ANATOMY", 178, 194], ["blood", "ANATOMY", 233, 238], ["renal", "ANATOMY", 251, 256], ["blood", "ANATOMY", 266, 271], ["serum", "ANATOMY", 302, 307], ["lymphocyte", "ANATOMY", 358, 368], ["respiratory failure", "DISEASE", 65, 84], ["oxygen", "CHEMICAL", 104, 110], ["inflammation", "DISEASE", 144, 156], ["shock", "DISEASE", 203, 208], ["renal failure", "DISEASE", 251, 264], ["blood urea nitrogen", "CHEMICAL", 266, 285], ["creatinine", "CHEMICAL", 308, 318], ["oxygen", "CHEMICAL", 104, 110], ["urea", "CHEMICAL", 272, 276], ["nitrogen", "CHEMICAL", 277, 285], ["creatinine", "CHEMICAL", 308, 318], ["oxygen", "SIMPLE_CHEMICAL", 104, 110], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 158, 176], ["white blood cell", "CELL", 178, 194], ["blood", "ORGANISM_SUBSTANCE", 233, 238], ["renal", "ORGAN", 251, 256], ["blood", "ORGANISM_SUBSTANCE", 266, 271], ["urea", "SIMPLE_CHEMICAL", 272, 276], ["anion", "SIMPLE_CHEMICAL", 287, 292], ["serum", "ORGANISM_SUBSTANCE", 302, 307], ["creatinine", "SIMPLE_CHEMICAL", 308, 318], ["lymphocyte", "CELL", 358, 368], ["C-reactive protein", "PROTEIN", 158, 176], ["progressive respiratory failure", "PROBLEM", 53, 84], ["respiratory rate", "TEST", 86, 102], ["oxygen saturation", "TEST", 104, 121], ["systemic inflammation", "PROBLEM", 135, 156], ["C-reactive protein", "PROBLEM", 158, 176], ["white blood cell count", "TEST", 178, 200], ["shock", "PROBLEM", 203, 208], ["systolic", "TEST", 210, 218], ["diastolic blood pressures", "TEST", 223, 248], ["renal failure", "PROBLEM", 251, 264], ["blood urea nitrogen", "TEST", 266, 285], ["anion gap", "TEST", 287, 296], ["serum creatinine", "TEST", 302, 318], ["COVID", "TEST", 348, 353], ["lymphocyte count", "TEST", 358, 374], ["progressive", "OBSERVATION_MODIFIER", 53, 64], ["respiratory failure", "OBSERVATION", 65, 84], ["systemic", "OBSERVATION_MODIFIER", 135, 143], ["inflammation", "OBSERVATION", 144, 156], ["renal", "ANATOMY", 251, 256], ["failure", "OBSERVATION", 257, 264]]], ["Respiratory rate (the earliest recorded value of the latest three assessments) had the highest predictive value in the RF model, and white blood cell count was the second highest.", [["white blood cell", "ANATOMY", 133, 149], ["white blood cell", "CELL", 133, 149], ["Respiratory rate", "TEST", 0, 16], ["white blood cell count", "TEST", 133, 155]]], ["Variables included in the final model reflected the importance of temporal changes in vital signs, markers of acid-base equilibrium and systemic inflammation, and predictors of myocardial injury and renal function.Predictive Performance of the ModelThe predictive performance of the RF-based model on the test dataset is presented in Table 2 .", [["myocardial", "ANATOMY", 177, 187], ["renal", "ANATOMY", 199, 204], ["inflammation", "DISEASE", 145, 157], ["myocardial injury", "DISEASE", 177, 194], ["myocardial", "MULTI-TISSUE_STRUCTURE", 177, 187], ["renal", "ORGAN", 199, 204], ["RF", "PROTEIN", 283, 285], ["temporal changes", "PROBLEM", 66, 82], ["vital signs", "TEST", 86, 97], ["acid-base equilibrium", "PROBLEM", 110, 131], ["systemic inflammation", "PROBLEM", 136, 157], ["myocardial injury", "PROBLEM", 177, 194], ["renal function", "PROBLEM", 199, 213], ["the test dataset", "TEST", 301, 317], ["base", "ANATOMY_MODIFIER", 115, 119], ["systemic", "OBSERVATION_MODIFIER", 136, 144], ["inflammation", "OBSERVATION", 145, 157], ["myocardial", "ANATOMY", 177, 187], ["injury", "OBSERVATION", 188, 194], ["renal", "ANATOMY", 199, 204]]], ["Of 2386 feature vectors, 89 represented patient-days where ICU transfer occurred within 24 h of the prediction time point.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["The AUC-ROC of the prediction model is shown in Figure 3 .DiscussionOur model provides a tool for dynamic risk quantification for ICU transfer within the next 24 h.", [["The AUC", "TEST", 0, 7]]], ["Clinical management of COVID-19 requires frequent monitoring and re-assessment among patients who may suffer rapid deterioration.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["COVID", "TEST", 23, 28], ["frequent monitoring", "TEST", 41, 60], ["re-assessment", "TEST", 65, 78], ["rapid deterioration", "PROBLEM", 109, 128]]], ["Although deterioration may be evident by corroboration of changes in vital signs, laboratory results, electrocardiograms, and information in nursing notes, frequent review of these important parameters might not be feasible in crisis situations.", [["deterioration", "PROBLEM", 9, 22], ["vital signs", "TEST", 69, 80], ["electrocardiograms", "TEST", 102, 120]]], ["Using machine learning, we developed a model for identifying deteriorating patients in need of ICU transfer by using data routinely collected during inpatient care.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]], ["This model could be easily automated as an alternative to manual clinical review.", [["manual clinical review", "TEST", 58, 80]]], ["Furthermore, inspection of important features in the model can provide insight into predictors and their plausible links to the pathophysiology of clinical deterioration among patients with COVID-19.Model Variables of InterestA key advantage of using an RF-based model is that the relative importance of predictive features is available for end users to interpret.", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["clinical deterioration", "PROBLEM", 147, 169], ["COVID", "TEST", 190, 195]]], ["Our finding that lymphocyte count is a significant predictor of ICU transfer correlates with previous reports that identified lymphopenia as a predictor of severe disease and poor prognosis [29, 30] .Model Variables of InterestAlthough age is clearly identified as a risk factor for needing ICU care among patients with COVID-19 [3] , patients above 65 years old have lower rates of ICU transfer, despite higher mortality [5] , possibly reflecting a greater preference for palliative or less aggressive care in older patients.", [["lymphocyte", "ANATOMY", 17, 27], ["lymphopenia", "DISEASE", 126, 137], ["lymphocyte", "CELL", 17, 27], ["patients", "ORGANISM", 306, 314], ["patients", "ORGANISM", 335, 343], ["patients", "ORGANISM", 517, 525], ["patients", "SPECIES", 306, 314], ["patients", "SPECIES", 335, 343], ["patients", "SPECIES", 517, 525], ["lymphocyte count", "TEST", 17, 33], ["lymphopenia", "PROBLEM", 126, 137], ["severe disease", "PROBLEM", 156, 170], ["ICU care", "TREATMENT", 291, 299], ["COVID", "TEST", 320, 325], ["palliative or less aggressive care", "TREATMENT", 473, 507], ["lymphocyte count", "OBSERVATION", 17, 33], ["lymphopenia", "OBSERVATION", 126, 137], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["disease", "OBSERVATION", 163, 170]]], ["We believe that the relatively low rank of age as a risk factor in our model could mean that our model incorporates actual patient data and patterns of clinical practice into its predictions.Model Variables of InterestAcute worsening of respiratory rate and oxygen saturation are used for identifying COVID-19 patients at risk of developing acute respiratory distress syndrome [31, 32] .", [["respiratory", "ANATOMY", 237, 248], ["respiratory", "ANATOMY", 347, 358], ["oxygen", "CHEMICAL", 258, 264], ["acute respiratory distress syndrome", "DISEASE", 341, 376], ["oxygen", "CHEMICAL", 258, 264], ["patient", "ORGANISM", 123, 130], ["oxygen", "SIMPLE_CHEMICAL", 258, 264], ["patients", "ORGANISM", 310, 318], ["patient", "SPECIES", 123, 130], ["patients", "SPECIES", 310, 318], ["a risk factor", "PROBLEM", 50, 63], ["InterestAcute worsening of respiratory rate", "PROBLEM", 210, 253], ["oxygen saturation", "TEST", 258, 275], ["COVID", "TEST", 301, 306], ["developing acute respiratory distress syndrome", "PROBLEM", 330, 376], ["InterestAcute", "OBSERVATION_MODIFIER", 210, 223], ["worsening", "OBSERVATION_MODIFIER", 224, 233], ["respiratory rate", "OBSERVATION", 237, 253], ["oxygen saturation", "OBSERVATION", 258, 275], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["respiratory distress", "OBSERVATION", 347, 367]]], ["The model ranks oxygen saturation with a significantly lower predictive value than respiratory rate.", [["respiratory", "ANATOMY", 83, 94], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["The model ranks oxygen saturation", "TEST", 0, 33], ["respiratory rate", "TEST", 83, 99], ["ranks", "OBSERVATION_MODIFIER", 10, 15], ["oxygen saturation", "OBSERVATION", 16, 33]]], ["A significant proportion of COVID-19 patients who are hospitalized need supplemental oxygen support.", [["oxygen", "CHEMICAL", 85, 91], ["oxygen", "CHEMICAL", 85, 91], ["patients", "ORGANISM", 37, 45], ["oxygen", "SIMPLE_CHEMICAL", 85, 91], ["patients", "SPECIES", 37, 45], ["supplemental oxygen support", "TREATMENT", 72, 99], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["oxygen support", "OBSERVATION", 85, 99]]], ["Clinical management of COVID-19 requires frequent monitoring and re-assessment among patients who may suffer rapid deterioration.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["COVID", "TEST", 23, 28], ["frequent monitoring", "TEST", 41, 60], ["re-assessment", "TEST", 65, 78], ["rapid deterioration", "PROBLEM", 109, 128]]], ["Although deterioration may be evident by corroboration of changes in vital signs, laboratory results, electrocardiograms, and information in nursing notes, frequent review of these important parameters might not be feasible in crisis situations.", [["deterioration", "PROBLEM", 9, 22], ["vital signs", "TEST", 69, 80], ["electrocardiograms", "TEST", 102, 120]]], ["Using machine learning, we developed a model for identifying deteriorating patients in need of ICU transfer by using data routinely collected during inpatient care.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]], ["This model could be easily automated as an alternative to manual clinical review.", [["manual clinical review", "TEST", 58, 80]]], ["Furthermore, inspection of important features in the model can provide insight into predictors and their plausible links to the pathophysiology of clinical deterioration among patients with COVID-19.Model Variables of InterestA key advantage of using an RF-based model is that the relative importance of predictive features is available for end users to interpret.", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["clinical deterioration", "PROBLEM", 147, 169], ["COVID", "TEST", 190, 195]]], ["Our finding that lymphocyte count is a significant predictor of ICU transfer correlates with previous reports that identified lymphopenia as a predictor of severe disease and poor prognosis [29, 30] .Model Variables of InterestAlthough age is clearly identified as a risk factor for needing ICU care among patients with COVID-19 [3] , patients above 65 years old have lower rates of ICU transfer, despite higher mortality [5] , possibly reflecting a greater preference for palliative or less aggressive care in older patients.", [["lymphocyte", "ANATOMY", 17, 27], ["lymphopenia", "DISEASE", 126, 137], ["lymphocyte", "CELL", 17, 27], ["patients", "ORGANISM", 306, 314], ["patients", "ORGANISM", 335, 343], ["patients", "ORGANISM", 517, 525], ["patients", "SPECIES", 306, 314], ["patients", "SPECIES", 335, 343], ["patients", "SPECIES", 517, 525], ["lymphocyte count", "TEST", 17, 33], ["lymphopenia", "PROBLEM", 126, 137], ["severe disease", "PROBLEM", 156, 170], ["ICU care", "TREATMENT", 291, 299], ["COVID", "TEST", 320, 325], ["palliative or less aggressive care", "TREATMENT", 473, 507], ["lymphocyte count", "OBSERVATION", 17, 33], ["lymphopenia", "OBSERVATION", 126, 137], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["disease", "OBSERVATION", 163, 170]]], ["We believe that the relatively low rank of age as a risk factor in our model could mean that our model incorporates actual patient data and patterns of clinical practice into its predictions.Model Variables of InterestAcute worsening of respiratory rate and oxygen saturation are used for identifying COVID-19 patients at risk of developing acute respiratory distress syndrome [31, 32] .", [["respiratory", "ANATOMY", 237, 248], ["respiratory", "ANATOMY", 347, 358], ["oxygen", "CHEMICAL", 258, 264], ["acute respiratory distress syndrome", "DISEASE", 341, 376], ["oxygen", "CHEMICAL", 258, 264], ["patient", "ORGANISM", 123, 130], ["oxygen", "SIMPLE_CHEMICAL", 258, 264], ["patients", "ORGANISM", 310, 318], ["patient", "SPECIES", 123, 130], ["patients", "SPECIES", 310, 318], ["a risk factor", "PROBLEM", 50, 63], ["InterestAcute worsening of respiratory rate", "PROBLEM", 210, 253], ["oxygen saturation", "TEST", 258, 275], ["COVID", "TEST", 301, 306], ["developing acute respiratory distress syndrome", "PROBLEM", 330, 376], ["InterestAcute", "OBSERVATION_MODIFIER", 210, 223], ["worsening", "OBSERVATION_MODIFIER", 224, 233], ["respiratory rate", "OBSERVATION", 237, 253], ["oxygen saturation", "OBSERVATION", 258, 275], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["respiratory distress", "OBSERVATION", 347, 367]]], ["The model ranks oxygen saturation with a significantly lower predictive value than respiratory rate.", [["respiratory", "ANATOMY", 83, 94], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["The model ranks oxygen saturation", "TEST", 0, 33], ["respiratory rate", "TEST", 83, 99], ["ranks", "OBSERVATION_MODIFIER", 10, 15], ["oxygen saturation", "OBSERVATION", 16, 33]]], ["A significant proportion of COVID-19 patients who are hospitalized need supplemental oxygen support.", [["oxygen", "CHEMICAL", 85, 91], ["oxygen", "CHEMICAL", 85, 91], ["patients", "ORGANISM", 37, 45], ["oxygen", "SIMPLE_CHEMICAL", 85, 91], ["patients", "SPECIES", 37, 45], ["supplemental oxygen support", "TREATMENT", 72, 99], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["oxygen support", "OBSERVATION", 85, 99]]], ["One possible explanation underlying the lower predictive value of oxygen saturation is that in patients with progressive hypoxia, a progressively greater fraction of inhaled oxygen (FiO 2 ) is delivered to maintain adequate percutaneous oxygen saturation (SpO 2 ) until the patient can no longer maintain normal oxygen saturation despite support from high-flow nasal oxygen or non-invasive ventilation.", [["percutaneous", "ANATOMY", 224, 236], ["nasal", "ANATOMY", 361, 366], ["oxygen", "CHEMICAL", 66, 72], ["hypoxia", "DISEASE", 121, 128], ["oxygen", "CHEMICAL", 174, 180], ["FiO 2", "CHEMICAL", 182, 187], ["oxygen", "CHEMICAL", 237, 243], ["oxygen", "CHEMICAL", 312, 318], ["oxygen", "CHEMICAL", 367, 373], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "CHEMICAL", 174, 180], ["FiO 2", "CHEMICAL", 182, 187], ["oxygen", "CHEMICAL", 237, 243], ["oxygen", "CHEMICAL", 312, 318], ["oxygen", "CHEMICAL", 367, 373], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["patients", "ORGANISM", 95, 103], ["oxygen", "SIMPLE_CHEMICAL", 174, 180], ["oxygen", "SIMPLE_CHEMICAL", 237, 243], ["patient", "ORGANISM", 274, 281], ["oxygen", "SIMPLE_CHEMICAL", 312, 318], ["oxygen", "SIMPLE_CHEMICAL", 367, 373], ["patients", "SPECIES", 95, 103], ["patient", "SPECIES", 274, 281], ["oxygen saturation", "TEST", 66, 83], ["progressive hypoxia", "PROBLEM", 109, 128], ["inhaled oxygen (FiO", "TREATMENT", 166, 185], ["adequate percutaneous oxygen saturation", "TREATMENT", 215, 254], ["high-flow nasal oxygen", "TREATMENT", 351, 373], ["non-invasive ventilation", "TREATMENT", 377, 401], ["possible explanation", "UNCERTAINTY", 4, 24], ["lower", "OBSERVATION_MODIFIER", 40, 45], ["oxygen saturation", "OBSERVATION", 66, 83], ["progressive", "OBSERVATION_MODIFIER", 109, 120], ["hypoxia", "OBSERVATION", 121, 128], ["oxygen saturation", "OBSERVATION", 312, 329]]], ["This makes SpO 2 a less sensitive reflection of disease progression until severe respiratory decompensation occurs.", [["respiratory", "ANATOMY", 81, 92], ["respiratory decompensation", "DISEASE", 81, 107], ["SpO 2", "CHEMICAL", 11, 16], ["SpO 2", "GENE_OR_GENE_PRODUCT", 11, 16], ["disease progression", "PROBLEM", 48, 67], ["severe respiratory decompensation", "PROBLEM", 74, 107], ["disease", "OBSERVATION", 48, 55], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["respiratory decompensation", "OBSERVATION", 81, 107]]], ["We propose to include FiO 2 , level of respiratory support, and SpO 2 as variables in future versions of this model.", [["FiO 2", "CHEMICAL", 22, 27], ["SpO 2", "GENE_OR_GENE_PRODUCT", 64, 69], ["FiO", "TREATMENT", 22, 25], ["respiratory support", "TREATMENT", 39, 58], ["respiratory support", "OBSERVATION", 39, 58]]], ["C-reactive protein has been reported as a marker of disease severity in early phases of COVID-19 infection and is positively correlated with COVID-19 pneumonia [33] .", [["infection", "DISEASE", 97, 106], ["pneumonia", "DISEASE", 150, 159], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["COVID-19", "CELL", 88, 96], ["C-reactive protein", "PROTEIN", 0, 18], ["COVID-19", "SPECIES", 88, 96], ["C-reactive protein", "PROBLEM", 0, 18], ["disease severity", "PROBLEM", 52, 68], ["COVID-19 infection", "PROBLEM", 88, 106], ["COVID", "TEST", 141, 146], ["pneumonia", "PROBLEM", 150, 159], ["reactive protein", "OBSERVATION", 2, 18], ["disease", "OBSERVATION", 52, 59], ["early phases", "OBSERVATION_MODIFIER", 72, 84], ["infection", "OBSERVATION", 97, 106], ["pneumonia", "OBSERVATION", 150, 159]]], ["Patients' vital signs (e.g., pulse rate, blood pressure, and temperature) are among the top 20 predictors in this model and are widely accepted as identifying patients in critical condition who are at risk of deterioration [34] .", [["blood", "ANATOMY", 41, 46], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["patients", "ORGANISM", 159, 167], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 159, 167], ["Patients' vital signs", "TEST", 0, 21], ["pulse rate", "TEST", 29, 39], ["blood pressure", "TEST", 41, 55], ["temperature", "TEST", 61, 72]]], ["Hematologic parameters such as red blood cell count, hemoglobin, platelet count, and white blood cell count are conventionally used markers of sepsis in critical care settings [35] ; thus, it is not surprising that they were predictive of COVID-19 in our model also.", [["red blood cell", "ANATOMY", 31, 45], ["platelet", "ANATOMY", 65, 73], ["white blood cell", "ANATOMY", 85, 101], ["sepsis", "DISEASE", 143, 149], ["red blood cell", "CELL", 31, 45], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 53, 63], ["platelet", "CELL", 65, 73], ["white blood cell", "CELL", 85, 101], ["hemoglobin", "PROTEIN", 53, 63], ["Hematologic parameters", "TEST", 0, 22], ["red blood cell count", "TEST", 31, 51], ["hemoglobin", "TEST", 53, 63], ["platelet count", "TEST", 65, 79], ["white blood cell count", "TEST", 85, 107], ["sepsis", "PROBLEM", 143, 149], ["COVID", "TEST", 239, 244], ["sepsis", "OBSERVATION", 143, 149]]], ["Abnormalities in potassium, sodium, and calcium also have been associated with severe COVID-19 [36] .Model StrengthsOur model has strengths in terms of methodology, utility, and scalability.", [["potassium", "CHEMICAL", 17, 26], ["sodium", "CHEMICAL", 28, 34], ["calcium", "CHEMICAL", 40, 47], ["potassium", "CHEMICAL", 17, 26], ["sodium", "CHEMICAL", 28, 34], ["calcium", "CHEMICAL", 40, 47], ["COVID-19", "CHEMICAL", 86, 94], ["potassium", "SIMPLE_CHEMICAL", 17, 26], ["sodium", "SIMPLE_CHEMICAL", 28, 34], ["calcium", "SIMPLE_CHEMICAL", 40, 47], ["Abnormalities", "TEST", 0, 13], ["potassium", "TEST", 17, 26], ["sodium", "TEST", 28, 34], ["calcium", "TEST", 40, 47], ["severe COVID", "PROBLEM", 79, 91]]], ["The labeling approach of feature vectors-using the last 3 observations, rather than the earliest or latest-made it easier to minimize chances of over-fitting despite the low sample size for training.", [["feature vectors", "TREATMENT", 25, 40]]], ["The cohort is diverse in distribution of key variables such as age, race, ethnicity, and length of hospitalization, supporting the generalizability of the model.", [["diverse", "OBSERVATION_MODIFIER", 14, 21]]], ["The model uses input variables mainly comprised of routine laboratory and clinical data, which are commonly available in most streaming data models across the U.S. Furthermore, the model can be adopted to different frequencies of assessments and different common input variables.", [["routine laboratory", "TEST", 51, 69], ["clinical data", "TEST", 74, 87], ["assessments", "TEST", 230, 241]]], ["It can be adjusted to use streaming data from the EMR and provide frequent predictions for real-time risk prioritization.", [["streaming data", "TEST", 26, 40]]], ["We use the Fast Healthcare Interoperability Resources (FHIR) format for facilitating data exchange and retrieval from an EPIC-supported EMR system.", [["facilitating data exchange", "TREATMENT", 72, 98], ["retrieval", "TREATMENT", 103, 112], ["an EPIC-supported EMR system", "TREATMENT", 118, 146]]], ["In addition, clinical documentation may not be perfect during crises, when normal documentation standards are relaxed due to the high work burden of clinicians.", [["clinical documentation", "TEST", 13, 35]]], ["Therefore, unavailable data (as in our case) may be the consequence of either clinical judgement on need for specific assessments or imperfect clinical documentation.Model StrengthsDespite the non-random pattern of data availability for specific variables, the imputation strategy and the RF model had reasonably high sensitivity.", [["specific assessments", "TEST", 109, 129], ["the imputation strategy", "TREATMENT", 257, 280], ["the RF model", "TEST", 285, 297]]], ["An additional asset of this model is that, unlike other models, key discriminatory variables underlying each prediction can be provided.Model LimitationsLow sample size and class imbalance resulting from low ICU transfer rates are major limitations to this version of the model, which resulted in low precision.", [["sample", "ANATOMY", 157, 163], ["Low sample size", "PROBLEM", 153, 168], ["class imbalance", "PROBLEM", 173, 188], ["size", "OBSERVATION_MODIFIER", 164, 168], ["class imbalance", "OBSERVATION", 173, 188], ["low", "OBSERVATION_MODIFIER", 204, 207], ["low precision", "OBSERVATION", 297, 310]]], ["Therefore, we recommend using this version of the model as a prioritization tool, not a tool for clinical decision support.", [["clinical decision support", "TREATMENT", 97, 122]]], ["For example, in this cohort, rates of hypertension and diabetes were lower than in others reported [4, 5, 37] .", [["hypertension", "DISEASE", 38, 50], ["diabetes", "DISEASE", 55, 63], ["hypertension", "PROBLEM", 38, 50], ["diabetes", "PROBLEM", 55, 63], ["hypertension", "OBSERVATION", 38, 50], ["diabetes", "OBSERVATION", 55, 63], ["lower", "OBSERVATION_MODIFIER", 69, 74]]], ["Variables related to systemic inflammation and the coagulation cascade (e.g., D-dimer, fibrinogen, ferritin, and lactate dehydrogenase) were not available for modeling when this model was generated.", [["inflammation", "DISEASE", 30, 42], ["lactate", "CHEMICAL", 113, 120], ["lactate", "CHEMICAL", 113, 120], ["D-dimer", "GENE_OR_GENE_PRODUCT", 78, 85], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 87, 97], ["ferritin", "GENE_OR_GENE_PRODUCT", 99, 107], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 113, 134], ["D-dimer", "PROTEIN", 78, 85], ["fibrinogen", "PROTEIN", 87, 97], ["ferritin", "PROTEIN", 99, 107], ["lactate dehydrogenase", "PROTEIN", 113, 134], ["systemic inflammation", "PROBLEM", 21, 42], ["the coagulation cascade", "TEST", 47, 70], ["D-dimer", "TEST", 78, 85], ["fibrinogen", "TEST", 87, 97], ["ferritin", "TEST", 99, 107], ["lactate dehydrogenase", "TEST", 113, 134], ["systemic", "OBSERVATION_MODIFIER", 21, 29], ["inflammation", "OBSERVATION", 30, 42]]], ["While our model provides high sensitivity, we believe that inclusion of these other markers, which have predictive and/or prognostic value [38] , could improve subsequent iterations of the model.", [["these other markers", "TEST", 72, 91]]], ["While SpO 2 without assessments of FiO 2 and level of oxygen support may not be sufficient to capture signs of progressive hypoxia, the inclusion of all three variables in subsequent versions of the model could also further improve its performance.", [["oxygen", "CHEMICAL", 54, 60], ["hypoxia", "DISEASE", 123, 130], ["SpO 2", "CHEMICAL", 6, 11], ["FiO 2", "CHEMICAL", 35, 40], ["oxygen", "CHEMICAL", 54, 60], ["SpO 2", "GENE_OR_GENE_PRODUCT", 6, 11], ["FiO 2", "GENE_OR_GENE_PRODUCT", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["assessments", "TEST", 20, 31], ["FiO", "TEST", 35, 38], ["oxygen support", "TREATMENT", 54, 68], ["progressive hypoxia", "PROBLEM", 111, 130], ["progressive", "OBSERVATION_MODIFIER", 111, 122], ["hypoxia", "OBSERVATION", 123, 130]]], ["However, given the low sample size of a single medical center in the acute phase of a pandemic, it may be difficult to generate a model with both high sensitivity and precision (positive predictive value).Practice ImplicationsAs a screening tool for development of critical illness, this model has multiple opportunities for clinical use.", [["critical illness", "DISEASE", 265, 281], ["the low sample size", "PROBLEM", 15, 34], ["a screening tool", "TEST", 229, 245], ["critical illness", "PROBLEM", 265, 281], ["low sample", "OBSERVATION_MODIFIER", 19, 29], ["size", "OBSERVATION_MODIFIER", 30, 34], ["acute phase", "OBSERVATION_MODIFIER", 69, 80]]], ["In addition to identifying patients with a potentially increased need for ICU transfer within 24 h, the tool can also be used for improving the coordination of patient transfers to the ICU.", [["patients", "ORGANISM", 27, 35], ["patient", "ORGANISM", 160, 167], ["patients", "SPECIES", 27, 35], ["patient", "SPECIES", 160, 167]]], ["The tool can be used to inform clinicians of patients at higher risk of a greater need for frequent assessments, and thereby can facilitate inclusion of clinicians less familiar with critical care medicine.Practice ImplicationsEarlier identification of high-risk patients could potentially reduce the use of invasive mechanical ventilation [39] , sparing patients from avoidable morbidity and lowering mortality from complications.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 263, 271], ["patients", "ORGANISM", 355, 363], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 355, 363], ["frequent assessments", "TEST", 91, 111], ["invasive mechanical ventilation", "TREATMENT", 308, 339], ["avoidable morbidity", "PROBLEM", 369, 388], ["lowering mortality", "PROBLEM", 393, 411], ["complications", "PROBLEM", 417, 430]]], ["Given the sensitivity of the model, it can effectively identify patients who are likely to be transferred to ICU within 24 h, reducing the chance of missing the patients in need of ICU care.", [["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 161, 169], ["ICU care", "TREATMENT", 181, 189]]], ["Moreover, clinical implementation of the tool can increase the rates of early ICU transfers, which can potentially translate into reduced mortality and shorter lengths of ICU stay [40, 41] , with favorable consequences on other complications affecting patient outcomes, such as delirium and sleep disorders [42, 43] .", [["delirium", "DISEASE", 278, 286], ["sleep disorders", "DISEASE", 291, 306], ["patient", "ORGANISM", 252, 259], ["patient", "SPECIES", 252, 259], ["other complications", "PROBLEM", 222, 241], ["delirium", "PROBLEM", 278, 286], ["sleep disorders", "PROBLEM", 291, 306]]], ["However, its positive predictive value and precision are limited, and it is not practical to perform labor-intensive interventions for all patients whom the model predicted are at high risk.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["intensive interventions", "TREATMENT", 107, 130], ["positive", "OBSERVATION_MODIFIER", 13, 21]]], ["Nonetheless, our model has clinical utility in the setting of a pandemic.", [["a pandemic", "PROBLEM", 62, 72], ["pandemic", "OBSERVATION", 64, 72]]], ["The high negative predictive value suggests that those identified as unlikely to require critical care in the next 24 h may be considered for a lower level of monitoring.ConclusionsOur RF-based tool can reliably be used for prioritizing COVID-19 patients not in the ICU but at risk for deterioration and requiring ICU transfer within 24 h.", [["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 246, 254], ["prioritizing COVID", "TREATMENT", 224, 242], ["deterioration", "PROBLEM", 286, 299]]], ["The model shows the importance of respiratory failure, shock, inflammation, and renal failure in the progression of COVID-19.", [["respiratory", "ANATOMY", 34, 45], ["renal", "ANATOMY", 80, 85], ["respiratory failure", "DISEASE", 34, 53], ["shock", "DISEASE", 55, 60], ["inflammation", "DISEASE", 62, 74], ["renal failure", "DISEASE", 80, 93], ["COVID-19", "CHEMICAL", 116, 124], ["renal", "ORGAN", 80, 85], ["respiratory failure", "PROBLEM", 34, 53], ["shock", "PROBLEM", 55, 60], ["inflammation", "PROBLEM", 62, 74], ["renal failure", "PROBLEM", 80, 93], ["COVID", "TEST", 116, 121], ["respiratory failure", "OBSERVATION", 34, 53], ["shock", "OBSERVATION", 55, 60], ["inflammation", "OBSERVATION", 62, 74], ["renal", "ANATOMY", 80, 85], ["failure", "OBSERVATION", 86, 93], ["progression", "OBSERVATION_MODIFIER", 101, 112]]], ["Such a predictive tool may have wide implications and utility in clinical practice and hospital operations.", [["hospital operations", "TREATMENT", 87, 106]]], ["More studies are needed to identify other ways to improve patient outcomes by early identification of COVID-19 patients at risk of deterioration.", [["patient", "ORGANISM", 58, 65], ["patients", "ORGANISM", 111, 119], ["patient", "SPECIES", 58, 65], ["patients", "SPECIES", 111, 119], ["COVID", "TEST", 102, 107], ["deterioration", "PROBLEM", 131, 144], ["deterioration", "OBSERVATION", 131, 144]]], ["Implementing machine learning models has the potential to build capacity within a hospital's continuous learning and quality improvement environment.ConclusionsSupplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/6/1668/s1, Table S1 : Hyperparameters used in the final model, Table S2", [["S2", "ANATOMY", 324, 326]]]], "8c831116b0a09987cc1f9239314f36a3b8e5e9d4": [["though the recent dominant biennial cycles of EV-D68 dynamics may not be stable, we show that a major EV-D68 epidemic, and hence an AFM outbreak, would still be possible in 2020 under normal epidemiological conditions.", [["EV-D68", "ORGANISM", 102, 108], ["EV-D68 dynamics", "TEST", 46, 61], ["a major EV", "TEST", 94, 104], ["an AFM outbreak", "PROBLEM", 129, 144], ["dominant", "OBSERVATION_MODIFIER", 18, 26], ["biennial cycles", "OBSERVATION", 27, 42]]], ["Significant social distancing due to the ongoing COVID-19 pandemic could reduce the size of an EV-D68 epidemic in 2020, illustrating the potential broader epidemiological impact of the pandemic.", [["EV-D68", "ORGANISM", 95, 101], ["the ongoing COVID", "TEST", 37, 54], ["pandemic", "PROBLEM", 58, 66], ["an EV", "TEST", 92, 97], ["the pandemic", "PROBLEM", 181, 193], ["size", "OBSERVATION_MODIFIER", 84, 88], ["pandemic", "OBSERVATION_MODIFIER", 185, 193]]]], "91be55f02caf0d2e1058a2446ca0bee5365673bc": [["IntroductionThe idea that the sleeping-waking brain is intimately related to complaints of unrefreshing sleep, musculoskeletal pain, fatigue, and suffering is not a novel notion.", [["brain", "ANATOMY", 46, 51], ["musculoskeletal", "ANATOMY", 111, 126], ["musculoskeletal pain", "DISEASE", 111, 131], ["fatigue", "DISEASE", 133, 140], ["brain", "ORGAN", 46, 51], ["unrefreshing sleep", "PROBLEM", 91, 109], ["musculoskeletal pain", "PROBLEM", 111, 131], ["fatigue", "PROBLEM", 133, 140], ["musculoskeletal", "ANATOMY", 111, 126]]], ["Its origins are found in the remote past.", [["origins", "OBSERVATION_MODIFIER", 4, 11]]], ["Over the millennia, its origins and significance have been immersed in religious beliefs in evil thoughts or sinful human behavior with special opportunities for redemption through rituals performed by healers, by sacrifice, or by prayer.", [["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["millennia", "OBSERVATION_MODIFIER", 9, 18]]], ["Even to this day, rheumatologists, who are often asked to assess and manage such afflicted patients, say that they have no relevance to their focus of interest in people with discernible objective evidence for arthritic or immunological disease pathology.", [["patients", "ORGANISM", 91, 99], ["people", "ORGANISM", 163, 169], ["patients", "SPECIES", 91, 99], ["people", "SPECIES", 163, 169], ["arthritic or immunological disease pathology", "PROBLEM", 210, 254], ["evidence for", "UNCERTAINTY", 197, 209], ["arthritic", "OBSERVATION", 210, 219]]], ["Even though such patients search for understanding and help with their affliction and suffering, they may face rejection by physicians or exploitation by remedies that do not improve their sleep or cure them of their bodily complaints.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["their bodily complaints", "PROBLEM", 211, 234], ["rejection", "OBSERVATION", 111, 120]]], ["This matter of despair and hopelessness is clearly and simply described in Ecclesiastes 2:23, \"All their days their work is grief and pain; even at night their minds do not rest.", [["hopelessness", "DISEASE", 27, 39], ["grief", "DISEASE", 124, 129], ["pain", "DISEASE", 134, 138], ["despair", "PROBLEM", 15, 22], ["hopelessness", "PROBLEM", 27, 39], ["grief", "PROBLEM", 124, 129], ["pain", "PROBLEM", 134, 138]]], ["Despite Ecclesiastes, a pessimistic perspective on the troubles of mankind, this chapter focuses on our efforts to bring scientific understanding to how the physiology of sleeping-waking brain allows us to better understand the origins and management of their widespread pain, suffering, and disability.IntroductionSuch people have acquired a variety of diagnostic labels by various medical disciplines, as though a mere diagnosis provides both understanding and treatment.", [["brain", "ANATOMY", 187, 192], ["pain", "DISEASE", 271, 275], ["disability", "DISEASE", 292, 302], ["brain", "ORGAN", 187, 192], ["people", "ORGANISM", 320, 326], ["people", "SPECIES", 320, 326], ["their widespread pain", "PROBLEM", 254, 275], ["treatment", "TREATMENT", 463, 472], ["widespread", "OBSERVATION_MODIFIER", 260, 270], ["pain", "OBSERVATION", 271, 275]]], ["At the turn of the last century, such people were given the label, \"fibrositis\" by an English neurologist, William Gower.", [["fibrositis", "DISEASE", 68, 78], ["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["fibrositis", "PROBLEM", 68, 78], ["fibrositis", "OBSERVATION", 68, 78]]], ["He believed that the basis of his patients' painful limbs and backs were the result of inflammation of fibrous tissue.", [["limbs", "ANATOMY", 52, 57], ["fibrous tissue", "ANATOMY", 103, 117], ["inflammation", "DISEASE", 87, 99], ["patients", "ORGANISM", 34, 42], ["limbs", "ORGANISM_SUBDIVISION", 52, 57], ["backs", "ORGANISM_SUBDIVISION", 62, 67], ["fibrous tissue", "TISSUE", 103, 117], ["patients", "SPECIES", 34, 42], ["his patients' painful limbs and backs", "PROBLEM", 30, 67], ["inflammation of fibrous tissue", "PROBLEM", 87, 117], ["limbs", "ANATOMY", 52, 57], ["backs", "ANATOMY", 62, 67], ["inflammation", "OBSERVATION", 87, 99], ["fibrous tissue", "OBSERVATION", 103, 117]]], ["When systematic studies of infectious or disease pathology could not be verified, the term became a wastebasket diagnosis used by rheumatologists to differentiate these patients from those with similar symptoms but having objective evidence for disease pathology.", [["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["systematic studies", "TEST", 5, 23], ["infectious", "PROBLEM", 27, 37], ["disease pathology", "PROBLEM", 41, 58], ["similar symptoms", "PROBLEM", 194, 210], ["disease pathology", "PROBLEM", 245, 262], ["infectious", "OBSERVATION_MODIFIER", 27, 37]]], ["Other medical specialists, to whom such afflicted people would visit, applied explanations that relate to their specialty's focus of interest.", [["people", "ORGANISM", 50, 56], ["people", "SPECIES", 50, 56]]], ["See Table 48 .1 for such a list of health-care specialist providers, their areas of interest, and diagnostic labels that are provided to such patients.IntroductionThe medical field becomes more complicated when such symptoms are found in patients with a known disease.", [["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 238, 246], ["such symptoms", "PROBLEM", 211, 224], ["a known disease", "PROBLEM", 252, 267], ["disease", "OBSERVATION", 260, 267]]], ["Even though the disease is successfully treated by well-established disease-modifying substances, they may remain chronically ill with unrefreshing sleep, widespread pain, tenderness, chronic fatigue, and psychological distress.", [["chronically ill", "DISEASE", 114, 129], ["pain", "DISEASE", 166, 170], ["tenderness", "DISEASE", 172, 182], ["chronic fatigue", "DISEASE", 184, 199], ["psychological distress", "DISEASE", 205, 227], ["the disease", "PROBLEM", 12, 23], ["unrefreshing sleep", "PROBLEM", 135, 153], ["widespread pain", "PROBLEM", 155, 170], ["tenderness", "PROBLEM", 172, 182], ["chronic fatigue", "PROBLEM", 184, 199], ["psychological distress", "PROBLEM", 205, 227], ["disease", "OBSERVATION", 16, 23], ["tenderness", "OBSERVATION", 172, 182], ["chronic", "OBSERVATION_MODIFIER", 184, 191], ["fatigue", "OBSERVATION", 192, 199]]], ["These features often occur in patients with systemic lupus erythematosis and rheumatoid arthritis.", [["systemic lupus erythematosis", "DISEASE", 44, 72], ["rheumatoid arthritis", "DISEASE", 77, 97], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["systemic lupus erythematosis", "PROBLEM", 44, 72], ["rheumatoid arthritis", "PROBLEM", 77, 97], ["systemic", "OBSERVATION_MODIFIER", 44, 52], ["lupus erythematosis", "OBSERVATION", 53, 72], ["rheumatoid arthritis", "OBSERVATION", 77, 97]]], ["Without the objective evidence for arthritic, neuroendocrine, or immunological disease pathology, the community of rheumatologists abandoned the term of ill-understood \"fibrositis\" and adopted the now-popular descriptive diagnosis, \"fibromyalgia\" (FM) or \"fibromyalgia syndrome\" (FMS).", [["neuroendocrine", "ANATOMY", 46, 60], ["fibrositis", "DISEASE", 169, 179], ["fibromyalgia", "DISEASE", 233, 245], ["FM", "DISEASE", 248, 250], ["fibromyalgia syndrome", "DISEASE", 256, 277], ["FMS", "DISEASE", 280, 283], ["neuroendocrine", "CELL", 46, 60], ["fibrositis", "CANCER", 169, 179], ["arthritic, neuroendocrine, or immunological disease pathology", "PROBLEM", 35, 96], ["\"fibrositis", "PROBLEM", 168, 179], ["fibromyalgia", "PROBLEM", 233, 245], ["\"fibromyalgia syndrome", "PROBLEM", 255, 277], ["evidence for", "UNCERTAINTY", 22, 34], ["arthritic", "OBSERVATION", 35, 44], ["fibrositis", "OBSERVATION", 169, 179], ["fibromyalgia syndrome", "OBSERVATION", 256, 277]]], ["The formalization of criteria for the diagnosis approved by the American College of Rheumatology in 1991 [1] permitted epidemiological studies to determine the prevalence of the syndrome.", [["epidemiological studies", "TEST", 119, 142], ["the syndrome", "PROBLEM", 174, 186], ["syndrome", "OBSERVATION", 178, 186]]], ["Subsequently, approximately 2 % of the US population (3.4 % women, 0.5 % men) were found to be affected [2] .", [["women", "ORGANISM", 60, 65], ["men", "ORGANISM", 73, 76], ["women", "SPECIES", 60, 65], ["men", "SPECIES", 73, 76], ["the US population", "TEST", 35, 52]]], ["Those with the diffuse musculoskeletal pains and debilitating fatigue in five European countries (France, Germany, Italy, Portugal, and Spain) affected 2.9 % of the population (3.6 % women and 2.1 % men) [3] , making this rheumatic disorder the second most common rheumatic ailment after osteoarthritis.IntroductionAbout the same time, infectious disease experts noted that pain and fatigue symptoms prevailed long after an acute infectious disease had past.", [["musculoskeletal", "ANATOMY", 23, 38], ["musculoskeletal pains", "DISEASE", 23, 44], ["fatigue", "DISEASE", 62, 69], ["rheumatic disorder", "DISEASE", 222, 240], ["rheumatic ailment", "DISEASE", 264, 281], ["osteoarthritis", "DISEASE", 288, 302], ["infectious disease", "DISEASE", 336, 354], ["pain", "DISEASE", 374, 378], ["fatigue", "DISEASE", 383, 390], ["women", "ORGANISM", 183, 188], ["men", "ORGANISM", 199, 202], ["women", "SPECIES", 183, 188], ["men", "SPECIES", 199, 202], ["the diffuse musculoskeletal pains", "PROBLEM", 11, 44], ["debilitating fatigue", "PROBLEM", 49, 69], ["the population", "TEST", 161, 175], ["this rheumatic disorder", "PROBLEM", 217, 240], ["osteoarthritis", "PROBLEM", 288, 302], ["pain", "PROBLEM", 374, 378], ["fatigue symptoms", "PROBLEM", 383, 399], ["an acute infectious disease", "PROBLEM", 421, 448], ["diffuse", "OBSERVATION_MODIFIER", 15, 22], ["musculoskeletal", "ANATOMY", 23, 38], ["pains", "OBSERVATION", 39, 44], ["debilitating", "OBSERVATION_MODIFIER", 49, 61], ["fatigue", "OBSERVATION", 62, 69], ["rheumatic", "OBSERVATION", 222, 231], ["most common", "OBSERVATION_MODIFIER", 252, 263], ["rheumatic", "OBSERVATION_MODIFIER", 264, 273], ["ailment", "OBSERVATION", 274, 281], ["osteoarthritis", "OBSERVATION", 288, 302], ["acute", "OBSERVATION_MODIFIER", 424, 429], ["infectious", "OBSERVATION", 430, 440]]], ["They variously diagnosed such patients as having a post-infectious or post-viral syndrome, myalgic encephalomyelitis (ME), and Epstein virus syndrome.", [["myalgic encephalomyelitis", "DISEASE", 91, 116], ["ME", "DISEASE", 118, 120], ["Epstein virus syndrome", "DISEASE", 127, 149], ["patients", "ORGANISM", 30, 38], ["Epstein virus", "ORGANISM", 127, 140], ["patients", "SPECIES", 30, 38], ["Epstein virus", "SPECIES", 127, 140], ["a post-infectious or post-viral syndrome", "PROBLEM", 49, 89], ["myalgic encephalomyelitis", "PROBLEM", 91, 116], ["Epstein virus syndrome", "PROBLEM", 127, 149], ["post-infectious", "OBSERVATION_MODIFIER", 51, 66], ["post-viral syndrome", "OBSERVATION", 70, 89], ["myalgic encephalomyelitis", "OBSERVATION", 91, 116], ["Epstein virus syndrome", "OBSERVATION", 127, 149]]], ["Where a sporadic cluster of such mysterious ailments appeared, diagnostic labels were attributed to geographic locations, e.g., in 1934, Los Angeles County Hospital disease also known at the time as \"atypical poliomyelitis\"; in 1948-1949, Akureyri disease (also called Iceland disease); and in 1955, London's Royal Free (Hospital) disease, which subsequently was thought to be a form of mass hysteria.", [["poliomyelitis", "DISEASE", 209, 222], ["Akureyri disease", "DISEASE", 239, 255], ["Iceland disease", "DISEASE", 269, 284], ["hysteria", "DISEASE", 392, 400], ["a sporadic cluster of such mysterious ailments", "PROBLEM", 6, 52], ["atypical poliomyelitis\"", "PROBLEM", 200, 223], ["Akureyri disease", "PROBLEM", 239, 255], ["disease", "PROBLEM", 331, 338], ["mass hysteria", "PROBLEM", 387, 400], ["atypical", "OBSERVATION_MODIFIER", 200, 208], ["poliomyelitis", "OBSERVATION", 209, 222], ["mass", "OBSERVATION", 387, 391]]], ["The absence of any verifiable evidence for any specific infectious agent or inflammatory disease pathology proved perplexing for infectious disease specialists.", [["infectious disease", "DISEASE", 129, 147], ["any specific infectious agent", "PROBLEM", 43, 72], ["inflammatory disease pathology", "PROBLEM", 76, 106], ["evidence for", "UNCERTAINTY", 30, 42], ["infectious", "OBSERVATION_MODIFIER", 56, 66], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88]]], ["The lack of objective evidence for a specific virus or specific infectious disease led to a committee of advisory experts to the US Centre for Disease Control to formalize criteria.", [["infectious disease", "DISEASE", 64, 82], ["a specific virus", "PROBLEM", 35, 51], ["specific infectious disease", "PROBLEM", 55, 82]]], ["The current diagnosis, chronic fatigue syndrome (CFS), came into existence [4] .", [["chronic fatigue syndrome", "DISEASE", 23, 47], ["CFS", "DISEASE", 49, 52], ["chronic fatigue syndrome", "PROBLEM", 23, 47], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["fatigue syndrome", "OBSERVATION", 31, 47]]], ["This vague descriptive label emerged in 1994 much to the chagrin of affected American patients who advocate for special recognition by government health agencies for their preferred term \"chronic immune deficiency syndrome.\"", [["chronic immune deficiency syndrome", "DISEASE", 188, 222], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["chronic immune deficiency syndrome", "PROBLEM", 188, 222], ["immune deficiency", "OBSERVATION", 196, 213]]], ["In the UK, the label chronic infectious neuromyasthenia encephalitis is preferred.", [["neuromyasthenia encephalitis", "DISEASE", 40, 68], ["UK", "GENE_OR_GENE_PRODUCT", 7, 9], ["the label chronic infectious neuromyasthenia encephalitis", "PROBLEM", 11, 68], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["infectious", "OBSERVATION_MODIFIER", 29, 39], ["neuromyasthenia encephalitis", "OBSERVATION", 40, 68]]], ["Often, there is an overlap among the variable clinical criteria adopted by committees of the various medical disciplines so that some authors have referred to such patients as coming under an umbrella of a cluster of overlapping ailments (see Table 48 .1).", [["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172]]], ["The overriding common feature is the absence of any known clinical features of disease or signs of any abnormalities in any radiological, hematological, histological, chemical, metabolic, or immunological tests.", [["disease", "PROBLEM", 79, 86], ["any abnormalities", "PROBLEM", 99, 116], ["immunological tests", "TEST", 191, 210], ["disease", "OBSERVATION", 79, 86]]], ["Nevertheless, the hunt for a viral etiology persists with the most current being the 1990 report in Science on the prevalence of a retrovirus, xenotropic murine leukemia virus-related virus (XMRV) finding in more than 60 % of the patients with CFS.", [["xenotropic murine leukemia virus", "DISEASE", 143, 175], ["CFS", "DISEASE", 244, 247], ["retrovirus", "ORGANISM", 131, 141], ["xenotropic murine leukemia virus-related virus", "ORGANISM", 143, 189], ["XMRV", "ORGANISM", 191, 195], ["patients", "ORGANISM", 230, 238], ["murine", "SPECIES", 154, 160], ["leukemia virus-related virus", "SPECIES", 161, 189], ["patients", "SPECIES", 230, 238], ["a retrovirus", "PROBLEM", 129, 141], ["xenotropic murine leukemia virus", "PROBLEM", 143, 175], ["related virus (XMRV)", "PROBLEM", 176, 196], ["CFS", "PROBLEM", 244, 247], ["retrovirus", "ANATOMY", 131, 141], ["xenotropic murine leukemia virus", "OBSERVATION", 143, 175]]], ["A viral etiology, however, remains relevant in selected populations with post-febrile persistent chronic fatigue and diffuse myalgia.", [["fatigue", "DISEASE", 105, 112], ["myalgia", "DISEASE", 125, 132], ["A viral etiology", "PROBLEM", 0, 16], ["febrile persistent chronic fatigue", "PROBLEM", 78, 112], ["diffuse myalgia", "PROBLEM", 117, 132], ["viral", "OBSERVATION_MODIFIER", 2, 7], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["fatigue", "OBSERVATION", 105, 112], ["diffuse", "OBSERVATION_MODIFIER", 117, 124], ["myalgia", "OBSERVATION", 125, 132]]], ["For example, following an outbreak in Toronto of severe acute respiratory syndrome (SARS), those who had survived and had no residual respiratory disease 1-3 years later had persistent diffuse myalgia, disabling fatigue, weakness with unrefreshing sleep, and anomalous increased sleep EEG alpha and the EEG sleep cyclical alternating pattern (CAP) in non-REM sleep.", [["respiratory", "ANATOMY", 134, 145], ["acute respiratory syndrome", "DISEASE", 56, 82], ["SARS", "DISEASE", 84, 88], ["respiratory disease", "DISEASE", 134, 153], ["myalgia", "DISEASE", 193, 200], ["fatigue", "DISEASE", 212, 219], ["weakness", "DISEASE", 221, 229], ["unrefreshing sleep", "DISEASE", 235, 253], ["EEG alpha", "GENE_OR_GENE_PRODUCT", 285, 294], ["severe acute respiratory syndrome", "PROBLEM", 49, 82], ["residual respiratory disease", "PROBLEM", 125, 153], ["persistent diffuse myalgia", "PROBLEM", 174, 200], ["disabling fatigue", "PROBLEM", 202, 219], ["weakness", "PROBLEM", 221, 229], ["unrefreshing sleep", "PROBLEM", 235, 253], ["anomalous increased sleep EEG alpha", "PROBLEM", 259, 294], ["the EEG sleep cyclical alternating pattern (CAP) in non-REM sleep", "PROBLEM", 299, 364], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82], ["no", "UNCERTAINTY", 122, 124], ["residual", "OBSERVATION_MODIFIER", 125, 133], ["respiratory disease", "OBSERVATION", 134, 153], ["persistent", "OBSERVATION_MODIFIER", 174, 184], ["diffuse", "OBSERVATION_MODIFIER", 185, 192], ["myalgia", "OBSERVATION", 193, 200], ["increased", "OBSERVATION_MODIFIER", 269, 278]]], ["The possibility that the SARS coronavirus, which is known to enter the brain during the acute phase, may have a continuing adverse influence on the sleeping waking brain with associated physical and behavioral symptoms [6] .IntroductionIn the absence of medical disease, these people with illunderstood poor sleep quality, chronic pain, and fatigue tend to be cast into the dark chasm of vague psychiatric labels.", [["brain", "ANATOMY", 71, 76], ["brain", "ANATOMY", 164, 169], ["SARS coronavirus", "DISEASE", 25, 41], ["chronic pain", "DISEASE", 323, 335], ["fatigue", "DISEASE", 341, 348], ["psychiatric", "DISEASE", 394, 405], ["SARS coronavirus", "ORGANISM", 25, 41], ["brain", "ORGAN", 71, 76], ["brain", "ORGAN", 164, 169], ["people", "ORGANISM", 277, 283], ["people", "SPECIES", 277, 283], ["SARS coronavirus", "SPECIES", 25, 41], ["the SARS coronavirus", "PROBLEM", 21, 41], ["a continuing adverse influence", "PROBLEM", 110, 140], ["associated physical and behavioral symptoms", "PROBLEM", 175, 218], ["medical disease", "PROBLEM", 254, 269], ["illunderstood poor sleep quality", "PROBLEM", 289, 321], ["chronic pain", "PROBLEM", 323, 335], ["fatigue", "PROBLEM", 341, 348], ["brain", "ANATOMY", 71, 76], ["chronic", "OBSERVATION_MODIFIER", 323, 330], ["pain", "OBSERVATION", 331, 335]]], ["The psychiatric diagnostic labels have changed over the course of five revisions of the American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM).", [["psychiatric", "DISEASE", 4, 15], ["Mental Disorders", "DISEASE", 164, 180], ["Mental Disorders", "PROBLEM", 164, 180]]], ["They range from neurasthenia and hysterical conversion disorder to somatoform pain disorder, somatization disorder, and now the DSM-5 feckless diagnosis, \"somatic symptom disorder\" [7] .", [["neurasthenia", "DISEASE", 16, 28], ["hysterical conversion disorder", "DISEASE", 33, 63], ["somatoform pain disorder", "DISEASE", 67, 91], ["somatization disorder", "DISEASE", 93, 114], ["somatic symptom disorder", "DISEASE", 155, 179], ["neurasthenia", "PROBLEM", 16, 28], ["hysterical conversion disorder", "PROBLEM", 33, 63], ["somatoform pain disorder", "PROBLEM", 67, 91], ["somatization disorder", "PROBLEM", 93, 114], ["somatic symptom disorder", "PROBLEM", 155, 179], ["hysterical conversion", "OBSERVATION", 33, 54]]], ["This chain of psychiatric labels represents a history of collective transient agreements by generations of US psychiatric committees that have applied some form of presumed scientific explanations to bodily complaints and sickness where there is no satisfactory medical or psychological explanation.", [["psychiatric", "DISEASE", 14, 25], ["psychiatric", "DISEASE", 110, 121], ["bodily complaints", "DISEASE", 200, 217], ["sickness", "DISEASE", 222, 230], ["bodily complaints", "PROBLEM", 200, 217], ["sickness", "PROBLEM", 222, 230], ["no", "UNCERTAINTY", 246, 248]]], ["Now, most of these earlier psychiatric diagnoses have been abandoned, in favor of an empirical, presumably less controversial, descriptive label.", [["psychiatric", "DISEASE", 27, 38], ["less controversial", "OBSERVATION_MODIFIER", 107, 125]]], ["As seen in Table 48 .1, the diagnostic labels adopted by various groups of health specialists are afflicted with similar scientific explanatory dilemmas.IntroductionIn the prescientific evolution of knowledge, such people and their ailments were given various religious or spiritual Chest pain, fatigue Atypical chest pain GI gastrointestinal, CFS chronic fatigue syndrome, SBS sick building syndrome, TMJ temporomandibular joint explanations.", [["chest", "ANATOMY", 312, 317], ["gastrointestinal", "ANATOMY", 326, 342], ["temporomandibular", "ANATOMY", 406, 423], ["Chest pain", "DISEASE", 283, 293], ["fatigue", "DISEASE", 295, 302], ["chest pain", "DISEASE", 312, 322], ["chronic fatigue syndrome", "DISEASE", 348, 372], ["sick building syndrome", "DISEASE", 378, 400], ["TMJ temporomandibular joint explanations", "DISEASE", 402, 442], ["people", "ORGANISM", 215, 221], ["people", "SPECIES", 215, 221], ["spiritual Chest pain", "PROBLEM", 273, 293], ["fatigue", "PROBLEM", 295, 302], ["Atypical chest pain", "PROBLEM", 303, 322], ["GI gastrointestinal", "PROBLEM", 323, 342], ["CFS chronic fatigue syndrome", "PROBLEM", 344, 372], ["SBS sick building syndrome", "PROBLEM", 374, 400], ["TMJ temporomandibular joint explanations", "PROBLEM", 402, 442], ["Chest", "ANATOMY", 283, 288], ["chest", "ANATOMY", 312, 317], ["gastrointestinal", "ANATOMY", 326, 342], ["chronic", "OBSERVATION_MODIFIER", 348, 355], ["fatigue syndrome", "OBSERVATION", 356, 372], ["TMJ", "ANATOMY", 402, 405], ["temporomandibular joint", "ANATOMY", 406, 429]]], ["In non-Western societies, the systems of beliefs, their respective special names, and remedial methods are deemed to be features of culture-bound syndromes.", [["culture-bound syndromes", "PROBLEM", 132, 155], ["bound syndromes", "OBSERVATION", 140, 155]]], ["For example, hwa-byung, a Korean folk illness is characterized by insomnia, pains, fatigue, weakness, gastrointestinal symptoms, and emotional distress.", [["gastrointestinal", "ANATOMY", 102, 118], ["folk illness", "DISEASE", 33, 45], ["insomnia", "DISEASE", 66, 74], ["pains", "DISEASE", 76, 81], ["fatigue", "DISEASE", 83, 90], ["weakness", "DISEASE", 92, 100], ["gastrointestinal symptoms", "DISEASE", 102, 127], ["emotional distress", "DISEASE", 133, 151], ["gastrointestinal", "ORGANISM_SUBDIVISION", 102, 118], ["a Korean folk illness", "PROBLEM", 24, 45], ["insomnia", "PROBLEM", 66, 74], ["pains", "PROBLEM", 76, 81], ["fatigue", "PROBLEM", 83, 90], ["weakness", "PROBLEM", 92, 100], ["gastrointestinal symptoms", "PROBLEM", 102, 127], ["emotional distress", "PROBLEM", 133, 151], ["insomnia", "OBSERVATION", 66, 74], ["gastrointestinal", "ANATOMY", 102, 118]]], ["Chinese patients who have sleep difficulties, headaches, various pains, fatigue, and sexual dysfunction are termed shenjing shuairuo.", [["sleep difficulties", "DISEASE", 26, 44], ["headaches", "DISEASE", 46, 55], ["pains", "DISEASE", 65, 70], ["fatigue", "DISEASE", 72, 79], ["sexual dysfunction", "DISEASE", 85, 103], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["sleep difficulties", "PROBLEM", 26, 44], ["headaches", "PROBLEM", 46, 55], ["various pains", "PROBLEM", 57, 70], ["fatigue", "PROBLEM", 72, 79], ["sexual dysfunction", "PROBLEM", 85, 103]]], ["Their society's belief is that the affected people's vital essence is being lost and life threatening.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50]]], ["In Latin-American societies, such frightened and emotionally distressed people with similar sleep and somatic symptoms are considered to be afflicted with susto or \"soul loss.\"", [["sleep and somatic symptoms", "DISEASE", 92, 118], ["soul loss", "DISEASE", 165, 174], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["somatic symptoms", "PROBLEM", 102, 118]]], ["Even now in the Western society, where there is no clear medical understanding of the cause or treatment of such ill-defined symptoms, these culture-bound belief systems and methods for treating these illnesses continue to prevail in our societies.", [["such ill-defined symptoms", "PROBLEM", 108, 133], ["these culture", "TEST", 135, 148], ["bound belief systems", "PROBLEM", 149, 169], ["these illnesses", "PROBLEM", 195, 210]]], ["Hence, there is a large industry of purveyors of herbal substances, acupuncture, moxibustion procedures, and useless remedies of various vitamins and minerals.", [["vitamins", "SIMPLE_CHEMICAL", 137, 145], ["minerals", "SIMPLE_CHEMICAL", 150, 158], ["herbal substances", "TREATMENT", 49, 66], ["acupuncture", "TREATMENT", 68, 79], ["moxibustion procedures", "TREATMENT", 81, 103], ["useless remedies", "TREATMENT", 109, 125], ["various vitamins and minerals", "TREATMENT", 129, 158], ["large", "OBSERVATION_MODIFIER", 18, 23], ["industry", "OBSERVATION", 24, 32], ["herbal substances", "OBSERVATION", 49, 66]]], ["Where there is a lack of faith in medical explanations, there is the hope that nontraditional methods would remedy the mysterious rheumatic symptoms.IntroductionRather than focusing on traditional rheumatic interests in joints, connective tissue, and muscles, current interest has shifted to the central nervous system as the source of hypersensitivity with application of pressure to various predesignated regions of the body and pain behavior that are readily observed by rheumatologists in examining their patients' musculoskeletal system.", [["joints", "ANATOMY", 220, 226], ["connective tissue", "ANATOMY", 228, 245], ["muscles", "ANATOMY", 251, 258], ["central nervous system", "ANATOMY", 296, 318], ["body", "ANATOMY", 422, 426], ["hypersensitivity", "DISEASE", 336, 352], ["pain", "DISEASE", 431, 435], ["joints", "TISSUE", 220, 226], ["connective tissue", "TISSUE", 228, 245], ["muscles", "ORGAN", 251, 258], ["central nervous system", "ANATOMICAL_SYSTEM", 296, 318], ["body", "ORGANISM_SUBDIVISION", 422, 426], ["patients", "ORGANISM", 509, 517], ["musculoskeletal", "ANATOMICAL_SYSTEM", 519, 534], ["system", "ANATOMICAL_SYSTEM", 535, 541], ["patients", "SPECIES", 509, 517], ["nontraditional methods", "TREATMENT", 79, 101], ["the mysterious rheumatic symptoms", "PROBLEM", 115, 148], ["IntroductionRather", "TREATMENT", 149, 167], ["traditional rheumatic interests in joints, connective tissue, and muscles", "PROBLEM", 185, 258], ["hypersensitivity", "PROBLEM", 336, 352], ["pressure", "TREATMENT", 373, 381], ["pain behavior", "PROBLEM", 431, 444], ["rheumatic", "OBSERVATION", 197, 206], ["joints", "ANATOMY", 220, 226], ["connective tissue", "ANATOMY", 228, 245], ["muscles", "ANATOMY", 251, 258], ["central", "ANATOMY_MODIFIER", 296, 303], ["nervous system", "ANATOMY", 304, 318], ["hypersensitivity", "OBSERVATION", 336, 352], ["body", "ANATOMY", 422, 426], ["musculoskeletal system", "ANATOMY", 519, 541]]], ["Based upon experimental evidence, Moldofsky proposed the hypothesis that the sleeping/waking brain is integral to the somatic and behavioral symptoms of these ill-understood painful, fatiguing, distressing, and often disabling chronic illnesses [8] .", [["brain", "ANATOMY", 93, 98], ["brain", "ORGAN", 93, 98], ["the somatic and behavioral symptoms", "PROBLEM", 114, 149], ["fatiguing", "PROBLEM", 183, 192], ["distressing", "PROBLEM", 194, 205], ["often disabling chronic illnesses", "PROBLEM", 211, 244]]], ["How does the sleeping-waking brain connect to these poorly understood somatic and behavioral symptoms? 2.", [["brain", "ANATOMY", 29, 34], ["brain", "ORGAN", 29, 34], ["somatic and behavioral symptoms", "PROBLEM", 70, 101]]], ["Does an understanding of the disturbances in the sleeping/waking brain favorably influence the management of these suffering patients?", [["brain", "ANATOMY", 65, 70], ["brain", "ORGAN", 65, 70], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["the disturbances", "PROBLEM", 25, 41]]], ["This chapter reviews advances in our scientific understanding of how the sleeping-waking brain is intimately connected to the widespread musculoskeletal pain, fatigue, and psychologically distressing symptoms of previously presumed to be unexplained medical illnesses, which have led to the current advances in their management.Review of EEG Sleep, Pain, and FatigueThe pioneering work of Moldofsky and colleagues yielded two critically important findings with regard to the relationship of sleep to widespread musculoskeletal pain and fatigue in rheumatological patients without known medical disease: 1) EEG sleep is disturbed in more than 90 % of FM patients who report persistently poor sleep quality and impaired quality of life [9, 10] .", [["brain", "ANATOMY", 89, 94], ["musculoskeletal", "ANATOMY", 137, 152], ["musculoskeletal", "ANATOMY", 511, 526], ["musculoskeletal pain", "DISEASE", 137, 157], ["fatigue", "DISEASE", 159, 166], ["Pain", "DISEASE", 349, 353], ["Fatigue", "DISEASE", 359, 366], ["musculoskeletal pain", "DISEASE", 511, 531], ["fatigue", "DISEASE", 536, 543], ["brain", "ORGAN", 89, 94], ["patients", "ORGANISM", 563, 571], ["patients", "ORGANISM", 653, 661], ["patients", "SPECIES", 563, 571], ["patients", "SPECIES", 653, 661], ["the widespread musculoskeletal pain", "PROBLEM", 122, 157], ["fatigue", "PROBLEM", 159, 166], ["psychologically distressing symptoms", "PROBLEM", 172, 208], ["unexplained medical illnesses", "PROBLEM", 238, 267], ["their management", "TREATMENT", 311, 327], ["EEG", "TEST", 338, 341], ["Pain", "PROBLEM", 349, 353], ["Fatigue", "PROBLEM", 359, 366], ["widespread musculoskeletal pain", "PROBLEM", 500, 531], ["fatigue", "PROBLEM", 536, 543], ["known medical disease", "PROBLEM", 580, 601], ["EEG sleep", "TEST", 606, 615], ["persistently poor sleep quality", "PROBLEM", 673, 704], ["musculoskeletal", "ANATOMY", 137, 152], ["musculoskeletal", "ANATOMY", 511, 526], ["pain", "OBSERVATION", 527, 531]]], ["2) Experimental sleep disturbance in healthy individuals can induce FM-like musculoskeletal pain and tenderness [11] .", [["musculoskeletal", "ANATOMY", 76, 91], ["sleep disturbance", "DISEASE", 16, 33], ["musculoskeletal pain", "DISEASE", 76, 96], ["tenderness", "DISEASE", 101, 111], ["Experimental sleep disturbance in healthy individuals", "PROBLEM", 3, 56], ["musculoskeletal pain", "PROBLEM", 76, 96], ["tenderness", "PROBLEM", 101, 111], ["sleep disturbance", "OBSERVATION", 16, 33], ["musculoskeletal", "ANATOMY", 76, 91], ["pain", "OBSERVATION", 92, 96]]], ["Manifestations of disturbed sleep typically comprise the experience of light and unrefreshing sleep, nocturnal restlessness with frequent awakenings, and at times, sleep-related loud snoring and breathing problems, or periodic involuntary leg movements.", [["leg", "ANATOMY", 239, 242], ["nocturnal restlessness", "DISEASE", 101, 123], ["snoring", "DISEASE", 183, 190], ["involuntary leg movements", "DISEASE", 227, 252], ["leg", "ORGANISM_SUBDIVISION", 239, 242], ["disturbed sleep", "PROBLEM", 18, 33], ["light and unrefreshing sleep", "PROBLEM", 71, 99], ["nocturnal restlessness", "PROBLEM", 101, 123], ["frequent awakenings", "PROBLEM", 129, 148], ["loud snoring", "PROBLEM", 178, 190], ["breathing problems", "PROBLEM", 195, 213], ["periodic involuntary leg movements", "PROBLEM", 218, 252], ["disturbed sleep", "OBSERVATION", 18, 33], ["leg", "ANATOMY", 239, 242]]], ["Typically, there is a variation in the diurnal pattern of symptoms.", [["a variation in the diurnal pattern of symptoms", "PROBLEM", 20, 66], ["variation", "OBSERVATION_MODIFIER", 22, 31]]], ["Upon awakening from their poor quality of sleep, patients usually experience generalized muscular stiffness, diffuse pain, and profound fatigue, which are unchanged or even increased compared to the previous evening.", [["muscular", "ANATOMY", 89, 97], ["muscular stiffness", "DISEASE", 89, 107], ["pain", "DISEASE", 117, 121], ["fatigue", "DISEASE", 136, 143], ["patients", "ORGANISM", 49, 57], ["muscular", "ORGANISM_SUBDIVISION", 89, 97], ["patients", "SPECIES", 49, 57], ["generalized muscular stiffness", "PROBLEM", 77, 107], ["diffuse pain", "PROBLEM", 109, 121], ["profound fatigue", "PROBLEM", 127, 143], ["muscular", "ANATOMY", 89, 97], ["stiffness", "OBSERVATION", 98, 107], ["diffuse", "OBSERVATION_MODIFIER", 109, 116], ["pain", "OBSERVATION", 117, 121], ["profound", "OBSERVATION_MODIFIER", 127, 135], ["fatigue", "OBSERVATION", 136, 143], ["unchanged", "OBSERVATION_MODIFIER", 155, 164], ["increased", "OBSERVATION_MODIFIER", 173, 182]]], ["They report improvement in symptoms with improved energy from late morning to mid-afternoon; then, thereafter there is a downhill course in symptoms as the day progresses.", [["symptoms", "PROBLEM", 27, 35], ["symptoms", "PROBLEM", 140, 148], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["The narrower the period of improvement, the more disabled is the patient.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["narrower", "OBSERVATION_MODIFIER", 4, 12], ["period", "OBSERVATION_MODIFIER", 17, 23], ["improvement", "OBSERVATION_MODIFIER", 27, 38]]], ["On the rare occasion, they might achieve a restful night of sleep and improved symptoms on the following day.", [["improved symptoms", "PROBLEM", 70, 87]]], ["Indeed, unrefreshing or nonrestorative sleep is closely correlated to the widespread pain and tender points in FM while psychological distress is not [12] .", [["pain", "DISEASE", 85, 89], ["psychological distress", "DISEASE", 120, 142], ["FM", "MULTI-TISSUE_STRUCTURE", 111, 113], ["the widespread pain", "PROBLEM", 70, 89], ["tender points in FM", "PROBLEM", 94, 113], ["psychological distress", "PROBLEM", 120, 142]]], ["FM subjects with light unrefreshing sleep have diurnal impairment in speed of performance on complex cognitive tasks, which are accompanied by sleepiness, fatigue, and negative mood.", [["diurnal impairment", "DISEASE", 47, 65], ["sleepiness", "DISEASE", 143, 153], ["fatigue", "DISEASE", 155, 162], ["light unrefreshing sleep", "PROBLEM", 17, 41], ["diurnal impairment", "PROBLEM", 47, 65], ["complex cognitive tasks", "PROBLEM", 93, 116], ["sleepiness", "PROBLEM", 143, 153], ["fatigue", "PROBLEM", 155, 162]]], ["Such psychological impairment could account for the functional disabilities that are encountered in a work environment and in social behavior.", [["psychological impairment", "DISEASE", 5, 29], ["functional disabilities", "DISEASE", 52, 75], ["Such psychological impairment", "PROBLEM", 0, 29]]], ["There may be an associated predisposition to emotional hypersensitivity resulting from distrust and insecure attachment in their personality, which is shown to be associated with the alpha-EEG anomaly during sleep [13] .Review of EEG Sleep, Pain, and FatigueThese disabling behavioral symptoms are commonly associated with disturbances in the physiology of sleep [8, 9] .", [["emotional hypersensitivity", "DISEASE", 45, 71], ["Pain", "DISEASE", 241, 245], ["Fatigue", "DISEASE", 251, 258], ["behavioral symptoms", "DISEASE", 274, 293], ["emotional hypersensitivity", "PROBLEM", 45, 71], ["the alpha-EEG anomaly", "PROBLEM", 179, 200], ["EEG", "TEST", 230, 233], ["Pain", "PROBLEM", 241, 245], ["Fatigue", "PROBLEM", 251, 258], ["These disabling behavioral symptoms", "PROBLEM", 258, 293], ["may be", "UNCERTAINTY", 6, 12]]], ["How these FM symptoms are linked to the subjective poor sleep quality and objective PSG measures continues to be of considerable interest in determining the pathophysiology of this illness.", [["FM", "MULTI-TISSUE_STRUCTURE", 10, 12], ["these FM symptoms", "PROBLEM", 4, 21], ["the subjective poor sleep quality", "PROBLEM", 36, 69], ["objective PSG measures", "TREATMENT", 74, 96], ["this illness", "PROBLEM", 176, 188]]], ["Early on, aspects of anomalous changes in EEG sleep physiology were identified in FM patients that were considered to be consistent with subjective poor quality of sleep.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["anomalous changes in EEG sleep physiology", "PROBLEM", 21, 62], ["subjective poor quality of sleep", "PROBLEM", 137, 169], ["anomalous", "OBSERVATION", 21, 30]]], ["Nocturnal polysomnography (PSG) shows a prominent EEG alpha frequency (8) (9) (10) (11) (12) Hz) rhythm in the central EEG regions during stages 2 and slow-wave sleep (SWS) NREM sleep (see Fig. 48 .1) but less frequently in patients with severely diminished or absent delta SWS [8] .", [["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["Nocturnal polysomnography", "TEST", 0, 25], ["PSG", "TEST", 27, 30], ["a prominent EEG alpha frequency", "PROBLEM", 38, 69], ["rhythm in the central EEG regions", "PROBLEM", 97, 130], ["slow-wave sleep (SWS) NREM sleep", "PROBLEM", 151, 183], ["severely diminished or absent delta SWS", "PROBLEM", 238, 277], ["prominent", "OBSERVATION_MODIFIER", 40, 49], ["central", "ANATOMY_MODIFIER", 111, 118], ["EEG", "ANATOMY", 119, 122], ["regions", "ANATOMY_MODIFIER", 123, 130], ["diminished", "OBSERVATION", 247, 257]]], ["As Hauri and Hawkins had noticed this alpha EEG anomaly to coincide with the delta frequency (0-<4 Hz) slow waves of SWS, they coined the term alpha-delta sleep, which they described in a small group of not depressed psychiatric patients with poorly understood illness who complained of chronic, somatic malaise, and fatigue [14] .", [["depressed", "DISEASE", 207, 216], ["psychiatric", "DISEASE", 217, 228], ["illness", "DISEASE", 261, 268], ["somatic malaise", "DISEASE", 296, 311], ["fatigue", "DISEASE", 317, 324], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["this alpha EEG anomaly", "PROBLEM", 33, 55], ["the delta frequency", "TEST", 73, 92], ["slow waves of SWS", "PROBLEM", 103, 120], ["chronic, somatic malaise", "PROBLEM", 287, 311], ["fatigue", "PROBLEM", 317, 324], ["chronic", "OBSERVATION_MODIFIER", 287, 294], ["malaise", "OBSERVATION", 304, 311]]], ["Subsequently, Moldofsky and colleagues reported this anomaly in patients with so-called fibrositis [11] , later considered by rheumatologists to be a wastebasket diagnosis because of the lack of replicated evidence of presumed inflammation of fibrous tissue.", [["fibrous tissue", "ANATOMY", 243, 257], ["fibrositis", "DISEASE", 88, 98], ["inflammation", "DISEASE", 227, 239], ["patients", "ORGANISM", 64, 72], ["fibrous tissue", "TISSUE", 243, 257], ["patients", "SPECIES", 64, 72], ["this anomaly", "PROBLEM", 48, 60], ["so-called fibrositis", "PROBLEM", 78, 98], ["inflammation of fibrous tissue", "PROBLEM", 227, 257], ["fibrositis", "OBSERVATION", 88, 98], ["inflammation", "OBSERVATION", 227, 239], ["fibrous tissue", "OBSERVATION", 243, 257]]], ["Subsequently, the symptoms were relabeled as FM or FMS.", [["FMS", "DISEASE", 51, 54], ["the symptoms", "PROBLEM", 14, 26], ["FMS", "PROBLEM", 51, 54]]], ["This anomalous alpha EEG sleep is seen predominantly in the frontal-central brain area in contrast to the alpha EEG frequency occurring in quiet wakefulness that is localized in the occipital region [15, 16] .", [["frontal-central brain area", "ANATOMY", 60, 86], ["occipital region", "ANATOMY", 182, 198], ["alpha", "GENE_OR_GENE_PRODUCT", 15, 20], ["frontal-central brain area", "TISSUE", 60, 86], ["This anomalous alpha EEG sleep", "PROBLEM", 0, 30], ["quiet wakefulness", "PROBLEM", 139, 156], ["alpha EEG sleep", "OBSERVATION", 15, 30], ["predominantly", "OBSERVATION_MODIFIER", 39, 52], ["frontal", "ANATOMY_MODIFIER", 60, 67], ["central", "ANATOMY_MODIFIER", 68, 75], ["brain", "ANATOMY", 76, 81], ["area", "ANATOMY_MODIFIER", 82, 86], ["alpha EEG", "ANATOMY", 106, 115], ["quiet wakefulness", "OBSERVATION", 139, 156], ["occipital", "ANATOMY", 182, 191], ["region", "ANATOMY_MODIFIER", 192, 198]]], ["Subsequently, reports of this anomalous increased alpha EEG activity in NREM sleep were reported in FM patients [8, [17] [18] [19] [20] [21] .", [["patients", "ORGANISM", 103, 111], ["[17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 116, 140], ["alpha EEG", "PROTEIN", 50, 59], ["patients", "SPECIES", 103, 111], ["this anomalous increased alpha EEG activity in NREM sleep", "PROBLEM", 25, 82], ["anomalous", "OBSERVATION_MODIFIER", 30, 39], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["alpha EEG activity", "OBSERVATION", 50, 68]]], ["Patients with FMS, however, are heterogeneous with respect to exhibiting the alpha anomaly [21] .", [["FMS", "DISEASE", 14, 17], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the alpha anomaly", "PROBLEM", 73, 90], ["heterogeneous", "OBSERVATION_MODIFIER", 32, 45], ["alpha anomaly", "OBSERVATION", 77, 90]]], ["This alpha activity in NREM sleep is not specific to FM, since it occurs in patients with other painful rheumatic diseases.", [["rheumatic diseases", "DISEASE", 104, 122], ["alpha", "GENE_OR_GENE_PRODUCT", 5, 10], ["FM", "MULTI-TISSUE_STRUCTURE", 53, 55], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["other painful rheumatic diseases", "PROBLEM", 90, 122], ["activity", "OBSERVATION_MODIFIER", 11, 19], ["painful", "OBSERVATION_MODIFIER", 96, 103], ["rheumatic", "OBSERVATION", 104, 113]]], ["Moreover, it is described to occur in patients with primary insomnia [22] .", [["primary insomnia", "DISEASE", 52, 68], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["primary insomnia", "PROBLEM", 52, 68]]], ["As EEG alpha-like rhythm is associated with mentation [16, 18] , alpha occurring in NREM sleep may represent a vigilant arousal state that interferes with bodily restorative functions [8] .", [["EEG alpha", "GENE_OR_GENE_PRODUCT", 3, 12], ["alpha", "GENE_OR_GENE_PRODUCT", 65, 70], ["EEG alpha", "PROTEIN", 3, 12], ["EEG alpha", "TEST", 3, 12], ["alpha occurring in NREM sleep", "PROBLEM", 65, 94], ["a vigilant arousal state", "PROBLEM", 109, 133]]], ["This abnormal EEG sleep feature may account for a common aspect of impaired sleep quality with symptoms of light sleep and sleep mentation with external environmental awareness and internal self-awareness of subjective discomfort.", [["impaired sleep", "DISEASE", 67, 81], ["This abnormal EEG sleep feature", "PROBLEM", 0, 31], ["impaired sleep quality", "PROBLEM", 67, 89], ["symptoms", "PROBLEM", 95, 103], ["light sleep", "PROBLEM", 107, 118], ["sleep mentation", "PROBLEM", 123, 138], ["external environmental awareness", "PROBLEM", 144, 176], ["subjective discomfort", "PROBLEM", 208, 229], ["impaired", "OBSERVATION", 67, 75]]], ["This sense of vigilance is shown to be associated with an underlying faulty personality characteristic in such people with the prominent alpha EEG sleep anomaly and physical illness which stems from a faulty interactional pattern of childhood personality development.", [["sleep anomaly", "DISEASE", 147, 160], ["physical illness", "DISEASE", 165, 181], ["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["an underlying faulty personality characteristic", "PROBLEM", 55, 102], ["the prominent alpha EEG sleep anomaly", "PROBLEM", 123, 160], ["physical illness", "PROBLEM", 165, 181], ["prominent", "OBSERVATION_MODIFIER", 127, 136]]], ["In formal personality testing of such people with the alpha EEG sleep anomaly, most of whom have FMS, they show a pattern of overall distrust and insecurity in interpersonal relationships.", [["sleep anomaly", "DISEASE", 64, 77], ["FMS", "DISEASE", 97, 100], ["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["formal personality testing", "TEST", 3, 29], ["the alpha EEG sleep anomaly", "PROBLEM", 50, 77]]], ["Consequently, this pervasive sense of insecurity and distrust, which are ingrained in their personalities, is thought to make them difficult to accept any medical therapeutic effort that results in perpetuation of chronic physical illness behavior [13] .Review of EEG Sleep, Pain, and FatigueA second physiological component of impaired sleep quality is thought to be a specific EEG pattern that contributes to unstable or nonrestorative sleep, a major diagnostic feature of FMS and CFS.", [["chronic physical illness behavior", "DISEASE", 214, 247], ["Pain", "DISEASE", 275, 279], ["impaired sleep", "DISEASE", 328, 342], ["FMS", "DISEASE", 475, 478], ["CFS", "DISEASE", 483, 486], ["chronic physical illness behavior", "PROBLEM", 214, 247], ["EEG", "TEST", 264, 267], ["Pain", "PROBLEM", 275, 279], ["FatigueA", "PROBLEM", 285, 293], ["impaired sleep quality", "PROBLEM", 328, 350], ["a specific EEG pattern", "PROBLEM", 368, 390], ["unstable or nonrestorative sleep", "PROBLEM", 411, 443], ["CFS", "PROBLEM", 483, 486], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["impaired sleep", "OBSERVATION", 328, 342]]], ["This objective physiological feature in the sleep EEG sleep comprises a high frequency of the CAP.", [["CAP", "DISEASE", 94, 97], ["the sleep EEG sleep", "PROBLEM", 40, 59], ["the CAP", "PROBLEM", 90, 97], ["CAP", "OBSERVATION_MODIFIER", 94, 97]]], ["The CAP phenomenon occurs variably throughout NREM sleep characterized by a frequency of approximately 20-30 cycles per second (see Fig. 48 .1).", [["The CAP phenomenon", "PROBLEM", 0, 18], ["CAP", "OBSERVATION_MODIFIER", 4, 7], ["phenomenon", "OBSERVATION", 8, 18]]], ["The specific type of CAP is reported to reflect a measure of relative stable-unstable sleep.", [["unstable sleep", "PROBLEM", 77, 91], ["CAP", "OBSERVATION", 21, 24], ["stable", "OBSERVATION_MODIFIER", 70, 76], ["unstable sleep", "OBSERVATION", 77, 91]]], ["In patients with FMS and CFS where unstable or nonrestorative sleep is commonly reported, there is an increase of CAP activity.", [["FMS", "DISEASE", 17, 20], ["CFS", "DISEASE", 25, 28], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["FMS", "PROBLEM", 17, 20], ["CFS", "PROBLEM", 25, 28], ["unstable or nonrestorative sleep", "PROBLEM", 35, 67], ["CAP activity", "PROBLEM", 114, 126], ["increase", "OBSERVATION_MODIFIER", 102, 110], ["CAP activity", "OBSERVATION", 114, 126]]], ["The sleep EEG dominant rhythm of CAP A1 and no significant ancillary increase in autonomic or peripheral EMG activity, as seen in CAP A2 and increased in CAP A3, is associated with sleep stability that is commonly found in young asymptomatic healthy people.", [["CAP A1", "GENE_OR_GENE_PRODUCT", 33, 39], ["EMG", "GENE_OR_GENE_PRODUCT", 105, 108], ["CAP A2", "GENE_OR_GENE_PRODUCT", 130, 136], ["CAP A3", "GENE_OR_GENE_PRODUCT", 154, 160], ["people", "ORGANISM", 250, 256], ["CAP A1", "PROTEIN", 33, 39], ["CAP A2", "PROTEIN", 130, 136], ["people", "SPECIES", 250, 256], ["The sleep EEG", "TEST", 0, 13], ["CAP A1", "PROBLEM", 33, 39], ["significant ancillary increase", "PROBLEM", 47, 77], ["autonomic or peripheral EMG activity", "PROBLEM", 81, 117], ["CAP A2", "PROBLEM", 130, 136], ["increased in CAP A3", "PROBLEM", 141, 160], ["sleep stability", "PROBLEM", 181, 196], ["CAP A1", "OBSERVATION_MODIFIER", 33, 39], ["no", "UNCERTAINTY", 44, 46], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["ancillary", "OBSERVATION_MODIFIER", 59, 68], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["peripheral", "ANATOMY_MODIFIER", 94, 104], ["EMG activity", "OBSERVATION", 105, 117], ["CAP", "OBSERVATION_MODIFIER", 130, 133], ["A2", "OBSERVATION_MODIFIER", 134, 136], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["CAP A3", "OBSERVATION", 154, 160], ["sleep stability", "OBSERVATION", 181, 196]]], ["In the subgroup CAP A2 and CAP A3, there is physiological evidence for progressive increases in sleep instability [23] [24] [25] .", [["increases in sleep instability", "DISEASE", 83, 113], ["CAP A2", "GENE_OR_GENE_PRODUCT", 16, 22], ["CAP A3", "GENE_OR_GENE_PRODUCT", 27, 33], ["CAP A3", "PROTEIN", 27, 33], ["CAP A3", "TREATMENT", 27, 33], ["progressive increases in sleep instability", "PROBLEM", 71, 113], ["CAP A2", "ANATOMY", 16, 22], ["CAP A3", "OBSERVATION", 27, 33], ["physiological evidence for", "UNCERTAINTY", 44, 70], ["progressive", "OBSERVATION_MODIFIER", 71, 82], ["increases", "OBSERVATION_MODIFIER", 83, 92], ["sleep instability", "OBSERVATION", 96, 113]]], ["This high amount of CAP correlates with the severity of pain as measured by the number of tender points in FMS [23] .", [["CAP", "DISEASE", 20, 23], ["pain", "DISEASE", 56, 60], ["FMS", "DISEASE", 107, 110], ["the severity of pain", "PROBLEM", 40, 60], ["FMS", "TEST", 107, 110], ["high", "OBSERVATION_MODIFIER", 5, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["CAP", "OBSERVATION_MODIFIER", 20, 23]]], ["The EEG CAP A2 and especially CAP A3 are associated with pathological sleep characterized by physiological evidence of motor and autonomic nervous system abnormalities, e.g., periodic limb movement (PLM) and sleep apnea disorders [24, 26] .", [["autonomic nervous system", "ANATOMY", 129, 153], ["limb", "ANATOMY", 184, 188], ["sleep apnea disorders", "DISEASE", 208, 229], ["EEG CAP A2", "GENE_OR_GENE_PRODUCT", 4, 14], ["CAP A3", "GENE_OR_GENE_PRODUCT", 30, 36], ["autonomic nervous system", "ANATOMICAL_SYSTEM", 129, 153], ["limb", "ORGANISM_SUBDIVISION", 184, 188], ["EEG CAP A2", "PROTEIN", 4, 14], ["CAP A3", "PROTEIN", 30, 36], ["The EEG CAP A2", "TEST", 0, 14], ["pathological sleep", "PROBLEM", 57, 75], ["motor and autonomic nervous system abnormalities", "PROBLEM", 119, 167], ["periodic limb movement (PLM)", "PROBLEM", 175, 203], ["sleep apnea disorders", "PROBLEM", 208, 229], ["autonomic nervous", "ANATOMY", 129, 146], ["limb movement", "OBSERVATION", 184, 197], ["sleep apnea", "OBSERVATION", 208, 219]]], ["Such clinically significant periodic PSG sleep disorders are found in a large sample of US patients with FMS.", [["sleep disorders", "DISEASE", 41, 56], ["FMS", "DISEASE", 105, 108], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["significant periodic PSG sleep disorders", "PROBLEM", 16, 56], ["FMS", "PROBLEM", 105, 108], ["PSG sleep disorders", "OBSERVATION", 37, 56], ["large", "OBSERVATION_MODIFIER", 72, 77]]], ["In this multicenter PSG study of more than 200 FMS patients, 94 % were female, with a mean body mass index of about 30 who had FMS for more than 5 years.", [["body", "ANATOMY", 91, 95], ["FMS", "DISEASE", 47, 50], ["FMS", "DISEASE", 127, 130], ["patients", "ORGANISM", 51, 59], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["patients", "SPECIES", 51, 59], ["this multicenter PSG study", "TEST", 3, 29], ["a mean body mass index", "TEST", 84, 106], ["mass", "OBSERVATION", 96, 100]]], ["Approximately 15 % had moderate to severe apnea-hypopnea respiratory index and 20 % had PLM disorder [24] .", [["apnea-hypopnea respiratory index", "DISEASE", 42, 74], ["PLM disorder", "DISEASE", 88, 100], ["moderate to severe apnea-hypopnea respiratory index", "PROBLEM", 23, 74], ["PLM disorder", "PROBLEM", 88, 100], ["moderate", "OBSERVATION_MODIFIER", 23, 31], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["apnea-hypopnea", "OBSERVATION", 42, 56], ["respiratory index", "OBSERVATION", 57, 74]]], ["Their sedentary behavior with resultant weight gain and obesity may have promoted the sleep apnea disorder and the coincident CAP A2 and A3 EEG unstable and nonrestorative sleep.Review of EEG Sleep, Pain, and FatigueAnother feature of sleep EEG disturbance, which is reported in FMS, is a decrease in stage 2 EEG sleep spindles [27] .", [["weight gain", "DISEASE", 40, 51], ["obesity", "DISEASE", 56, 63], ["sleep apnea disorder", "DISEASE", 86, 106], ["Pain", "DISEASE", 199, 203], ["FMS", "DISEASE", 279, 282], ["resultant weight gain", "PROBLEM", 30, 51], ["obesity", "PROBLEM", 56, 63], ["the sleep apnea disorder", "PROBLEM", 82, 106], ["A3 EEG", "TEST", 137, 143], ["nonrestorative sleep", "PROBLEM", 157, 177], ["EEG", "TEST", 188, 191], ["Pain", "PROBLEM", 199, 203], ["sleep EEG disturbance", "PROBLEM", 235, 256], ["a decrease in stage 2 EEG sleep spindles", "PROBLEM", 287, 327], ["obesity", "OBSERVATION", 56, 63], ["sleep apnea", "OBSERVATION", 86, 97], ["decrease", "OBSERVATION_MODIFIER", 289, 297]]], ["The presence of EEG sleep spindles, a characteristic of this stage of NREM sleep, is hypothesized to be a physiological feature of sleep stability.", [["EEG sleep spindles", "PROBLEM", 16, 34], ["NREM sleep", "PROBLEM", 70, 80], ["sleep stability", "PROBLEM", 131, 146], ["EEG sleep spindles", "OBSERVATION", 16, 34], ["sleep stability", "OBSERVATION", 131, 146]]], ["This hypothesis is supported by the shorter duration of stage 2 sleep periods, which is normally dominated by CAP A1.", [["CAP A1", "GENE_OR_GENE_PRODUCT", 110, 116], ["stage 2 sleep periods", "PROBLEM", 56, 77], ["shorter", "OBSERVATION_MODIFIER", 36, 43], ["normally", "OBSERVATION_MODIFIER", 88, 96], ["dominated", "OBSERVATION_MODIFIER", 97, 106], ["CAP A1", "OBSERVATION", 110, 116]]], ["In addition, there is increased frequency of EEG sleep stage shifts [28] , increased sleep awakenings, and decreased sleep efficiency (ratio of time asleep/time in bed) [23, 29] .Review of EEG Sleep, Pain, and FatigueMoreover, there is a reduction of SWS in FM patients [11, [19] [20] [21] 29] .", [["sleep awakenings", "DISEASE", 85, 101], ["Pain", "DISEASE", 200, 204], ["SWS", "DISEASE", 251, 254], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 261, 269], ["increased frequency of EEG sleep stage shifts", "PROBLEM", 22, 67], ["increased sleep awakenings", "PROBLEM", 75, 101], ["decreased sleep efficiency", "PROBLEM", 107, 133], ["EEG", "TEST", 189, 192], ["Pain", "PROBLEM", 200, 204], ["a reduction of SWS", "PROBLEM", 236, 254], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["decreased", "OBSERVATION_MODIFIER", 107, 116], ["sleep efficiency", "OBSERVATION", 117, 133], ["reduction", "OBSERVATION_MODIFIER", 238, 247]]], ["One such study showed that decreased SWS is correlated with high-phasic EEG alpha rhythm [21] .", [["One such study", "TEST", 0, 14], ["decreased SWS", "PROBLEM", 27, 40], ["decreased", "OBSERVATION", 27, 36]]], ["The finding of reduced SWS in FMS patients also coincides with nocturnal neuroendocrine abnormalities of increased nocturnal cortisol levels and decreased release of growth hormone (GH) [30] .", [["neuroendocrine", "ANATOMY", 73, 87], ["SWS", "DISEASE", 23, 26], ["FMS", "DISEASE", 30, 33], ["cortisol", "CHEMICAL", 125, 133], ["cortisol", "CHEMICAL", 125, 133], ["patients", "ORGANISM", 34, 42], ["neuroendocrine", "ANATOMICAL_SYSTEM", 73, 87], ["cortisol", "SIMPLE_CHEMICAL", 125, 133], ["growth hormone", "GENE_OR_GENE_PRODUCT", 166, 180], ["GH", "GENE_OR_GENE_PRODUCT", 182, 184], ["patients", "SPECIES", 34, 42], ["reduced SWS in FMS", "PROBLEM", 15, 33], ["nocturnal neuroendocrine abnormalities", "PROBLEM", 63, 101], ["increased nocturnal cortisol levels", "PROBLEM", 105, 140], ["decreased release of growth hormone", "PROBLEM", 145, 180], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["SWS", "OBSERVATION", 23, 26], ["increased", "OBSERVATION_MODIFIER", 105, 114]]], ["Quantitative studies suggest that the duration of SWS serves to regulate homeostasis and is correlated with the amount of prior waking.", [["Quantitative studies", "TEST", 0, 20]]], ["That is, SWS increases following extended wakefulness and is decreased during nocturnal sleep following a daytime nap containing SWS [31] .", [["nocturnal sleep", "PROBLEM", 78, 93], ["decreased", "OBSERVATION_MODIFIER", 61, 70]]], ["This decreased amount of SWS in FM might indicate an impairment of the SWS homeostatic drive.", [["FM", "MULTI-TISSUE_STRUCTURE", 32, 34], ["SWS in FM", "PROBLEM", 25, 34], ["decreased", "OBSERVATION_MODIFIER", 5, 14], ["amount", "OBSERVATION_MODIFIER", 15, 21], ["impairment", "OBSERVATION", 53, 63], ["SWS homeostatic drive", "OBSERVATION", 71, 92]]], ["Some sleep abnormalities in FM patients have not been consistently reported.", [["sleep abnormalities", "DISEASE", 5, 24], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Some sleep abnormalities in FM", "PROBLEM", 0, 30], ["sleep", "OBSERVATION_MODIFIER", 5, 10], ["abnormalities", "OBSERVATION", 11, 24]]], ["In some studies, for example, FM patients are reported to be not significantly different from controls with respect to alpha sleep EEG activity or the duration of SWS [28, 32] .", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["some studies", "TEST", 3, 15], ["alpha sleep EEG", "TEST", 119, 134]]], ["It is unclear whether these discrepancies result from heterogeneity of sleep pathology in FM patients, technical considerations such as differences in scoring of sleep EEG alpha anomalies, or the night-to-night variability in many sleep measures, including SWS [33] .Relationship Between Sleep and Pain Processing Epidemiological StudiesAmong patients with FMS, poor sleep quality is shown to be a key in the vicious cycle of feeling unrefreshed after sleep, morning aching/stiffness, fatigue, and dyscognition.", [["Pain", "DISEASE", 298, 302], ["FMS", "DISEASE", 357, 360], ["morning aching", "DISEASE", 459, 473], ["stiffness", "DISEASE", 474, 483], ["fatigue", "DISEASE", 485, 492], ["dyscognition", "DISEASE", 498, 510], ["patients", "ORGANISM", 93, 101], ["EEG alpha", "GENE_OR_GENE_PRODUCT", 168, 177], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 343, 351], ["these discrepancies", "PROBLEM", 22, 41], ["sleep pathology", "PROBLEM", 71, 86], ["sleep EEG alpha anomalies", "PROBLEM", 162, 187], ["Pain", "PROBLEM", 298, 302], ["Epidemiological Studies", "TEST", 314, 337], ["FMS", "PROBLEM", 357, 360], ["poor sleep quality", "PROBLEM", 362, 380], ["morning aching/stiffness", "PROBLEM", 459, 483], ["fatigue", "PROBLEM", 485, 492], ["dyscognition", "PROBLEM", 498, 510], ["unclear whether", "UNCERTAINTY", 6, 21]]], ["Several prospective clinical studies report a correlation between poor sleep quality and FM symptoms.", [["Several prospective clinical studies", "TEST", 0, 36], ["poor sleep quality", "PROBLEM", 66, 84], ["FM symptoms", "PROBLEM", 89, 100]]], ["A statistical path analysis of a large population of FM patients found that a night of increased sleep disturbance correlates with increased pain, which predicted poorer physical functioning and subsequently greater depression [9] .", [["sleep disturbance", "DISEASE", 97, 114], ["pain", "DISEASE", 141, 145], ["depression", "DISEASE", 216, 226], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["A statistical path analysis", "TEST", 0, 27], ["increased sleep disturbance", "PROBLEM", 87, 114], ["increased pain", "PROBLEM", 131, 145], ["subsequently greater depression", "PROBLEM", 195, 226], ["large", "OBSERVATION_MODIFIER", 33, 38], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["pain", "OBSERVATION", 141, 145]]], ["In another study, poor sleep quality mediates the impact of increased pain upon fatigue [34] .", [["pain", "DISEASE", 70, 74], ["fatigue", "DISEASE", 80, 87], ["another study", "TEST", 3, 16], ["poor sleep quality", "PROBLEM", 18, 36], ["increased pain upon fatigue", "PROBLEM", 60, 87]]], ["These studies extend previous findings that a night of poor sleep is followed by a day of increased pain [35] .", [["pain", "DISEASE", 100, 104], ["These studies", "TEST", 0, 13], ["increased pain", "PROBLEM", 90, 104]]], ["Moreover, after accounting for the effects of positive and negative events and pain on daily mood ratings, sleep duration and quality are prospectively related to affect and fatigue.", [["pain", "DISEASE", 79, 83], ["fatigue", "DISEASE", 174, 181], ["positive and negative events", "PROBLEM", 46, 74], ["pain", "PROBLEM", 79, 83], ["daily mood ratings", "TEST", 87, 105], ["fatigue", "PROBLEM", 174, 181]]], ["Inadequate sleep has a cumulative effect on negative affect and prevents mood recovery from days with a high number of negative events [36] .Clinical Experimental StudiesAs described above, Moldofsky and colleagues were the first to attribute functional disturbances in the sleeping-waking brain to the etiological core of promoting FM symptoms.", [["brain", "ANATOMY", 290, 295], ["FM", "ANATOMY", 333, 335], ["brain", "ORGAN", 290, 295], ["FM", "MULTI-TISSUE_STRUCTURE", 333, 335], ["Inadequate sleep", "PROBLEM", 0, 16], ["Clinical Experimental StudiesAs", "TEST", 141, 172], ["functional disturbances", "PROBLEM", 243, 266], ["promoting FM symptoms", "PROBLEM", 323, 344]]], ["In 1975 and 1976 publications, they showed that by interrupting SWS with auditory stimuli, an FM-like state including variable aching, fatigue, and increased sensitivity to pain pressure could be induced in healthy normal nonathletic subjects [11, 37] .", [["fatigue", "DISEASE", 135, 142], ["pain", "DISEASE", 173, 177], ["auditory stimuli", "TEST", 73, 89], ["an FM-like state", "PROBLEM", 91, 107], ["variable aching", "PROBLEM", 118, 133], ["fatigue", "PROBLEM", 135, 142], ["increased sensitivity to pain pressure", "PROBLEM", 148, 186]]], ["They also showed in a small pilot study that under similar experimental prospective sleep and symptom test circumstances, several members of the University of Toronto track team did not experience such pain and fatigue symptoms.", [["pain", "DISEASE", 202, 206], ["fatigue", "DISEASE", 211, 218], ["a small pilot study", "TEST", 20, 39], ["symptom test", "TEST", 94, 106], ["such pain", "PROBLEM", 197, 206], ["fatigue symptoms", "PROBLEM", 211, 227]]], ["This preliminary finding suggests that aerobic physical fitness is involved in preventing or reducing the emergence of these symptoms.", [["these symptoms", "PROBLEM", 119, 133]]], ["Since then, other researchers have confirmed that selective deprivation or disruption of sleep induces increased bodily sensitivity, decreased pain threshold, and reports of nonrestorative sleep [8, [38] [39] [40] [41] [42] .", [["pain", "DISEASE", 143, 147], ["[38] [39] [40", "SIMPLE_CHEMICAL", 199, 212], ["selective deprivation", "PROBLEM", 50, 71], ["disruption of sleep induces", "PROBLEM", 75, 102], ["increased bodily sensitivity", "PROBLEM", 103, 131], ["decreased pain threshold", "PROBLEM", 133, 157], ["nonrestorative sleep", "PROBLEM", 174, 194]]], ["One study involving presumably fit US military men found a reduction of pain threshold, albeit not significantly different from controls [42] .", [["pain", "DISEASE", 72, 76], ["men", "ORGANISM", 47, 50], ["men", "SPECIES", 47, 50], ["One study", "TEST", 0, 9], ["pain threshold", "PROBLEM", 72, 86], ["reduction", "OBSERVATION_MODIFIER", 59, 68]]], ["Another experimental clinical study of sleep deprivation does not alter somatosensory (nonnociceptive) functions [39] .", [["somatosensory", "ANATOMY", 72, 85], ["Another experimental clinical study", "TEST", 0, 35], ["sleep deprivation", "PROBLEM", 39, 56]]], ["Furthermore, the effects of interruptions of SWS increases sensitivity to both painful and nonpainful stimuli, such as bright light, loud sounds, and strong odors [40] .", [["SWS", "PROBLEM", 45, 48], ["nonpainful stimuli", "TEST", 91, 109], ["bright light, loud sounds", "TEST", 119, 144]]], ["In this study, selective sleep deprivation of middleaged, sedentary women (similar to the major demographic population of FM patients) also produced impairment in diffuse noxious inhibitory controls (DNIC), similar to that observed in FM patients [40] .", [["women", "ORGANISM", 68, 73], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 238, 246], ["women", "SPECIES", 68, 73], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 238, 246], ["this study", "TEST", 3, 13], ["selective sleep deprivation", "TREATMENT", 15, 42], ["impairment in diffuse noxious inhibitory controls (DNIC)", "PROBLEM", 149, 205], ["diffuse", "OBSERVATION_MODIFIER", 163, 170]]], ["Recovery after sleep deprivation results in increased amounts of SWS and normalization of pain threshold [8] .", [["pain", "DISEASE", 90, 94], ["sleep deprivation", "PROBLEM", 15, 32], ["increased amounts of SWS", "PROBLEM", 44, 68], ["pain threshold", "PROBLEM", 90, 104], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["amounts", "OBSERVATION_MODIFIER", 54, 61]]], ["The importance of SWS in maintaining homeostatic properties of the CNS is purported to involve downregulation of synapses [43, 44] .Clinical Experimental StudiesSynaptic upregulation, a feature of a state of central sensitization and pain augmentation, may be caused by disturbances in the physiology of sleep that leads to impaired sleep quality and nonrestorative sleep symptoms.", [["CNS", "ANATOMY", 67, 70], ["pain", "DISEASE", 234, 238], ["CNS", "ANATOMICAL_SYSTEM", 67, 70], ["central sensitization", "PROBLEM", 208, 229], ["pain augmentation", "PROBLEM", 234, 251], ["disturbances in the physiology of sleep", "PROBLEM", 270, 309], ["impaired sleep quality", "PROBLEM", 324, 346], ["nonrestorative sleep symptoms", "PROBLEM", 351, 380], ["central sensitization", "OBSERVATION", 208, 229]]], ["Consequently, total sleep deprivation and REM sleep deprivation adversely affects pain threshold and pain behavior [40] , which also occurs as the result of the experimental induced loss of the terminal four hours of sleep with its REM and non-REM sleep [45] .Disordered Metabolic FunctionsDespite the absence of specific structural pathology, there is evidence for disordered metabolic functions that involve the sleeping/waking brain.", [["brain", "ANATOMY", 430, 435], ["pain", "DISEASE", 82, 86], ["pain", "DISEASE", 101, 105], ["brain", "ORGAN", 430, 435], ["total sleep deprivation", "TREATMENT", 14, 37], ["REM sleep deprivation", "TREATMENT", 42, 63], ["pain threshold", "PROBLEM", 82, 96], ["pain behavior", "PROBLEM", 101, 114], ["non-REM sleep", "PROBLEM", 240, 253], ["Disordered Metabolic Functions", "PROBLEM", 260, 290], ["specific structural pathology", "PROBLEM", 313, 342], ["disordered metabolic functions", "PROBLEM", 366, 396], ["Metabolic Functions", "OBSERVATION", 271, 290], ["pathology", "OBSERVATION", 333, 342], ["evidence for", "UNCERTAINTY", 353, 365], ["metabolic functions", "OBSERVATION", 377, 396], ["brain", "ANATOMY", 430, 435]]], ["These include a decrease in sleeprelated prolactin, decrease in GH and its metabolites, disturbances in the hypothalamic-cortical adrenal axis, and elevation of cerebral spinal fluid substance P (SP) [46] [47] [48] [49] [50] [51] [52] [53] .", [["hypothalamic-cortical adrenal", "ANATOMY", 108, 137], ["cerebral spinal fluid", "ANATOMY", 161, 182], ["SP) [46] [47] [48] [49] [50]", "CHEMICAL", 196, 224], ["prolactin", "GENE_OR_GENE_PRODUCT", 41, 50], ["GH", "GENE_OR_GENE_PRODUCT", 64, 66], ["cortical adrenal", "MULTI-TISSUE_STRUCTURE", 121, 137], ["cerebral", "ORGAN", 161, 169], ["47] [48] [49] [50] [51] [52] [53]", "SIMPLE_CHEMICAL", 206, 239], ["a decrease in sleeprelated prolactin", "PROBLEM", 14, 50], ["decrease in GH and its metabolites", "PROBLEM", 52, 86], ["disturbances in the hypothalamic-cortical adrenal axis", "PROBLEM", 88, 142], ["elevation of cerebral spinal fluid substance", "PROBLEM", 148, 192], ["decrease", "OBSERVATION_MODIFIER", 16, 24], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["cortical", "ANATOMY_MODIFIER", 121, 129], ["adrenal axis", "ANATOMY", 130, 142], ["elevation", "OBSERVATION_MODIFIER", 148, 157], ["cerebral spinal", "ANATOMY", 161, 176]]], ["Furthermore, specific dysfunctions in neurotransmitter functions are shown to contribute to bodily sensitivity and disordered sleep.", [["specific dysfunctions in neurotransmitter functions", "PROBLEM", 13, 64], ["bodily sensitivity", "PROBLEM", 92, 110], ["disordered sleep", "PROBLEM", 115, 131]]], ["For example, inhibition of serotonin (5HT) synthesis by p-chlorophenylalanine induces insomnia and a hyperalgesic state in animals and humans [54] .", [["serotonin", "CHEMICAL", 27, 36], ["5HT", "CHEMICAL", 38, 41], ["p-chlorophenylalanine", "CHEMICAL", 56, 77], ["insomnia", "DISEASE", 86, 94], ["serotonin", "CHEMICAL", 27, 36], ["5HT", "CHEMICAL", 38, 41], ["p-chlorophenylalanine", "CHEMICAL", 56, 77], ["serotonin", "SIMPLE_CHEMICAL", 27, 36], ["5HT", "SIMPLE_CHEMICAL", 38, 41], ["p-chlorophenylalanine", "SIMPLE_CHEMICAL", 56, 77], ["humans", "ORGANISM", 135, 141], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 135, 141], ["serotonin (5HT) synthesis", "TREATMENT", 27, 52], ["insomnia", "PROBLEM", 86, 94], ["a hyperalgesic state", "PROBLEM", 99, 119]]], ["The increased levels of SP that are found in the CSF of FMS patients led to experimental studies that demonstrated that SP operates through a neurokinin (NK) pathway to influence nociception and sleep.", [["NK", "ANATOMY", 154, 156], ["FMS", "DISEASE", 56, 59], ["SP", "GENE_OR_GENE_PRODUCT", 24, 26], ["CSF", "GENE_OR_GENE_PRODUCT", 49, 52], ["patients", "ORGANISM", 60, 68], ["SP", "SIMPLE_CHEMICAL", 120, 122], ["neurokinin", "GENE_OR_GENE_PRODUCT", 142, 152], ["NK", "GENE_OR_GENE_PRODUCT", 154, 156], ["SP", "PROTEIN", 24, 26], ["SP", "PROTEIN", 120, 122], ["patients", "SPECIES", 60, 68], ["The increased levels of SP", "PROBLEM", 0, 26], ["experimental studies", "TEST", 76, 96], ["a neurokinin (NK) pathway", "TREATMENT", 140, 165], ["nociception", "TEST", 179, 190], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["levels", "OBSERVATION_MODIFIER", 14, 20]]], ["Intracerebral ventricular administration of SP in sufficient quantities that did not induce nociceptive response in mice delayed onset of sleep and provoked awakenings from sleep.", [["ventricular", "ANATOMY", 14, 25], ["SP", "CHEMICAL", 44, 46], ["ventricular", "MULTI-TISSUE_STRUCTURE", 14, 25], ["mice", "ORGANISM", 116, 120], ["SP", "PROTEIN", 44, 46], ["mice", "SPECIES", 116, 120], ["Intracerebral ventricular administration", "TREATMENT", 0, 40], ["ventricular", "ANATOMY", 14, 25]]], ["An NK-1 receptor antagonist reversed the interfering effect upon sleep by SP [55] .", [["NK", "ANATOMY", 3, 5], ["SP", "CHEMICAL", 74, 76], ["NK-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 3, 27], ["An NK", "TEST", 0, 5], ["receptor antagonist", "TREATMENT", 8, 27]]], ["This research demonstrates that the blocking of the SP-induced insomnia by prior treatment of the mice with NK1 receptor antagonist provides support to the notion of the arousing effect of increased SP on the sleeping/waking brain.", [["brain", "ANATOMY", 225, 230], ["SP", "CHEMICAL", 52, 54], ["insomnia", "DISEASE", 63, 71], ["SP", "CHEMICAL", 199, 201], ["SP", "SIMPLE_CHEMICAL", 52, 54], ["mice", "ORGANISM", 98, 102], ["NK1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 108, 131], ["brain", "ORGAN", 225, 230], ["SP", "PROTEIN", 52, 54], ["NK1 receptor", "PROTEIN", 108, 120], ["SP", "PROTEIN", 199, 201], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["the SP-induced insomnia", "PROBLEM", 48, 71], ["NK1 receptor antagonist", "TREATMENT", 108, 131], ["support", "TREATMENT", 141, 148], ["increased SP", "PROBLEM", 189, 201], ["increased", "OBSERVATION_MODIFIER", 189, 198], ["brain", "ANATOMY", 225, 230]]], ["Moreover, this research provides an experimental animal model for studying sleep disturbances and musculoskeletal pain.Disordered Metabolic FunctionsFunctional neuroimaging of FMS patients support the hypothesis of deficits in CNS inhibition and central pain augmentation.", [["musculoskeletal", "ANATOMY", 98, 113], ["CNS", "ANATOMY", 227, 230], ["sleep disturbances", "DISEASE", 75, 93], ["musculoskeletal pain", "DISEASE", 98, 118], ["FMS", "DISEASE", 176, 179], ["pain", "DISEASE", 254, 258], ["patients", "ORGANISM", 180, 188], ["CNS", "ANATOMICAL_SYSTEM", 227, 230], ["patients", "SPECIES", 180, 188], ["studying sleep disturbances", "PROBLEM", 66, 93], ["musculoskeletal pain", "PROBLEM", 98, 118], ["Disordered Metabolic Functions", "PROBLEM", 119, 149], ["deficits in CNS inhibition", "PROBLEM", 215, 241], ["central pain augmentation", "PROBLEM", 246, 271], ["musculoskeletal", "ANATOMY", 98, 113], ["central", "ANATOMY_MODIFIER", 246, 253]]], ["FMS patients are reported to have a premature decrease in gray matter volume in the cingulate, insular, medial frontal cortices, and parahippocampal gyri, which may be associated with affective disturbances and chronic widespread pain [56] .", [["gray matter", "ANATOMY", 58, 69], ["cingulate", "ANATOMY", 84, 93], ["insular", "ANATOMY", 95, 102], ["medial frontal cortices", "ANATOMY", 104, 127], ["parahippocampal gyri", "ANATOMY", 133, 153], ["FMS", "DISEASE", 0, 3], ["premature decrease in gray matter volume", "DISEASE", 36, 76], ["affective disturbances", "DISEASE", 184, 206], ["pain", "DISEASE", 230, 234], ["patients", "ORGANISM", 4, 12], ["gray matter", "MULTI-TISSUE_STRUCTURE", 58, 69], ["cingulate", "MULTI-TISSUE_STRUCTURE", 84, 93], ["insular", "MULTI-TISSUE_STRUCTURE", 95, 102], ["frontal cortices", "MULTI-TISSUE_STRUCTURE", 111, 127], ["parahippocampal gyri", "MULTI-TISSUE_STRUCTURE", 133, 153], ["patients", "SPECIES", 4, 12], ["a premature decrease in gray matter volume in the cingulate, insular, medial frontal cortices, and parahippocampal gyri", "PROBLEM", 34, 153], ["affective disturbances", "PROBLEM", 184, 206], ["chronic widespread pain", "PROBLEM", 211, 234], ["premature", "OBSERVATION_MODIFIER", 36, 45], ["decrease", "OBSERVATION_MODIFIER", 46, 54], ["gray", "OBSERVATION_MODIFIER", 58, 62], ["matter volume", "OBSERVATION", 63, 76], ["cingulate", "ANATOMY_MODIFIER", 84, 93], ["insular", "ANATOMY_MODIFIER", 95, 102], ["medial", "ANATOMY_MODIFIER", 104, 110], ["frontal cortices", "ANATOMY", 111, 127], ["parahippocampal gyri", "ANATOMY", 133, 153], ["may be associated with", "UNCERTAINTY", 161, 183], ["chronic", "OBSERVATION_MODIFIER", 211, 218], ["widespread", "OBSERVATION_MODIFIER", 219, 229]]], ["Whereas the duration of pain or functional pain disability was not related with gray matter vol-umes, there is the suggestion that there is a trend of reduction in the anterior cingulate cortex (ACC) gray matter volume.", [["anterior cingulate cortex", "ANATOMY", 168, 193], ["ACC) gray matter", "ANATOMY", 195, 211], ["pain", "DISEASE", 24, 28], ["pain", "DISEASE", 43, 47], ["disability", "DISEASE", 48, 58], ["anterior cingulate cortex", "MULTI-TISSUE_STRUCTURE", 168, 193], ["ACC", "CANCER", 195, 198], ["pain", "PROBLEM", 24, 28], ["functional pain disability", "PROBLEM", 32, 58], ["a trend of reduction in the anterior cingulate cortex (ACC) gray matter volume", "PROBLEM", 140, 218], ["reduction", "OBSERVATION_MODIFIER", 151, 160], ["anterior", "ANATOMY_MODIFIER", 168, 176], ["cingulate cortex", "ANATOMY", 177, 193]]], ["In another brain imaging study, FM patients showed lower ACC connectivity to the bilateral hippocampi, amygdala, brainstem, and rostral ventromedial medulla, which are brain areas involved in the descending inhibitory modulation of pain and increased central nervous system sensitization [57] .", [["brain", "ANATOMY", 11, 16], ["hippocampi", "ANATOMY", 91, 101], ["amygdala", "ANATOMY", 103, 111], ["brainstem", "ANATOMY", 113, 122], ["rostral ventromedial medulla", "ANATOMY", 128, 156], ["brain areas", "ANATOMY", 168, 179], ["central nervous system", "ANATOMY", 251, 273], ["pain", "DISEASE", 232, 236], ["brain", "ORGAN", 11, 16], ["patients", "ORGANISM", 35, 43], ["ACC", "GENE_OR_GENE_PRODUCT", 57, 60], ["hippocampi", "ORGAN", 91, 101], ["amygdala", "CANCER", 103, 111], ["brainstem", "ORGAN", 113, 122], ["ventromedial medulla", "MULTI-TISSUE_STRUCTURE", 136, 156], ["brain", "ORGAN", 168, 173], ["central nervous system", "ANATOMICAL_SYSTEM", 251, 273], ["patients", "SPECIES", 35, 43], ["another brain imaging study", "TEST", 3, 30], ["lower ACC connectivity to the bilateral hippocampi, amygdala, brainstem, and rostral ventromedial medulla", "PROBLEM", 51, 156], ["pain", "PROBLEM", 232, 236], ["increased central nervous system sensitization", "PROBLEM", 241, 287], ["bilateral", "ANATOMY_MODIFIER", 81, 90], ["hippocampi", "ANATOMY", 91, 101], ["amygdala", "ANATOMY", 103, 111], ["brainstem", "ANATOMY", 113, 122], ["rostral", "ANATOMY_MODIFIER", 128, 135], ["ventromedial", "ANATOMY_MODIFIER", 136, 148], ["medulla", "ANATOMY", 149, 156], ["brain", "ANATOMY", 168, 173], ["descending", "ANATOMY_MODIFIER", 196, 206], ["pain", "OBSERVATION", 232, 236], ["increased", "OBSERVATION_MODIFIER", 241, 250], ["central nervous", "OBSERVATION", 251, 266]]], ["Furthermore, sleep deprivation that has an adverse effect on pain perception and cognitive functioning alters dopamine metabolism (D2 receptor) in the striatum, which merits further study because of this neurotransmitter involvement in sleep/wake mechanisms [58] .Disordered Metabolic FunctionsIncreased overnight sympathetic activity using electrocardiographic methodology is consistent with the notion of circadian autonomic metabolic dysfunction associated with an arousal disturbance during the sleep of patients with FM [59] .Disordered Metabolic FunctionsIn conclusion, the continuing search for biological and behavioral etiological factors has resulted in the absence of a specific triggering event to the onset of symptoms.", [["striatum", "ANATOMY", 151, 159], ["pain", "DISEASE", 61, 65], ["dopamine", "CHEMICAL", 110, 118], ["metabolic dysfunction", "DISEASE", 427, 448], ["dopamine", "CHEMICAL", 110, 118], ["dopamine", "SIMPLE_CHEMICAL", 110, 118], ["D2 receptor", "GENE_OR_GENE_PRODUCT", 131, 142], ["striatum", "MULTI-TISSUE_STRUCTURE", 151, 159], ["patients", "ORGANISM", 508, 516], ["D2 receptor", "PROTEIN", 131, 142], ["patients", "SPECIES", 508, 516], ["sleep deprivation", "PROBLEM", 13, 30], ["an adverse effect", "PROBLEM", 40, 57], ["pain perception", "PROBLEM", 61, 76], ["dopamine metabolism (D2 receptor", "TREATMENT", 110, 142], ["further study", "TEST", 174, 187], ["this neurotransmitter involvement", "PROBLEM", 199, 232], ["Disordered Metabolic Functions", "PROBLEM", 264, 294], ["Increased overnight sympathetic activity", "PROBLEM", 294, 334], ["electrocardiographic methodology", "TEST", 341, 373], ["circadian autonomic metabolic dysfunction", "PROBLEM", 407, 448], ["an arousal disturbance", "PROBLEM", 465, 487], ["Disordered Metabolic Functions", "PROBLEM", 531, 561], ["biological and behavioral etiological factors", "PROBLEM", 602, 647], ["symptoms", "PROBLEM", 723, 731], ["striatum", "ANATOMY", 151, 159], ["Metabolic Functions", "OBSERVATION", 275, 294], ["Increased", "OBSERVATION_MODIFIER", 294, 303], ["consistent with", "UNCERTAINTY", 377, 392], ["metabolic dysfunction", "OBSERVATION", 427, 448], ["Metabolic Functions", "OBSERVATION", 542, 561]]], ["This absence of a medically explanatory specific triggering etiological agent has led to the belief in a combined genetic and environmental predisposition to these pain and fatigue syndromes.", [["pain", "DISEASE", 164, 168], ["fatigue", "DISEASE", 173, 180], ["these pain", "PROBLEM", 158, 168], ["fatigue syndromes", "PROBLEM", 173, 190]]], ["Accordingly, a pattern of specific genes may become activated by a variety of noxious triggering influences.", [["noxious triggering influences", "PROBLEM", 78, 107]]], ["Examples include industrial or motor vehicle accidents, psychologically traumatic events (e.g., posttraumatic stress injury), and viral infection with a consequent chronic M.E. or post viral CFS, e.g., post-viral SARS [6] .", [["accidents", "DISEASE", 45, 54], ["traumatic", "DISEASE", 72, 81], ["posttraumatic stress injury", "DISEASE", 96, 123], ["viral infection", "DISEASE", 130, 145], ["CFS", "DISEASE", 191, 194], ["SARS", "DISEASE", 213, 217], ["psychologically traumatic events", "PROBLEM", 56, 88], ["posttraumatic stress injury", "PROBLEM", 96, 123], ["viral infection", "PROBLEM", 130, 145], ["a consequent chronic M.E.", "PROBLEM", 151, 176], ["post viral CFS", "PROBLEM", 180, 194], ["post-viral SARS", "PROBLEM", 202, 217], ["viral", "OBSERVATION_MODIFIER", 130, 135], ["infection", "OBSERVATION", 136, 145], ["chronic", "OBSERVATION_MODIFIER", 164, 171], ["viral CFS", "OBSERVATION", 185, 194]]], ["These potential triggering events may adversely affect the operations of the sleeping/waking brain with associated abnormal metabolic and neurophysiologic functions.", [["brain", "ANATOMY", 93, 98], ["brain", "ORGAN", 93, 98], ["the sleeping/waking brain", "PROBLEM", 73, 98], ["associated abnormal metabolic and neurophysiologic functions", "PROBLEM", 104, 164]]], ["The resulting neurophysiological dysfunctions affect inhibitory and reciprocal excitability sensory operations, which clinically manifest as hypersensitivities to various external noxious stimuli, e.g., application of pressure, loud noise, bright light, or unpleasant odors.", [["The resulting neurophysiological dysfunctions affect inhibitory", "PROBLEM", 0, 63], ["reciprocal excitability sensory operations", "PROBLEM", 68, 110], ["hypersensitivities", "PROBLEM", 141, 159], ["various external noxious stimuli", "TEST", 163, 195], ["pressure", "TEST", 218, 226], ["loud noise", "PROBLEM", 228, 238], ["unpleasant odors", "PROBLEM", 257, 273], ["neurophysiological dysfunctions", "OBSERVATION", 14, 45]]], ["Organ sensory dysfunctions may be affected with reactive hypermotility (e.g., irritable bowel or bladder syndromes).", [["Organ", "ANATOMY", 0, 5], ["bowel", "ANATOMY", 88, 93], ["bladder", "ANATOMY", 97, 104], ["Organ sensory dysfunctions", "DISEASE", 0, 26], ["hypermotility", "DISEASE", 57, 70], ["irritable bowel or bladder syndromes", "DISEASE", 78, 114], ["bowel", "ORGAN", 88, 93], ["bladder", "ORGAN", 97, 104], ["Organ sensory dysfunctions", "PROBLEM", 0, 26], ["reactive hypermotility", "PROBLEM", 48, 70], ["irritable bowel", "PROBLEM", 78, 93], ["bladder syndromes", "PROBLEM", 97, 114], ["sensory dysfunctions", "OBSERVATION", 6, 26], ["may be", "UNCERTAINTY", 27, 33], ["reactive", "OBSERVATION_MODIFIER", 48, 56], ["hypermotility", "OBSERVATION", 57, 70], ["bowel", "ANATOMY", 88, 93], ["bladder", "ANATOMY", 97, 104]]], ["Such clinical experiences may evolve into a psychological distressing pattern of self-perpetuating chronic unrefreshing sleep, widespread pain, fatigue, and psychosocial behavioral problems.", [["pain", "DISEASE", 138, 142], ["fatigue", "DISEASE", 144, 151], ["behavioral problems", "DISEASE", 170, 189], ["a psychological distressing pattern", "PROBLEM", 42, 77], ["chronic unrefreshing sleep", "PROBLEM", 99, 125], ["widespread pain", "PROBLEM", 127, 142], ["fatigue", "PROBLEM", 144, 151], ["psychosocial behavioral problems", "PROBLEM", 157, 189], ["widespread", "OBSERVATION_MODIFIER", 127, 137], ["pain", "OBSERVATION", 138, 142]]], ["In their search for help, those affected (often females) are labeled with diagnoses that reflect the education, special focus of interest, and belief system in particular methods of treatments employed by health professionals in their practices (see Table 48 .1).ManagementCurrently, although no cure is on the horizon, the awareness, research, and improved knowledge of FMS are benefitting the development of methods of management of the illness.ManagementNonspecific sleep and behavioral measures such as sleep hygiene, gentle aerobic fitness, and cognitive behavioral techniques, together with a variety of sleep-promoting sedative, analgesic, and antidepressant remedies are being employed to treat pain symptoms.", [["FMS", "DISEASE", 371, 374], ["antidepressant", "CHEMICAL", 651, 665], ["pain", "DISEASE", 703, 707], ["management", "TREATMENT", 421, 431], ["the illness", "PROBLEM", 435, 446], ["Management", "TREATMENT", 447, 457], ["Nonspecific sleep", "PROBLEM", 457, 474], ["behavioral measures", "TREATMENT", 479, 498], ["sleep hygiene", "TREATMENT", 507, 520], ["gentle aerobic fitness", "TREATMENT", 522, 544], ["cognitive behavioral techniques", "TREATMENT", 550, 581], ["promoting sedative", "TREATMENT", 616, 634], ["analgesic", "TREATMENT", 636, 645], ["antidepressant remedies", "TREATMENT", 651, 674], ["pain symptoms", "PROBLEM", 703, 716], ["no", "UNCERTAINTY", 293, 295]]], ["These include reports of experimental trials of medications, various remedies, and behavioral procedures based upon various ideas about mechanisms involved in the promotion of pain and fatigue symptoms.", [["pain", "DISEASE", 176, 180], ["fatigue", "DISEASE", 185, 192], ["medications", "TREATMENT", 48, 59], ["various remedies", "TREATMENT", 61, 77], ["behavioral procedures", "TREATMENT", 83, 104], ["pain", "PROBLEM", 176, 180], ["fatigue symptoms", "PROBLEM", 185, 201]]], ["Some have resulted in the government approval of pharmaceutical agents.", [["pharmaceutical agents", "TREATMENT", 49, 70]]], ["Some have been rejected for a variety of reasons and some are in various phases of experimental trials.", [["experimental trials", "TREATMENT", 83, 102], ["rejected", "OBSERVATION", 15, 23]]], ["These are briefly reviewed below.Approved Neuroregulatory DrugsOver the past several years, three CNS drugs, pregabalin (a drug with anticonvulsant properties), duloxetine, and milnacipran (drugs initially marketed as antidepressants), have been approved for the treatment of FM by the US Food and Drug Administration (FDA).", [["CNS", "ANATOMY", 98, 101], ["pregabalin", "CHEMICAL", 109, 119], ["duloxetine", "CHEMICAL", 161, 171], ["milnacipran", "CHEMICAL", 177, 188], ["antidepressants", "CHEMICAL", 218, 233], ["FM", "DISEASE", 276, 278], ["pregabalin", "CHEMICAL", 109, 119], ["duloxetine", "CHEMICAL", 161, 171], ["milnacipran", "CHEMICAL", 177, 188], ["pregabalin", "SIMPLE_CHEMICAL", 109, 119], ["duloxetine", "SIMPLE_CHEMICAL", 161, 171], ["milnacipran", "SIMPLE_CHEMICAL", 177, 188], ["CNS drugs", "TREATMENT", 98, 107], ["pregabalin", "TREATMENT", 109, 119], ["anticonvulsant properties)", "TREATMENT", 133, 159], ["duloxetine", "TREATMENT", 161, 171], ["milnacipran", "TREATMENT", 177, 188], ["drugs", "TREATMENT", 190, 195], ["antidepressants", "TREATMENT", 218, 233], ["the treatment of FM", "TREATMENT", 259, 278]]], ["Pregabalin and duloxetine are approved by Health Canada, but none of these drugs are approved by the European Medicines Agency.", [["Pregabalin", "CHEMICAL", 0, 10], ["duloxetine", "CHEMICAL", 15, 25], ["Pregabalin", "CHEMICAL", 0, 10], ["duloxetine", "CHEMICAL", 15, 25], ["Pregabalin", "SIMPLE_CHEMICAL", 0, 10], ["duloxetine", "SIMPLE_CHEMICAL", 15, 25], ["Pregabalin", "TREATMENT", 0, 10], ["duloxetine", "TREATMENT", 15, 25], ["these drugs", "TREATMENT", 69, 80]]], ["The neurotransmitter modulatory agent pregabalin, which is an alpha 2 -delta ligand that causes increased cellular expression of calcium channels, reduces the expression of SP and noradrenaline.", [["cellular", "ANATOMY", 106, 114], ["pregabalin", "CHEMICAL", 38, 48], ["calcium", "CHEMICAL", 129, 136], ["noradrenaline", "CHEMICAL", 180, 193], ["pregabalin", "CHEMICAL", 38, 48], ["calcium", "CHEMICAL", 129, 136], ["noradrenaline", "CHEMICAL", 180, 193], ["pregabalin", "SIMPLE_CHEMICAL", 38, 48], ["alpha 2 -delta", "GENE_OR_GENE_PRODUCT", 62, 76], ["cellular", "CELL", 106, 114], ["calcium", "SIMPLE_CHEMICAL", 129, 136], ["SP", "GENE_OR_GENE_PRODUCT", 173, 175], ["noradrenaline", "SIMPLE_CHEMICAL", 180, 193], ["alpha 2 -delta ligand", "PROTEIN", 62, 83], ["calcium channels", "PROTEIN", 129, 145], ["SP", "PROTEIN", 173, 175], ["The neurotransmitter modulatory agent pregabalin", "TREATMENT", 0, 48], ["increased cellular expression of calcium channels", "PROBLEM", 96, 145], ["SP and noradrenaline", "TREATMENT", 173, 193], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["cellular expression", "OBSERVATION", 106, 125], ["calcium channels", "OBSERVATION", 129, 145]]], ["Studies show that this drug improves the pain, quality of sleep, and fatigue in FMS.", [["pain", "DISEASE", 41, 45], ["fatigue", "DISEASE", 69, 76], ["FMS", "DISEASE", 80, 83], ["Studies", "TEST", 0, 7], ["the pain", "PROBLEM", 37, 45], ["quality of sleep", "PROBLEM", 47, 63], ["fatigue in FMS", "PROBLEM", 69, 83]]], ["Duloxetine and milnacipran are noradrenaline-serotonin reuptake inhibitors, which are known to be helpful in improving mood and also benefit pain and sleep in animal studies and neuropathic pain in humans.Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsA US multicenter randomized placebo-controlled 8-week trial (RCT) with sodium oxybate given in a 4.5-or 6-g qhs dose improved sleep physiology with reduced percent CAP A2/A3 rate and increased SWS in addition to improvement of the self ratings of quality of sleep and reduction of pain and fatigue in FMS patients [24] .Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsA meta-analysis of five RCT trials with 10-40 mg cyclobenzaprine, given at variable times during the day, showed an overall global improvement in FM, a short-term modest improvement in pain, moderate improvement in sleep, and no improvement in fatigue or tender points.", [["Duloxetine", "CHEMICAL", 0, 10], ["milnacipran", "CHEMICAL", 15, 26], ["noradrenaline", "CHEMICAL", 31, 44], ["serotonin", "CHEMICAL", 45, 54], ["pain", "DISEASE", 141, 145], ["neuropathic pain", "DISEASE", 178, 194], ["sodium oxybate", "CHEMICAL", 348, 362], ["pain", "DISEASE", 558, 562], ["fatigue", "DISEASE", 567, 574], ["FMS", "DISEASE", 578, 581], ["cyclobenzaprine", "CHEMICAL", 718, 733], ["pain", "DISEASE", 854, 858], ["fatigue", "DISEASE", 913, 920], ["Duloxetine", "CHEMICAL", 0, 10], ["milnacipran", "CHEMICAL", 15, 26], ["noradrenaline", "CHEMICAL", 31, 44], ["serotonin", "CHEMICAL", 45, 54], ["sodium oxybate", "CHEMICAL", 348, 362], ["cyclobenzaprine", "CHEMICAL", 718, 733], ["Duloxetine", "SIMPLE_CHEMICAL", 0, 10], ["milnacipran", "SIMPLE_CHEMICAL", 15, 26], ["noradrenaline-serotonin", "SIMPLE_CHEMICAL", 31, 54], ["humans", "ORGANISM", 198, 204], ["sodium oxybate", "SIMPLE_CHEMICAL", 348, 362], ["patients", "ORGANISM", 582, 590], ["cyclobenzaprine", "SIMPLE_CHEMICAL", 718, 733], ["humans", "SPECIES", 198, 204], ["patients", "SPECIES", 582, 590], ["humans", "SPECIES", 198, 204], ["Duloxetine", "TREATMENT", 0, 10], ["milnacipran", "TREATMENT", 15, 26], ["noradrenaline", "TREATMENT", 31, 44], ["serotonin reuptake inhibitors", "TREATMENT", 45, 74], ["benefit pain", "PROBLEM", 133, 145], ["animal studies", "TEST", 159, 173], ["neuropathic pain in humans", "PROBLEM", 178, 204], ["Neuroregulatory Medicinal AgentsA", "TREATMENT", 245, 278], ["multicenter randomized placebo", "TREATMENT", 282, 312], ["sodium oxybate", "TREATMENT", 348, 362], ["sleep physiology", "PROBLEM", 403, 419], ["reduced percent CAP A2/A3 rate", "PROBLEM", 425, 455], ["increased SWS", "PROBLEM", 460, 473], ["pain", "PROBLEM", 558, 562], ["fatigue in FMS", "PROBLEM", 567, 581], ["Neuroregulatory Medicinal", "TREATMENT", 637, 662], ["five RCT trials", "TREATMENT", 688, 703], ["cyclobenzaprine", "TREATMENT", 718, 733], ["pain", "PROBLEM", 854, 858], ["fatigue", "PROBLEM", 913, 920], ["tender points", "PROBLEM", 924, 937], ["neuropathic", "OBSERVATION_MODIFIER", 178, 189], ["pain", "OBSERVATION", 190, 194], ["overall", "OBSERVATION_MODIFIER", 785, 792], ["global", "OBSERVATION_MODIFIER", 793, 799], ["improvement", "OBSERVATION_MODIFIER", 800, 811], ["pain", "OBSERVATION", 854, 858], ["moderate", "OBSERVATION_MODIFIER", 860, 868], ["improvement", "OBSERVATION_MODIFIER", 869, 880], ["no", "UNCERTAINTY", 895, 897], ["improvement", "OBSERVATION_MODIFIER", 898, 909], ["tender", "OBSERVATION_MODIFIER", 924, 930]]], ["However, 85 % of patients experienced untoward effects, commonly drowsiness, dizziness, and dry mouth [60] .", [["dizziness", "DISEASE", 77, 86], ["dry mouth", "DISEASE", 92, 101], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["untoward effects", "PROBLEM", 38, 54], ["commonly drowsiness", "PROBLEM", 56, 75], ["dizziness", "PROBLEM", 77, 86], ["dry mouth", "PROBLEM", 92, 101]]], ["A recent two-site RCT of 1-4 mg cyclobenzaprine at bedtime (mean dose of about 3 mg) showed improved pain, tenderness, depression, and sleep quality or sleep stability as measured with sleep EEG CAP.", [["cyclobenzaprine", "CHEMICAL", 32, 47], ["pain", "DISEASE", 101, 105], ["tenderness", "DISEASE", 107, 117], ["depression", "DISEASE", 119, 129], ["cyclobenzaprine", "CHEMICAL", 32, 47], ["cyclobenzaprine", "SIMPLE_CHEMICAL", 32, 47], ["cyclobenzaprine", "TREATMENT", 32, 47], ["improved pain", "PROBLEM", 92, 105], ["tenderness", "PROBLEM", 107, 117], ["depression", "PROBLEM", 119, 129], ["sleep quality", "PROBLEM", 135, 148], ["sleep stability", "PROBLEM", 152, 167], ["sleep EEG CAP", "PROBLEM", 185, 198], ["tenderness", "OBSERVATION", 107, 117], ["depression", "OBSERVATION", 119, 129]]], ["More subjects taking the low dose of cyclobenzaprine versus the placebo group had more nights of restorative sleep which was accompanied by improved fatigue and depression [25] .This drug is under further FDA development.Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsSome effort has been directed to remedying aspects of abnormal neuroendocrine function, e.g., about one third of patients with low levels of insulin-like growth factor 1 (IGF-1), a surrogate marker for low GH secretion, have been treated with daily injections of GH.", [["neuroendocrine", "ANATOMY", 356, 370], ["cyclobenzaprine", "CHEMICAL", 37, 52], ["fatigue", "DISEASE", 149, 156], ["depression", "DISEASE", 161, 171], ["cyclobenzaprine", "CHEMICAL", 37, 52], ["cyclobenzaprine", "SIMPLE_CHEMICAL", 37, 52], ["neuroendocrine", "ANATOMICAL_SYSTEM", 356, 370], ["patients", "ORGANISM", 406, 414], ["insulin-like growth factor 1", "GENE_OR_GENE_PRODUCT", 434, 462], ["IGF-1", "GENE_OR_GENE_PRODUCT", 464, 469], ["GH", "GENE_OR_GENE_PRODUCT", 499, 501], ["GH", "GENE_OR_GENE_PRODUCT", 556, 558], ["insulin-like growth factor 1", "PROTEIN", 434, 462], ["IGF", "PROTEIN", 464, 467], ["patients", "SPECIES", 406, 414], ["cyclobenzaprine", "TREATMENT", 37, 52], ["the placebo group", "TREATMENT", 60, 77], ["restorative sleep", "PROBLEM", 97, 114], ["improved fatigue", "PROBLEM", 140, 156], ["depression", "PROBLEM", 161, 171], ["Neuroregulatory Medicinal Agents", "TREATMENT", 261, 293], ["abnormal neuroendocrine function", "PROBLEM", 347, 379], ["low levels of insulin", "PROBLEM", 420, 441], ["IGF", "TEST", 464, 467], ["a surrogate marker", "TEST", 472, 490], ["low GH secretion", "PROBLEM", 495, 511], ["daily injections of GH", "TREATMENT", 536, 558], ["neuroendocrine function", "OBSERVATION", 356, 379]]], ["In a 9-month randomized, placebo-controlled, double-blind study, there was an increase in IGF-1, and a reduction in pain and tenderness.", [["pain", "DISEASE", 116, 120], ["tenderness", "DISEASE", 125, 135], ["IGF-1", "GENE_OR_GENE_PRODUCT", 90, 95], ["IGF", "PROTEIN", 90, 93], ["placebo", "TREATMENT", 25, 32], ["double-blind study", "TEST", 45, 63], ["an increase in IGF", "PROBLEM", 75, 93], ["a reduction in pain", "PROBLEM", 101, 120], ["tenderness", "PROBLEM", 125, 135], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["reduction", "OBSERVATION_MODIFIER", 103, 112], ["pain", "OBSERVATION", 116, 120], ["tenderness", "OBSERVATION", 125, 135]]], ["On the other hand, GH, which is reduced in patients with FMS, improved symptoms, but its high cost and the need for daily injections make its use impractical [61] .Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsA single non-RCT of pramipexole, a dopamine agonist, is reported to be helpful for pain, fatigue, and overall function in a subset of FMS patients, half of whom were also taking narcotics [62] .Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsNo consistent abnormalities have been reported in the secretion of melatonin in patients with either CFS or FMS, nor has its administration been found to be useful in controlled studies [63] .", [["FMS", "DISEASE", 57, 60], ["pramipexole", "CHEMICAL", 256, 267], ["dopamine", "CHEMICAL", 271, 279], ["pain", "DISEASE", 319, 323], ["fatigue", "DISEASE", 325, 332], ["FMS", "DISEASE", 370, 373], ["melatonin", "CHEMICAL", 569, 578], ["CFS", "DISEASE", 603, 606], ["FMS", "DISEASE", 610, 613], ["pramipexole", "CHEMICAL", 256, 267], ["dopamine", "CHEMICAL", 271, 279], ["narcotics", "CHEMICAL", 414, 423], ["melatonin", "CHEMICAL", 569, 578], ["GH", "GENE_OR_GENE_PRODUCT", 19, 21], ["patients", "ORGANISM", 43, 51], ["pramipexole", "SIMPLE_CHEMICAL", 256, 267], ["dopamine", "SIMPLE_CHEMICAL", 271, 279], ["patients", "ORGANISM", 374, 382], ["melatonin", "SIMPLE_CHEMICAL", 569, 578], ["patients", "ORGANISM", 582, 590], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 374, 382], ["patients", "SPECIES", 582, 590], ["FMS", "PROBLEM", 57, 60], ["improved symptoms", "PROBLEM", 62, 79], ["its high cost", "PROBLEM", 85, 98], ["daily injections", "TREATMENT", 116, 132], ["Neuroregulatory Medicinal Agents", "TREATMENT", 204, 236], ["pramipexole", "TREATMENT", 256, 267], ["a dopamine agonist", "TREATMENT", 269, 287], ["pain", "PROBLEM", 319, 323], ["fatigue", "PROBLEM", 325, 332], ["narcotics", "TREATMENT", 414, 423], ["Neuroregulatory Medicinal Agents", "TREATMENT", 470, 502], ["consistent abnormalities", "PROBLEM", 505, 529], ["CFS or FMS", "PROBLEM", 603, 613], ["reduced", "OBSERVATION_MODIFIER", 32, 39], ["abnormalities", "OBSERVATION", 516, 529]]], ["Furthermore, the use of morning bright light treatment, which tends to modify the timing of the nocturnal secretion of melatonin and is helpful in seasonal affective disorder, does not benefit sleep, pain, or mood symptoms in patients with FMS [64] .Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsFinally, patients with primary sleep disorders such as restless legs/PLM disorder and sleep apnea have not as yet been subject to RCT for pain and fatigue with the well-established remedies for such conditions.", [["legs", "ANATOMY", 386, 390], ["melatonin", "CHEMICAL", 119, 128], ["affective disorder", "DISEASE", 156, 174], ["pain", "DISEASE", 200, 204], ["mood symptoms", "DISEASE", 209, 222], ["FMS", "DISEASE", 240, 243], ["primary sleep disorders", "DISEASE", 345, 368], ["restless legs/PLM disorder", "DISEASE", 377, 403], ["sleep apnea", "DISEASE", 408, 419], ["pain", "DISEASE", 460, 464], ["fatigue", "DISEASE", 469, 476], ["melatonin", "CHEMICAL", 119, 128], ["melatonin", "SIMPLE_CHEMICAL", 119, 128], ["patients", "ORGANISM", 226, 234], ["patients", "ORGANISM", 331, 339], ["legs", "ORGANISM_SUBDIVISION", 386, 390], ["patients", "SPECIES", 226, 234], ["patients", "SPECIES", 331, 339], ["morning bright light treatment", "TREATMENT", 24, 54], ["the nocturnal secretion of melatonin", "TREATMENT", 92, 128], ["seasonal affective disorder", "PROBLEM", 147, 174], ["pain", "PROBLEM", 200, 204], ["mood symptoms", "PROBLEM", 209, 222], ["Neuroregulatory Medicinal Agents", "TREATMENT", 290, 322], ["primary sleep disorders", "PROBLEM", 345, 368], ["restless legs", "PROBLEM", 377, 390], ["PLM disorder", "PROBLEM", 391, 403], ["sleep apnea", "PROBLEM", 408, 419], ["pain", "PROBLEM", 460, 464], ["fatigue", "PROBLEM", 469, 476], ["such conditions", "PROBLEM", 516, 531], ["PLM", "ANATOMY", 391, 394]]], ["In particular, a further study of pramipexole (and similar dopamine agonist) is required to determine whether the improvement noted in some patients [62] may be related to the reduction in restless legs/PLM sleep disorder that occur in some patients.Unapproved Randomized Control Trials of Neuroregulatory Medicinal AgentsIn conclusion, advances in our scientific understanding of how the sleeping-waking brain is intimately connected to the widespread musculoskeletal pain, fatigue, and psychologically distressing symptoms of previously presumed to be unexplained medical illnesses, and current advances in medical knowledge is leading to the improved management of the FMS and similar pervasive syndromes with chronic unrefreshing sleep, diffuse myalgia, fatigue, and psychological distress.", [["legs", "ANATOMY", 198, 202], ["brain", "ANATOMY", 405, 410], ["musculoskeletal", "ANATOMY", 453, 468], ["pramipexole", "CHEMICAL", 34, 45], ["dopamine", "CHEMICAL", 59, 67], ["sleep disorder", "DISEASE", 207, 221], ["musculoskeletal pain", "DISEASE", 453, 473], ["fatigue", "DISEASE", 475, 482], ["FMS", "DISEASE", 672, 675], ["chronic unrefreshing sleep", "DISEASE", 713, 739], ["myalgia", "DISEASE", 749, 756], ["fatigue", "DISEASE", 758, 765], ["psychological distress", "DISEASE", 771, 793], ["pramipexole", "CHEMICAL", 34, 45], ["dopamine", "CHEMICAL", 59, 67], ["pramipexole", "SIMPLE_CHEMICAL", 34, 45], ["dopamine", "SIMPLE_CHEMICAL", 59, 67], ["patients", "ORGANISM", 140, 148], ["legs", "ORGANISM_SUBDIVISION", 198, 202], ["patients", "ORGANISM", 241, 249], ["brain", "ORGAN", 405, 410], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 241, 249], ["a further study", "TEST", 15, 30], ["pramipexole", "TREATMENT", 34, 45], ["similar dopamine agonist", "TREATMENT", 51, 75], ["the reduction in restless legs", "PROBLEM", 172, 202], ["PLM sleep disorder", "PROBLEM", 203, 221], ["Neuroregulatory Medicinal Agents", "TREATMENT", 290, 322], ["the widespread musculoskeletal pain", "PROBLEM", 438, 473], ["fatigue", "PROBLEM", 475, 482], ["psychologically distressing symptoms", "PROBLEM", 488, 524], ["unexplained medical illnesses", "PROBLEM", 554, 583], ["the FMS", "PROBLEM", 668, 675], ["similar pervasive syndromes", "PROBLEM", 680, 707], ["chronic unrefreshing sleep", "PROBLEM", 713, 739], ["diffuse myalgia", "PROBLEM", 741, 756], ["fatigue", "PROBLEM", 758, 765], ["psychological distress", "PROBLEM", 771, 793], ["reduction", "OBSERVATION_MODIFIER", 176, 185], ["legs", "ANATOMY", 198, 202], ["PLM sleep", "OBSERVATION", 203, 212], ["musculoskeletal", "ANATOMY", 453, 468], ["pain", "OBSERVATION", 469, 473], ["chronic", "OBSERVATION_MODIFIER", 713, 720], ["diffuse", "OBSERVATION_MODIFIER", 741, 748], ["myalgia", "OBSERVATION", 749, 756]]]], "be3bdfa49d9808a8800adec9f9a02108d43defd3": [["IntroductionProtein interaction plays essential role in cell structure and function.", [["cell", "ANATOMY", 56, 60], ["cell", "CELL", 56, 60], ["cell structure", "OBSERVATION", 56, 70]]], ["In a simpli fi ed diagram of a signaling pathway, upon interaction of a ligand, the receptor alters its conformation, such as dimerization, phosphorylation, and ubiquitination, leading to recruitment of intracellular molecules and subsequent activation of downstream signal cascades.", [["intracellular", "ANATOMY", 203, 216], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 203, 216], ["intracellular molecules", "PROTEIN", 203, 226], ["phosphorylation", "TREATMENT", 140, 155], ["ubiquitination", "PROBLEM", 161, 175], ["intracellular molecules", "PROBLEM", 203, 226], ["downstream signal cascades", "PROBLEM", 256, 282]]], ["Each level of the signaling cascades requires protein interaction to work as a well-assembled, multifunctional protein complex essential for signal transduction.", [["multifunctional protein complex", "PROTEIN", 95, 126], ["signal transduction", "TREATMENT", 141, 160]]], ["The functionality of proteins relies on their ability to interact with one another, whereas pathogenic conditions can re fl ect the perturbations of these protein interactions.IntroductionNumerous protein-protein interaction (PPI) methods have been developed, but only a few of them are used for large-scale PPI detection, including yeast twohybrid (YTH), protein fragment complementation assay (PCA), luciferase-mediated interactome (LUMIER), mammalian protein-protein interaction trap (MAPPIT), protein array, and af fi nity puri fi cation coupled with tandem mass spectrometry (AP-MS).", [["luciferase", "GENE_OR_GENE_PRODUCT", 402, 412], ["YTH", "PROTEIN", 350, 353], ["luciferase", "PROTEIN", 402, 412], ["mammalian protein-protein interaction trap", "PROTEIN", 444, 486], ["MAPPIT", "PROTEIN", 488, 494], ["yeast", "SPECIES", 333, 338], ["yeast", "SPECIES", 333, 338], ["pathogenic conditions", "PROBLEM", 92, 113], ["these protein interactions", "PROBLEM", 149, 175], ["Numerous protein-protein interaction (PPI) methods", "TREATMENT", 188, 238], ["large-scale PPI detection", "TREATMENT", 296, 321], ["yeast twohybrid (YTH)", "PROBLEM", 333, 354], ["protein fragment complementation assay", "TEST", 356, 394], ["PCA", "TEST", 396, 399], ["luciferase", "TEST", 402, 412], ["mammalian protein", "TEST", 444, 461], ["MAPPIT", "TEST", 488, 494], ["protein array", "TEST", 497, 510], ["af fi", "TEST", 516, 521], ["tandem mass spectrometry", "PROBLEM", 555, 579]]], ["The YTH system is the fi rst assay for analysis of large-scale protein-protein interactions and widely accepted method (Fields and Song 1989 ) .", [["analysis", "TEST", 39, 47], ["large", "OBSERVATION_MODIFIER", 51, 56]]], ["In YTH system, interested gene (bait, X) is fused to the DNA-binding (DB) domain of a transcription factor such as Gal4 (DB-X), while the interacting protein (prey, Y) is fused to an activation domain (AD) such as Gal4-AD (AD-Y).", [["bait, X)", "GENE_OR_GENE_PRODUCT", 32, 40], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["Gal4", "GENE_OR_GENE_PRODUCT", 115, 119], ["DB-X", "GENE_OR_GENE_PRODUCT", 121, 125], ["prey, Y)", "GENE_OR_GENE_PRODUCT", 159, 167], ["Gal4", "GENE_OR_GENE_PRODUCT", 214, 218], ["AD-Y", "GENE_OR_GENE_PRODUCT", 223, 227], ["YTH", "PROTEIN", 3, 6], ["X", "DNA", 38, 39], ["DNA-binding (DB) domain", "PROTEIN", 57, 80], ["transcription factor", "PROTEIN", 86, 106], ["Gal4", "PROTEIN", 115, 119], ["DB", "PROTEIN", 121, 123], ["X", "PROTEIN", 124, 125], ["interacting protein", "PROTEIN", 138, 157], ["prey, Y)", "PROTEIN", 159, 167], ["activation domain", "PROTEIN", 183, 200], ["AD", "PROTEIN", 202, 204], ["Gal4", "PROTEIN", 214, 218], ["AD", "PROTEIN", 219, 221], ["AD", "PROTEIN", 223, 225], ["Y", "PROTEIN", 226, 227], ["a transcription factor", "PROBLEM", 84, 106], ["Gal4 (DB-X)", "TREATMENT", 115, 126], ["an activation domain", "PROBLEM", 180, 200]]], ["Physical interaction between X and Y brings AD and DB together, which reconstitutes the transcription factor and subsequently activates the downstream reporter genes (Fields and Song 1989 ) .", [["AD", "DISEASE", 44, 46], ["X", "CELLULAR_COMPONENT", 29, 30], ["AD", "GENE_OR_GENE_PRODUCT", 44, 46], ["X", "DNA", 29, 30], ["DB", "PROTEIN", 51, 53], ["transcription factor", "PROTEIN", 88, 108], ["downstream reporter genes", "DNA", 140, 165]]], ["Like the YTH, PCA requires that bait and prey are each fused with incomplete fragments of a third protein, which acts as a reporter.", [["YTH", "PROTEIN", 9, 12], ["incomplete fragments", "PROBLEM", 66, 86], ["a third protein", "TREATMENT", 90, 105]]], ["Interaction between bait and prey proteins brings the fragments of reporter protein in close enough proximity to allow them to form a functional reporter protein (Rossi et al. 1997 ) .", [["bait and prey proteins", "PROTEIN", 20, 42], ["reporter protein", "PROTEIN", 67, 83], ["functional reporter protein", "PROTEIN", 134, 161], ["bait and prey proteins", "TREATMENT", 20, 42], ["reporter protein", "TREATMENT", 67, 83]]], ["When fl uorescent proteins are reconstituted, the PCA is called bimolecular fl uorescence complementation assay (Kerppola 2009 ) .", [["fl uorescent proteins", "GENE_OR_GENE_PRODUCT", 5, 26], ["fl uorescent proteins", "PROTEIN", 5, 26], ["fl uorescent proteins", "TREATMENT", 5, 26]]], ["LUMIER is basically a co-immunoprecipitation assay, in which bait is linked to an epitope for puri fi cation and prey protein is fused to renilla or fi re fl y luciferase for detection (Barrios-Rodiles et al. 2005 ) .", [["puri fi cation", "GENE_OR_GENE_PRODUCT", 94, 108], ["renilla", "GENE_OR_GENE_PRODUCT", 138, 145], ["luciferase", "GENE_OR_GENE_PRODUCT", 160, 170], ["LUMIER", "PROTEIN", 0, 6], ["puri fi cation", "PROTEIN", 94, 108], ["prey protein", "PROTEIN", 113, 125], ["renilla", "PROTEIN", 138, 145], ["luciferase", "PROTEIN", 160, 170], ["a co-immunoprecipitation assay", "TEST", 20, 50], ["an epitope for puri fi cation", "TREATMENT", 79, 108]]], ["In the MAPPIT, bait and prey proteins are linked to signaling de fi cient cytokine receptor chimeras.", [["MAPPIT", "GENE_OR_GENE_PRODUCT", 7, 13], ["MAPPIT", "PROTEIN", 7, 13], ["bait and prey proteins", "PROTEIN", 15, 37], ["fi cient cytokine receptor chimeras", "PROTEIN", 65, 100]]], ["Interaction of bait and prey restores JAK-STAT cascade after the receptor has been stimulated with ligand, which leads to STAT3-dependent reporter gene activation (Eyckerman et al. 2001 ) .", [["JAK", "GENE_OR_GENE_PRODUCT", 38, 41], ["STAT", "GENE_OR_GENE_PRODUCT", 42, 46], ["STAT3", "GENE_OR_GENE_PRODUCT", 122, 127], ["JAK", "PROTEIN", 38, 41], ["STAT", "PROTEIN", 42, 46], ["STAT3", "PROTEIN", 122, 127], ["reporter gene", "DNA", 138, 151]]], ["Protein microarray is a microscopic array glass slide on which interested proteins have been af fi xed at separate locations in an ordered manner using a variety of available chemical linkers (MacBeath 2002 ) .", [["Protein microarray", "TEST", 0, 18], ["a microscopic array glass slide", "TEST", 22, 53], ["available chemical linkers", "TREATMENT", 165, 191]]], ["Protein microarrays are typically high-density arrays that are used to identify novel proteins or protein-protein interactions.", [["Protein microarrays", "TEST", 0, 19], ["typically high-density arrays", "PROBLEM", 24, 53], ["novel proteins", "PROBLEM", 80, 94], ["protein-protein interactions", "PROBLEM", 98, 126], ["density arrays", "OBSERVATION_MODIFIER", 39, 53]]], ["Antibody microarrays are the most common analytical microarray.IntroductionAP-MS is biochemical puri fi cation of protein complexes followed by characterization of their components by mass spectrometry.", [["puri fi cation", "SIMPLE_CHEMICAL", 96, 110], ["protein complexes", "PROTEIN", 114, 131], ["Antibody microarrays", "TEST", 0, 20], ["protein complexes", "PROBLEM", 114, 131], ["mass spectrometry", "PROBLEM", 184, 201], ["mass spectrometry", "OBSERVATION", 184, 201]]], ["Instead, AP-MS detects multi-protein complexes.", [["multi-protein complexes", "PROTEIN", 23, 46], ["multi-protein complexes", "OBSERVATION", 23, 46]]], ["Various tags have been developed, such as FLAG tag, HA tag, glutathione S-transferase (GST) tags, the calmodulin-binding peptide, the streptavidin-binding peptide, or the in vivo biotinylation of the target tagged peptide using coexpression of the BirA ligase (Waugh 2005 ) .", [["glutathione", "CHEMICAL", 60, 71], ["glutathione", "CHEMICAL", 60, 71], ["FLAG", "GENE_OR_GENE_PRODUCT", 42, 46], ["HA tag", "GENE_OR_GENE_PRODUCT", 52, 58], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 60, 85], ["GST", "GENE_OR_GENE_PRODUCT", 87, 90], ["calmodulin", "GENE_OR_GENE_PRODUCT", 102, 112], ["streptavidin", "SIMPLE_CHEMICAL", 134, 146], ["BirA", "GENE_OR_GENE_PRODUCT", 248, 252], ["FLAG tag", "DNA", 42, 50], ["HA tag", "PROTEIN", 52, 58], ["glutathione S-transferase", "PROTEIN", 60, 85], ["GST", "PROTEIN", 87, 90], ["calmodulin", "PROTEIN", 102, 112], ["BirA ligase", "PROTEIN", 248, 259], ["Various tags", "TEST", 0, 12], ["FLAG tag", "TEST", 42, 50], ["HA tag", "TEST", 52, 58], ["glutathione S-transferase (GST) tags", "TEST", 60, 96], ["the calmodulin-binding peptide", "PROBLEM", 98, 128], ["the streptavidin-binding peptide", "TREATMENT", 130, 162]]], ["With af fi nity tag, protein complexes are enriched fi rst by af fi nity puri fi cation.", [["protein complexes", "PROTEIN", 21, 38]]], ["One early developed AP-MS is to use the tandem af fi nity puri fi cation (TAP) tag (Puig et al. 2001 ) .", [["TAP", "PROTEIN", 74, 77], ["the tandem af fi nity puri fi cation (TAP) tag", "TREATMENT", 36, 82]]], ["The original TAP tag is composed of a protein A tag and a calmodulin-binding peptide for two sequential enrichment puri fi cations.", [["calmodulin", "CHEMICAL", 58, 68], ["TAP", "GENE_OR_GENE_PRODUCT", 13, 16], ["calmodulin", "SIMPLE_CHEMICAL", 58, 68], ["puri fi cations", "SIMPLE_CHEMICAL", 115, 130], ["TAP tag", "PROTEIN", 13, 20], ["protein A tag", "PROTEIN", 38, 51], ["calmodulin", "PROTEIN", 58, 68], ["The original TAP tag", "TREATMENT", 0, 20], ["a protein A tag", "TREATMENT", 36, 51], ["a calmodulin-binding peptide", "TREATMENT", 56, 84], ["two sequential enrichment puri fi cations", "TREATMENT", 89, 130], ["TAP tag", "OBSERVATION", 13, 20]]], ["In the fi rst puri fi cation step, the protein complex is isolated from the cell lysate using immunoglobulin gamma (IgG) resin with high protein A af fi nity.", [["cell lysate", "ANATOMY", 76, 87], ["cell lysate", "ORGANISM_SUBSTANCE", 76, 87], ["immunoglobulin gamma", "GENE_OR_GENE_PRODUCT", 94, 114], ["IgG", "GENE_OR_GENE_PRODUCT", 116, 119], ["protein complex", "PROTEIN", 39, 54], ["immunoglobulin gamma", "PROTEIN", 94, 114], ["IgG", "PROTEIN", 116, 119], ["protein A af fi nity", "PROTEIN", 137, 157], ["the protein complex", "PROBLEM", 35, 54], ["the cell lysate", "TEST", 72, 87], ["immunoglobulin gamma (IgG) resin", "TREATMENT", 94, 126]]], ["After protein complex is cleaved from the protein A tag with TEV protease, the eluate undergoes second puri fi cation on an immobilized calmodulin column.IntroductionTo date, AP-MS has been performed in combination with other techniques, such as biochemical fractionation and chemical cross-linking, for characterization of protein complex.", [["TEV protease", "GENE_OR_GENE_PRODUCT", 61, 73], ["puri fi cation", "SIMPLE_CHEMICAL", 103, 117], ["calmodulin", "GENE_OR_GENE_PRODUCT", 136, 146], ["protein complex", "PROTEIN", 6, 21], ["protein A tag", "PROTEIN", 42, 55], ["TEV protease", "PROTEIN", 61, 73], ["protein complex", "PROTEIN", 324, 339], ["protein complex", "PROBLEM", 6, 21], ["TEV protease", "TREATMENT", 61, 73], ["second puri fi cation", "TREATMENT", 96, 117], ["an immobilized calmodulin column", "TREATMENT", 121, 153], ["biochemical fractionation", "TREATMENT", 246, 271], ["chemical cross-linking", "TREATMENT", 276, 298], ["protein complex", "PROBLEM", 324, 339], ["immobilized calmodulin column", "OBSERVATION", 124, 153]]], ["Combining biochemical fractionations, like size fractionation, with AP-MS can provide a more precise characterization of multi-protein complexes according to the factions.", [["multi-protein complexes", "PROTEIN", 121, 144], ["Combining biochemical fractionations", "PROBLEM", 0, 36], ["size fractionation", "TREATMENT", 43, 61], ["multi-protein complexes", "PROBLEM", 121, 144], ["biochemical fractionations", "OBSERVATION", 10, 36], ["size", "OBSERVATION_MODIFIER", 43, 47], ["fractionation", "OBSERVATION_MODIFIER", 48, 61]]], ["For example, a combination of TAP puri fi cation with standard gel fi ltration has allowed for a better characterization of RNA polymerase II complex (Mueller and Jaehning 2002 ) .", [["TAP puri fi cation", "SIMPLE_CHEMICAL", 30, 48], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 124, 141], ["TAP", "PROTEIN", 30, 33], ["RNA polymerase II complex", "PROTEIN", 124, 149], ["TAP puri fi cation", "TREATMENT", 30, 48], ["standard gel fi ltration", "TREATMENT", 54, 78]]], ["Crosslinker is used for detecting weak interactions, such as membrane complex, which may be interrupted by detergents in lysis buffer.", [["membrane", "ANATOMY", 61, 69], ["membrane", "CELLULAR_COMPONENT", 61, 69], ["membrane complex", "PROTEIN", 61, 77], ["weak interactions", "PROBLEM", 34, 51], ["lysis buffer", "TREATMENT", 121, 133]]], ["A combination of TAP with in vivo cross-linking with formaldehyde was used to identify novel proteasome interactors (Tagwerker et al. 2006 ) .", [["formaldehyde", "CHEMICAL", 53, 65], ["formaldehyde", "CHEMICAL", 53, 65], ["TAP", "GENE_OR_GENE_PRODUCT", 17, 20], ["formaldehyde", "SIMPLE_CHEMICAL", 53, 65], ["TAP", "PROTEIN", 17, 20], ["proteasome interactors", "PROTEIN", 93, 115], ["TAP", "TREATMENT", 17, 20], ["formaldehyde", "TREATMENT", 53, 65], ["TAP", "OBSERVATION", 17, 20]]], ["AP-MS can also be combined with quantitative proteomics approaches, such as SILAC and ICAT, to better understand the dynamics of protein complex assembly.", [["protein complex", "PROTEIN", 129, 144], ["SILAC and ICAT", "TREATMENT", 76, 90]]], ["Stable isotope labeling by amino acids in cell culture (SILAC) is an approach for in vivo incorporation of a label into proteins for mass spectrometry (MS)-based quantitative proteomics (Ong et al. 2002 ) .", [["cell culture", "ANATOMY", 42, 54], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "AMINO_ACID", 27, 38], ["cell culture", "CELL", 42, 54], ["amino acids", "TEST", 27, 38], ["cell culture", "TEST", 42, 54], ["mass spectrometry", "PROBLEM", 133, 150], ["isotope", "OBSERVATION", 7, 14]]], ["Isotope-coded af fi nity tags (ICAT) are complementary to SILAC and measure dynamic changes in complexes isolated from tissues or organisms that cannot be metabolically labeled (Gygi et al. 1999 ) .", [["tissues", "ANATOMY", 119, 126], ["tissues", "TISSUE", 119, 126], ["Isotope", "TEST", 0, 7], ["SILAC", "TEST", 58, 63], ["dynamic changes in complexes", "PROBLEM", 76, 104], ["organisms", "PROBLEM", 130, 139]]], ["Both entail labeling the samples with isotope labels that allow the mass spectrometer to distinguish between identical proteins in separate samples.", [["samples", "ANATOMY", 25, 32], ["samples", "ANATOMY", 140, 147], ["isotope labels", "TREATMENT", 38, 52], ["the mass spectrometer", "TEST", 64, 85]]], ["Differentially labeled samples are combined and analyzed together, and the differences in the peak intensities of the isotope pairs accurately re fl ect difference in the abundance of the corresponding proteins.IntroductionGiven the fundamental importance of protein interactions, systematically mapping protein-protein interaction (PPI) in various species has dramatically increased in recent years.", [["samples", "ANATOMY", 23, 30], ["samples", "CANCER", 23, 30], ["Differentially labeled samples", "TEST", 0, 30], ["the isotope pairs", "PROBLEM", 114, 131], ["protein interactions", "TREATMENT", 259, 279], ["systematically mapping protein-protein interaction (PPI", "TREATMENT", 281, 336], ["various species", "PROBLEM", 341, 356], ["dramatically", "OBSERVATION_MODIFIER", 361, 373], ["increased", "OBSERVATION_MODIFIER", 374, 383]]], ["Using high-throughput YTH, proteome-wide physical interaction maps have been generated for several organisms: Saccharomyces cerevisiae (Fromont-Racine et al. 1997 ; Uetz et al. 2000 ; Ito et al. 2001 ) , Caenorhabditis elegans (Walhout et al. 2000 ; Reboul et al. 2003 ; Li et al. 2004 ) , Drosophila melanogaster (Giot et al. 2003 ; Guruharsha et al. 2011 ) , and human (Guruharsha et al. 2011 ; Rual et al. 2005 ) .", [["Saccharomyces cerevisiae", "ORGANISM", 110, 134], ["Caenorhabditis elegans", "ORGANISM", 204, 226], ["Drosophila melanogaster", "ORGANISM", 290, 313], ["human", "ORGANISM", 365, 370], ["YTH", "PROTEIN", 22, 25], ["Saccharomyces cerevisiae", "SPECIES", 110, 134], ["Caenorhabditis elegans", "SPECIES", 204, 226], ["Drosophila melanogaster", "SPECIES", 290, 313], ["human", "SPECIES", 365, 370], ["Saccharomyces cerevisiae", "SPECIES", 110, 134], ["Caenorhabditis elegans", "SPECIES", 204, 226], ["Drosophila melanogaster", "SPECIES", 290, 313], ["human", "SPECIES", 365, 370], ["proteome", "TEST", 27, 35], ["Saccharomyces cerevisiae", "TREATMENT", 110, 134]]], ["Virus-host protein interactomes were also explored, such as severe acute respiratory syndrome (SARS)-coronavirus (Pfefferle et al. 2011 ) , Kaposi sarcoma herpesvirus (KSHV), and Varicella zoster virus (VZV) (Uetz et al. 2006 ; Rozen et al. 2008 ) .", [["acute respiratory syndrome (SARS)-coronavirus", "DISEASE", 67, 112], ["Kaposi sarcoma herpesvirus", "DISEASE", 140, 166], ["Varicella zoster", "DISEASE", 179, 195], ["Virus", "ORGANISM", 0, 5], ["coronavirus", "ORGANISM", 101, 112], ["Kaposi sarcoma herpesvirus", "ORGANISM", 140, 166], ["KSHV", "ORGANISM", 168, 172], ["Varicella zoster virus", "ORGANISM", 179, 201], ["VZV", "ORGANISM", 203, 206], ["-coronavirus", "SPECIES", 100, 112], ["Kaposi sarcoma herpesvirus", "SPECIES", 140, 166], ["Varicella zoster virus", "SPECIES", 179, 201], ["severe acute respiratory syndrome (SARS)-coronavirus", "SPECIES", 60, 112], ["Kaposi sarcoma herpesvirus", "SPECIES", 140, 166], ["KSHV", "SPECIES", 168, 172], ["Varicella zoster virus", "SPECIES", 179, 201], ["VZV", "SPECIES", 203, 206], ["Virus", "PROBLEM", 0, 5], ["host protein interactomes", "PROBLEM", 6, 31], ["severe acute respiratory syndrome", "PROBLEM", 60, 93], ["SARS)", "PROBLEM", 95, 100], ["coronavirus", "PROBLEM", 101, 112], ["Kaposi sarcoma herpesvirus (KSHV)", "PROBLEM", 140, 173], ["Varicella zoster virus", "PROBLEM", 179, 201], ["host protein interactomes", "OBSERVATION", 6, 31], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["respiratory syndrome", "OBSERVATION", 73, 93], ["Kaposi sarcoma", "OBSERVATION", 140, 154], ["Varicella", "ANATOMY", 179, 188], ["zoster virus", "OBSERVATION", 189, 201]]], ["In addition to global mapping, protein interaction networks of several important signal pathways, such as MAPK (Bandyopadhyay et al. 2010 ) , TGF b ( Tewari et al. 2004 , SMAD (Colland et al. 2004 ) , and PI3K-mTOR (Pilot-Storck et al. 2010 ) , have been investigated.IntroductionIn addition to YTH, AP-MS is another widely used PPI tool to map protein interactomes.", [["YTH", "CHEMICAL", 295, 298], ["MAPK", "GENE_OR_GENE_PRODUCT", 106, 110], ["TGF b", "GENE_OR_GENE_PRODUCT", 142, 147], ["PI3K-mTOR", "GENE_OR_GENE_PRODUCT", 205, 214], ["protein interaction networks", "PROTEIN", 31, 59], ["MAPK", "PROTEIN", 106, 110], ["TGF b", "PROTEIN", 142, 147], ["SMAD", "PROTEIN", 171, 175], ["PI3K", "PROTEIN", 205, 209], ["mTOR", "PROTEIN", 210, 214], ["protein interactomes", "PROTEIN", 345, 365], ["global mapping", "TEST", 15, 29], ["PPI tool", "TREATMENT", 329, 337]]], ["Due to many advantages that will be discussed later, AP-MS mapping protein interaction network of various signal pathways has dramatically increased in recent years.", [["AP", "PROTEIN", 53, 55], ["AP-MS mapping", "TEST", 53, 66], ["dramatically", "OBSERVATION_MODIFIER", 126, 138], ["increased", "OBSERVATION_MODIFIER", 139, 148]]], ["Global-wide interactomes have been established in Escherichia coli (Hu et al. 2009 ) and Mycoplasma pneumonia (Kuhner et al. 2009 ) , Saccharomyces cerevisiae (Krogan et al. 2006 ; Gavin et al. 2006 ; Ho et al. 2002 ) , Drosophila melanogaster (Guruharsha et al. 2011 ) , and HIV-host interactome (Jager et al. 2012 ) .", [["Mycoplasma pneumonia", "DISEASE", 89, 109], ["Escherichia coli", "ORGANISM", 50, 66], ["Mycoplasma pneumonia", "ORGANISM", 89, 109], ["Saccharomyces cerevisiae", "ORGANISM", 134, 158], ["Drosophila melanogaster", "ORGANISM", 220, 243], ["Escherichia coli", "SPECIES", 50, 66], ["Mycoplasma pneumonia", "SPECIES", 89, 109], ["Saccharomyces cerevisiae", "SPECIES", 134, 158], ["Drosophila melanogaster", "SPECIES", 220, 243], ["HIV", "SPECIES", 276, 279], ["Escherichia coli", "SPECIES", 50, 66], ["Mycoplasma pneumonia", "SPECIES", 89, 109], ["Saccharomyces cerevisiae", "SPECIES", 134, 158], ["Drosophila melanogaster", "SPECIES", 220, 243], ["Global-wide interactomes", "PROBLEM", 0, 24], ["Escherichia coli", "PROBLEM", 50, 66], ["Mycoplasma pneumonia", "PROBLEM", 89, 109], ["Saccharomyces cerevisiae", "TREATMENT", 134, 158], ["Drosophila melanogaster", "PROBLEM", 220, 243], ["wide interactomes", "OBSERVATION", 7, 24], ["Escherichia coli", "OBSERVATION", 50, 66], ["Mycoplasma", "OBSERVATION_MODIFIER", 89, 99], ["pneumonia", "OBSERVATION", 100, 109]]], ["In vertebrate, this approach has so far been used to de fi ne proteomic subspaces or speci fi c signal pathways: antiviral innate immunity pathway (Li et al. 2011 ) , autophagy pathway (Behrends et al. 2010 ) , deubiquitinase interactome (Sowa et al. 2009 ) , endoplasmic reticulum-associated protein degradation network (ERAD) (Christianson et al. 2012 ) , TNF pathway (Bouwmeester et al. 2004 ) , proteasome interaction network (Guerrero et al. 2008 ) , and disease-related protein network (Ewing et al. 2007 ) .IntroductionSystematic identi fi cation of protein interactions within an organism will facilitate systems-level studies of biological processes.", [["endoplasmic reticulum", "ANATOMY", 260, 281], ["speci fi c", "GENE_OR_GENE_PRODUCT", 85, 95], ["deubiquitinase", "GENE_OR_GENE_PRODUCT", 211, 225], ["endoplasmic reticulum-associated protein", "GENE_OR_GENE_PRODUCT", 260, 300], ["TNF", "GENE_OR_GENE_PRODUCT", 358, 361], ["endoplasmic reticulum-associated protein degradation network", "PROTEIN", 260, 320], ["ERAD", "PROTEIN", 322, 326], ["TNF", "PROTEIN", 358, 361], ["proteasome", "PROTEIN", 399, 409], ["antiviral innate immunity pathway", "TREATMENT", 113, 146], ["endoplasmic reticulum", "PROBLEM", 260, 281], ["IntroductionSystematic identi fi cation", "TREATMENT", 514, 553], ["protein interactions", "PROBLEM", 557, 577], ["an organism", "PROBLEM", 585, 596], ["endoplasmic reticulum", "ANATOMY", 260, 281]]], ["Current binary PPI networks are mainly generated by high-throughput yeast two-hybrid.", [["yeast", "SPECIES", 68, 73], ["yeast", "SPECIES", 68, 73], ["Current binary PPI networks", "TREATMENT", 0, 27]]], ["Due to the small overlap of these maps, it has been assumed that these maps are of low quality containing many false positives (Parrish et al. 2006 ) .", [["these maps", "TEST", 28, 38], ["these maps", "TEST", 65, 75], ["small", "OBSERVATION_MODIFIER", 11, 16], ["overlap", "OBSERVATION", 17, 24], ["low quality", "OBSERVATION_MODIFIER", 83, 94], ["false positives", "OBSERVATION", 111, 126]]], ["Recent efforts to map interactions using AP-MS illustrate the promise to measure speci fi c protein interactions in vivo (instead of in yeast) and provide a more powerful tool to model the in vivo interactome.", [["speci fi c", "GENE_OR_GENE_PRODUCT", 81, 91], ["speci fi c protein", "PROTEIN", 81, 99], ["yeast", "SPECIES", 136, 141], ["yeast", "SPECIES", 136, 141], ["AP-MS illustrate", "TREATMENT", 41, 57]]], ["First, I discuss the advantages of AP-MS versus YTH, and then focus the details of the methodology, applications, and perspectives of AP-MS.AP-MS Versus YTHDespite the wide acceptance of YTH system for protein-protein interaction analysis and discovery, high-throughput YTH for protein interaction network bears several major limitations: (1) Reporter analysis method indirectly re fl ects protein-protein interaction which usually leads to high false positives.", [["YTH", "SIMPLE_CHEMICAL", 48, 51], ["YTH", "PROTEIN", 187, 190], ["YTH", "PROTEIN", 270, 273], ["AP", "TEST", 134, 136], ["protein-protein interaction analysis", "TEST", 202, 238], ["protein interaction network", "PROBLEM", 278, 305], ["Reporter analysis method", "TEST", 343, 367], ["protein interaction", "PROBLEM", 398, 417], ["high false positives", "PROBLEM", 441, 461], ["false positives", "OBSERVATION", 446, 461]]], ["For example, proteins with transcriptional activity can lead to autoactivation of the reporter genes.", [["reporter genes", "DNA", 86, 100], ["transcriptional activity", "PROBLEM", 27, 51]]], ["(2) Some heterologous protein expressions are incompatible or toxic to yeast, i.e., membrane proteins which are unlikely to be appropriately assayed as a fusion with a reconstituted transcription factor in YTH.", [["membrane", "ANATOMY", 84, 92], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["YTH", "GENE_OR_GENE_PRODUCT", 206, 209], ["membrane proteins", "PROTEIN", 84, 101], ["reconstituted transcription factor", "PROTEIN", 168, 202], ["YTH", "PROTEIN", 206, 209], ["yeast", "SPECIES", 71, 76], ["yeast", "SPECIES", 71, 76], ["Some heterologous protein expressions", "PROBLEM", 4, 41], ["toxic to yeast", "PROBLEM", 62, 76], ["membrane proteins", "PROBLEM", 84, 101], ["a fusion", "TREATMENT", 152, 160], ["protein expressions", "OBSERVATION", 22, 41], ["toxic", "OBSERVATION_MODIFIER", 62, 67]]], ["(3) YTH cannot re fl ect the endogenous protein interactions in the relevant organism.", [["the endogenous protein interactions", "PROBLEM", 25, 60], ["endogenous protein interactions", "OBSERVATION", 29, 60]]], ["(4) Lots of signaling pathways in vertebrates do not exist in yeast.", [["yeast", "SPECIES", 62, 67], ["yeast", "SPECIES", 62, 67], ["signaling pathways in vertebrates", "PROBLEM", 12, 45], ["yeast", "OBSERVATION", 62, 67]]], ["Thus, interactions triggered by posttranslational modi fi cations do not occur in yeast, resulting in many intrinsic false negatives.", [["yeast", "SPECIES", 82, 87], ["yeast", "SPECIES", 82, 87], ["posttranslational modi fi cations", "TREATMENT", 32, 65], ["many intrinsic false negatives", "PROBLEM", 102, 132], ["false negatives", "OBSERVATION", 117, 132]]], ["In addition, in high-throughput YTH, the bait expression is not monitored.", [["YTH", "PROTEIN", 32, 35], ["high", "OBSERVATION_MODIFIER", 16, 20]]], ["Heterologous full-length protein expression, especially high-molecular-weight protein, expects to have low expression level in yeast.AP-MS Versus YTHAlthough both YTH and AP-MS detect protein-protein interaction, they have several distinct differences (Table 2 .1 ).", [["high-molecular-weight protein", "PROTEIN", 56, 85], ["yeast", "SPECIES", 127, 132], ["yeast", "SPECIES", 127, 132], ["Heterologous full-length protein expression", "TEST", 0, 43], ["low expression level in yeast", "PROBLEM", 103, 132], ["AP", "TEST", 133, 135], ["YTHAlthough", "TEST", 146, 157], ["YTH", "TEST", 163, 166], ["AP-MS", "TEST", 171, 176], ["protein-protein interaction", "PROBLEM", 184, 211], ["low expression", "OBSERVATION_MODIFIER", 103, 117], ["distinct", "OBSERVATION_MODIFIER", 231, 239]]], ["AP-MS couples af fi nity puri fi cation with mass spectrometry and requires more labor works and sophisticated equipments.", [["mass spectrometry", "PROBLEM", 45, 62]]], ["Basically, baits can be expressed in any cell line, which investigator is interested in.", [["cell line", "ANATOMY", 41, 50], ["cell line", "CELL", 41, 50], ["cell line", "OBSERVATION", 41, 50]]], ["After antibiotic selection, bait expression levels are monitored in stable cell lines by western blot, and cell line expressing low bait protein level (close to endogenous level) is usually chosen for following af fi nity puri fi cation.", [["cell lines", "ANATOMY", 75, 85], ["cell line", "ANATOMY", 107, 116], ["cell lines", "CELL", 75, 85], ["cell line", "CELL", 107, 116], ["cell lines", "CELL_LINE", 75, 85], ["antibiotic selection", "TREATMENT", 6, 26], ["bait expression levels", "TEST", 28, 50], ["cell line", "TREATMENT", 107, 116], ["low bait protein level", "PROBLEM", 128, 150], ["stable", "OBSERVATION_MODIFIER", 68, 74], ["cell lines", "OBSERVATION", 75, 85]]], ["Since the bait expression is close to the counterpart endogenous protein level, we expect the puri fi ed complex re fl ects the endogenous protein interactions under physiological conditions.", [["puri fi ed complex", "PROTEIN", 94, 112], ["fl", "PROTEIN", 116, 118], ["endogenous protein interactions", "OBSERVATION", 128, 159]]], ["AP-MS also can be used to detect dynamic protein interactions dependent on protein posttranslational modi fi cation by signal stimulation.", [["modi fi cation", "GENE_OR_GENE_PRODUCT", 101, 115], ["protein posttranslational modi fi cation", "PROTEIN", 75, 115], ["dynamic protein interactions", "PROBLEM", 33, 61], ["protein posttranslational modi fi cation", "TREATMENT", 75, 115]]], ["Unlike YTH detecting one-to-one interaction (aka binary interaction), AP-MS analyzes the entire bait complex and provides all prey information in one run.", [["YTH", "CHEMICAL", 7, 10], ["YTH", "SIMPLE_CHEMICAL", 7, 10], ["YTH", "PROTEIN", 7, 10], ["AP", "PROTEIN", 70, 72], ["bait complex", "PROTEIN", 96, 108]]], ["However, the puri fi ed complex represents a mix of direct and indirect binding partners since the nature of the interactions identi fi ed in AP-MS data cannot be determined to be either direct or indirect.", [["puri fi ed complex", "PROTEIN", 13, 31], ["AP-MS data", "TEST", 142, 152]]], ["Last, protein abundance and speci fi city in different cell lines also limits the detection of protein complex.", [["cell lines", "ANATOMY", 55, 65], ["cell lines", "CELL", 55, 65], ["cell lines", "CELL_LINE", 55, 65], ["protein complex", "PROTEIN", 95, 110], ["protein abundance", "TEST", 6, 23], ["different cell lines", "TREATMENT", 45, 65], ["protein complex", "PROBLEM", 95, 110], ["abundance", "OBSERVATION_MODIFIER", 14, 23], ["speci fi", "OBSERVATION_MODIFIER", 28, 36], ["different cell lines", "OBSERVATION", 45, 65], ["protein complex", "OBSERVATION", 95, 110]]], ["For example, MIB1 and MIB2 have comparable af fi nity with TBK1, but we did not detect MIB2 in TBK1 complex in 293T cells by AP-MS.", [["293T cells", "ANATOMY", 111, 121], ["MIB1", "GENE_OR_GENE_PRODUCT", 13, 17], ["MIB2", "GENE_OR_GENE_PRODUCT", 22, 26], ["TBK1", "GENE_OR_GENE_PRODUCT", 59, 63], ["MIB2", "GENE_OR_GENE_PRODUCT", 87, 91], ["TBK1", "GENE_OR_GENE_PRODUCT", 95, 99], ["293T cells", "CELL", 111, 121], ["MIB1", "PROTEIN", 13, 17], ["MIB2", "PROTEIN", 22, 26], ["TBK1", "PROTEIN", 59, 63], ["MIB2", "PROTEIN", 87, 91], ["TBK1 complex", "PROTEIN", 95, 107], ["293T cells", "CELL_LINE", 111, 121], ["MIB1", "TEST", 13, 17], ["MIB2", "TEST", 22, 26], ["TBK1", "PROBLEM", 59, 63], ["TBK1", "OBSERVATION", 59, 63]]], ["Using real-time PCR, we found MIB1 predominantly expressed in 293T cell line (Li et al. 2011 ) .", [["293T cell line", "ANATOMY", 62, 76], ["MIB1", "GENE_OR_GENE_PRODUCT", 30, 34], ["293T cell line", "CELL", 62, 76], ["MIB1", "PROTEIN", 30, 34], ["293T cell line", "CELL_LINE", 62, 76], ["MIB1", "TEST", 30, 34], ["293T cell line", "OBSERVATION", 62, 76]]], ["Taken all together, AP-MS overcomes the limitations of YTH discussed above except several disadvantages over YTH: high cost, indirect interaction, and cell type speci fi city.Methodology of AP-MSThe pipeline of AP-MS from gene construction to interaction network mapping is shown in Fig. 2 .1 (Li et al. 2011 ) .", [["cell", "ANATOMY", 151, 155], ["YTH", "CHEMICAL", 109, 112], ["YTH", "SIMPLE_CHEMICAL", 55, 58], ["YTH", "SIMPLE_CHEMICAL", 109, 112], ["cell", "CELL", 151, 155], ["AP", "PROTEIN", 211, 213], ["AP-MS from gene construction", "TREATMENT", 211, 239]]], ["In brief, interested gene is tagged with desirable epitopes such as FLAG, GST, His, and biotin.", [["biotin", "CHEMICAL", 88, 94], ["His", "CHEMICAL", 79, 82], ["biotin", "CHEMICAL", 88, 94], ["FLAG", "GENE_OR_GENE_PRODUCT", 68, 72], ["GST", "GENE_OR_GENE_PRODUCT", 74, 77], ["His", "GENE_OR_GENE_PRODUCT", 79, 82], ["biotin", "SIMPLE_CHEMICAL", 88, 94], ["epitopes", "PROTEIN", 51, 59], ["FLAG", "PROTEIN", 68, 72], ["GST", "PROTEIN", 74, 77], ["His", "PROTEIN", 79, 82], ["biotin", "PROTEIN", 88, 94], ["FLAG, GST", "TEST", 68, 77], ["biotin", "TREATMENT", 88, 94]]], ["Depending on the puri fi cation strategy, one or two tags (usually tandem tags) are adopted.", [["the puri fi cation strategy", "TREATMENT", 13, 40]]], ["These vectors should carry one antibiotic resistance gene for mammalian cell stable line selection.", [["cell", "ANATOMY", 72, 76], ["mammalian cell", "CELL", 62, 76], ["antibiotic resistance gene", "DNA", 31, 57], ["These vectors", "TREATMENT", 0, 13], ["one antibiotic resistance gene", "TREATMENT", 27, 57], ["mammalian cell stable line selection", "TREATMENT", 62, 98], ["mammalian cell", "OBSERVATION", 62, 76], ["stable line", "OBSERVATION", 77, 88]]], ["After transfection or infection into the desirable mammalian cell line, cells are selected by designated antibiotics to obtain stably and close to endogenous protein expression.", [["cell line", "ANATOMY", 61, 70], ["cells", "ANATOMY", 72, 77], ["infection", "DISEASE", 22, 31], ["mammalian cell line", "CELL", 51, 70], ["cells", "CELL", 72, 77], ["mammalian cell line", "CELL_LINE", 51, 70], ["transfection", "TREATMENT", 6, 18], ["infection", "PROBLEM", 22, 31], ["antibiotics", "TREATMENT", 105, 116], ["infection", "OBSERVATION", 22, 31], ["mammalian cell line", "OBSERVATION", 51, 70], ["protein expression", "OBSERVATION", 158, 176]]], ["Protein complexes are precipitated from lysates of bulk cells by using various immobilized matrixes, such as resin conjugated with antibody.", [["lysates", "ANATOMY", 40, 47], ["cells", "ANATOMY", 56, 61], ["lysates", "ORGANISM_SUBSTANCE", 40, 47], ["cells", "CELL", 56, 61], ["Protein complexes", "PROTEIN", 0, 17], ["bulk cells", "CELL_TYPE", 51, 61], ["Protein complexes", "TEST", 0, 17], ["lysates of bulk cells", "PROBLEM", 40, 61], ["various immobilized matrixes", "TREATMENT", 71, 99], ["resin conjugated with antibody", "TREATMENT", 109, 139], ["bulk cells", "OBSERVATION", 51, 61]]], ["Protein complexes are then eluated from the matrixes after several washing steps to remove nonspeci fi c interactors.", [["nonspeci fi c", "GENE_OR_GENE_PRODUCT", 91, 104], ["Protein complexes", "PROTEIN", 0, 17], ["nonspeci fi c interactors", "PROTEIN", 91, 116], ["Protein complexes", "TEST", 0, 17], ["several washing steps", "TREATMENT", 59, 80], ["complexes", "OBSERVATION", 8, 17]]], ["Protein complex is either separated on gel following silver staining or precipitated.", [["silver", "CHEMICAL", 53, 59], ["silver", "CHEMICAL", 53, 59], ["silver", "SIMPLE_CHEMICAL", 53, 59], ["Protein complex", "PROTEIN", 0, 15], ["Protein complex", "PROBLEM", 0, 15], ["silver staining", "PROBLEM", 53, 68], ["complex", "OBSERVATION", 8, 15]]], ["Sliced gel bands or solution samples are analyzed by mass spectrometry.", [["samples", "ANATOMY", 29, 36], ["Sliced gel bands", "TREATMENT", 0, 16], ["solution samples", "TEST", 20, 36]]], ["After data collection and statistical analysis, protein interaction network is generated and ready for validation and further function analysis.VectorTo purify protein complex closing to physiological level, cell line stably expressing tagged bait is a prerequisite.", [["cell line", "ANATOMY", 208, 217], ["VectorTo", "GENE_OR_GENE_PRODUCT", 144, 152], ["cell line", "CELL", 208, 217], ["protein interaction network", "PROTEIN", 48, 75], ["VectorTo", "PROTEIN", 144, 152], ["protein complex", "PROTEIN", 160, 175], ["data collection", "TEST", 6, 21], ["statistical analysis", "TEST", 26, 46], ["protein interaction network", "TEST", 48, 75], ["validation", "TEST", 103, 113], ["further function analysis", "TEST", 118, 143], ["VectorTo", "TREATMENT", 144, 152], ["protein complex", "PROBLEM", 160, 175], ["cell line", "TREATMENT", 208, 217], ["cell line", "OBSERVATION", 208, 217]]], ["Therefore, antibiotic resistance gene should be included in the vector for stable cell line selection.", [["cell line", "ANATOMY", 82, 91], ["cell line", "CELL", 82, 91], ["antibiotic resistance gene", "DNA", 11, 37], ["antibiotic resistance gene", "TREATMENT", 11, 37], ["stable cell line selection", "TREATMENT", 75, 101], ["stable cell line", "OBSERVATION", 75, 91]]], ["Genes of interest also needs to be tagged in-frame with an epitope (at either the N or C terminus), which is used to af fi nity purify the tagged protein (aka bait) along with its interacting partners (aka prey).", [["N or C terminus", "PROTEIN", 82, 97], ["tagged protein", "PROTEIN", 139, 153], ["aka bait", "PROTEIN", 155, 163], ["aka prey", "PROTEIN", 202, 210]]], ["Any af fi nity tag can be used for AP-MS in theory, and most successful tags developed to date are FLAG, HA, S-tag, and tandem af fi nity puri fi cation (TAP) tag.", [["FLAG", "GENE_OR_GENE_PRODUCT", 99, 103], ["HA", "SIMPLE_CHEMICAL", 105, 107], ["puri fi cation", "SIMPLE_CHEMICAL", 138, 152], ["FLAG", "PROTEIN", 99, 103], ["HA, S-tag, and tandem af fi nity puri fi cation (TAP) tag", "PROTEIN", 105, 162], ["FLAG", "TEST", 99, 103], ["HA", "PROBLEM", 105, 107]]], ["Each puri fi cation tag has advantages and disadvantages, and the appropriate technique should be selected depending on the goals of the experiment.", [["Each puri fi cation tag", "TREATMENT", 0, 23], ["the appropriate technique", "TREATMENT", 62, 87]]], ["For example, a single FLAG or HA epitope only adds 8-11 amino acids (Li et al. 2011 ) , while the TAP tag adds a >20-kDa tag (Krogan et al. 2006 ) which may cause more nonspeci fi c binding.", [["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 56, 67], ["FLAG", "GENE_OR_GENE_PRODUCT", 22, 26], ["amino acids", "AMINO_ACID", 56, 67], ["TAP", "GENE_OR_GENE_PRODUCT", 98, 101], ["nonspeci fi c", "GENE_OR_GENE_PRODUCT", 168, 181], ["FLAG", "PROTEIN", 22, 26], ["HA epitope", "PROTEIN", 30, 40], ["TAP tag", "PROTEIN", 98, 105], ["a single FLAG or HA epitope", "PROBLEM", 13, 40], ["amino acids", "TEST", 56, 67], ["the TAP tag", "TEST", 94, 105]]], ["Because tag may interfere with protein expression or interaction, both N-terminal and C-terminal fusion could be tested for optimal AP-MS.", [["N", "CHEMICAL", 71, 72], ["C", "CHEMICAL", 86, 87], ["tag", "GENE_OR_GENE_PRODUCT", 8, 11], ["N-terminal", "PROTEIN", 71, 81], ["protein expression", "PROBLEM", 31, 49], ["terminal and C-terminal fusion", "TREATMENT", 73, 103]]], ["For example, membrane protein may need to put the tag on the C-terminal or after signal peptide on the N-terminus.", [["membrane", "ANATOMY", 13, 21], ["C", "CHEMICAL", 61, 62], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["membrane protein", "PROTEIN", 13, 29], ["C-terminal", "PROTEIN", 61, 71], ["N-terminus", "PROTEIN", 103, 113], ["membrane protein", "PROBLEM", 13, 29], ["the tag", "TEST", 46, 53]]], ["Furthermore, two kinds of puri fi cation methods (single and tandem puri fi cation) are used for AP-MS, which requires bait fused with single or double epitopes, respectively.Puri fi cationDepending on the number of tags on the vector, there are one-step and two-step puri fi cation methods for speci fi c protein complex, cell line, or organism.", [["cell line", "ANATOMY", 323, 332], ["puri fi cation", "SIMPLE_CHEMICAL", 26, 40], ["speci fi c protein", "GENE_OR_GENE_PRODUCT", 295, 313], ["cell line", "CELL", 323, 332], ["speci fi c protein complex", "PROTEIN", 295, 321], ["cell line", "CELL_LINE", 323, 332], ["puri fi cation methods", "TREATMENT", 26, 48], ["single and tandem puri fi cation", "TREATMENT", 50, 82], ["AP-MS", "TEST", 97, 102], ["single or double epitopes", "TREATMENT", 135, 160], ["two-step puri fi cation methods", "TREATMENT", 259, 290], ["speci fi c protein complex", "PROBLEM", 295, 321], ["cell line", "TREATMENT", 323, 332], ["organism", "PROBLEM", 337, 345], ["cell line", "OBSERVATION", 323, 332]]], ["Originally developed for yeast, the fi rst TAP tag consists of calmodulin-binding peptide (CBP), followed by tobacco etch virus protease (TEV protease) cleavage site and protein A with high af fi nity to immunoglobulin gamma (IgG).", [["calmodulin-binding peptide", "GENE_OR_GENE_PRODUCT", 63, 89], ["CBP", "GENE_OR_GENE_PRODUCT", 91, 94], ["tobacco etch virus protease", "GENE_OR_GENE_PRODUCT", 109, 136], ["TEV protease", "GENE_OR_GENE_PRODUCT", 138, 150], ["immunoglobulin gamma", "GENE_OR_GENE_PRODUCT", 204, 224], ["IgG", "GENE_OR_GENE_PRODUCT", 226, 229], ["fi rst TAP tag", "PROTEIN", 36, 50], ["calmodulin", "PROTEIN", 63, 73], ["CBP", "PROTEIN", 91, 94], ["tobacco etch virus protease", "PROTEIN", 109, 136], ["TEV protease) cleavage site", "PROTEIN", 138, 165], ["protein A", "PROTEIN", 170, 179], ["immunoglobulin gamma", "PROTEIN", 204, 224], ["IgG", "PROTEIN", 226, 229], ["yeast", "SPECIES", 25, 30], ["yeast", "SPECIES", 25, 30], ["tobacco etch virus", "SPECIES", 109, 127], ["yeast", "PROBLEM", 25, 30], ["the fi rst TAP tag", "TEST", 32, 50], ["calmodulin-binding peptide", "PROBLEM", 63, 89], ["CBP", "TEST", 91, 94], ["tobacco etch virus protease", "TREATMENT", 109, 136], ["TEV protease)", "TREATMENT", 138, 151], ["protein A", "TEST", 170, 179]]], ["Protein complex is fi rst puri fi ed from the cell lysate on an IgG af fi nity resin and cleaved from the protein A tag with TEV protease.", [["cell lysate", "ANATOMY", 46, 57], ["cell lysate", "ORGANISM_SUBSTANCE", 46, 57], ["TEV protease", "GENE_OR_GENE_PRODUCT", 125, 137], ["Protein complex", "PROTEIN", 0, 15], ["IgG", "PROTEIN", 64, 67], ["protein A tag", "PROTEIN", 106, 119], ["TEV protease", "PROTEIN", 125, 137], ["Protein complex", "PROBLEM", 0, 15], ["the cell lysate", "TREATMENT", 42, 57], ["an IgG af fi nity resin", "TREATMENT", 61, 84], ["TEV protease", "TREATMENT", 125, 137], ["complex", "OBSERVATION_MODIFIER", 8, 15], ["fi rst", "OBSERVATION_MODIFIER", 19, 25], ["cell lysate", "OBSERVATION", 46, 57]]], ["The eluate is then enriched in a second af fi nity puri fi cation step on an immobilized calmodulin column.", [["calmodulin", "GENE_OR_GENE_PRODUCT", 89, 99], ["an immobilized calmodulin column", "TREATMENT", 74, 106], ["calmodulin column", "OBSERVATION", 89, 106]]], ["Several variants of TAP with different combinations of tags, such as FLAG-HA double tags, are developed.", [["TAP", "GENE_OR_GENE_PRODUCT", 20, 23], ["FLAG", "GENE_OR_GENE_PRODUCT", 69, 73], ["TAP", "PROTEIN", 20, 23], ["FLAG", "PROTEIN", 69, 73], ["TAP", "TREATMENT", 20, 23], ["different combinations of tags", "PROBLEM", 29, 59], ["FLAG-HA double tags", "TREATMENT", 69, 88], ["TAP", "OBSERVATION", 20, 23]]], ["Usually, one-step puri fi cations on average preserve weaker or more transient protein-protein interactions in the price of a higher number of nonspeci fi c binding proteins.", [["puri fi cations", "SIMPLE_CHEMICAL", 18, 33], ["nonspeci fi c binding proteins", "GENE_OR_GENE_PRODUCT", 143, 173], ["nonspeci fi c binding proteins", "PROTEIN", 143, 173]]], ["Conversely, the tandem procedure tends to yield cleaner results, but weak interactions can be lost.", [["the tandem procedure", "TREATMENT", 12, 32]]], ["FLAG and HA double tags are most commonly applied for tandem puri fi cation of protein complexes.", [["FLAG", "GENE_OR_GENE_PRODUCT", 0, 4], ["FLAG", "PROTEIN", 0, 4], ["protein complexes", "PROTEIN", 79, 96], ["FLAG and HA double tags", "TREATMENT", 0, 23], ["protein complexes", "OBSERVATION", 79, 96]]], ["We compared the effect of tandem tag versus single tag puri fi cation on the yield of total prey and HCIP by examining four protein complexes puri fi ed by single puri fi cation with FLAG versus a two-step puri fi cation with FLAG followed by HA (Li and Dorf 2013 ) .", [["Li", "CHEMICAL", 247, 249], ["HCIP", "SIMPLE_CHEMICAL", 101, 105], ["puri fi cation", "SIMPLE_CHEMICAL", 163, 177], ["FLAG", "GENE_OR_GENE_PRODUCT", 183, 187], ["puri fi cation", "SIMPLE_CHEMICAL", 206, 220], ["FLAG", "GENE_OR_GENE_PRODUCT", 226, 230], ["tandem tag", "DNA", 26, 36], ["protein complexes", "PROTEIN", 124, 141], ["FLAG", "PROTEIN", 183, 187], ["FLAG", "PROTEIN", 226, 230], ["tandem tag", "TREATMENT", 26, 36], ["single tag puri fi cation", "TREATMENT", 44, 69], ["a two-step puri fi cation", "TREATMENT", 195, 220]]], ["MS analysis revealed that the number of total interactors was dramatically reduced in all protein complexes (TBK1, NAP1, IRF3, and SINTBAD) isolated by TAP puri fi cation.", [["TBK1", "GENE_OR_GENE_PRODUCT", 109, 113], ["NAP1", "GENE_OR_GENE_PRODUCT", 115, 119], ["IRF3", "GENE_OR_GENE_PRODUCT", 121, 125], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 131, 138], ["TAP puri fi cation", "GENE_OR_GENE_PRODUCT", 152, 170], ["protein complexes", "PROTEIN", 90, 107], ["TBK1", "PROTEIN", 109, 113], ["NAP1", "PROTEIN", 115, 119], ["IRF3", "PROTEIN", 121, 125], ["SINTBAD", "PROTEIN", 131, 138], ["TAP", "PROTEIN", 152, 155], ["MS analysis", "TEST", 0, 11], ["total interactors", "PROBLEM", 40, 57], ["dramatically reduced", "PROBLEM", 62, 82], ["TBK1", "TEST", 109, 113], ["NAP1", "PROBLEM", 115, 119], ["IRF3", "TEST", 121, 125]]], ["However, the ratio of HCIP to total prey did not increase.", [["HCIP", "GENE_OR_GENE_PRODUCT", 22, 26], ["HCIP", "PROTEIN", 22, 26], ["the ratio", "TEST", 9, 18], ["HCIP", "TEST", 22, 26], ["total prey", "TEST", 30, 40], ["increase", "OBSERVATION_MODIFIER", 49, 57]]], ["Consistently, more HCIP were detected by single-step af fi nity puri fi cation ( Fig. 2.", [["HCIP", "CHEMICAL", 19, 23], ["HCIP", "CHEMICAL", 19, 23], ["HCIP", "SIMPLE_CHEMICAL", 19, 23], ["puri fi cation", "SIMPLE_CHEMICAL", 64, 78], ["HCIP", "PROTEIN", 19, 23]]], ["In brief, tandem puri fi cation reduces the NSBP at the price of HCIP loss.", [["NSBP", "CHEMICAL", 44, 48], ["HCIP", "CHEMICAL", 65, 69], ["puri fi cation", "SIMPLE_CHEMICAL", 17, 31], ["NSBP", "SIMPLE_CHEMICAL", 44, 48], ["HCIP", "SIMPLE_CHEMICAL", 65, 69], ["tandem puri fi cation", "TREATMENT", 10, 31], ["HCIP loss", "PROBLEM", 65, 74], ["HCIP loss", "OBSERVATION", 65, 74]]], ["Due to on average more than 90% of proteins as nonspeci fi c binding protein in one-step puri fi cation, researchers prefer to tandem af fi nity puri fi cation to get a cleaner background if they only study on a few protein complexes.", [["nonspeci fi c binding protein", "GENE_OR_GENE_PRODUCT", 47, 76], ["puri fi cation", "SIMPLE_CHEMICAL", 89, 103], ["nonspeci fi c binding protein", "PROTEIN", 47, 76], ["protein complexes", "PROTEIN", 216, 233], ["binding protein", "TEST", 61, 76]]], ["However, if the study is to map the protein interaction network of a speci fi c signaling pathway, NSBP from one-step puri fi cation can be excluded by statistical analysis of the whole database.Mass Spectrometric Protein Identi fi cationIn most proteomics experiments, the puri fi ed proteins are separated by onedimensional SDS-PAGE and stained with a mass spectrometry-compatible dye such as silver, SYPRO ruby, or Coomassie.", [["silver", "CHEMICAL", 395, 401], ["silver", "CHEMICAL", 395, 401], ["Coomassie", "CHEMICAL", 418, 427], ["speci fi c", "GENE_OR_GENE_PRODUCT", 69, 79], ["NSBP", "SIMPLE_CHEMICAL", 99, 103], ["puri fi cation", "SIMPLE_CHEMICAL", 118, 132], ["silver", "SIMPLE_CHEMICAL", 395, 401], ["Coomassie", "SIMPLE_CHEMICAL", 418, 427], ["NSBP", "PROTEIN", 99, 103], ["puri fi ed proteins", "PROTEIN", 274, 293], ["the study", "TEST", 12, 21], ["NSBP", "TEST", 99, 103], ["the whole database", "TEST", 176, 194], ["Mass", "PROBLEM", 195, 199], ["a mass spectrometry", "PROBLEM", 352, 371], ["silver, SYPRO ruby", "TREATMENT", 395, 413], ["Coomassie", "PROBLEM", 418, 427]]], ["SDS-PAGE separation removes unwanted contaminants such as buffer components from the protein sample, and the sample complexity is decreased by separating the proteins according to molecular weight.", [["sample", "ANATOMY", 109, 115], ["PAGE separation", "TREATMENT", 4, 19], ["unwanted contaminants", "PROBLEM", 28, 49], ["buffer components", "TREATMENT", 58, 75], ["the protein sample", "TEST", 81, 99], ["the sample complexity", "TEST", 105, 126], ["decreased", "OBSERVATION_MODIFIER", 130, 139]]], ["In some cases, like IRF3 complexes shown in Fig. 2 .1 , unique bands are only found in the bait complex with stimulation, indicating these interacting proteins are dependent on ligand stimulation.Mass Spectrometric Protein Identi fi cationIndividual protein bands of interest are excised, or the entire lane is cut into approximately 1-mm 3 pieces.", [["IRF3", "GENE_OR_GENE_PRODUCT", 20, 24], ["IRF3 complexes", "PROTEIN", 20, 34], ["bait complex", "PROTEIN", 91, 103], ["interacting proteins", "PROTEIN", 139, 159], ["IRF3 complexes", "PROBLEM", 20, 34], ["unique bands", "PROBLEM", 56, 68], ["these interacting proteins", "PROBLEM", 133, 159], ["Mass", "PROBLEM", 196, 200], ["Individual protein bands", "TREATMENT", 239, 263], ["IRF3 complexes", "OBSERVATION", 20, 34], ["protein bands", "OBSERVATION", 250, 263]]], ["Gel pieces were then subjected to an in-gel trypsin digestion procedure to produce peptides for mass spectrometry analysis.", [["trypsin", "PROTEIN", 44, 51], ["Gel pieces", "TREATMENT", 0, 10], ["an in-gel trypsin digestion procedure", "TREATMENT", 34, 71], ["mass spectrometry analysis", "TEST", 96, 122]]], ["But the extraction ef fi ciency of peptides from a gel is low and dependent on the primary structure of the peptide.", [["the extraction", "TREATMENT", 4, 18], ["low", "OBSERVATION", 58, 61]]], ["As an alternative approach to in-gel digestion, protein mixtures can be digested in solution without prior separation (Behrends et al. 2010 ) .", [["an alternative approach", "TREATMENT", 3, 26], ["-gel digestion", "TREATMENT", 32, 46], ["protein mixtures", "TREATMENT", 48, 64]]], ["Because buffer components, such as detergents, interfere with the mass spectrometry ionization process, protein samples need to be precipitated with trichloroacetic acid (TCA), washed, and redissolved in a digestion buffer.", [["trichloroacetic acid", "CHEMICAL", 149, 169], ["TCA", "CHEMICAL", 171, 174], ["trichloroacetic acid", "CHEMICAL", 149, 169], ["TCA", "CHEMICAL", 171, 174], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 149, 169], ["TCA", "SIMPLE_CHEMICAL", 171, 174], ["the mass spectrometry ionization process", "TREATMENT", 62, 102], ["protein samples", "TEST", 104, 119], ["trichloroacetic acid", "TREATMENT", 149, 169], ["a digestion buffer", "TREATMENT", 204, 222]]], ["The main advantages of solution digestion are the reduction of the time and a higher recovery of peptides compared to in-gel digestion.", [["solution digestion", "TREATMENT", 23, 41], ["a higher recovery of peptides", "TREATMENT", 76, 105], ["main", "OBSERVATION_MODIFIER", 4, 8], ["solution digestion", "OBSERVATION", 23, 41], ["reduction", "OBSERVATION_MODIFIER", 50, 59]]], ["However, bear in mind that some proteins like membrane proteins are resistant to be redissolved.", [["membrane", "ANATOMY", 46, 54], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["membrane proteins", "PROTEIN", 46, 63], ["some proteins like membrane proteins", "PROBLEM", 27, 63], ["membrane proteins", "OBSERVATION", 46, 63], ["redissolved", "OBSERVATION_MODIFIER", 84, 95]]], ["The peptide mixture can be directly introduced into the mass spectrometer or separated by HPLC before mass spectrometric analysis (LC-MS).", [["The peptide mixture", "TREATMENT", 0, 19], ["mass spectrometric analysis", "TEST", 102, 129], ["mass", "OBSERVATION", 56, 60]]], ["The two primary mass spectrometry methods developed for identi fi cation of proteins are electrospray ionization (ESI) (Fenn et al. 1989 ) and matrix-assisted laser desorption/ionization (MALDI) (Hillenkamp et al. 1991 ) .", [["identi fi cation", "SIMPLE_CHEMICAL", 56, 72], ["The two primary mass spectrometry methods", "TREATMENT", 0, 41], ["identi fi cation of proteins", "TREATMENT", 56, 84], ["matrix-assisted laser desorption/ionization (MALDI", "TREATMENT", 143, 193], ["primary", "OBSERVATION_MODIFIER", 8, 15], ["mass", "OBSERVATION", 16, 20]]], ["Electrospray ionization mass spectrometry is a desorption ionization method.", [["Electrospray ionization", "TREATMENT", 0, 23], ["a desorption ionization method", "TREATMENT", 45, 75]]], ["A sample solution is sprayed from a small tube into a strong electric fi eld in the presence of a fl ow of warm nitrogen to assist desolvation.", [["nitrogen", "CHEMICAL", 112, 120], ["tube", "TISSUE", 42, 46], ["A sample solution", "TREATMENT", 0, 17], ["a small tube", "TREATMENT", 34, 46], ["a strong electric fi eld", "TREATMENT", 52, 76], ["warm nitrogen", "TREATMENT", 107, 120], ["small tube", "OBSERVATION", 36, 46]]], ["The droplets formed evaporate in a region maintained at a vacuum of several torr causing the charge to increase on the droplets.", [["droplets", "ANATOMY", 4, 12], ["The droplets", "TREATMENT", 0, 12], ["the droplets", "TREATMENT", 115, 127], ["evaporate", "OBSERVATION_MODIFIER", 20, 29], ["vacuum", "OBSERVATION", 58, 64], ["increase", "OBSERVATION_MODIFIER", 103, 111]]], ["The multiply charged ions then enter the analyzer.", [["multiply", "OBSERVATION_MODIFIER", 4, 12], ["charged", "OBSERVATION", 13, 20]]], ["The most obvious feature of an ESI spectrum is that the ions carry multiple charges, which reduces their mass-to-charge ratio compared to a singly charged species.", [["an ESI spectrum", "PROBLEM", 28, 43], ["the ions carry multiple charges", "PROBLEM", 52, 83], ["their mass", "PROBLEM", 99, 109], ["a singly charged species", "PROBLEM", 138, 162], ["most obvious", "OBSERVATION_MODIFIER", 4, 16], ["ESI", "OBSERVATION", 31, 34], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["charges", "OBSERVATION", 76, 83], ["mass", "OBSERVATION", 105, 109]]], ["This advantage allows mass spectra to be obtained for large molecules.", [["mass spectra", "PROBLEM", 22, 34], ["large molecules", "PROBLEM", 54, 69]]], ["A major disadvantage is that this technique cannot analyze mixtures very well.", [["this technique", "TREATMENT", 29, 43]]], ["First, desorption is triggered by a UV laser beam.", [["a UV laser beam", "TREATMENT", 34, 49]]], ["Matrix material heavily absorbs UV laser light, leading to the ablation of upper layer (~micron) of the matrix material.", [["matrix", "ANATOMY", 104, 110], ["matrix material", "CELLULAR_COMPONENT", 104, 119], ["Matrix material", "PROBLEM", 0, 15], ["UV laser light", "TREATMENT", 32, 46], ["the ablation of upper layer (~micron) of the matrix material", "TREATMENT", 59, 119], ["heavily", "OBSERVATION_MODIFIER", 16, 23], ["absorbs", "OBSERVATION_MODIFIER", 24, 31], ["UV", "OBSERVATION_MODIFIER", 32, 34], ["laser light", "OBSERVATION_MODIFIER", 35, 46], ["ablation", "OBSERVATION", 63, 71], ["upper", "ANATOMY_MODIFIER", 75, 80], ["layer", "ANATOMY_MODIFIER", 81, 86], ["matrix", "ANATOMY", 104, 110]]], ["A hot plume produced during the ablation contains many species: neutral and ionized matrix molecules, protonated and deprotonated matrix molecules, matrix clusters, and nanodroplets.", [["matrix", "CELLULAR_COMPONENT", 148, 154], ["A hot plume", "PROBLEM", 0, 11], ["the ablation", "TREATMENT", 28, 40], ["neutral and ionized matrix molecules", "TREATMENT", 64, 100], ["protonated and deprotonated matrix molecules", "TREATMENT", 102, 146], ["nanodroplets", "TREATMENT", 169, 181]]], ["In the most common instrumental designs, ESI and MALDI are performed with mass spectrometers capable of tandem mass spectrometry (MS/ MS) experiments.", [["ESI and MALDI", "TEST", 41, 54], ["mass spectrometers", "TEST", 74, 92], ["tandem mass spectrometry", "PROBLEM", 104, 128]]], ["Ion traps, quadrupole time-of-fl ight instruments (Q-TOF), Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometers (FTMS), and the Orbitrap are the most common types of instrumentation now used in high-end protein analysis.Quanti fi cation and DynamicsMost protein interactomes only represent as static entities, which however only poorly captures the dynamics of complex composition.", [["high-end protein", "PROTEIN", 211, 227], ["Ion traps", "TEST", 0, 9], ["quadrupole time", "TEST", 11, 26], ["Fourier transform ion cyclotron resonance", "TEST", 59, 100], ["mass spectrometers", "PROBLEM", 110, 128], ["FTMS", "TEST", 130, 134], ["the Orbitrap", "TEST", 141, 153], ["instrumentation", "TREATMENT", 183, 198], ["Quanti fi cation", "TREATMENT", 237, 253], ["instrumentation", "OBSERVATION", 183, 198]]], ["There has been increasing efforts to detect dynamic views of interactomes using various modi fi ed AP-MS.", [["increasing", "OBSERVATION_MODIFIER", 15, 25]]], ["Systematic methods to map dynamic changes include semi-quanti fi cation based on total spectral counts or ion intensities of precursor peptide (MS1) or fragment ions (MS2) and use of isotopic labeling approaches to obtain more accurate relative quanti fi cation.", [["semi-quanti fi cation", "SIMPLE_CHEMICAL", 50, 71], ["quanti fi cation", "GENE_OR_GENE_PRODUCT", 245, 261], ["Systematic methods", "TREATMENT", 0, 18], ["map dynamic changes", "TREATMENT", 22, 41], ["semi-quanti fi cation", "TREATMENT", 50, 71], ["total spectral counts", "TEST", 81, 102], ["precursor peptide", "PROBLEM", 125, 142], ["fragment ions", "PROBLEM", 152, 165], ["isotopic labeling approaches", "TREATMENT", 183, 211]]], ["Relative quanti fi cation methods such as the stable isotope labeling by amino acids in cell culture (SILAC) detect differences in protein abundance among samples using nonradioactive isotopic labeling.", [["cell culture", "ANATOMY", 88, 100], ["samples", "ANATOMY", 155, 162], ["amino acids", "CHEMICAL", 73, 84], ["amino acids", "CHEMICAL", 73, 84], ["amino acids", "AMINO_ACID", 73, 84], ["cell", "CELL", 88, 92], ["Relative quanti fi cation methods", "TREATMENT", 0, 33], ["amino acids", "TEST", 73, 84], ["cell culture", "TEST", 88, 100], ["nonradioactive isotopic labeling", "TREATMENT", 169, 201]]], ["Although relative quantitation is more costly and time-consuming, and less sensitive to experimental bias than label-free quantitation, it entails labeling the samples with stable isotope labels that allow the mass spectrometer to distinguish between identical proteins in separate samples.", [["samples", "ANATOMY", 160, 167], ["samples", "ANATOMY", 282, 289], ["label-free quantitation", "TEST", 111, 134], ["the mass spectrometer", "TEST", 206, 227], ["quantitation", "OBSERVATION", 18, 30]]], ["Differentially labeled samples are combined and analyzed together, and the differences in the peak intensities of the isotope pairs accurately re fl ect difference in the abundance of the corresponding proteins.", [["samples", "ANATOMY", 23, 30], ["samples", "CANCER", 23, 30], ["Differentially labeled samples", "TEST", 0, 30], ["the isotope pairs", "PROBLEM", 114, 131]]], ["Thus, relative quantitation may discover the dynamic interactions by comparing the change of identical protein abundances from same bait cells with and without extracellular stimulation.", [["bait cells", "ANATOMY", 132, 142], ["extracellular", "ANATOMY", 160, 173], ["cells", "CELL", 137, 142], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 160, 173], ["bait cells", "CELL_TYPE", 132, 142], ["identical protein abundances", "PROBLEM", 93, 121], ["same bait cells", "PROBLEM", 127, 142], ["extracellular stimulation", "TREATMENT", 160, 185], ["protein abundances", "OBSERVATION", 103, 121], ["bait cells", "OBSERVATION", 132, 142], ["without", "UNCERTAINTY", 152, 159]]], ["Absolute quantitation of proteins is also developed by using isotopic peptides entails spiking known concentrations of synthetic, heavy isotopologues of target peptides into an experimental sample (Mirgorodskaya et al. 2012 ) .", [["Absolute quantitation of proteins", "PROBLEM", 0, 33], ["isotopic peptides entails", "TREATMENT", 61, 86], ["target peptides", "TREATMENT", 153, 168]]], ["However, the cost of absolute quantitation is too high and not realistic for large-scale interactome mapping.Quanti fi cation and DynamicsAs quantitative methods become more robust, there will be increasing demand for detection of dynamic protein interaction upon extracellular stimulation.", [["extracellular", "ANATOMY", 264, 277], ["Quanti fi cation", "SIMPLE_CHEMICAL", 109, 125], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 264, 277], ["absolute quantitation", "TEST", 21, 42], ["large-scale interactome mapping", "TREATMENT", 77, 108], ["Quanti fi cation", "TREATMENT", 109, 125], ["dynamic protein interaction", "PROBLEM", 231, 258], ["extracellular stimulation", "TREATMENT", 264, 289], ["too high", "OBSERVATION_MODIFIER", 46, 54], ["protein interaction", "OBSERVATION", 239, 258]]], ["For example, we revealed that ~20% protein interactions are dependent on ligand stimulation, such as viral dsRNA mimics poly(dI:dC), in the h uman i nnate i mmunity i nteractome for type I i nterferon (HI5) (Li et al. 2011 ) .", [["ligand stimulation", "TREATMENT", 73, 91]]], ["Another example in insulin pathway, Glatter et al. de fi ned the interaction network of insulin receptor/target of rapamycin pathway in Drosophila (Glatter et al. 2011 ) .", [["rapamycin", "CHEMICAL", 115, 124], ["rapamycin", "CHEMICAL", 115, 124], ["insulin", "GENE_OR_GENE_PRODUCT", 19, 26], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 88, 104], ["rapamycin", "GENE_OR_GENE_PRODUCT", 115, 124], ["Drosophila", "ORGANISM", 136, 146], ["insulin receptor", "PROTEIN", 88, 104], ["Drosophila", "SPECIES", 136, 146], ["Drosophila", "SPECIES", 136, 146], ["insulin pathway", "TREATMENT", 19, 34], ["insulin receptor", "TREATMENT", 88, 104], ["rapamycin pathway", "TREATMENT", 115, 132]]], ["They found that 22% of the detected interactions were regulated by insulin.", [["insulin", "GENE_OR_GENE_PRODUCT", 67, 74], ["insulin", "PROTEIN", 67, 74], ["insulin", "TREATMENT", 67, 74]]], ["In addition to the quantitative power of mass spectrometry, it is also crucial to establish a stable cell line sensitive to stimulations.", [["cell line", "ANATOMY", 101, 110], ["cell line", "CELL", 101, 110], ["stable cell line", "CELL_LINE", 94, 110], ["mass spectrometry", "PROBLEM", 41, 58], ["mass", "OBSERVATION", 41, 45], ["stable", "OBSERVATION_MODIFIER", 94, 100], ["cell line", "OBSERVATION", 101, 110]]], ["When overexpressed in cells, bait protein may not respond to stimuli as sensitive as the corres ponding endogenous protein.Data Collection and AnalysisIn most cases, the raw data fi les are fi rst processed by the software controlling the respective mass spectrometry instrument.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["bait protein", "PROTEIN", 29, 41], ["corres ponding endogenous protein", "PROTEIN", 89, 122], ["bait protein", "TEST", 29, 41], ["stimuli", "TEST", 61, 68], ["Data Collection", "TEST", 123, 138], ["Analysis", "TEST", 143, 151], ["mass", "OBSERVATION", 250, 254]]], ["A valid approach for validation of the chosen parameters is to search the obtained data sets against a decoy protein database.", [["A valid approach", "TREATMENT", 0, 16], ["a decoy protein database", "TEST", 101, 125]]], ["The data also need to be further fi ltered by setting speci fi c thresholds such as a minimum peptide length or a speci fi c number of peptides to consider a protein identi fi cation.", [["protein identi fi cation", "PROTEIN", 158, 182], ["a minimum peptide length", "TREATMENT", 84, 108], ["a protein identi fi cation", "TREATMENT", 156, 182]]], ["Mass spectrometry has some intrinsic problems, such as the common problem of carryovers between mass spectrometry runs.", [["Mass spectrometry", "PROBLEM", 0, 17], ["some intrinsic problems", "PROBLEM", 22, 45], ["mass spectrometry runs", "PROBLEM", 96, 118], ["intrinsic", "OBSERVATION_MODIFIER", 27, 36], ["problems", "OBSERVATION", 37, 45]]], ["To circumvent the carryover problem in mass spectrometry, we usually analyze the repeated sample in different batch.", [["mass spectrometry", "PROBLEM", 39, 56], ["mass", "OBSERVATION", 39, 43]]], ["The record of each batch of MS runs will also help to discriminate the carryovers.Data Collection and AnalysisIn addition to mass spectrometry, af fi nity puri fi cation also has its own inherent false positives and false negatives, which is critical general limitation encountered in the interpretation of the AP-MS due to lack of binary interaction information.", [["MS runs", "PROBLEM", 28, 35], ["Data Collection", "TEST", 82, 97], ["mass spectrometry", "TEST", 125, 142], ["false negatives", "PROBLEM", 216, 231], ["false positives", "OBSERVATION", 196, 211], ["false negatives", "OBSERVATION", 216, 231]]], ["False positives are nonspeci fi c binding proteins and contaminants found in puri fi ed bait complex.", [["nonspeci fi c binding proteins", "GENE_OR_GENE_PRODUCT", 20, 50], ["puri fi ed bait complex", "GENE_OR_GENE_PRODUCT", 77, 100], ["nonspeci fi c binding proteins", "PROTEIN", 20, 50], ["puri fi ed bait complex", "PROTEIN", 77, 100], ["False positives", "TEST", 0, 15], ["nonspeci fi c binding proteins", "PROBLEM", 20, 50], ["positives", "OBSERVATION", 6, 15]]], ["Several types of false positives are present in typical af fi nity puri fi ed protein samples.", [["samples", "ANATOMY", 86, 93], ["false positives", "PROBLEM", 17, 32], ["false positives", "OBSERVATION", 17, 32]]], ["The most common ones are from researchers' hands when they perform puri fi cation and handle samples.", [["samples", "ANATOMY", 93, 100], ["hands", "ORGANISM_SUBDIVISION", 43, 48], ["puri fi cation", "SIMPLE_CHEMICAL", 67, 81], ["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["These contaminants usually are keratin proteins and easy to remove from the dataset.", [["keratin", "GENE_OR_GENE_PRODUCT", 31, 38], ["keratin proteins", "PROTEIN", 31, 47], ["keratin proteins", "PROBLEM", 31, 47]]], ["There are also other various kinds of nonspeci fi c binding proteins: (1) proteins binding to af fi nity matrices, like STK38 and PRMT5; (2) proteins bind to af fi nity tag, like KIF11 binding to FLAG tag; (3) abundant proteins (e.g., actin, tubulin); (4) proteins prefer binding to speci fi c domain, like ribosomal proteins binding to baits with nucleic acid-binding domain; (5) and heat-shock proteins for protein folding.", [["ribosomal", "ANATOMY", 307, 316], ["nonspeci fi c binding proteins", "GENE_OR_GENE_PRODUCT", 38, 68], ["STK38", "GENE_OR_GENE_PRODUCT", 120, 125], ["PRMT5", "GENE_OR_GENE_PRODUCT", 130, 135], ["KIF11", "GENE_OR_GENE_PRODUCT", 179, 184], ["FLAG", "GENE_OR_GENE_PRODUCT", 196, 200], ["actin", "GENE_OR_GENE_PRODUCT", 235, 240], ["tubulin", "GENE_OR_GENE_PRODUCT", 242, 249], ["speci fi c", "GENE_OR_GENE_PRODUCT", 283, 293], ["heat-shock proteins", "GENE_OR_GENE_PRODUCT", 385, 404], ["nonspeci fi c binding proteins", "PROTEIN", 38, 68], ["STK38", "PROTEIN", 120, 125], ["PRMT5; (2) proteins", "PROTEIN", 130, 149], ["af fi nity tag", "PROTEIN", 158, 172], ["KIF11", "PROTEIN", 179, 184], ["FLAG tag", "PROTEIN", 196, 204], ["abundant proteins", "PROTEIN", 210, 227], ["actin", "PROTEIN", 235, 240], ["tubulin", "PROTEIN", 242, 249], ["speci fi c domain", "PROTEIN", 283, 300], ["ribosomal proteins", "PROTEIN", 307, 325], ["nucleic acid-binding domain", "PROTEIN", 348, 375], ["heat-shock proteins", "PROTEIN", 385, 404], ["nonspeci fi c binding proteins", "PROBLEM", 38, 68], ["proteins binding", "PROBLEM", 74, 90], ["af fi nity matrices", "TEST", 94, 113], ["PRMT5", "TEST", 130, 135], ["proteins bind", "TEST", 141, 154], ["af fi nity tag", "TEST", 158, 172], ["FLAG tag", "TEST", 196, 204], ["abundant proteins", "PROBLEM", 210, 227], ["ribosomal proteins binding", "PROBLEM", 307, 333], ["nucleic acid-binding domain", "PROBLEM", 348, 375], ["heat-shock proteins", "TREATMENT", 385, 404], ["protein folding", "PROBLEM", 409, 424], ["binding proteins", "OBSERVATION", 52, 68], ["ribosomal proteins", "OBSERVATION", 307, 325]]], ["Therefore, it is important to use cell line stably expressing baits at near physiological levels to avoid NSBPs, as transient overexpression may probably result in protein aggregation and improper intracellular localization.", [["cell line", "ANATOMY", 34, 43], ["intracellular", "ANATOMY", 197, 210], ["NSBPs", "DISEASE", 106, 111], ["cell line", "CELL", 34, 43], ["NSBPs", "GENE_OR_GENE_PRODUCT", 106, 111], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 197, 210], ["NSBPs", "PROTEIN", 106, 111], ["cell line", "TREATMENT", 34, 43], ["NSBPs", "PROBLEM", 106, 111], ["transient overexpression", "PROBLEM", 116, 140], ["protein aggregation", "PROBLEM", 164, 183], ["improper intracellular localization", "PROBLEM", 188, 223], ["protein aggregation", "OBSERVATION", 164, 183], ["intracellular localization", "OBSERVATION", 197, 223]]], ["To discriminate NSBP from the protein complex, repetition of AP-MS is mandatory.", [["NSBP", "CANCER", 16, 20], ["NSBP", "PROTEIN", 16, 20], ["protein complex", "PROTEIN", 30, 45]]], ["In our experiences, NSBPs are dramatically different in two independent AP-MS of the same bait.", [["NSBPs", "SIMPLE_CHEMICAL", 20, 25], ["dramatically", "OBSERVATION_MODIFIER", 30, 42], ["different", "OBSERVATION_MODIFIER", 43, 52]]], ["Proper controls including cells expressing GFP with the same epitope will be also useful to exclude NSBPs.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["GFP", "GENE_OR_GENE_PRODUCT", 43, 46], ["NSBPs", "PATHOLOGICAL_FORMATION", 100, 105], ["GFP", "PROTEIN", 43, 46], ["NSBPs", "PROTEIN", 100, 105], ["NSBPs", "PROBLEM", 100, 105]]], ["Last, large database with the same af fi nity tag and the same cell line background from high-throughput study will be a good resource for identi fi cation of NSBPs and HCIPs.", [["cell line", "ANATOMY", 63, 72], ["cell line", "CELL", 63, 72], ["identi fi cation", "SIMPLE_CHEMICAL", 139, 155], ["NSBPs", "SIMPLE_CHEMICAL", 159, 164], ["HCIPs", "SIMPLE_CHEMICAL", 169, 174], ["fi nity tag", "DNA", 38, 49], ["large database", "TEST", 6, 20], ["NSBPs and HCIPs", "TREATMENT", 159, 174], ["large", "OBSERVATION_MODIFIER", 6, 11], ["cell line", "OBSERVATION", 63, 72]]], ["If a protein is often isolated with many unrelated bait proteins, it is easily recognized through analysis of the high-throughput data.", [["bait proteins", "PROTEIN", 51, 64], ["a protein", "TEST", 3, 12], ["many unrelated bait proteins", "PROBLEM", 36, 64]]], ["However, systematic large-scale experiment does not allow for the subjective and individual evaluation of their results, which means the removal of potential contaminating proteins cannot be based on judging individual puri fi cations.", [["puri fi cations", "SIMPLE_CHEMICAL", 219, 234], ["systematic large-scale experiment", "PROBLEM", 9, 42], ["individual evaluation", "TEST", 81, 102], ["the removal", "TREATMENT", 133, 144], ["potential contaminating proteins", "PROBLEM", 148, 180], ["large", "OBSERVATION_MODIFIER", 20, 25]]], ["Therefore, statistic tools for analysis of database are required to fi lter out nonspeci fi c proteins and yield high-con fi dence interacting proteins.Data Collection and AnalysisFor statistical analysis of AP-MS data, three main parameters are protein abundance, uniqueness (the frequency of observed protein in database), and reproduci bility.", [["nonspeci fi c proteins", "GENE_OR_GENE_PRODUCT", 80, 102], ["nonspeci fi c proteins", "PROTEIN", 80, 102], ["con fi dence interacting proteins", "PROTEIN", 118, 151], ["statistic tools", "TEST", 11, 26], ["analysis of database", "TEST", 31, 51], ["interacting proteins", "PROBLEM", 131, 151], ["Data Collection", "TEST", 152, 167], ["Analysis", "TEST", 172, 180], ["statistical analysis", "TEST", 184, 204], ["AP-MS data", "TEST", 208, 218]]], ["Total spectral counts (TSC) have gained acceptance as a practical, label-free, semiquantitative measure of protein abundance in proteomics study.", [["Total spectral counts", "TEST", 0, 21], ["proteomics study", "TEST", 128, 144]]], ["Several computational tools have been developed for the processing of AP-MS data, like CompPASS (Sowa et al. 2009 ) , SAINT (Breitkreutz et al. 2010 ) , and MiST (Jager et al. 2012 ) .Data Collection and AnalysisWe designed a simpli fi ed method for analysis of AP-MS data, combining three main parameters: protein abundance, uniqueness (the frequency of observed protein in the database), and reproducibility.", [["AP-MS data", "TEST", 70, 80], ["Data Collection", "TEST", 184, 199], ["AP-MS data", "TEST", 262, 272], ["protein abundance", "PROBLEM", 307, 324]]], ["Total spectral counts (TSC) have gained acceptance as a practical, label-free, semiquantitative measure of protein abundance for proteomics studies.", [["Total spectral counts", "TEST", 0, 21], ["proteomics studies", "TEST", 129, 147]]], ["We adopted the z -score statistic to compare protein abundance because z -score calculates the probability of TSC occurring within a normal distribution.", [["TSC", "DISEASE", 110, 113], ["TSC", "CANCER", 110, 113], ["protein abundance", "TEST", 45, 62], ["z -score", "TEST", 71, 79], ["TSC", "PROBLEM", 110, 113], ["TSC", "OBSERVATION", 110, 113], ["normal", "OBSERVATION", 133, 139], ["distribution", "OBSERVATION_MODIFIER", 140, 152]]], ["However, z -score does not re fl ect reproducibility.", [["z -score", "TEST", 9, 17]]], ["In our protocol, each protein complex is tested in 4 MS runs, so reproducibility can be readily factored into the analysis. z -Score also does not analyze information about prey occurrence (i.e., prey uniqueness).", [["protein complex", "PROTEIN", 22, 37], ["each protein complex", "TEST", 17, 37], ["the analysis", "TEST", 110, 122]]], ["To explore the likelihood that an interaction is speci fi c, we set a value of prey occurrence at <5%.", [["speci fi c", "GENE_OR_GENE_PRODUCT", 49, 59]]], ["We now propose a simple 3-stage scoring system to identify HCIP.", [["HCIP", "DISEASE", 59, 63], ["HCIP", "PROTEIN", 59, 63]]], ["This algorithm combines z -score plus prey occurrence and reproducibility (ZSPORE) (Li and Dorf 2013 ) .", [["This algorithm", "TEST", 0, 14]]], ["In the ZSPORE scoring system, each interaction must pass all three criteria to merit classi fi cation as HCIP.", [["classi fi cation", "SIMPLE_CHEMICAL", 85, 101], ["HCIP", "SIMPLE_CHEMICAL", 105, 109]]], ["The fl owchart of ZSPORE is shown as in Fig. 2.3 , and a detailed description is provided in Sect.", [["ZSPORE", "DNA", 18, 24]]], ["Taken together, the ZSPORE method combines three parameters ( z -score based on TSC, prey occurrence, and reproducibility) and is a simple, ef fi cient, and robust way to analyze AP-MS data.Data Collection and AnalysisAs with any large screening database, AP-MS also has false negatives, like lacking many known protein-protein interactions documented previously.", [["ZSPORE", "DNA", 20, 26], ["the ZSPORE method", "TREATMENT", 16, 33], ["AP-MS data", "TEST", 179, 189], ["Data Collection", "TEST", 190, 205], ["AnalysisAs", "TEST", 210, 220], ["any large screening database", "TEST", 226, 254], ["AP-MS", "TEST", 256, 261], ["false negatives", "PROBLEM", 271, 286], ["false negatives", "OBSERVATION", 271, 286]]], ["First, statistical analysis tool may fi lter out the known interaction as a nonspeci fi c binding.", [["nonspeci fi c", "GENE_OR_GENE_PRODUCT", 76, 89], ["statistical analysis tool", "TEST", 7, 32]]], ["Second, the nature and location of the tag might interfere bait protein function and disrupt its interactions.", [["tag", "GENE_OR_GENE_PRODUCT", 39, 42]]], ["Third, to parallel comparison, all AP-MS experiments are performed in a same single condition.", [["all AP-MS experiments", "TEST", 31, 52]]], ["The generic conditions of af fi nity puri fi cation may be too harsh to preserve some protein interactions, such as the buffer for membrane proteins should be different from other ones.", [["membrane", "ANATOMY", 131, 139], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["membrane proteins", "PROTEIN", 131, 148], ["af fi nity puri fi cation", "TREATMENT", 26, 51], ["some protein interactions", "PROBLEM", 81, 106], ["membrane proteins", "TREATMENT", 131, 148]]], ["Fourth, the known protein interaction depends on different stimulation.", [["the known protein interaction", "PROBLEM", 8, 37], ["different stimulation", "TREATMENT", 49, 70], ["protein interaction", "OBSERVATION", 18, 37]]], ["Some proteins may be involved in several pathways and have different interactors in response to the relevant stimulation.", [["may be", "UNCERTAINTY", 14, 20]]], ["Last, the absence of detection is often due to the protein expression level in the speci fi c cell type, especially when the cells have relative low abundances of the protein.Network Mapping and AnalysisTo visualize the protein interaction network formed by HCIPs and baits, graphic representation of two protein interactions basically consists of drawing two circles (nodes) linked by a line (edge).", [["speci fi c cell type", "ANATOMY", 83, 103], ["cells", "ANATOMY", 125, 130], ["speci fi c cell type", "CELL", 83, 103], ["cells", "CELL", 125, 130], ["HCIPs", "GENE_OR_GENE_PRODUCT", 258, 263], ["speci fi c cell type", "CELL_LINE", 83, 103], ["protein interaction network", "PROTEIN", 220, 247], ["HCIPs", "PROTEIN", 258, 263], ["the protein expression level", "PROBLEM", 47, 75], ["relative low abundances of the protein", "PROBLEM", 136, 174], ["Network Mapping", "TEST", 175, 190], ["two protein interactions", "PROBLEM", 301, 325], ["cell type", "OBSERVATION", 94, 103], ["low abundances", "OBSERVATION_MODIFIER", 145, 159], ["nodes", "OBSERVATION", 369, 374]]], ["For comprehensive and dynamic visualization of the network, various kinds of attributes can be applied to the node and the edge by representation of different color and line thickness.", [["node", "ANATOMY", 110, 114], ["node", "MULTI-TISSUE_STRUCTURE", 110, 114], ["node", "OBSERVATION", 110, 114], ["edge", "OBSERVATION_MODIFIER", 123, 127], ["different", "OBSERVATION_MODIFIER", 149, 158], ["color", "OBSERVATION_MODIFIER", 159, 164], ["line", "OBSERVATION_MODIFIER", 169, 173], ["thickness", "OBSERVATION_MODIFIER", 174, 183]]], ["In addition, the functional classi fi cations of HCIPs can be analyzed by a few online programs.", [["HCIPs", "SIMPLE_CHEMICAL", 49, 54], ["the functional classi fi cations of HCIPs", "TREATMENT", 13, 54]]], ["For example, HCIP list can be uploaded to PANTHER (Thomas et al. 2003 ) or DAVID (da Huang et al. 2009 ) via a web interface.", [["HCIP", "PROTEIN", 13, 17]]], ["These programs group these proteins by protein domains, molecular functions, biological processes, and signal pathways.", [["protein domains", "PROTEIN", 39, 54], ["these proteins", "TEST", 21, 35], ["protein domains", "TEST", 39, 54]]], ["The functional classi fi cations may help discover common threads underlying the proteins of interest.", [["classi fi cations", "SIMPLE_CHEMICAL", 15, 32], ["The functional classi fi cations", "TREATMENT", 0, 32]]], ["Another approach is to obtain clues from known protein interactions to discover regulation mechanisms.", [["known protein interactions", "PROBLEM", 41, 67]]], ["Several protein-protein interaction databases are available for online search, repository, and free download, such as BioGRID, STRING, IntAct, and MINT.", [["BioGRID", "PROTEIN", 118, 125], ["STRING", "PROTEIN", 127, 133], ["IntAct", "PROTEIN", 135, 141], ["MINT", "PROTEIN", 147, 151], ["Several protein", "TEST", 0, 15], ["online search", "TEST", 64, 77]]], ["The latest version searches 31,739 publications for 510,188 raw protein and genetic interactions from major model organism species .", [["raw protein", "PROBLEM", 60, 71], ["genetic interactions", "PROBLEM", 76, 96], ["major model organism species", "PROBLEM", 102, 130], ["organism species", "OBSERVATION", 114, 130]]], ["The STRING is a database of known and predicted protein interactions.", [["STRING", "PROTEIN", 4, 10]]], ["STRING quantitatively integrates interaction data from these sources for a large number of organisms and transfers information between these organisms where applicable (Szklarczyk et al. 2011 ) .", [["a large number of organisms", "PROBLEM", 73, 100], ["these organisms", "TEST", 135, 150]]], ["The IntAct database provides a freely available, open-source database system and analysis tools for molecular interaction data (Kerrien et al. 2012 ) .", [["analysis tools", "TEST", 81, 95]]], ["The MINT database focuses on experimentally veri fi ed protein-protein interactions mined from the scienti fi c literature by expert curators (Licata et al. 2012 ) .Network Mapping and AnalysisAP-MS raw data also can be deposited in the Tranche repository (Smith et al. 2011 ) , which is a distributed fi le system into which any sort of proteomics data may be uploaded.", [["Network Mapping", "TEST", 165, 180], ["AnalysisAP", "TEST", 185, 195], ["proteomics data", "TEST", 338, 353]]], ["In summary, all these free online programs are useful and convenient research tools for mapping, analysis, and repository of AP-MS data.ProtocolsAP-MS has applied for mapping of protein interactome of various cellular signaling pathways in mammalian cells.", [["cellular", "ANATOMY", 209, 217], ["mammalian cells", "ANATOMY", 240, 255], ["ProtocolsAP", "CHEMICAL", 136, 147], ["cellular", "CELL", 209, 217], ["mammalian cells", "CELL", 240, 255], ["mammalian cells", "CELL_TYPE", 240, 255], ["mapping", "TEST", 88, 95], ["analysis", "TEST", 97, 105], ["AP-MS data", "TEST", 125, 135], ["MS", "PROBLEM", 148, 150], ["various cellular", "OBSERVATION", 201, 217], ["signaling pathways", "OBSERVATION", 218, 236], ["mammalian cells", "OBSERVATION", 240, 255]]], ["Our lab has established an ef fi cient AP-MS pipeline for de fi ning protein interaction network and successfully applied in several pathways including h uman i nnate i mmunity i nteractome for type I i nterferon (HI5) (Li et al. 2011 ) , mi RNA pathway i nteractome (Mii), and in fl uenza-host (iHost) protein interaction network (Li and Dorf, unpublished data) .", [["Mii", "PROTEIN", 268, 271], ["fl uenza-host (iHost) protein interaction network", "PROTEIN", 281, 330], ["Dorf", "PROTEIN", 339, 343]]], ["Detailed pipeline of our AP-MS is provided in this section, and how this applies on different pathways in mammalian cells will be discussed.Bait Selection and cDNA CloningGenes known to regulate the studied signaling pathway are usually selected as primary baits.", [["cells", "ANATOMY", 116, 121], ["mammalian cells", "CELL", 106, 121], ["mammalian cells", "CELL_TYPE", 106, 121], ["cDNA CloningGenes", "DNA", 159, 176], ["mammalian cells", "TREATMENT", 106, 121], ["Bait Selection", "TREATMENT", 140, 154], ["cDNA CloningGenes", "TREATMENT", 159, 176]]], ["Baits cover from extracellular signals like ligands to cognate receptors on cell membrane and to signaling intermediates, kinases, and transcription factors involved in these signaling pathways and their family members.", [["extracellular", "ANATOMY", 17, 30], ["cell membrane", "ANATOMY", 76, 89], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 30], ["cell membrane", "CELLULAR_COMPONENT", 76, 89], ["cognate receptors", "PROTEIN", 55, 72], ["kinases", "PROTEIN", 122, 129], ["transcription factors", "PROTEIN", 135, 156]]], ["After analysis of primary bait AP-MS, some new and important HCIPs with primary baits are also chosen to be as secondary baits.", [["HCIPs", "SIMPLE_CHEMICAL", 61, 66], ["primary baits", "TREATMENT", 72, 85], ["new", "OBSERVATION_MODIFIER", 43, 46]]], ["Secondary baits will validate the association with primary baits but also expand the protein interaction network, provide new insights into this signaling pathway, and cross talk with other pathways.Bait Selection and cDNA CloningBait cDNAs can be tagged with various epitopes, such as FLAG or HA epitope.", [["FLAG", "GENE_OR_GENE_PRODUCT", 286, 290], ["HA epitope", "GENE_OR_GENE_PRODUCT", 294, 304], ["cDNA", "DNA", 218, 222], ["Bait cDNAs", "DNA", 230, 240], ["epitopes", "PROTEIN", 268, 276], ["FLAG", "PROTEIN", 286, 290], ["HA epitope", "PROTEIN", 294, 304], ["primary baits", "TREATMENT", 51, 64], ["Bait Selection", "TREATMENT", 199, 213], ["cDNA CloningBait cDNAs", "TREATMENT", 218, 240], ["various epitopes", "PROBLEM", 260, 276], ["HA epitope", "PROBLEM", 294, 304]]], ["As we discussed earlier, commercially available anti-FLAG beads have much higher af fi nity than anti-HA beads.", [["anti-FLAG", "GENE_OR_GENE_PRODUCT", 48, 57], ["anti-HA", "GENE_OR_GENE_PRODUCT", 97, 104], ["anti-HA beads", "PROTEIN", 97, 110], ["anti-FLAG beads", "TREATMENT", 48, 63], ["anti-HA beads", "TREATMENT", 97, 110]]], ["We use two mammalian expression vectors, pCMV-3Tag8 (Stratagene) and viral expression vector, pLPCX (Clontech), for transfection and infection, respectively.", [["infection", "DISEASE", 133, 142], ["pCMV-3Tag8", "GENE_OR_GENE_PRODUCT", 41, 51], ["pLPCX", "GENE_OR_GENE_PRODUCT", 94, 99], ["Clontech", "GENE_OR_GENE_PRODUCT", 101, 109], ["mammalian expression vectors", "DNA", 11, 39], ["pCMV", "DNA", 41, 45], ["3Tag8", "DNA", 46, 51], ["Stratagene", "DNA", 53, 63], ["viral expression vector", "DNA", 69, 92], ["pLPCX", "DNA", 94, 99], ["Clontech", "DNA", 101, 109], ["two mammalian expression vectors", "TREATMENT", 7, 39], ["pCMV", "TREATMENT", 41, 45], ["3Tag8 (Stratagene)", "TREATMENT", 46, 64], ["viral expression vector", "TREATMENT", 69, 92], ["pLPCX (Clontech)", "TREATMENT", 94, 110], ["transfection", "PROBLEM", 116, 128], ["infection", "PROBLEM", 133, 142], ["infection", "OBSERVATION", 133, 142]]], ["Vector pCMV-3Tag8 harbors a hygromycin resistance gene, while pLPCX confers cells' resistance to puromycin.Establishment of Stable Cell Line and Cell StimulationTransfection and transduction are two common DNA delivery methods into mammalian cells.", [["cells", "ANATOMY", 76, 81], ["Cell", "ANATOMY", 131, 135], ["Cell", "ANATOMY", 145, 149], ["cells", "ANATOMY", 242, 247], ["hygromycin", "CHEMICAL", 28, 38], ["pLPCX", "CHEMICAL", 62, 67], ["puromycin", "CHEMICAL", 97, 106], ["hygromycin", "CHEMICAL", 28, 38], ["puromycin", "CHEMICAL", 97, 106], ["pCMV-3Tag8", "GENE_OR_GENE_PRODUCT", 7, 17], ["hygromycin", "GENE_OR_GENE_PRODUCT", 28, 38], ["pLPCX", "GENE_OR_GENE_PRODUCT", 62, 67], ["cells", "CELL", 76, 81], ["puromycin", "SIMPLE_CHEMICAL", 97, 106], ["Cell Line", "CELL", 131, 140], ["Cell", "CELL", 145, 149], ["DNA", "CELLULAR_COMPONENT", 206, 209], ["mammalian cells", "CELL", 232, 247], ["Vector pCMV-3Tag8", "DNA", 0, 17], ["hygromycin resistance gene", "DNA", 28, 54], ["pLPCX", "DNA", 62, 67], ["mammalian cells", "CELL_TYPE", 232, 247], ["Vector pCMV", "TREATMENT", 0, 11], ["a hygromycin resistance gene", "TREATMENT", 26, 54], ["puromycin", "TREATMENT", 97, 106], ["Stable Cell Line", "TREATMENT", 124, 140], ["Cell StimulationTransfection", "TREATMENT", 145, 173], ["transduction", "TREATMENT", 178, 190], ["two common DNA delivery methods", "TREATMENT", 195, 226], ["hygromycin resistance", "OBSERVATION", 28, 49], ["Stable", "OBSERVATION_MODIFIER", 124, 130], ["Cell Line", "OBSERVATION", 131, 140], ["Cell StimulationTransfection", "OBSERVATION", 145, 173], ["mammalian cells", "OBSERVATION", 232, 247]]], ["For cell lines easy to be transfected like HEK293 cells, bait constructs are directly transfected into cells.", [["cell lines", "ANATOMY", 4, 14], ["HEK293 cells", "ANATOMY", 43, 55], ["cells", "ANATOMY", 103, 108], ["cell lines", "CELL", 4, 14], ["HEK293 cells", "CELL", 43, 55], ["cells", "CELL", 103, 108], ["cell lines", "CELL_LINE", 4, 14], ["HEK293 cells", "CELL_LINE", 43, 55], ["bait constructs", "DNA", 57, 72], ["cell lines", "TREATMENT", 4, 14], ["bait constructs", "TREATMENT", 57, 72], ["cell lines", "OBSERVATION", 4, 14], ["HEK293 cells", "OBSERVATION", 43, 55]]], ["For cell lines with low transfection ef fi ciency, such as THP-1 cell line, bait gene needs to be fi rst packaged into retroviral virion.", [["cell lines", "ANATOMY", 4, 14], ["THP-1 cell line", "ANATOMY", 59, 74], ["cell lines", "CELL", 4, 14], ["THP-1 cell line", "CELL", 59, 74], ["retroviral", "ORGANISM", 119, 129], ["cell lines", "CELL_LINE", 4, 14], ["THP-1 cell line", "CELL_LINE", 59, 74], ["bait gene", "DNA", 76, 85], ["cell lines", "TREATMENT", 4, 14], ["low transfection ef fi ciency", "TREATMENT", 20, 49], ["THP-1 cell line", "TREATMENT", 59, 74], ["retroviral virion", "TREATMENT", 119, 136], ["cell lines", "OBSERVATION", 4, 14], ["low transfection", "OBSERVATION_MODIFIER", 20, 36], ["cell line", "OBSERVATION", 65, 74], ["retroviral virion", "OBSERVATION", 119, 136]]], ["The following infection will allow bait gene to integrate into cell genome DNA and subsequent expression in cells.", [["cell", "ANATOMY", 63, 67], ["cells", "ANATOMY", 108, 113], ["infection", "DISEASE", 14, 23], ["cell", "CELL", 63, 67], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["cells", "CELL", 108, 113], ["bait gene", "DNA", 35, 44], ["cell genome DNA", "DNA", 63, 78], ["The following infection", "PROBLEM", 0, 23], ["bait gene", "TREATMENT", 35, 44], ["cell genome DNA", "TREATMENT", 63, 78], ["subsequent expression in cells", "PROBLEM", 83, 113]]], ["Two days after transfection and infection, cells are treated with puromycin or hygromycin for 14 days.", [["cells", "ANATOMY", 43, 48], ["infection", "DISEASE", 32, 41], ["puromycin", "CHEMICAL", 66, 75], ["hygromycin", "CHEMICAL", 79, 89], ["puromycin", "CHEMICAL", 66, 75], ["hygromycin", "CHEMICAL", 79, 89], ["cells", "CELL", 43, 48], ["puromycin", "SIMPLE_CHEMICAL", 66, 75], ["hygromycin", "SIMPLE_CHEMICAL", 79, 89], ["transfection", "TREATMENT", 15, 27], ["infection", "PROBLEM", 32, 41], ["cells", "PROBLEM", 43, 48], ["puromycin", "TREATMENT", 66, 75], ["hygromycin", "TREATMENT", 79, 89], ["infection", "OBSERVATION", 32, 41]]], ["Single colonies are picked and expanded in 6-well plates.", [["colonies", "ANATOMY", 7, 15], ["colonies", "OBSERVATION", 7, 15], ["expanded", "OBSERVATION_MODIFIER", 31, 39], ["well plates", "OBSERVATION_MODIFIER", 45, 56]]], ["Protein expression levels in each colony are determined by immunoblotting.", [["colony", "ANATOMY", 34, 40], ["Protein expression levels", "TEST", 0, 25], ["immunoblotting", "TEST", 59, 73]]], ["Colony with protein expression close to endogenous level is picked up for AP-MS.Establishment of Stable Cell Line and Cell StimulationMost protein interactomes are descriptions of homeostasis of a speci fi c signaling pathway, such as DUB network (Sowa et al. 2009 ) , autophagy interaction network (Behrends et al. 2010 ) , and ERAD interactome (Christianson et al. 2012 ) .", [["Cell", "ANATOMY", 104, 108], ["Cell", "ANATOMY", 118, 122], ["Cell Line", "CELL", 104, 113], ["Cell", "CELL", 118, 122], ["speci fi c", "GENE_OR_GENE_PRODUCT", 197, 207], ["DUB", "GENE_OR_GENE_PRODUCT", 235, 238], ["DUB network", "PROTEIN", 235, 246], ["ERAD", "PROTEIN", 329, 333], ["protein expression", "PROBLEM", 12, 30], ["Stable Cell Line", "TREATMENT", 97, 113], ["Cell Stimulation", "TREATMENT", 118, 134], ["protein expression", "OBSERVATION", 12, 30], ["Stable", "OBSERVATION_MODIFIER", 97, 103], ["Cell Line", "OBSERVATION", 104, 113], ["Cell Stimulation", "OBSERVATION", 118, 134]]], ["However, many protein interactions depend on protein posttranslational modi fi cations induced by different stimuli.", [["modi fi cations", "SIMPLE_CHEMICAL", 71, 86], ["many protein interactions", "PROBLEM", 9, 34], ["protein posttranslational modi fi cations", "TREATMENT", 45, 86]]], ["For example, we found that about 20% interactions were ligand dependent in HI5 protein interaction network (Li et al. 2011 ) .", [["HI5", "GENE_OR_GENE_PRODUCT", 75, 78], ["HI5", "PROTEIN", 75, 78]]], ["We also noticed many new interactions between in fl uenza virus protein and human host after viral infection (Li and Dorf, unpublished data) .", [["viral infection", "DISEASE", 93, 108], ["fl uenza virus", "ORGANISM", 49, 63], ["human", "ORGANISM", 76, 81], ["fl uenza virus protein", "PROTEIN", 49, 71], ["human", "SPECIES", 76, 81], ["uenza virus", "SPECIES", 52, 63], ["human", "SPECIES", 76, 81], ["fl uenza virus protein", "TREATMENT", 49, 71], ["viral infection", "PROBLEM", 93, 108], ["many", "OBSERVATION_MODIFIER", 16, 20], ["new", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 99, 108]]], ["Therefore, in our pipeline for AP-MS, each stable cell line is divided into two groups, and cells are treated with ligand speci fi c for the signaling pathway or infected with virus for studying virus-host interactome.Complex Puri fi cationEach group of cells is cultured in four or fi ve 15-cm 2 culture dishes (about 5 \u00d7 10 7 cells) to scale up for af fi nity puri fi cation.", [["cell line", "ANATOMY", 50, 59], ["cells", "ANATOMY", 92, 97], ["cells", "ANATOMY", 254, 259], ["cells", "ANATOMY", 328, 333], ["cell line", "CELL", 50, 59], ["cells", "CELL", 92, 97], ["speci fi c", "GENE_OR_GENE_PRODUCT", 122, 132], ["cells", "CELL", 254, 259], ["cells", "CELL", 328, 333], ["puri fi cation", "SIMPLE_CHEMICAL", 362, 376], ["stable cell line", "CELL_LINE", 43, 59], ["each stable cell line", "TREATMENT", 38, 59], ["the signaling pathway", "PROBLEM", 137, 158], ["virus", "PROBLEM", 176, 181], ["culture dishes", "TEST", 297, 311], ["scale", "TEST", 338, 343], ["stable", "OBSERVATION_MODIFIER", 43, 49], ["cell line", "OBSERVATION", 50, 59]]], ["Cells are lysed in 10 ml TAP buffer (50 mM Tris HCl [pH 7.5], 10 mM MgCl 2 , 100 mM NaCl, 0.5% Nonidet P40, 10% glycerol, phosphatase inhibitors, and protease inhibitors).", [["Cells", "ANATOMY", 0, 5], ["Tris HCl", "CHEMICAL", 43, 51], ["NaCl", "CHEMICAL", 84, 88], ["glycerol", "CHEMICAL", 112, 120], ["Tris HCl", "CHEMICAL", 43, 51], ["MgCl 2", "CHEMICAL", 68, 74], ["NaCl", "CHEMICAL", 84, 88], ["Nonidet P40", "CHEMICAL", 95, 106], ["glycerol", "CHEMICAL", 112, 120], ["Cells", "CELL", 0, 5], ["Nonidet P40", "SIMPLE_CHEMICAL", 95, 106], ["glycerol", "SIMPLE_CHEMICAL", 112, 120], ["Cells", "TEST", 0, 5], ["pH", "TEST", 53, 55], ["MgCl", "TEST", 68, 72], ["NaCl", "TEST", 84, 88], ["glycerol", "TREATMENT", 112, 120], ["phosphatase inhibitors", "TREATMENT", 122, 144], ["protease inhibitors", "TREATMENT", 150, 169]]], ["After shaking on ice for 30 min, cell lysates were centrifuged for 30 min at 15,000 rpm.", [["cell lysates", "ANATOMY", 33, 45], ["cell lysates", "ORGANISM_SUBSTANCE", 33, 45], ["cell lysates", "TEST", 33, 45]]], ["Supernatants are collected and precleared with 50 m l of protein A/G resin.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["G resin", "SIMPLE_CHEMICAL", 67, 74], ["protein A", "PROTEIN", 57, 66], ["protein A/G resin", "TREATMENT", 57, 74]]], ["Cell lysates are added to 20 m l anti-FLAG M2 resin (Sigma) and incubated on a shaker for 12 h.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["Cell lysates", "TREATMENT", 0, 12]]], ["Then the anti-FLAG resin is 3\u00d7 washed (15 min/time) with 10 ml TAP buffer.", [["anti-FLAG", "GENE_OR_GENE_PRODUCT", 9, 18], ["the anti-FLAG resin", "TREATMENT", 5, 24], ["10 ml TAP buffer", "TREATMENT", 57, 73]]], ["After removing the wash buffer, the resin is transferred to a spin column (Sigma) and incubated with 40 m l 3\u00d7 FLAG peptide (Sigma) for 1 h at 4\u00b0C in a shaker.", [["FLAG", "GENE_OR_GENE_PRODUCT", 111, 115], ["the wash buffer", "TREATMENT", 15, 30], ["the resin", "TREATMENT", 32, 41]]], ["Eluates are collected by centrifugation and stored at \u221280\u00b0C.Silver StainingPuri fi ed complexes are loaded on 4-15% NuPAGE gels (Invitrogen) and run about 1 cm 2 distance for 8 min at 200 V. Gels were stained using the SilverQuest Staining Kit (Invitrogen).", [["NuPAGE", "CHEMICAL", 116, 122], ["Silver StainingPuri fi ed complexes", "PROTEIN", 60, 95], ["Silver StainingPuri fi ed complexes", "TREATMENT", 60, 95], ["4-15% NuPAGE gels", "TREATMENT", 110, 127], ["the SilverQuest Staining Kit (Invitrogen", "TREATMENT", 215, 255]]], ["Each entire stained lane was excised and rinsed twice with 50% acetonitrile.Mass SpectrometryThe Taplin Biological Mass Spectrometry Facility (Harvard Medical School) performs MS analysis for our samples.", [["lane", "ANATOMY", 20, 24], ["samples", "ANATOMY", 196, 203], ["acetonitrile", "CHEMICAL", 63, 75], ["acetonitrile", "CHEMICAL", 63, 75], ["acetonitrile", "SIMPLE_CHEMICAL", 63, 75], ["Each entire stained lane", "TREATMENT", 0, 24], ["50% acetonitrile", "TREATMENT", 59, 75], ["Mass Spectrometry", "PROBLEM", 76, 93], ["MS analysis", "TEST", 176, 187], ["our samples", "TEST", 192, 203], ["Spectrometry", "OBSERVATION", 81, 93]]], ["Excised gel bands were cut into approximately 1-mm 3 pieces.", [["Excised gel bands", "TREATMENT", 0, 17], ["gel bands", "OBSERVATION", 8, 17], ["approximately 1-mm", "OBSERVATION_MODIFIER", 32, 50]]], ["Gel pieces are then subjected to a modi fi ed in-gel trypsin digestion procedure.", [["trypsin", "PROTEIN", 53, 60], ["gel trypsin digestion procedure", "TREATMENT", 49, 80]]], ["Gel pieces were washed and dehydrated with acetonitrile for 10 min followed by removal of acetonitrile.", [["acetonitrile", "CHEMICAL", 43, 55], ["acetonitrile", "CHEMICAL", 90, 102], ["acetonitrile", "CHEMICAL", 43, 55], ["acetonitrile", "CHEMICAL", 90, 102], ["acetonitrile", "SIMPLE_CHEMICAL", 43, 55], ["acetonitrile", "SIMPLE_CHEMICAL", 90, 102], ["Gel pieces", "TREATMENT", 0, 10], ["acetonitrile", "TREATMENT", 43, 55], ["removal of acetonitrile", "TREATMENT", 79, 102]]], ["Pieces were then completely dried in a speed-vac.", [["Pieces", "TREATMENT", 0, 6], ["vac", "TREATMENT", 45, 48], ["vac", "ANATOMY", 45, 48]]], ["Gel pieces were rehydrated with 50 mM ammonium bicarbonate solution containing 12.5 ng/ m l modi fi ed sequencing grade trypsin (Promega, Madison, WI) at 4\u00b0C. After 45 min, the excess trypsin solution was removed and replaced with 50 mM ammonium bicarbonate solution to just cover the gel pieces.", [["ammonium bicarbonate", "CHEMICAL", 38, 58], ["ammonium bicarbonate", "CHEMICAL", 237, 257], ["ammonium bicarbonate", "CHEMICAL", 38, 58], ["ammonium bicarbonate", "CHEMICAL", 237, 257], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 38, 58], ["trypsin", "GENE_OR_GENE_PRODUCT", 184, 191], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 237, 257], ["trypsin", "PROTEIN", 120, 127], ["Gel pieces", "TREATMENT", 0, 10], ["50 mM ammonium bicarbonate solution", "TREATMENT", 32, 67], ["the excess trypsin solution", "TREATMENT", 173, 200], ["50 mM ammonium bicarbonate solution", "TREATMENT", 231, 266], ["the gel pieces", "TREATMENT", 281, 295], ["gel pieces", "OBSERVATION", 285, 295]]], ["Peptides were later extracted by removing the ammonium bicarbonate solution, followed by one wash with a solution containing 50% acetonitrile and 1% formic acid.", [["ammonium bicarbonate", "CHEMICAL", 46, 66], ["acetonitrile", "CHEMICAL", 129, 141], ["formic acid", "CHEMICAL", 149, 160], ["ammonium bicarbonate", "CHEMICAL", 46, 66], ["acetonitrile", "CHEMICAL", 129, 141], ["formic acid", "CHEMICAL", 149, 160], ["ammonium", "SIMPLE_CHEMICAL", 46, 54], ["bicarbonate", "SIMPLE_CHEMICAL", 55, 66], ["acetonitrile", "SIMPLE_CHEMICAL", 129, 141], ["formic acid", "SIMPLE_CHEMICAL", 149, 160], ["the ammonium bicarbonate solution", "TREATMENT", 42, 75], ["a solution", "TREATMENT", 103, 113], ["50% acetonitrile", "TREATMENT", 125, 141], ["1% formic acid", "TREATMENT", 146, 160]]], ["The extracts were then dried in a speed-vac (~1 h) and stored at 4\u00b0C until analysis.Mass SpectrometryOn the day of analysis, the samples were reconstituted in 5-10 m l of HPLC solvent A (2.5% acetonitrile, 0.1% formic acid).", [["extracts", "ANATOMY", 4, 12], ["samples", "ANATOMY", 129, 136], ["acetonitrile", "CHEMICAL", 192, 204], ["formic acid", "CHEMICAL", 211, 222], ["acetonitrile", "CHEMICAL", 192, 204], ["formic acid", "CHEMICAL", 211, 222], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["acetonitrile", "SIMPLE_CHEMICAL", 192, 204], ["formic acid", "SIMPLE_CHEMICAL", 211, 222], ["The extracts", "TREATMENT", 0, 12], ["vac", "TREATMENT", 40, 43], ["analysis", "TEST", 75, 83], ["analysis", "TEST", 115, 123], ["the samples", "TEST", 125, 136], ["HPLC solvent A", "TREATMENT", 171, 185], ["2.5% acetonitrile", "TREATMENT", 187, 204], ["vac", "ANATOMY", 40, 43]]], ["A nanoscale reverse-phase HPLC capillary column was created by packing 5 m m C18 spherical silica beads into a fused silica capillary (100-m m inner diameter x ~12-cm length) with a fl ame-drawn tip.", [["silica", "CHEMICAL", 91, 97], ["silica", "CHEMICAL", 117, 123], ["A nanoscale reverse-phase HPLC capillary column", "TREATMENT", 0, 47], ["packing 5 m m C18 spherical silica beads", "TREATMENT", 63, 103], ["a fused silica capillary (100-m m inner diameter", "TREATMENT", 109, 157], ["a fl ame-drawn tip", "TREATMENT", 180, 198], ["capillary column", "OBSERVATION", 31, 47], ["silica beads", "OBSERVATION", 91, 103], ["silica capillary", "ANATOMY", 117, 133]]], ["After equilibrating the column, each sample was loaded via a FAMOS auto sampler (LC Packings, San Francisco, CA) onto the column.", [["sample", "ANATOMY", 37, 43], ["a FAMOS auto sampler (LC Packings", "TREATMENT", 59, 92], ["column", "ANATOMY", 24, 30], ["column", "ANATOMY", 122, 128]]], ["A gradient was formed and peptides were eluted with increasing concentrations of solvent B (97.5% acetonitrile, 0.1% formic acid).Mass SpectrometryAs peptides eluted, they were subjected to electrospray ionization and then entered into an LTQ Velos ion trap mass spectrometer (Thermo Fisher, San Jose, CA).", [["solvent B", "CHEMICAL", 81, 90], ["acetonitrile", "CHEMICAL", 98, 110], ["formic acid", "CHEMICAL", 117, 128], ["acetonitrile", "CHEMICAL", 98, 110], ["formic acid", "CHEMICAL", 117, 128], ["B", "SIMPLE_CHEMICAL", 89, 90], ["acetonitrile", "SIMPLE_CHEMICAL", 98, 110], ["formic acid", "SIMPLE_CHEMICAL", 117, 128], ["A gradient", "TEST", 0, 10], ["increasing concentrations of solvent B", "TREATMENT", 52, 90], ["acetonitrile", "TEST", 98, 110], ["Mass Spectrometry", "PROBLEM", 130, 147], ["electrospray ionization", "TEST", 190, 213], ["gradient", "OBSERVATION_MODIFIER", 2, 10], ["Spectrometry", "OBSERVATION", 135, 147]]], ["Peptides were detected, isolated, and fragmented to produce a tandem mass spectrum of speci fi c fragment ions for each peptide.", [["speci fi c fragment ions", "SIMPLE_CHEMICAL", 86, 110], ["Peptides", "PROBLEM", 0, 8], ["a tandem mass", "PROBLEM", 60, 73], ["speci fi c fragment ions", "TREATMENT", 86, 110], ["tandem", "OBSERVATION_MODIFIER", 62, 68], ["mass", "OBSERVATION", 69, 73], ["fragment ions", "OBSERVATION", 97, 110]]], ["Peptide sequences (and hence protein identity) were determined by matching protein databases with the acquired fragmentation pattern by the software program SEQUEST (Thermo Fisher, San Jose, CA).", [["Peptide sequences", "TEST", 0, 17], ["matching protein databases", "TEST", 66, 92], ["the acquired fragmentation pattern", "PROBLEM", 98, 132]]], ["The human IPI database (ver.", [["human", "ORGANISM", 4, 9], ["human IPI database", "DNA", 4, 22], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human IPI database", "TEST", 0, 22]]], ["Precursor mass tolerance was set to \u00b12.0 Da, and MS/MS tolerance was set to 1.0 Da.", [["Precursor mass tolerance", "PROBLEM", 0, 24], ["MS/MS tolerance", "PROBLEM", 49, 64], ["mass", "OBSERVATION", 10, 14]]], ["Filtering was performed using the SEQUEST primary score, Xcorr, and delta-Corr.", [["Xcorr", "TEST", 57, 62]]], ["Spectral matches were further manually examined, and multiple identi fi ed peptides (>1) per protein were required.Statistical Analysis of Mass Spectrometry DataAs with many screening methods, un fi ltered AP-MS data contain many nonspeci fi c binding proteins due to some intrinsic characteristics, such as nonspeci fi c binding to bead or tag, protein aggregation, and carryover during MS runs.", [["nonspeci fi c binding proteins", "GENE_OR_GENE_PRODUCT", 230, 260], ["nonspeci fi c", "GENE_OR_GENE_PRODUCT", 308, 321], ["nonspeci fi c binding proteins", "PROTEIN", 230, 260], ["nonspeci fi c", "PROTEIN", 308, 321], ["Spectral matches", "TEST", 0, 16], ["multiple identi fi ed peptides", "TREATMENT", 53, 83], ["Mass Spectrometry", "PROBLEM", 139, 156], ["many screening methods", "TEST", 169, 191], ["MS data", "TEST", 209, 216], ["many nonspeci fi c binding proteins", "PROBLEM", 225, 260], ["some intrinsic characteristics", "PROBLEM", 268, 298], ["protein aggregation", "PROBLEM", 346, 365]]], ["We now describe a simple ef fi cient statistic method, z -score plus prey occurrence and reproducibility (ZSPORE) scoring system, for identi fi cation of HCIP.", [["HCIP", "CHEMICAL", 154, 158], ["HCIP", "SIMPLE_CHEMICAL", 154, 158], ["statistic method", "TEST", 37, 53]]], ["Using this pipeline, we achieve a higher ef fi ciency of AP-MS and better identi fi cation of high-con fi dence interacting proteins.", [["AP", "PROTEIN", 57, 59], ["high-con fi dence interacting proteins", "PROTEIN", 94, 132], ["this pipeline", "TREATMENT", 6, 19], ["interacting proteins", "PROBLEM", 112, 132]]], ["The methods and criteria used to remove nonspeci fi c binding proteins and identify high-con fi dence interacting proteins include:Statistical Analysis of Mass Spectrometry Data(a) GFP and controls.", [["nonspeci fi c binding proteins", "GENE_OR_GENE_PRODUCT", 40, 70], ["GFP", "GENE_OR_GENE_PRODUCT", 181, 184], ["nonspeci fi c binding proteins", "PROTEIN", 40, 70], ["high-con fi dence interacting proteins", "PROTEIN", 84, 122], ["binding proteins", "TEST", 54, 70]]], ["AP-MS of GFP-FLAG and various controls, such as non-FLAG IgG conjugated resin for AP-MS, were used to identify nonspeci fi c binding proteins in the database. (b) z -Score.", [["GFP-FLAG", "GENE_OR_GENE_PRODUCT", 9, 17], ["nonspeci fi c binding proteins", "GENE_OR_GENE_PRODUCT", 111, 141], ["GFP", "PROTEIN", 9, 12], ["FLAG", "PROTEIN", 13, 17], ["non-FLAG IgG", "PROTEIN", 48, 60], ["nonspeci fi c binding proteins", "PROTEIN", 111, 141], ["GFP", "TEST", 9, 12], ["FLAG and various controls", "PROBLEM", 13, 38], ["non-FLAG IgG conjugated resin", "TREATMENT", 48, 77], ["AP-MS", "TEST", 82, 87]]], ["A z -score (aka a standard score) indicates how many standard deviations an element is from the mean.", [["A z -score", "TEST", 0, 10], ["standard deviations", "OBSERVATION", 53, 72]]], ["To calculate z -score, mass spectrometry data were transformed into a \"stats table,\" where the columns are total spectral counts (TSC) from 4 MS runs, the rows are bait-associated proteins (Table 2.", [["bait-associated proteins", "PROTEIN", 164, 188], ["Table 2", "PROTEIN", 190, 197], ["mass spectrometry data", "TEST", 23, 45], ["the columns", "TEST", 91, 102], ["total spectral counts", "TEST", 107, 128], ["TSC", "TEST", 130, 133], ["4 MS runs", "PROBLEM", 140, 149]]], ["Then we calculated z -score of each X i,j (i prey interacts with j bait) based on the maximum total spectral counts (TSC) of 4 MS runs.", [["j bait", "TREATMENT", 65, 71], ["the maximum total spectral counts", "TEST", 82, 115], ["4 MS runs", "PROBLEM", 125, 134]]], ["For HI5 database analysis, we set the cutoff of z -score as 2.Statistical Analysis of Mass Spectrometry Dataz is the z-score, X is the value of the element, m is the population mean, and s is the standard deviation. (c) Prey occurrence.", [["HI5", "DNA", 4, 7], ["HI5 database analysis", "TEST", 4, 25], ["Mass Spectrometry", "PROBLEM", 86, 103], ["Mass", "OBSERVATION", 86, 90], ["standard deviation", "OBSERVATION", 196, 214]]], ["We considered any prey associated with a single bait as an HCIP while preys associated with all baits as NSBP.", [["NSBP", "PROBLEM", 105, 109]]], ["In HI5, we showed that preys that interact with less than 5 baits represented statistically signi fi cant interactions in HI5 dataset.", [["HI5", "CELL_LINE", 3, 6]]], ["So the threshold for prey occurrence in HI5 is set as 4.", [["HI5", "DNA", 40, 43]]], ["Due to known high interconnectivity among selected baits, bait-to-bait interactions were considered as HCIP. (d) Reproducibility.", [["HCIP", "PROTEIN", 103, 107], ["high interconnectivity", "OBSERVATION_MODIFIER", 13, 35]]], ["To account for possible variations in the list of background contaminants observed in our dataset that were not identi fi ed by other statistical approaches, we intentionally sequenced each duplicate puri fi ed complex in different experiments.", [["puri fi ed complex", "GENE_OR_GENE_PRODUCT", 200, 218], ["puri fi ed complex", "PROTEIN", 200, 218], ["background contaminants", "PROBLEM", 50, 73]]], ["Any protein that did not appear in different puri fi cations was considered an NSBP and manually removed from HCIP list.Construction of Protein Interaction Map and Bioinformatics AnalysisAfter statistical analysis of dataset, all pairwise interactions are collected and analyzed by Cytoscape.", [["puri fi cations", "SIMPLE_CHEMICAL", 45, 60], ["Any protein", "PROBLEM", 0, 11], ["an NSBP", "TEST", 76, 83], ["Map", "TEST", 156, 159], ["statistical analysis", "TEST", 193, 213]]], ["Except generating interaction map, the functional classi fi cations of HCIPs also need to be analyzed.", [["HCIPs", "SIMPLE_CHEMICAL", 71, 76], ["the functional classi fi cations of HCIPs", "TREATMENT", 35, 76], ["interaction map", "OBSERVATION", 18, 33]]], ["Interactors can be grouped by protein domains, molecular functions, biological processes, and signal pathways, which may help discover common mechanism underlying the proteins of interest.", [["protein domains", "PROTEIN", 30, 45]]], ["To fi gure out the new interactions in database, several protein-protein interaction databases such as BioGRID, STRING, IntAct, and MINT can be used to identify the known interaction.", [["BioGRID", "PROTEIN", 103, 110], ["STRING", "PROTEIN", 112, 118], ["IntAct", "PROTEIN", 120, 126], ["MINT", "PROTEIN", 132, 136], ["new", "OBSERVATION_MODIFIER", 19, 22]]], ["However, protein interactions in new publication will not be included in these databases.", [["protein interactions", "PROBLEM", 9, 29]]], ["As with any screening approach, the database does not represent a fi nal or complete interaction network.PerspectivesUnderstanding how proteins interact in complex and dynamic networks is the key to dissect the complexity of many genotype-to-phenotype relationships.", [["any screening approach", "TEST", 8, 30]]], ["Comprehensive analysis of protein-protein interactions is still a challenging endeavor of functional proteomics.", [["Comprehensive analysis", "TEST", 0, 22], ["protein-protein interactions", "PROBLEM", 26, 54]]], ["Since intrinsic negatives are inherent to every technique, the physical interaction data generated by AP-MS may carry many false positives and negatives.", [["many false positives", "PROBLEM", 118, 138], ["negatives", "OBSERVATION", 16, 25], ["false positives", "OBSERVATION", 123, 138]]], ["Thus, AP-MS is unlikely to grasp the entire interactome.", [["AP", "GENE_OR_GENE_PRODUCT", 6, 8]]], ["Since most AP-MS data represent static graph of PPI map, advanced methods have to be developed and focused on dynamic and spatial changes in PPI.PerspectivesWe have presented the general principles of the AP-MS approach and highlighted some recent developed technologies and successful applications on various signaling pathways.", [["PPI map", "TREATMENT", 48, 55], ["advanced methods", "TREATMENT", 57, 73], ["PPI", "TREATMENT", 141, 144], ["successful applications", "TREATMENT", 275, 298]]], ["Despite of the increasing AP-MS data and analysis tools, there are still many major challenges.", [["the increasing AP-MS data", "PROBLEM", 11, 36], ["analysis tools", "TEST", 41, 55], ["many", "OBSERVATION_MODIFIER", 73, 77], ["major", "OBSERVATION_MODIFIER", 78, 83], ["challenges", "OBSERVATION", 84, 94]]], ["It includes (1) the speci fi city of protein complex in different cells and tissues, (2) the dynamics of protein complex with different stimulations or posttranslational modi fi cations, (3) the absolute and relative quantitation of proteins, (4) mapping of transient or weak PPI and endogenous PPI from native cells and tissues, (5) the integration of PPI data sets with the other functional data sets, (6) the standardization and benchmarking for interactome mapping, and (7) the challenges for primary cells like neuronal cells and the detection of weak endogenous interaction.", [["cells", "ANATOMY", 66, 71], ["tissues", "ANATOMY", 76, 83], ["cells", "ANATOMY", 311, 316], ["tissues", "ANATOMY", 321, 328], ["primary cells", "ANATOMY", 497, 510], ["neuronal cells", "ANATOMY", 516, 530], ["cells", "CELL", 66, 71], ["tissues", "TISSUE", 76, 83], ["cells", "CELL", 311, 316], ["tissues", "TISSUE", 321, 328], ["cells", "CELL", 505, 510], ["neuronal cells", "CELL", 516, 530], ["protein complex", "PROTEIN", 37, 52], ["protein complex", "PROTEIN", 105, 120], ["native cells", "CELL_TYPE", 304, 316], ["primary cells", "CELL_TYPE", 497, 510], ["neuronal cells", "CELL_TYPE", 516, 530], ["protein complex in different cells and tissues", "PROBLEM", 37, 83], ["protein complex", "PROBLEM", 105, 120], ["different stimulations", "TREATMENT", 126, 148], ["posttranslational modi fi cations", "TREATMENT", 152, 185], ["relative quantitation of proteins", "PROBLEM", 208, 241], ["transient or weak PPI", "PROBLEM", 258, 279], ["endogenous PPI", "TREATMENT", 284, 298], ["PPI data", "TEST", 353, 361], ["interactome mapping", "TEST", 449, 468], ["primary cells", "PROBLEM", 497, 510], ["neuronal cells", "PROBLEM", 516, 530], ["the detection", "TEST", 535, 548], ["weak endogenous interaction", "PROBLEM", 552, 579], ["different cells", "OBSERVATION", 56, 71], ["tissues", "ANATOMY", 76, 83], ["weak PPI", "OBSERVATION", 271, 279], ["endogenous PPI", "OBSERVATION", 284, 298], ["native cells", "OBSERVATION", 304, 316], ["neuronal cells", "OBSERVATION", 516, 530]]], ["Given the different types of mass spectrometric instrumentation, ionization processes, and software platforms, the assessment of published data becomes increasingly dif fi cult.", [["mass spectrometric instrumentation", "TREATMENT", 29, 63], ["ionization processes", "TEST", 65, 85], ["software platforms", "TEST", 91, 109], ["the assessment", "TEST", 111, 125], ["published data", "TEST", 129, 143], ["increasingly dif fi cult", "PROBLEM", 152, 176], ["mass", "OBSERVATION", 29, 33], ["spectrometric instrumentation", "OBSERVATION", 34, 63]]], ["To facilitate sharing experimental data, common standards in data acquisition, data interpretation, and data storage are required.", [["data acquisition", "TEST", 61, 77], ["data interpretation", "TEST", 79, 98]]], ["Many processes in a cell depend on PPI, and perturbations of these interactions can lead to diseases.", [["cell", "ANATOMY", 20, 24], ["cell", "CELL", 20, 24], ["Many processes", "PROBLEM", 0, 14], ["PPI", "TREATMENT", 35, 38], ["diseases", "PROBLEM", 92, 100], ["cell depend", "OBSERVATION_MODIFIER", 20, 31]]], ["Comprehensive knowledge of PPI network of signaling pathways will not only give us insights on how the cells respond to stimulation but will also provide new drug targets for therapeutic application.", [["cells", "ANATOMY", 103, 108], ["cells", "CELL", 103, 108], ["new drug targets", "TREATMENT", 154, 170], ["therapeutic application", "TREATMENT", 175, 198]]], ["Moreover, many viral and bacterial pathogens rely on host PPIs to survive in host cells and tissues and exert their damaging effects.", [["cells", "ANATOMY", 82, 87], ["tissues", "ANATOMY", 92, 99], ["host cells", "CELL", 77, 87], ["tissues", "TISSUE", 92, 99], ["host cells", "CELL_TYPE", 77, 87], ["many viral and bacterial pathogens", "PROBLEM", 10, 44], ["host PPIs", "TREATMENT", 53, 62], ["bacterial pathogens", "OBSERVATION", 25, 44]]], ["Ultimately, such high-quality PPI networks will become invaluable resources for better understanding the mechanisms underlying major human diseases and will enable the better de fi nition of drug targets.", [["human", "ORGANISM", 133, 138], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["such high-quality PPI networks", "TREATMENT", 12, 42], ["major human diseases", "PROBLEM", 127, 147], ["drug targets", "TREATMENT", 191, 203]]], ["Shitao Li , Ph.D., USA Shitao Li is a research fellow in Department of Microbiology and Immunobiology, Harvard Medical School.", [["Li", "CHEMICAL", 30, 32]]], ["Dr. Li studies on protein interaction network using proteomics approach.", [["proteomics approach", "TREATMENT", 52, 71]]], ["He has mapped a dynamic antiviral innate immunity protein interaction network and currently is working on virus-host protein interaction network.", [["a dynamic antiviral innate immunity protein interaction network", "TREATMENT", 14, 77]]], ["By examining the protein network, he is investigating the signaling mechanisms controlling innate antiviral immunity and new drug targets for host defense to viral infection.", [["viral infection", "DISEASE", 158, 173], ["innate antiviral immunity", "TREATMENT", 91, 116], ["new drug targets", "TREATMENT", 121, 137], ["viral infection", "PROBLEM", 158, 173], ["viral", "OBSERVATION_MODIFIER", 158, 163], ["infection", "OBSERVATION", 164, 173]]], ["He published his research on several prestigious journals such as Nature, Immunity, and Molecular Cell.", [["Cell", "ANATOMY", 98, 102], ["Cell", "CELL", 98, 102], ["Molecular Cell", "OBSERVATION", 88, 102]]]], "bd46c298f59ed56172a513e7f6be52362e98557f": [["IntroductionSevere acute respiratory syndrome (SARS) is a new emerging human disease, resulting in progressive respiratory failure and death in close to 10% of infected individuals (Ksiazek et al., 2003; Peiris et al., 2003) .", [["respiratory", "ANATOMY", 111, 122], ["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["respiratory failure", "DISEASE", 111, 130], ["death", "DISEASE", 135, 140], ["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["a new emerging human disease", "PROBLEM", 56, 84], ["progressive respiratory failure", "PROBLEM", 99, 130], ["death", "PROBLEM", 135, 140], ["infected individuals", "PROBLEM", 160, 180], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["new", "OBSERVATION_MODIFIER", 58, 61], ["progressive", "OBSERVATION_MODIFIER", 99, 110], ["respiratory failure", "OBSERVATION", 111, 130]]], ["A novel coronavirus was identified as the etiological agent of SARS and designated as SARS coronavirus (SARS-CoV) Fouchier et al., 2003) .", [["SARS", "DISEASE", 63, 67], ["SARS coronavirus", "DISEASE", 86, 102], ["SARS", "DISEASE", 104, 108], ["coronavirus", "ORGANISM", 8, 19], ["SARS coronavirus", "ORGANISM", 86, 102], ["SARS coronavirus", "SPECIES", 86, 102], ["SARS-CoV", "SPECIES", 104, 112], ["A novel coronavirus", "PROBLEM", 0, 19], ["SARS", "PROBLEM", 63, 67], ["SARS coronavirus", "PROBLEM", 86, 102], ["coronavirus", "OBSERVATION", 8, 19]]], ["The full-length genome sequence of SARS-CoV was elucidated within weeks after the identification of this novel pathogen (Marra et al., 2003; Rota et al., 2003) .", [["SARS-CoV", "ORGANISM", 35, 43], ["full-length genome sequence", "DNA", 4, 31], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "PROBLEM", 35, 43]]], ["The angiotensinconverting enzyme 2 (ACE2) was identified as a functional receptor for SARS-CoV (Li et al., 2003) .", [["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 4, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["angiotensinconverting enzyme 2", "PROTEIN", 4, 34], ["ACE2", "PROTEIN", 36, 40], ["SARS-CoV", "SPECIES", 86, 94], ["The angiotensinconverting enzyme", "TEST", 0, 32], ["ACE2", "TEST", 36, 40], ["SARS", "PROBLEM", 86, 90]]], ["In spite of the remarkable pace of discovery, there are not vaccines or effective therapies currently available. * Corresponding author.", [["vaccines", "TREATMENT", 60, 68], ["effective therapies", "TREATMENT", 72, 91]]], ["Tel.: +886 4 2205 3366x8503; fax: +886 4 2205 3764.IntroductionE-mail address: cyhsiang@mail.cmu.edu.tw (C.-Y. Hsiang).", [["+886 4 2205 3366x8503", "CHEMICAL", 6, 27]]], ["SARS-CoV spike (S) protein is a large type I transmembrane glycoprotein projected from viral envelope (Bosch et al., 2003) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV spike (S)", "GENE_OR_GENE_PRODUCT", 0, 18], ["SARS-CoV spike (S) protein", "PROTEIN", 0, 26], ["type I transmembrane glycoprotein", "PROTEIN", 38, 71], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV spike (S) protein", "PROBLEM", 5, 26], ["a large type I transmembrane glycoprotein", "PROBLEM", 30, 71], ["large", "OBSERVATION_MODIFIER", 32, 37]]], ["SARS-CoV S protein consists of two functional domains S1 (residues 1-667) and S2 (residues 668-1255) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 0, 10], ["S2", "GENE_OR_GENE_PRODUCT", 78, 80], ["SARS-CoV S protein", "PROTEIN", 0, 18], ["S1", "PROTEIN", 54, 56], ["residues 1-667", "PROTEIN", 58, 72], ["S2", "PROTEIN", 78, 80], ["residues 668-1255", "PROTEIN", 82, 99], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV S protein", "TEST", 5, 18], ["S2", "ANATOMY", 78, 80]]], ["S1 contains the receptor-binding site and is responsible for binding to cellular receptors on the target cells (Li et al., 2003) .", [["cellular", "ANATOMY", 72, 80], ["cells", "ANATOMY", 105, 110], ["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["cellular", "CELL", 72, 80], ["cells", "CELL", 105, 110], ["S1", "PROTEIN", 0, 2], ["receptor-binding site", "DNA", 16, 37], ["cellular receptors", "PROTEIN", 72, 90], ["target cells", "CELL_TYPE", 98, 110], ["binding site", "OBSERVATION", 25, 37]]], ["S2 contains two heptad repeat regions (HR1 and HR2), which assemble into a six-helix bundle and result in membrane fusion Tripet et al., 2004) .", [["membrane", "ANATOMY", 106, 114], ["HR2", "GENE_OR_GENE_PRODUCT", 47, 50], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["S2", "PROTEIN", 0, 2], ["heptad repeat regions", "PROTEIN", 16, 37], ["HR1", "PROTEIN", 39, 42], ["HR2", "PROTEIN", 47, 50], ["six-helix bundle", "PROTEIN", 75, 91], ["two heptad repeat regions", "PROBLEM", 12, 37], ["a six-helix bundle", "TREATMENT", 73, 91], ["two", "OBSERVATION_MODIFIER", 12, 15], ["heptad", "OBSERVATION_MODIFIER", 16, 22], ["regions", "ANATOMY_MODIFIER", 30, 37]]], ["Moreover, S protein contains important virus-neutralizing epitopes that elicit neutralizing antibody in the host species (Chen et al., 2005; Hofmann et al., 2004a; Sui et al., 2004) .", [["S protein", "PROTEIN", 10, 19], ["virus-neutralizing epitopes", "PROTEIN", 39, 66], ["neutralizing antibody", "PROTEIN", 79, 100], ["S protein", "TEST", 10, 19], ["important virus", "PROBLEM", 29, 44], ["neutralizing epitopes", "TREATMENT", 45, 66], ["neutralizing antibody", "TEST", 79, 100]]], ["Several reports indicated that blocking the binding of the S protein to cellular receptors can prevent virus entry.", [["cellular", "ANATOMY", 72, 80], ["cellular", "CELL", 72, 80], ["S protein", "PROTEIN", 59, 68], ["cellular receptors", "PROTEIN", 72, 90], ["the S protein", "TREATMENT", 55, 68], ["cellular receptors", "TREATMENT", 72, 90]]], ["For examples, antibody against S protein efficiently neutralizes SARS-CoV and inhibits syncytial formation between S protein and ACE2 (Keng et al., 2005; Sui et al., 2004) .", [["syncytial", "ANATOMY", 87, 96], ["antibody against S protein", "GENE_OR_GENE_PRODUCT", 14, 40], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["syncytial", "ORGANISM", 87, 96], ["S protein", "GENE_OR_GENE_PRODUCT", 115, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["S protein", "PROTEIN", 31, 40], ["S protein", "PROTEIN", 115, 124], ["ACE2", "PROTEIN", 129, 133], ["SARS-CoV", "SPECIES", 65, 73], ["antibody", "TEST", 14, 22], ["S protein", "TEST", 31, 40], ["CoV", "PROBLEM", 70, 73], ["syncytial formation", "PROBLEM", 87, 106], ["S protein", "TEST", 115, 124], ["ACE2", "TEST", 129, 133]]], ["Furthermore, soluble S or ACE2 protein blocks S protein mediates infection (Hofmann et al., 2004b; Moore et al., 2004; Wong et al., 2004) .", [["infection", "DISEASE", 65, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["S protein", "GENE_OR_GENE_PRODUCT", 46, 55], ["soluble S or ACE2 protein", "PROTEIN", 13, 38], ["S protein", "PROTEIN", 46, 55], ["soluble S", "TREATMENT", 13, 22], ["ACE2 protein blocks", "TREATMENT", 26, 45], ["protein mediates infection", "PROBLEM", 48, 74]]], ["These finding suggested that S protein might be an attractive target for drug development.", [["S protein", "GENE_OR_GENE_PRODUCT", 29, 38], ["S protein", "PROTEIN", 29, 38], ["S protein", "PROBLEM", 29, 38]]], ["Recently, small peptides derived from the HR regions of SARS-CoV S protein have been shown to inhibit SARS-CoV infection by the interference of SARS-CoV fusion with target cells Ni et al., 2005; Zhu et al., 2004; Yuan et al., 2004) .", [["cells", "ANATOMY", 172, 177], ["SARS-CoV infection", "DISEASE", 102, 120], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 56, 66], ["SARS-CoV", "ORGANISM", 102, 110], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["HR regions", "PROTEIN", 42, 52], ["SARS-CoV S protein", "PROTEIN", 56, 74], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 144, 152], ["small peptides", "PROBLEM", 10, 24], ["SARS", "PROBLEM", 56, 60], ["CoV S protein", "TEST", 61, 74], ["SARS", "PROBLEM", 102, 106], ["CoV infection", "PROBLEM", 107, 120], ["SARS", "PROBLEM", 144, 148], ["CoV fusion", "TREATMENT", 149, 159], ["small", "OBSERVATION_MODIFIER", 10, 15], ["peptides", "OBSERVATION", 16, 24], ["SARS", "OBSERVATION", 56, 60]]], ["We designed a series of peptides corresponding to SARS-CoV S protein to evaluate the inhibitory potential of small peptides on both the binding of S protein and the infectivity of S-protein-pseudotyped retrovirus to Vero E6 cells in this study.", [["Vero E6 cells", "ANATOMY", 216, 229], ["S protein", "GENE_OR_GENE_PRODUCT", 147, 156], ["S-protein", "GENE_OR_GENE_PRODUCT", 180, 189], ["pseudotyped", "ORGANISM", 190, 201], ["retrovirus", "ORGANISM", 202, 212], ["Vero E6 cells", "CELL", 216, 229], ["SARS-CoV S protein", "PROTEIN", 50, 68], ["S protein", "PROTEIN", 147, 156], ["S-protein", "PROTEIN", 180, 189], ["Vero E6 cells", "CELL_LINE", 216, 229], ["Vero E6", "SPECIES", 216, 223], ["a series of peptides", "TREATMENT", 12, 32], ["SARS-CoV S protein", "TEST", 50, 68], ["small peptides", "PROBLEM", 109, 123], ["S protein", "TEST", 147, 156], ["S-protein", "TEST", 180, 189], ["pseudotyped retrovirus", "PROBLEM", 190, 212], ["this study", "TEST", 233, 243], ["small", "OBSERVATION_MODIFIER", 109, 114], ["peptides", "OBSERVATION", 115, 123], ["pseudotyped retrovirus", "OBSERVATION", 190, 212], ["E6 cells", "OBSERVATION", 221, 229]]], ["This approach of utilizing compounds that block receptor interaction has proven useful in other viral systems, including human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (DeClercq, 2001; van Compernolle et al., 2003) .", [["human immunodeficiency virus type 1 (HIV-1) and hepatitis C", "DISEASE", 121, 180], ["human immunodeficiency virus type 1", "ORGANISM", 121, 156], ["HIV-1", "ORGANISM", 158, 163], ["hepatitis C virus", "ORGANISM", 169, 186], ["human immunodeficiency virus type 1", "SPECIES", 121, 156], ["HIV-1", "SPECIES", 158, 163], ["hepatitis C virus", "SPECIES", 169, 186], ["human immunodeficiency virus type 1", "SPECIES", 121, 156], ["HIV-1", "SPECIES", 158, 163], ["hepatitis C virus", "SPECIES", 169, 186], ["block receptor interaction", "PROBLEM", 42, 68], ["other viral systems", "PROBLEM", 90, 109], ["human immunodeficiency virus type", "PROBLEM", 121, 154], ["HIV", "TEST", 158, 161], ["hepatitis C virus", "PROBLEM", 169, 186], ["hepatitis", "ANATOMY", 169, 178]]], ["Results of this study indicated that SP-10 (residues 668-679) was a potent inhibitor and abolished binding of the S protein to ACE2 and Vero E6 cells.Design and synthesis of peptidesThe hydrophilicity, surface probability, and chain flexibility of SARS-CoV S protein were calculated by PeptideStructure program of Genetics Computer Group according to Kyte and Doolittle plots, Emini prediction, and Karplus and Schulz prediction, respectively (Emini et al., 1985; Karplus and Schulz, 1985; Kyte and Doolittle, 1982) .", [["Vero E6 cells", "ANATOMY", 136, 149], ["surface", "ANATOMY", 202, 209], ["SP-10 (residues 668-679", "CHEMICAL", 37, 60], ["SP-10", "GENE_OR_GENE_PRODUCT", 37, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 127, 131], ["Vero E6 cells", "CELL", 136, 149], ["SP", "PROTEIN", 37, 39], ["S protein", "PROTEIN", 114, 123], ["ACE2", "PROTEIN", 127, 131], ["Vero E6 cells", "CELL_LINE", 136, 149], ["SARS-CoV S protein", "PROTEIN", 248, 266], ["Vero E6", "SPECIES", 136, 143], ["this study", "TEST", 11, 21], ["SP", "TEST", 37, 39], ["a potent inhibitor", "TREATMENT", 66, 84], ["the S protein", "TEST", 110, 123], ["ACE2", "TEST", 127, 131], ["Vero E6 cells", "TREATMENT", 136, 149], ["Design and synthesis of peptides", "TREATMENT", 150, 182], ["The hydrophilicity", "PROBLEM", 182, 200], ["surface probability", "PROBLEM", 202, 221], ["SARS-CoV S protein", "TEST", 248, 266], ["Emini prediction", "TEST", 377, 393], ["E6 cells", "OBSERVATION", 141, 149], ["hydrophilicity", "OBSERVATION_MODIFIER", 186, 200], ["surface", "OBSERVATION_MODIFIER", 202, 209]]], ["The peptides of 12 residues from SARS-CoV S protein were synthesized by solid-phase method (CytoMol Corp., Union City, CA, USA).", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 33, 43], ["SARS-CoV S protein", "PROTEIN", 33, 51], ["SARS-CoV", "SPECIES", 33, 41], ["The peptides of 12 residues", "PROBLEM", 0, 27], ["SARS", "PROBLEM", 33, 37], ["CoV S protein", "TEST", 38, 51]]], ["The purity (>97%) and composition of peptides were assessed by highpressure liquid chromatography and electrospray mass spectrometry.", [["The purity", "TEST", 0, 10], ["composition of peptides", "TREATMENT", 22, 45], ["highpressure liquid chromatography", "TEST", 63, 97]]], ["The peptides were dissolved in water to a final concentration of 50 g/l and stored at \u221220 \u2022 C.Expression and purification of recombinant SARS-CoV S proteinThe SARS-CoV S gene was cloned into pET-28b(+) (Novagen, Madison, WI, USA) to create the pET-spike expression plasmid (Ho et al., 2004) .", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 137, 147], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 159, 169], ["Novagen", "ORGANISM", 203, 210], ["pET", "GENE_OR_GENE_PRODUCT", 244, 247], ["recombinant SARS-CoV S protein", "PROTEIN", 125, 155], ["SARS-CoV S gene", "DNA", 159, 174], ["pET", "DNA", 191, 194], ["pET-spike expression plasmid", "DNA", 244, 272], ["SARS-CoV", "SPECIES", 137, 145], ["SARS-CoV", "SPECIES", 159, 167], ["The peptides", "TREATMENT", 0, 12], ["recombinant SARS", "PROBLEM", 125, 141], ["CoV S protein", "TEST", 142, 155], ["The SARS", "TEST", 155, 163], ["CoV S gene", "TEST", 164, 174], ["pET", "TEST", 191, 194], ["the pET", "TEST", 240, 247]]], ["Recombinant S protein was expressed in Escherichia coli (E. coli) BL21(DE3)pLysS strain by transforming the pET-spike to produce an N-terminal fusion with six histidine residues.", [["histidine", "CHEMICAL", 159, 168], ["N", "CHEMICAL", 132, 133], ["histidine", "CHEMICAL", 159, 168], ["Recombinant S protein", "GENE_OR_GENE_PRODUCT", 0, 21], ["Escherichia coli", "ORGANISM", 39, 55], ["E. coli", "ORGANISM", 57, 64], ["pET", "GENE_OR_GENE_PRODUCT", 108, 111], ["Recombinant S protein", "PROTEIN", 0, 21], ["pET", "PROTEIN", 108, 111], ["N-terminal fusion", "PROTEIN", 132, 149], ["Escherichia coli", "SPECIES", 39, 55], ["E. coli", "SPECIES", 57, 64], ["Escherichia coli", "SPECIES", 39, 55], ["E. coli", "SPECIES", 57, 64], ["Recombinant S protein", "TEST", 0, 21], ["Escherichia coli", "PROBLEM", 39, 55], ["E. coli", "PROBLEM", 57, 64], ["strain", "PROBLEM", 81, 87], ["the pET", "TEST", 104, 111], ["an N-terminal fusion", "TREATMENT", 129, 149], ["six histidine residues", "TREATMENT", 155, 177], ["Escherichia coli", "OBSERVATION", 39, 55], ["terminal fusion", "OBSERVATION", 134, 149], ["histidine residues", "OBSERVATION", 159, 177]]], ["The expression and purification of recombinant SARS-CoV S protein were performed as described previously (Ho et al., 2004) .", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 47, 57], ["recombinant SARS-CoV S protein", "PROTEIN", 35, 65], ["SARS-CoV", "SPECIES", 47, 55], ["recombinant SARS", "PROBLEM", 35, 51], ["CoV S protein", "TEST", 52, 65]]], ["Protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and quantified with a Bradford assay (Bio-Rad, Hercules, CA, USA).", [["sodium dodecyl sulfate", "CHEMICAL", 24, 46], ["sodium dodecyl sulfate", "CHEMICAL", 24, 46], ["polyacrylamide", "CHEMICAL", 47, 61], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 24, 46], ["Protein", "TEST", 0, 7], ["sodium dodecyl sulfate", "TREATMENT", 24, 46], ["polyacrylamide gel electrophoresis", "TREATMENT", 47, 81], ["a Bradford assay", "TEST", 102, 118]]], ["Recombinant S protein produced by baculovirus expression system was purchased from Protein Science (Meriden, CT, USA).Biotinylation of recombinant S proteinRecombinant E. coli-expressed or baculovirus-expressed S protein was mixed with Sulfo-NHS-LS-biotin (Pierce, Rockford, IL, USA) in a ratio of 1:10.", [["Sulfo-NHS-LS-biotin", "CHEMICAL", 236, 255], ["biotin", "CHEMICAL", 249, 255], ["Recombinant S protein", "GENE_OR_GENE_PRODUCT", 0, 21], ["baculovirus", "ORGANISM", 34, 45], ["baculovirus", "ORGANISM", 189, 200], ["S protein", "GENE_OR_GENE_PRODUCT", 211, 220], ["Sulfo-NHS-LS-biotin", "SIMPLE_CHEMICAL", 236, 255], ["Recombinant S protein", "PROTEIN", 0, 21], ["recombinant S proteinRecombinant E. coli-expressed or baculovirus-expressed S protein", "PROTEIN", 135, 220], ["baculovirus", "SPECIES", 34, 45], ["baculovirus", "SPECIES", 189, 200], ["Recombinant S protein", "TEST", 0, 21], ["baculovirus expression system", "PROBLEM", 34, 63], ["CT", "TEST", 109, 111], ["baculovirus", "PROBLEM", 189, 200], ["S protein", "TEST", 211, 220], ["Sulfo", "TEST", 236, 241]]], ["After a 2 h-incubation on ice, the unincorporated biotin was removed by centricon-10 filtration (Millipore, Bedford, MA, USA), and the biotinylated S protein was stored at 4 \u2022 C until further analysis.", [["biotin", "CHEMICAL", 50, 56], ["centricon-10 filtration", "CHEMICAL", 72, 95], ["biotin", "CHEMICAL", 50, 56], ["biotin", "SIMPLE_CHEMICAL", 50, 56], ["biotinylated S protein", "PROTEIN", 135, 157], ["ice", "TREATMENT", 26, 29], ["the unincorporated biotin", "TREATMENT", 31, 56], ["the biotinylated S protein", "TREATMENT", 131, 157], ["further analysis", "TEST", 184, 200]]], ["Sulfo-NHS-LS-biotin should be prepared freshly by dissolving in water.Biotinylated enzyme-linked immunosorbent assay (ELISA)Microtiter plates (MaxiSorp Nunc-Immum TM plates, Nunc, Denmark) were coated at 4 \u2022 C overnight with 50 l of spike, ACE2 (R&D Systems, Minneapolis, MN, USA), or bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA), which was diluted in 0.05 M carbonate buffer (16 mM Na 2 CO 2 , 34 mM NaHCO 3 , pH 9.6).", [["serum", "ANATOMY", 292, 297], ["Sulfo-NHS-LS-biotin", "CHEMICAL", 0, 19], ["Na", "CHEMICAL", 393, 395], ["Sulfo-NHS-LS-biotin", "CHEMICAL", 0, 19], ["carbonate", "CHEMICAL", 369, 378], ["Na 2 CO 2", "CHEMICAL", 393, 402], ["NaHCO 3", "CHEMICAL", 411, 418], ["Sulfo-NHS-LS-biotin", "SIMPLE_CHEMICAL", 0, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 240, 244], ["bovine", "ORGANISM", 285, 291], ["serum", "ORGANISM_SUBSTANCE", 292, 297], ["albumin", "SIMPLE_CHEMICAL", 298, 305], ["BSA", "SIMPLE_CHEMICAL", 307, 310], ["carbonate", "SIMPLE_CHEMICAL", 369, 378], ["ACE2", "PROTEIN", 240, 244], ["bovine", "SPECIES", 285, 291], ["bovine", "SPECIES", 285, 291], ["Sulfo", "TEST", 0, 5], ["biotin", "TREATMENT", 13, 19], ["Biotinylated enzyme-linked immunosorbent assay", "TEST", 70, 116], ["ELISA", "TEST", 118, 123], ["Microtiter plates", "TEST", 124, 141], ["MaxiSorp", "TEST", 143, 151], ["Nunc", "TEST", 152, 156], ["Immum TM plates", "TREATMENT", 157, 172], ["spike", "PROBLEM", 233, 238], ["ACE2 (R&D Systems", "TREATMENT", 240, 257], ["bovine serum albumin", "TEST", 285, 305], ["0.05 M carbonate buffer", "TREATMENT", 362, 385], ["mM NaHCO", "TEST", 408, 416], ["pH", "TEST", 421, 423]]], ["The wells were rinsed with 200 l washing buffer (0.5% Tween 20 in phosphate-buffered saline (PBS) (137 mM NaCl, 1.4 mM KH 2 PO 4 , 4.3 mM Na 2 HPO 4 , 2.7 mM KCl, pH 7.2)), and blocked with 200 l blocking buffer (5% BSA in washing buffer) by incubating at 37 \u2022 C for 30 min.", [["phosphate", "CHEMICAL", 66, 75], ["NaCl", "CHEMICAL", 106, 110], ["Na", "CHEMICAL", 138, 140], ["Tween 20", "CHEMICAL", 54, 62], ["phosphate", "CHEMICAL", 66, 75], ["NaCl", "CHEMICAL", 106, 110], ["KH 2 PO 4", "CHEMICAL", 119, 128], ["Na 2 HPO 4", "CHEMICAL", 138, 148], ["KCl", "CHEMICAL", 158, 161], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 66, 91], ["BSA", "SIMPLE_CHEMICAL", 216, 219], ["200 l washing buffer", "TREATMENT", 27, 47], ["phosphate-buffered saline (PBS", "TREATMENT", 66, 96], ["NaCl", "TEST", 106, 110], ["KH", "TEST", 119, 121], ["Na", "TEST", 138, 140], ["HPO", "TEST", 143, 146], ["KCl", "TEST", 158, 161], ["pH", "TEST", 163, 165], ["200 l blocking buffer", "TREATMENT", 190, 211]]], ["The absorbed protein in each well was challenged with 50 l diluted biotinylated protein and incubated at 37 \u2022 C for 1 h.", [["absorbed protein", "PROTEIN", 4, 20], ["biotinylated protein", "PROTEIN", 67, 87], ["50 l diluted biotinylated protein", "TREATMENT", 54, 87]]], ["After three washes with washing buffer, 50 l diluted peroxidaseconjugated avidin was added to each well and incubated at 37 \u2022 C for 1 h.", [["avidin", "GENE_OR_GENE_PRODUCT", 74, 80], ["washing buffer", "TREATMENT", 24, 38], ["50 l diluted peroxidaseconjugated avidin", "TREATMENT", 40, 80]]], ["Following three washes, 50 l chromogenic substrate, 2,2 -azinobis(3-ethylbenzthiazoline-sulfonic acid) (Sigma, St. Louis, MO, USA), was added to each well and incubated at 37 \u2022 C for 15 min.", [["2,2 -azinobis(3-ethylbenzthiazoline-sulfonic acid", "CHEMICAL", 52, 101], ["2,2 -azinobis(3-ethylbenzthiazoline-sulfonic acid)", "CHEMICAL", 52, 102], ["2,2 -azinobis(3-ethylbenzthiazoline-sulfonic acid", "SIMPLE_CHEMICAL", 52, 101], ["50 l chromogenic substrate", "TREATMENT", 24, 50], ["-azinobis", "TEST", 56, 65], ["ethylbenzthiazoline-sulfonic acid", "TREATMENT", 68, 101]]], ["The absorbance was read at 405 nm in an ELISA plate reader (Anthos Labtec Instruments, Austria).Biotinylated enzyme-linked immunosorbent assay (ELISA)For the competition assay, biotinylated S protein (1 nmol) was mixed with 10 nmol peptide and incubated at 37 \u2022 C with shaking.", [["biotinylated S protein", "GENE_OR_GENE_PRODUCT", 177, 199], ["biotinylated S protein", "PROTEIN", 177, 199], ["The absorbance", "TEST", 0, 14], ["Biotinylated enzyme-linked immunosorbent assay", "TEST", 96, 142], ["the competition assay", "TEST", 154, 175], ["biotinylated S protein", "TREATMENT", 177, 199], ["10 nmol peptide", "TREATMENT", 224, 239], ["shaking", "PROBLEM", 269, 276]]], ["After a 2 h-incubation, the mixture was added to wells, which were coated with ACE2, and incubated at 37 \u2022 C for 1 h.", [["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["ACE2", "PROTEIN", 79, 83], ["a 2 h-incubation", "TREATMENT", 6, 22], ["the mixture", "TREATMENT", 24, 35], ["ACE2", "TREATMENT", 79, 83]]], ["Following three washes, peroxidase-conjugated avidin and chromatic substrate were sequentially added.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 24, 34], ["conjugated avidin", "SIMPLE_CHEMICAL", 35, 52], ["peroxidase", "PROTEIN", 24, 34], ["three washes", "TREATMENT", 10, 22], ["peroxidase-conjugated avidin", "TREATMENT", 24, 52], ["chromatic substrate", "TREATMENT", 57, 76]]], ["The absorbance was read at 405 nm in an ELISA plate reader.", [["The absorbance", "TEST", 0, 14]]], ["The inhibition was calculated by [1 \u2212 (OD value of mixture containing peptide and spike/OD value of mixture containing spike only)] \u00d7 100.Immunofluorescence assay (IFA)Vero E6 cells (10 4 cells) were seeded in 24-well plates containing glass coverslips and incubated at 37 \u2022 C for 1 day.", [["Vero E6 cells", "ANATOMY", 168, 181], ["cells", "ANATOMY", 188, 193], ["Vero E6 cells", "CELL", 168, 181], ["cells", "CELL", 188, 193], ["Vero E6 cells", "CELL_LINE", 168, 181], ["OD value of mixture containing peptide", "TREATMENT", 39, 77], ["spike/OD value of mixture", "TREATMENT", 82, 107], ["Immunofluorescence assay", "TEST", 138, 162], ["IFA", "TEST", 164, 167], ["Vero E6 cells", "PROBLEM", 168, 181], ["glass coverslips", "TREATMENT", 236, 252]]], ["The coverslips were then rinsed with PBS, fixed with 3.7% PBS-buffed formaldehyde at room temperature for 30 min, and blocked with 1% BSA at 37 \u2022 C for 1 h.", [["formaldehyde", "CHEMICAL", 69, 81], ["BSA", "CHEMICAL", 134, 137], ["formaldehyde", "CHEMICAL", 69, 81], ["formaldehyde", "SIMPLE_CHEMICAL", 69, 81], ["BSA", "SIMPLE_CHEMICAL", 134, 137], ["The coverslips", "TREATMENT", 0, 14], ["PBS", "TREATMENT", 37, 40], ["1% BSA", "TREATMENT", 131, 137]]], ["After four washes with PBS, biotin-labeled S protein was added to each coverslip and incubated at 4 \u2022 C overnight.", [["biotin", "CHEMICAL", 28, 34], ["biotin", "CHEMICAL", 28, 34], ["PBS", "SIMPLE_CHEMICAL", 23, 26], ["biotin", "SIMPLE_CHEMICAL", 28, 34], ["biotin-labeled S protein", "PROTEIN", 28, 52], ["PBS", "TREATMENT", 23, 26], ["biotin-labeled S protein", "TREATMENT", 28, 52]]], ["Following four washes with PBS, diluted fluorescence-conjugated streptavidin (Chemicon, Temecula, CA, USA) was added and incubated at 37 \u2022 C for 90 min in the dark.", [["streptavidin", "SIMPLE_CHEMICAL", 64, 76], ["PBS", "TREATMENT", 27, 30], ["diluted fluorescence", "TEST", 32, 52], ["conjugated streptavidin", "TREATMENT", 53, 76], ["Chemicon", "TEST", 78, 86]]], ["The coverslips were then washed four times with PBS, placed onto glass slides, mounted with fluoromount G (Electron Microscopy Sciences, Hatfield, PA, USA), and observed under a confocal microscope (Leica, Germany).Infection with S-protein-pseudotyped retrovirusRecombinant retroviruses expressing a luciferase reporter gene and pseudotyped with S proteins were produced as described previously Sui et al., 2005) .", [["pseudotyped retrovirusRecombinant retroviruses", "ORGANISM", 240, 286], ["luciferase", "GENE_OR_GENE_PRODUCT", 300, 310], ["pseudotyped", "ORGANISM", 329, 340], ["luciferase reporter gene", "DNA", 300, 324], ["S proteins", "PROTEIN", 346, 356], ["The coverslips", "TREATMENT", 0, 14], ["PBS", "TREATMENT", 48, 51], ["a confocal microscope", "TEST", 176, 197], ["Infection", "PROBLEM", 215, 224], ["S-protein-pseudotyped retrovirusRecombinant retroviruses", "TREATMENT", 230, 286], ["pseudotyped with S proteins", "PROBLEM", 329, 356]]], ["Briefly, 293T cells were cotransfected with a plasmid pcDNA-spike encoding S protein, a plasmid pCMV R8.2 encoding HIV-1 Gag-Pol, and a plasmid pHIV-Luc encoding the firefly luciferase reporter gene under control of the HIV-1 long terminal repeat.", [["293T cells", "ANATOMY", 9, 19], ["plasmid", "ANATOMY", 46, 53], ["plasmid", "ANATOMY", 88, 95], ["293T cells", "CELL", 9, 19], ["pcDNA-spike encoding S protein", "GENE_OR_GENE_PRODUCT", 54, 84], ["HIV-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["Pol", "GENE_OR_GENE_PRODUCT", 125, 128], ["pHIV", "GENE_OR_GENE_PRODUCT", 144, 148], ["Luc", "GENE_OR_GENE_PRODUCT", 149, 152], ["firefly luciferase reporter gene", "GENE_OR_GENE_PRODUCT", 166, 198], ["HIV-1", "ORGANISM", 220, 225], ["long terminal repeat", "CELLULAR_COMPONENT", 226, 246], ["293T cells", "CELL_LINE", 9, 19], ["S protein", "PROTEIN", 75, 84], ["plasmid pCMV R8.2", "DNA", 88, 105], ["HIV-1 Gag-Pol", "DNA", 115, 128], ["pHIV", "DNA", 144, 148], ["Luc", "DNA", 149, 152], ["firefly luciferase reporter gene", "DNA", 166, 198], ["HIV-1 long terminal repeat", "DNA", 220, 246], ["HIV-1", "SPECIES", 115, 120], ["HIV-1", "SPECIES", 220, 225], ["HIV-1", "SPECIES", 115, 120], ["HIV-1", "SPECIES", 220, 225], ["a plasmid pcDNA", "TEST", 44, 59], ["a plasmid pCMV", "TEST", 86, 100], ["a plasmid pHIV", "TREATMENT", 134, 148]]], ["Forty-eight hours later, viral supernatants were harvested and stored at \u221280 \u2022 C. S-protein-pseudotyped retroviruses were then mixed with various amounts of SP-10 and incubated at 37 \u2022 C with shaking.", [["supernatants", "ANATOMY", 31, 43], ["SP-10", "CHEMICAL", 157, 162], ["S-protein", "GENE_OR_GENE_PRODUCT", 82, 91], ["pseudotyped", "ORGANISM", 92, 103], ["retroviruses", "ORGANISM", 104, 116], ["SP", "PROTEIN", 157, 159], ["viral supernatants", "PROBLEM", 25, 43], ["pseudotyped retroviruses", "PROBLEM", 92, 116], ["SP", "TEST", 157, 159], ["shaking", "PROBLEM", 192, 199], ["pseudotyped retroviruses", "OBSERVATION", 92, 116]]], ["After a 2 h-incubation, the mixture was added to ACE2-expression Vero E6 cells in a 96-well plate.", [["cells", "ANATOMY", 73, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["Vero E6 cells", "CELL", 65, 78], ["ACE2", "PROTEIN", 49, 53], ["Vero E6 cells", "CELL_LINE", 65, 78], ["Vero E6", "SPECIES", 65, 72], ["a 2 h-incubation", "TREATMENT", 6, 22], ["the mixture", "TREATMENT", 24, 35], ["ACE2", "TEST", 49, 53], ["Vero E6 cells", "TREATMENT", 65, 78], ["E6 cells", "OBSERVATION", 70, 78]]], ["Fortyeight hours postinfection, cells were harvested and the luciferase activity was assayed as previously described (Hsiang et al., 2005) .", [["cells", "ANATOMY", 32, 37], ["cells", "CELL", 32, 37], ["luciferase", "GENE_OR_GENE_PRODUCT", 61, 71], ["luciferase", "PROTEIN", 61, 71], ["the luciferase activity", "TEST", 57, 80]]], ["Relative infectivity was presented as comparison with the relative luciferase unit (RLU) relative to untreated cells.Statistical analysisData were presented as mean \u00b1 standard error.", [["cells", "ANATOMY", 111, 116], ["luciferase", "GENE_OR_GENE_PRODUCT", 67, 77], ["cells", "CELL", 111, 116], ["luciferase unit", "DNA", 67, 82], ["RLU", "PROTEIN", 84, 87], ["untreated cells", "CELL_TYPE", 101, 116], ["Relative infectivity", "PROBLEM", 0, 20], ["Statistical analysisData", "TEST", 117, 141], ["infectivity", "OBSERVATION", 9, 20], ["untreated cells", "OBSERVATION", 101, 116]]], ["Student's ttest was used for comparisons between two experiments.", [["Student's ttest", "TEST", 0, 15]]], ["A value of p < 0.05 was considered statistically significant.Recombinant S protein binds to ACE2 in a dose-dependent mannerIn order to investigate the binding ability of S protein to ACE2, we expressed and purified the SARS-CoV S protein from E. coli.", [["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["S protein", "GENE_OR_GENE_PRODUCT", 170, 179], ["ACE2", "GENE_OR_GENE_PRODUCT", 183, 187], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 219, 229], ["E. coli", "ORGANISM", 243, 250], ["Recombinant S protein", "PROTEIN", 61, 82], ["ACE2", "PROTEIN", 92, 96], ["S protein", "PROTEIN", 170, 179], ["ACE2", "PROTEIN", 183, 187], ["SARS-CoV S protein", "PROTEIN", 219, 237], ["E. coli", "SPECIES", 243, 250], ["SARS-CoV", "SPECIES", 219, 227], ["E. coli", "SPECIES", 243, 250], ["A value", "TEST", 0, 7], ["ACE2", "TEST", 92, 96], ["ACE2", "TEST", 183, 187], ["the SARS", "TEST", 215, 223], ["CoV S protein", "TEST", 224, 237], ["E. coli", "PROBLEM", 243, 250], ["E. coli", "OBSERVATION", 243, 250]]], ["The 138-kDa recombinant S protein was expressed in soluble form, and the amount of recombinant S protein recovered was approximately 0.2-0.3 mg/100 ml of bacterial culture (Ho et al., 2004) .", [["138-kDa recombinant S protein", "PROTEIN", 4, 33], ["recombinant S protein", "PROTEIN", 83, 104], ["recombinant S protein", "TEST", 83, 104], ["bacterial culture", "TEST", 154, 171]]], ["Biotinylated ELISA and Western blot show the S protein can bind to Vero E6 cell lysate (Ho et al., 2004) .", [["cell lysate", "ANATOMY", 75, 86], ["S protein", "PROTEIN", 45, 54], ["Vero E6", "SPECIES", 67, 74], ["Biotinylated ELISA", "TEST", 0, 18], ["the S protein", "TREATMENT", 41, 54]]], ["Since ACE2 is the functional receptor for SARS-CoV (Li et al., 2003) , we designed an ELISA assay with ACE2 instead of Vero E6 cell lysate coated onto the plate.", [["cell lysate", "ANATOMY", 127, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 103, 107], ["ACE2", "PROTEIN", 6, 10], ["ACE2", "PROTEIN", 103, 107], ["SARS-CoV", "SPECIES", 42, 50], ["Vero E6", "SPECIES", 119, 126], ["SARS", "PROBLEM", 42, 46], ["an ELISA assay", "TEST", 83, 97], ["ACE2", "TREATMENT", 103, 107], ["Vero E6 cell lysate", "TREATMENT", 119, 138], ["E6 cell lysate", "OBSERVATION", 124, 138], ["plate", "ANATOMY", 155, 160]]], ["The biotinylated S protein was added to the ELISA plate coated with ACE2 and the interaction was measured using peroxidase-conjugated avidin and peroxidase substrate.Recombinant S protein binds to ACE2 in a dose-dependent mannerThe ACE2 was coated on ELISA plates and challenged with biotin-labeled S protein.", [["biotin", "CHEMICAL", 284, 290], ["biotin", "CHEMICAL", 284, 290], ["biotinylated S protein", "GENE_OR_GENE_PRODUCT", 4, 26], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["peroxidase", "SIMPLE_CHEMICAL", 112, 122], ["avidin", "GENE_OR_GENE_PRODUCT", 134, 140], ["peroxidase", "GENE_OR_GENE_PRODUCT", 145, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 197, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 232, 236], ["biotin", "SIMPLE_CHEMICAL", 284, 290], ["biotinylated S protein", "PROTEIN", 4, 26], ["ACE2", "PROTEIN", 68, 72], ["peroxidase", "PROTEIN", 112, 122], ["peroxidase substrate", "PROTEIN", 145, 165], ["Recombinant S protein", "PROTEIN", 166, 187], ["ACE2", "PROTEIN", 197, 201], ["ACE2", "PROTEIN", 232, 236], ["biotin-labeled S protein", "PROTEIN", 284, 308], ["The biotinylated S protein", "TREATMENT", 0, 26], ["the ELISA plate", "TREATMENT", 40, 55], ["ACE2", "TREATMENT", 68, 72], ["peroxidase-conjugated avidin", "TREATMENT", 112, 140], ["peroxidase substrate", "TREATMENT", 145, 165], ["ACE2", "TEST", 197, 201], ["The ACE2", "TREATMENT", 228, 236], ["ELISA plates", "TREATMENT", 251, 263], ["biotin", "TREATMENT", 284, 290]]], ["The binding ability of S protein to ACE2 was evaluated by the OD value.", [["S protein", "GENE_OR_GENE_PRODUCT", 23, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["S protein", "PROTEIN", 23, 32], ["ACE2", "PROTEIN", 36, 40], ["ACE2", "TEST", 36, 40]]], ["Analysis of SARS-CoV S protein and ACE2 interaction by biotinylated ELISA.", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 12, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["SARS-CoV S protein", "PROTEIN", 12, 30], ["ACE2", "PROTEIN", 35, 39], ["SARS-CoV", "SPECIES", 12, 20], ["Analysis", "TEST", 0, 8], ["SARS", "TEST", 12, 16], ["CoV S protein", "TEST", 17, 30], ["ACE2 interaction", "PROBLEM", 35, 51], ["biotinylated ELISA", "TEST", 55, 73]]], ["The wells were coated with 1 ng of ACE2 and challenged with various amounts of biotin-labeled S protein (\u1b79), biotin-labeled BSA ( ) or biotin ( ).", [["biotin", "CHEMICAL", 79, 85], ["biotin", "CHEMICAL", 109, 115], ["BSA", "CHEMICAL", 124, 127], ["biotin", "CHEMICAL", 135, 141], ["biotin", "CHEMICAL", 79, 85], ["biotin", "CHEMICAL", 109, 115], ["biotin", "CHEMICAL", 135, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["biotin", "SIMPLE_CHEMICAL", 79, 85], ["\u1b79", "SIMPLE_CHEMICAL", 105, 106], ["biotin-labeled BSA", "SIMPLE_CHEMICAL", 109, 127], ["biotin", "SIMPLE_CHEMICAL", 135, 141], ["ACE2", "PROTEIN", 35, 39], ["biotin-labeled S protein", "PROTEIN", 79, 103], ["1 ng of ACE2", "TREATMENT", 27, 39], ["biotin-labeled S protein", "TREATMENT", 79, 103], ["biotin-labeled BSA", "TREATMENT", 109, 127]]], ["Following three washes, peroxidase-conjugated avidin and chromatic substrate were sequentially added.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 24, 34], ["conjugated avidin", "SIMPLE_CHEMICAL", 35, 52], ["peroxidase", "PROTEIN", 24, 34], ["three washes", "TREATMENT", 10, 22], ["peroxidase-conjugated avidin", "TREATMENT", 24, 52], ["chromatic substrate", "TREATMENT", 57, 76]]], ["The absorbance was read at 405 nm in an ELISA plate reader.", [["The absorbance", "TEST", 0, 14]]], ["Values are mean \u00b1 standard error of four independent assays. biotin or biotin-labeled BSA did not bind to ACE2 in this assay.", [["biotin", "CHEMICAL", 61, 67], ["biotin", "CHEMICAL", 71, 77], ["BSA", "CHEMICAL", 86, 89], ["biotin", "CHEMICAL", 61, 67], ["biotin", "CHEMICAL", 71, 77], ["biotin", "SIMPLE_CHEMICAL", 61, 67], ["biotin", "SIMPLE_CHEMICAL", 71, 77], ["BSA", "SIMPLE_CHEMICAL", 86, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["ACE2", "PROTEIN", 106, 110], ["Values", "TEST", 0, 6], ["mean", "TEST", 11, 15], ["biotin", "TREATMENT", 61, 67], ["ACE2", "TEST", 106, 110]]], ["Additionally, S protein did not bind to the wells coated with the control protein BSA (data not shown).", [["BSA", "GENE_OR_GENE_PRODUCT", 82, 85], ["S protein", "PROTEIN", 14, 23], ["protein BSA", "PROTEIN", 74, 85], ["the control protein BSA", "TEST", 62, 85]]], ["These results demonstrated the specificity of biotinylated ELISA.", [["biotinylated ELISA", "PROBLEM", 46, 64]]], ["S protein bound to ACE2 in a dose-dependent manner.", [["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["S protein", "PROTEIN", 0, 9], ["ACE2", "PROTEIN", 19, 23], ["ACE2", "TEST", 19, 23]]], ["The interaction between S protein and ACE2 displayed a sigmoidal curve between 0.001 and 10 g/ml S protein, indicating that S protein bound to ACE2 cooperatively.", [["S protein", "GENE_OR_GENE_PRODUCT", 24, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 143, 147], ["S protein", "PROTEIN", 24, 33], ["ACE2", "PROTEIN", 38, 42], ["S protein", "PROTEIN", 97, 106], ["S protein", "PROTEIN", 124, 133], ["ACE2", "PROTEIN", 143, 147], ["S protein", "TEST", 24, 33], ["ACE2", "TEST", 38, 42], ["a sigmoidal curve", "TEST", 53, 70], ["S protein bound", "PROBLEM", 124, 139]]], ["Moreover, the binding ability of S protein to ACE2 was saturated when the concentration of S protein exceeded 10 g/ml, suggesting that one molecule of recombinant S protein probably bound to 1.15 molecules of ACE2.", [["S protein", "GENE_OR_GENE_PRODUCT", 33, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["recombinant S protein", "GENE_OR_GENE_PRODUCT", 151, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 209, 213], ["S protein", "PROTEIN", 33, 42], ["ACE2", "PROTEIN", 46, 50], ["S protein", "PROTEIN", 91, 100], ["recombinant S protein", "PROTEIN", 151, 172], ["1.15 molecules", "PROTEIN", 191, 205], ["ACE2", "PROTEIN", 209, 213], ["ACE2", "TEST", 46, 50], ["the concentration of S protein", "TREATMENT", 70, 100], ["recombinant S protein", "PROBLEM", 151, 172], ["ACE2", "TEST", 209, 213]]], ["These results revealed the specificity of biotinylated ELISA in analyzing the receptor-binding ability of S protein.", [["S protein", "GENE_OR_GENE_PRODUCT", 106, 115], ["S protein", "PROTEIN", 106, 115], ["biotinylated ELISA", "TEST", 42, 60]]], ["It also suggested that recombinant S protein could serve as a probe to analyze the interaction between SARS-CoV and cellular receptors.Small peptides block the binding of S protein to ACE2We designed 14 small peptides derived from S protein to analyze their inhibitory effects on the interaction of S protein and ACE2.", [["cellular", "ANATOMY", 116, 124], ["recombinant S protein", "GENE_OR_GENE_PRODUCT", 23, 44], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["cellular", "CELL", 116, 124], ["S protein", "GENE_OR_GENE_PRODUCT", 231, 240], ["S protein", "GENE_OR_GENE_PRODUCT", 299, 308], ["ACE2", "GENE_OR_GENE_PRODUCT", 313, 317], ["recombinant S protein", "PROTEIN", 23, 44], ["SARS-CoV and cellular receptors", "PROTEIN", 103, 134], ["S protein", "PROTEIN", 171, 180], ["ACE2We", "PROTEIN", 184, 190], ["S protein", "PROTEIN", 231, 240], ["S protein", "PROTEIN", 299, 308], ["ACE2", "PROTEIN", 313, 317], ["SARS-CoV", "SPECIES", 103, 111], ["recombinant S protein", "PROBLEM", 23, 44], ["SARS", "PROBLEM", 103, 107], ["Small peptides block", "PROBLEM", 135, 155], ["ACE2We", "TREATMENT", 184, 190], ["small peptides", "PROBLEM", 203, 217], ["S protein", "TREATMENT", 231, 240], ["ACE2", "TEST", 313, 317], ["peptides block", "OBSERVATION", 141, 155]]], ["Interaction of viral proteins with cellular receptors is mostly determined by hydrophobic interaction, surface charge distribution, and geometry (Dimitrov, 2004) .", [["cellular", "ANATOMY", 35, 43], ["surface", "ANATOMY", 103, 110], ["cellular", "CELL", 35, 43], ["viral proteins", "PROTEIN", 15, 29], ["cellular receptors", "PROTEIN", 35, 53], ["viral proteins", "PROBLEM", 15, 29], ["cellular receptors", "TEST", 35, 53], ["viral proteins", "OBSERVATION", 15, 29]]], ["In an attempt to design the small peptides, we analyzed the hydrophilicity, surface probability, and chain flexibility of SARS-CoV S protein according to Kyte and Doolittle plots, Emini prediction, and Karplus and Schulz prediction, respectively (Emini et al., 1985; Karplus and Schulz, 1985; Kyte and Doolittle, 1982) .", [["surface", "ANATOMY", 76, 83], ["SARS-CoV S protein", "PROTEIN", 122, 140], ["SARS-CoV", "SPECIES", 122, 130], ["the small peptides", "PROBLEM", 24, 42], ["surface probability", "TEST", 76, 95], ["SARS", "PROBLEM", 122, 126], ["CoV S protein", "TEST", 127, 140], ["Kyte", "TEST", 154, 158], ["Doolittle plots", "TEST", 163, 178], ["Emini prediction", "TEST", 180, 196]]], ["Based on these criteria, we designed 14 synthetic peptides of 12 residues ( Table 1 ).", [["14 synthetic peptides", "TREATMENT", 37, 58]]], ["The hydrophilic index of 14 small peptides ranged from 1.3344 to \u22120.3012, with an average of 0.042.", [["The hydrophilic index", "TEST", 0, 21], ["small peptides", "TEST", 28, 42], ["hydrophilic", "OBSERVATION_MODIFIER", 4, 15], ["index", "OBSERVATION_MODIFIER", 16, 21], ["small", "OBSERVATION_MODIFIER", 28, 33], ["peptides", "OBSERVATION", 34, 42]]], ["We employed the Chou-Fasman method which suggested that SP-3 and SP-14 form an \u2423-helical structure while SP-4, SP-8, and SP-10 form a \u2424-sheet (Chou and Fasman, 1978) .Small peptides block the binding of S protein to ACE2To evaluate the inhibitory effects of the 14 small peptides on the interaction between S protein and ACE2, we mixed 10 nmol of each peptide with 1 nmol of biotin-labeled S protein, incubated the mixture at 37 \u2022 C for 2 h, and added to ACE2-coated wells.", [["biotin", "CHEMICAL", 375, 381], ["biotin", "CHEMICAL", 375, 381], ["SP-3", "GENE_OR_GENE_PRODUCT", 56, 60], ["SP-14", "GENE_OR_GENE_PRODUCT", 65, 70], ["SP-4", "GENE_OR_GENE_PRODUCT", 105, 109], ["SP-8", "GENE_OR_GENE_PRODUCT", 111, 115], ["SP-10", "SIMPLE_CHEMICAL", 121, 126], ["ACE2To", "GENE_OR_GENE_PRODUCT", 216, 222], ["S protein", "GENE_OR_GENE_PRODUCT", 307, 316], ["ACE2", "GENE_OR_GENE_PRODUCT", 321, 325], ["biotin", "SIMPLE_CHEMICAL", 375, 381], ["ACE2", "GENE_OR_GENE_PRODUCT", 455, 459], ["SP", "PROTEIN", 56, 58], ["SP", "PROTEIN", 65, 67], ["\u2423-helical structure", "PROTEIN", 79, 98], ["SP", "PROTEIN", 105, 107], ["SP", "PROTEIN", 111, 113], ["SP", "PROTEIN", 121, 123], ["S protein", "PROTEIN", 203, 212], ["ACE2To", "PROTEIN", 216, 222], ["S protein", "PROTEIN", 307, 316], ["ACE2", "PROTEIN", 321, 325], ["biotin-labeled S protein", "PROTEIN", 375, 399], ["ACE2", "PROTEIN", 455, 459], ["Small peptides block", "PROBLEM", 167, 187], ["the 14 small peptides", "PROBLEM", 258, 279], ["ACE2", "TEST", 321, 325], ["each peptide", "TREATMENT", 347, 359], ["biotin-labeled S protein", "TREATMENT", 375, 399], ["ACE2-coated wells", "TREATMENT", 455, 472], ["peptides block", "OBSERVATION", 173, 187]]], ["As shown in Fig. 2 , pre-incubation of biotinylated S protein with BSA slightly inhibited the binding of S protein to ACE2, with the inhibitory percentage of 7%.", [["BSA", "CHEMICAL", 67, 70], ["biotinylated S protein", "GENE_OR_GENE_PRODUCT", 39, 61], ["BSA", "SIMPLE_CHEMICAL", 67, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["biotinylated S protein", "PROTEIN", 39, 61], ["S protein", "PROTEIN", 105, 114], ["ACE2", "PROTEIN", 118, 122], ["biotinylated S protein", "TEST", 39, 61], ["BSA", "TEST", 67, 70], ["ACE2", "TEST", 118, 122], ["the inhibitory percentage", "TEST", 129, 154]]], ["Preincubation of biotinylated S protein with the peptide (endoG, EGWRRRREDARAAL) derived from human endonuclease G inhibited the binding of S protein to ACE2, with the inhibitory percentage of 30%.", [["biotinylated S protein", "GENE_OR_GENE_PRODUCT", 17, 39], ["human", "ORGANISM", 94, 99], ["endonuclease G", "GENE_OR_GENE_PRODUCT", 100, 114], ["S protein", "GENE_OR_GENE_PRODUCT", 140, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 153, 157], ["biotinylated S protein", "PROTEIN", 17, 39], ["human endonuclease G", "PROTEIN", 94, 114], ["S protein", "PROTEIN", 140, 149], ["ACE2", "PROTEIN", 153, 157], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["biotinylated S protein", "TREATMENT", 17, 39], ["the peptide (endoG, EGWRRRREDARAAL)", "TREATMENT", 45, 80], ["human endonuclease G", "TREATMENT", 94, 114], ["ACE2", "TEST", 153, 157], ["the inhibitory percentage", "TEST", 164, 189]]], ["However, SP-4, SP-8, SP-10, SP-11, and SP-12 significantly blocked the binding of S protein to ACE2, exhibiting 50-90% inhibition at 10 nmol.", [["SP-4, SP-8, SP-10, SP-11", "CHEMICAL", 9, 33], ["SP-12", "CHEMICAL", 39, 44], ["SP-4", "GENE_OR_GENE_PRODUCT", 9, 13], ["SP-8", "SIMPLE_CHEMICAL", 15, 19], ["SP-10", "SIMPLE_CHEMICAL", 21, 26], ["SP-11", "SIMPLE_CHEMICAL", 28, 33], ["SP-12", "SIMPLE_CHEMICAL", 39, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["SP", "PROTEIN", 9, 11], ["S protein", "PROTEIN", 82, 91], ["ACE2", "PROTEIN", 95, 99], ["SP", "TEST", 9, 11], ["SP", "TEST", 15, 17], ["SP", "TEST", 21, 23], ["SP", "TEST", 28, 30], ["SP", "TEST", 39, 41], ["ACE2", "TEST", 95, 99]]], ["Therefore, these results suggested that SP-4, SP-8, SP-10, SP-11, and SP-12 were potential inhibitors of the interaction between S protein and ACE2.A novel putative receptor-binding region of S protein is identified by a peptide-scanning methodSP-4, SP-8, and SP-10 blocked the ACE2 and S protein interaction in a dose-dependent manner (Fig. 3) .", [["SP-8", "CHEMICAL", 250, 254], ["SP-10", "CHEMICAL", 260, 265], ["SP-4", "GENE_OR_GENE_PRODUCT", 40, 44], ["SP-8", "GENE_OR_GENE_PRODUCT", 46, 50], ["SP-10", "GENE_OR_GENE_PRODUCT", 52, 57], ["SP-11", "GENE_OR_GENE_PRODUCT", 59, 64], ["SP-12", "GENE_OR_GENE_PRODUCT", 70, 75], ["S protein", "GENE_OR_GENE_PRODUCT", 129, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 143, 147], ["SP-8", "SIMPLE_CHEMICAL", 250, 254], ["SP-10", "SIMPLE_CHEMICAL", 260, 265], ["ACE2", "GENE_OR_GENE_PRODUCT", 278, 282], ["S protein", "GENE_OR_GENE_PRODUCT", 287, 296], ["S protein", "PROTEIN", 129, 138], ["ACE2", "PROTEIN", 143, 147], ["putative receptor-binding region", "PROTEIN", 156, 188], ["S protein", "PROTEIN", 192, 201], ["ACE2", "PROTEIN", 278, 282], ["S protein", "PROTEIN", 287, 296], ["SP", "TEST", 40, 42], ["SP", "TEST", 46, 48], ["SP", "TEST", 52, 54], ["SP", "TEST", 59, 61], ["SP", "TEST", 70, 72], ["ACE2", "TEST", 143, 147], ["S protein", "TEST", 192, 201], ["a peptide", "TEST", 219, 228], ["scanning methodSP", "TEST", 229, 246], ["SP", "TEST", 250, 252], ["SP", "TEST", 260, 262]]], ["The IC 50 values of SP-4, SP-8, and SP-10 were 4.3 \u00b1 2.18, 6.99 \u00b1 0.71, and 1.88 \u00b1 0.52 nmol, respectively.", [["SP-4", "GENE_OR_GENE_PRODUCT", 20, 24], ["SP-8", "CELL", 26, 30], ["SP-10", "SIMPLE_CHEMICAL", 36, 41], ["SP", "PROTEIN", 20, 22], ["The IC", "TEST", 0, 6], ["SP", "TEST", 20, 22], ["SP", "TEST", 26, 28], ["SP", "TEST", 36, 38]]], ["SP-11 and SP-12 were excluded because they bound not only S protein but also BSA (data not shown).", [["SP-11", "CHEMICAL", 0, 5], ["SP-12", "GENE_OR_GENE_PRODUCT", 10, 15], ["BSA", "SIMPLE_CHEMICAL", 77, 80], ["SP", "PROTEIN", 0, 2], ["SP", "PROTEIN", 10, 12], ["S protein", "PROTEIN", 58, 67], ["BSA", "PROTEIN", 77, 80], ["SP", "TEST", 0, 2], ["SP", "TEST", 10, 12], ["BSA", "TEST", 77, 80]]], ["To further identify the biologically active peptides, the peptide-scanning method that involved synthesizing overlapping peptides of 12 residues covering additional amino acids on both the amino and carboxy ends of SP-10 was used.", [["amino acids", "CHEMICAL", 165, 176], ["amino acids", "CHEMICAL", 165, 176], ["amino", "CHEMICAL", 189, 194], ["carboxy", "CHEMICAL", 199, 206], ["amino acids", "AMINO_ACID", 165, 176], ["amino", "AMINO_ACID", 189, 194], ["SP", "PROTEIN", 215, 217], ["the peptide-scanning method", "TEST", 54, 81], ["synthesizing overlapping peptides", "TREATMENT", 96, 129], ["additional amino acids", "TREATMENT", 154, 176], ["the amino and carboxy ends of SP", "TREATMENT", 185, 217]]], ["The inhibitory potential of small overlapping peptides on the SARS-CoV S protein and ACE2 interaction was analyzed by competitive biotinylated ELISA.", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 62, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["SARS-CoV S protein", "PROTEIN", 62, 80], ["ACE2", "PROTEIN", 85, 89], ["SARS-CoV", "SPECIES", 62, 70], ["small overlapping peptides", "PROBLEM", 28, 54], ["the SARS", "TEST", 58, 66], ["CoV S protein", "TEST", 67, 80], ["ACE2 interaction", "PROBLEM", 85, 101], ["small", "OBSERVATION_MODIFIER", 28, 33], ["overlapping", "OBSERVATION_MODIFIER", 34, 45], ["peptides", "OBSERVATION", 46, 54]]], ["SP-10-2 (residues 660-671), SP-10-3 (residues 664-675), SP-10-4 (residues 672-683) had inhibitory activities, with the IC 50 values of 6.21 \u00b1 2.13, 5.47 \u00b1 0.41, and 2.07 \u00b1 1.01 nmol, respectively (Table 2) .", [["SP-10-2 (residues 660-671", "CHEMICAL", 0, 25], ["SP-10-3 (residues 664-675", "CHEMICAL", 28, 53], ["SP-10-4 (residues 672-683", "CHEMICAL", 56, 81], ["SP-10-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["SP", "PROTEIN", 0, 2], ["SP", "TEST", 0, 2], ["SP", "TEST", 28, 30], ["SP", "TEST", 56, 58]]], ["However, SP-10-1 (residues 648-659) and SP-10-5 (residues 676-687) did not block the ACE2 and S protein interaction.", [["SP-10-1", "CHEMICAL", 9, 16], ["SP-10-5 (residues 676-687", "CHEMICAL", 40, 65], ["SP-10-1", "GENE_OR_GENE_PRODUCT", 9, 16], ["SP-10", "GENE_OR_GENE_PRODUCT", 40, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["S protein", "GENE_OR_GENE_PRODUCT", 94, 103], ["SP", "PROTEIN", 9, 11], ["ACE2", "PROTEIN", 85, 89], ["S protein", "PROTEIN", 94, 103], ["SP", "TEST", 9, 11], ["SP", "TEST", 40, 42]]], ["These findings suggested that the region spanning residues 660-683 of SARS-CoV S protein may interact with ACE2.", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 70, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["SARS-CoV S protein", "PROTEIN", 70, 88], ["ACE2", "PROTEIN", 107, 111], ["SARS-CoV", "SPECIES", 70, 78], ["the region spanning residues", "PROBLEM", 30, 58], ["SARS", "PROBLEM", 70, 74], ["CoV S protein", "TREATMENT", 75, 88], ["ACE2", "TEST", 107, 111]]], ["Inhibitory effects of peptides on the SARS-CoV S protein and ACE2 interaction by competitive biotinylated ELISA.", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 38, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["SARS-CoV S protein", "PROTEIN", 38, 56], ["ACE2", "PROTEIN", 61, 65], ["SARS-CoV", "SPECIES", 38, 46], ["Inhibitory effects of peptides", "PROBLEM", 0, 30], ["the SARS", "TEST", 34, 42], ["CoV S protein", "TEST", 43, 56], ["ACE2 interaction", "PROBLEM", 61, 77]]], ["Biotin-labeled S protein (1 nmol) was mixed with 10 nmol of synthetic peptides or BSA and incubated at 37 \u2022 C with shaking.", [["Biotin", "CHEMICAL", 0, 6], ["BSA", "CHEMICAL", 82, 85], ["Biotin", "CHEMICAL", 0, 6], ["Biotin", "SIMPLE_CHEMICAL", 0, 6], ["S protein", "GENE_OR_GENE_PRODUCT", 15, 24], ["BSA", "SIMPLE_CHEMICAL", 82, 85], ["Biotin-labeled S protein", "PROTEIN", 0, 24], ["Biotin", "TEST", 0, 6], ["synthetic peptides", "TREATMENT", 60, 78], ["BSA", "TEST", 82, 85], ["shaking", "PROBLEM", 115, 122]]], ["After a 2-h incubation, the mixtures were added to wells, which were coated with 1 ng of ACE2 and incubated at 37 \u2022 C for 1 h.", [["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["ACE2", "PROTEIN", 89, 93], ["a 2-h incubation", "TREATMENT", 6, 22], ["the mixtures", "TREATMENT", 24, 36], ["1 ng of ACE2", "TREATMENT", 81, 93]]], ["Following three washes, peroxidase-conjugated avidin and chromatic substrate were sequentially added.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 24, 34], ["conjugated avidin", "SIMPLE_CHEMICAL", 35, 52], ["peroxidase", "PROTEIN", 24, 34], ["three washes", "TREATMENT", 10, 22], ["peroxidase-conjugated avidin", "TREATMENT", 24, 52], ["chromatic substrate", "TREATMENT", 57, 76]]], ["The absorbance was read at 405 nm in an ELISA plate reader.", [["The absorbance", "TEST", 0, 14]]], ["Values are mean \u00b1 standard error of six independent assays. ** p < 0.01, compared with BSA.SP-10 blocks both the binding of S protein and the infectivity of S-protein-pseudotyped retrovirus to Vero E6 cellsThe inhibitory potential of SP-10 on the SARS-CoV S protein and Vero E6 cell interaction was further analyzed by IFA and S-protein-pseudotyped retrovirus infectivity.", [["Vero E6 cells", "ANATOMY", 193, 206], ["cell", "ANATOMY", 278, 282], ["SP-10", "CHEMICAL", 91, 96], ["SP-10", "CHEMICAL", 234, 239], ["BSA", "SIMPLE_CHEMICAL", 87, 90], ["SP-10", "GENE_OR_GENE_PRODUCT", 91, 96], ["S protein", "GENE_OR_GENE_PRODUCT", 124, 133], ["S-protein", "GENE_OR_GENE_PRODUCT", 157, 166], ["pseudotyped", "ORGANISM", 167, 178], ["retrovirus", "ORGANISM", 179, 189], ["Vero E6 cells", "CELL", 193, 206], ["SP-10", "GENE_OR_GENE_PRODUCT", 234, 239], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 247, 257], ["Vero E6 cell", "CELL", 270, 282], ["S-protein", "GENE_OR_GENE_PRODUCT", 327, 336], ["pseudotyped retrovirus", "ORGANISM", 337, 359], ["SP", "PROTEIN", 91, 93], ["S protein", "PROTEIN", 124, 133], ["S-protein", "PROTEIN", 157, 166], ["Vero E6 cells", "CELL_LINE", 193, 206], ["SP", "PROTEIN", 234, 236], ["SARS-CoV S protein", "PROTEIN", 247, 265], ["Vero E6", "SPECIES", 193, 200], ["SARS-CoV", "SPECIES", 247, 255], ["Values", "TEST", 0, 6], ["mean", "TEST", 11, 15], ["S protein", "TEST", 124, 133], ["S-protein", "TEST", 157, 166], ["pseudotyped retrovirus", "PROBLEM", 167, 189], ["Vero E6 cells", "TREATMENT", 193, 206], ["SP", "TEST", 234, 236], ["the SARS", "TEST", 243, 251], ["CoV S protein", "TEST", 252, 265], ["Vero E6 cell interaction", "PROBLEM", 270, 294], ["IFA", "TEST", 319, 322], ["S-protein", "TEST", 327, 336], ["pseudotyped retrovirus infectivity", "PROBLEM", 337, 371], ["E6 cells", "OBSERVATION", 198, 206], ["E6 cell", "OBSERVATION", 275, 282], ["pseudotyped retrovirus infectivity", "OBSERVATION", 337, 371]]], ["Vero E6 cells were treated with BSA, biotin-labeled S protein or SP-10/biotinlabeled S protein mixture, and stained with fluorescenceconjugated streptavidin.", [["Vero E6 cells", "ANATOMY", 0, 13], ["BSA", "CHEMICAL", 32, 35], ["biotin", "CHEMICAL", 37, 43], ["biotin", "CHEMICAL", 37, 43], ["Vero E6 cells", "CELL", 0, 13], ["BSA", "SIMPLE_CHEMICAL", 32, 35], ["biotin", "SIMPLE_CHEMICAL", 37, 43], ["SP-10", "SIMPLE_CHEMICAL", 65, 70], ["streptavidin", "GENE_OR_GENE_PRODUCT", 144, 156], ["Vero E6 cells", "CELL_LINE", 0, 13], ["biotin-labeled S protein", "PROTEIN", 37, 61], ["SP", "PROTEIN", 65, 67], ["fluorescenceconjugated streptavidin", "PROTEIN", 121, 156], ["Vero E6", "SPECIES", 0, 7], ["Vero E6 cells", "PROBLEM", 0, 13], ["BSA", "TEST", 32, 35], ["biotin", "TEST", 37, 43], ["labeled S protein", "TEST", 44, 61], ["SP", "TEST", 65, 67], ["biotinlabeled S protein mixture", "TEST", 71, 102], ["fluorescenceconjugated streptavidin", "TREATMENT", 121, 156], ["E6 cells", "OBSERVATION", 5, 13]]], ["BSA-treated cells showed negative result, whereas the biotinylated S protein-treated Vero E6 cells showed the strong fluorescence (Fig. 4A) .", [["cells", "ANATOMY", 12, 17], ["Vero E6 cells", "ANATOMY", 85, 98], ["BSA", "CHEMICAL", 0, 3], ["BSA", "SIMPLE_CHEMICAL", 0, 3], ["cells", "CELL", 12, 17], ["biotinylated S protein", "GENE_OR_GENE_PRODUCT", 54, 76], ["Vero E6 cells", "CELL", 85, 98], ["BSA-treated cells", "CELL_LINE", 0, 17], ["biotinylated S protein", "PROTEIN", 54, 76], ["Vero E6 cells", "CELL_LINE", 85, 98], ["Vero E6", "SPECIES", 85, 92], ["BSA", "TEST", 0, 3], ["the biotinylated S protein", "TEST", 50, 76], ["Vero E6 cells", "TEST", 85, 98]]], ["Treatment of Vero E6 cells with SP-10/biotin-labeled S protein mixture diminished the cell-associated fluorescence in a dose-dependent manner.", [["Vero E6 cells", "ANATOMY", 13, 26], ["cell", "ANATOMY", 86, 90], ["SP-10/biotin", "CHEMICAL", 32, 44], ["biotin", "CHEMICAL", 38, 44], ["Vero E6 cells", "CELL", 13, 26], ["SP-10", "GENE_OR_GENE_PRODUCT", 32, 37], ["biotin", "SIMPLE_CHEMICAL", 38, 44], ["cell", "CELL", 86, 90], ["Vero E6 cells", "CELL_LINE", 13, 26], ["SP", "PROTEIN", 32, 34], ["Vero E6", "SPECIES", 13, 20], ["Vero E6 cells", "TEST", 13, 26], ["SP", "TEST", 32, 34], ["biotin", "TEST", 38, 44], ["labeled S protein mixture", "TEST", 45, 70], ["Vero E6 cells", "OBSERVATION", 13, 26]]], ["Because the S protein expressed in E. coli is not glycosylated, we further analyzed the inhibitory potential of SP-10 using glycosylated S protein purified from baculovirus.", [["SP-10", "CHEMICAL", 112, 117], ["E. coli", "ORGANISM", 35, 42], ["SP-10", "GENE_OR_GENE_PRODUCT", 112, 117], ["glycosylated S protein", "GENE_OR_GENE_PRODUCT", 124, 146], ["baculovirus", "ORGANISM", 161, 172], ["S protein", "PROTEIN", 12, 21], ["SP", "PROTEIN", 112, 114], ["glycosylated S protein", "PROTEIN", 124, 146], ["E. coli", "SPECIES", 35, 42], ["E. coli", "SPECIES", 35, 42], ["baculovirus", "SPECIES", 161, 172], ["the S protein", "TEST", 8, 21], ["E. coli", "PROBLEM", 35, 42], ["SP", "TEST", 112, 114], ["glycosylated S protein", "TREATMENT", 124, 146], ["baculovirus", "TREATMENT", 161, 172], ["E. coli", "OBSERVATION", 35, 42]]], ["Similar results were obtained by using the recombinant S protein produced by baculovirus expression system (Fig. 4B) .", [["baculovirus", "ORGANISM", 77, 88], ["recombinant S protein", "PROTEIN", 43, 64], ["baculovirus", "SPECIES", 77, 88], ["the recombinant S protein", "TREATMENT", 39, 64]]], ["These results indicated that SP-10 was capable of blocking the binding of S protein to Vero cells.", [["Vero cells", "ANATOMY", 87, 97], ["SP-10", "CHEMICAL", 29, 34], ["SP-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["Vero cells", "CELL", 87, 97], ["SP", "PROTEIN", 29, 31], ["S protein", "PROTEIN", 74, 83], ["Vero cells", "CELL_LINE", 87, 97], ["SP", "TEST", 29, 31], ["Vero cells", "OBSERVATION", 87, 97]]], ["Table 2 The IC 50 values of overlapping peptides covering additional amino acids on both the amino and carboxy ends of SP-10 Peptide a Amino acid sequence IC 50 (nmol) b SP-10-1 (648-659) CDIPIGAGICAS >20 SP-10-2 (660-671) YHTVSLLRSTSQ 6.21 \u00b1 2.13 SP-10-3 (664-675) SLLRSTSQKSIV 5.47 \u00b1 0.41 SP-10 (668-679) STSQKSIVAYTM 1.88 \u00b1 0.52 SP-10-4 (672-683) KSIVAYTMSLGA 2.07 \u00b1 1.01 SP-10-5 (676-687) AYTMSLGADSSI >20 a Numbers in the brackets are the beginning and end residues for each peptide corresponding to S protein. b The IC 50 value of each peptide was determined as the quantity of peptide required to inhibit the interaction between S protein and ACE2 at 50%.", [["amino acids", "CHEMICAL", 69, 80], ["Amino acid", "CHEMICAL", 135, 145], ["amino acids", "CHEMICAL", 69, 80], ["amino", "CHEMICAL", 93, 98], ["carboxy", "CHEMICAL", 103, 110], ["Amino acid", "CHEMICAL", 135, 145], ["amino acids", "AMINO_ACID", 69, 80], ["amino", "AMINO_ACID", 93, 98], ["Amino acid", "SIMPLE_CHEMICAL", 135, 145], ["ACE2", "GENE_OR_GENE_PRODUCT", 650, 654], ["amino and carboxy ends", "PROTEIN", 93, 115], ["SP", "PROTEIN", 119, 121], ["S protein", "PROTEIN", 505, 514], ["S protein", "PROTEIN", 636, 645], ["ACE2", "PROTEIN", 650, 654], ["overlapping peptides", "TREATMENT", 28, 48], ["additional amino acids", "TREATMENT", 58, 80], ["the amino and carboxy ends of SP", "TREATMENT", 89, 121], ["a Amino acid sequence IC", "TEST", 133, 157], ["CDIPIGAGICAS", "TEST", 188, 200], ["YHTVSLLRSTSQ", "TEST", 223, 235], ["SLLRSTSQKSIV", "TEST", 266, 278], ["SP", "TEST", 291, 293], ["STSQKSIVAYTM", "TEST", 307, 319], ["KSIVAYTMSLGA", "TEST", 350, 362], ["AYTMSLGADSSI", "TEST", 393, 405], ["a Numbers in the brackets", "TREATMENT", 410, 435], ["S protein", "TEST", 636, 645], ["ACE2", "TEST", 650, 654]]], ["Values are mean \u00b1 standard error of four independent assays.", [["Values", "TEST", 0, 6], ["mean", "TEST", 11, 15]]], ["Inhibitory effects of SP-4, SP-8, and SP-10 on the SARS-CoV S protein and ACE2 interaction by competitive biotinylated ELISA.", [["SP-4", "CHEMICAL", 22, 26], ["SP-8", "CHEMICAL", 28, 32], ["SP-10", "CHEMICAL", 38, 43], ["SP-4", "GENE_OR_GENE_PRODUCT", 22, 26], ["SP-8", "GENE_OR_GENE_PRODUCT", 28, 32], ["SP-10", "SIMPLE_CHEMICAL", 38, 43], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 51, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["SP", "PROTEIN", 22, 24], ["SP", "PROTEIN", 38, 40], ["SARS-CoV S protein", "PROTEIN", 51, 69], ["ACE2", "PROTEIN", 74, 78], ["SARS-CoV", "SPECIES", 51, 59], ["SP", "TEST", 22, 24], ["SP", "TEST", 28, 30], ["the SARS", "TEST", 47, 55], ["CoV S protein", "TREATMENT", 56, 69], ["ACE2 interaction", "PROBLEM", 74, 90]]], ["Biotin-labeled S protein (1 nmol) was mixed with various amounts of SP-4 (A), SP-8 (B) or SP-10 (C), and incubated at 37 \u2022 C with shaking.", [["Biotin", "CHEMICAL", 0, 6], ["SP-4", "CHEMICAL", 68, 72], ["SP-8", "CHEMICAL", 78, 82], ["SP-10", "CHEMICAL", 90, 95], ["Biotin", "CHEMICAL", 0, 6], ["Biotin-labeled S protein", "GENE_OR_GENE_PRODUCT", 0, 24], ["SP-4", "SIMPLE_CHEMICAL", 68, 72], ["A", "SIMPLE_CHEMICAL", 74, 75], ["SP-8", "SIMPLE_CHEMICAL", 78, 82], ["B", "SIMPLE_CHEMICAL", 84, 85], ["SP-10", "SIMPLE_CHEMICAL", 90, 95], ["C", "SIMPLE_CHEMICAL", 97, 98], ["Biotin-labeled S protein", "PROTEIN", 0, 24], ["SP", "PROTEIN", 68, 70], ["SP", "PROTEIN", 78, 80], ["SP", "PROTEIN", 90, 92], ["Biotin", "TEST", 0, 6], ["labeled S protein", "TEST", 7, 24], ["SP", "TEST", 68, 70], ["SP", "TEST", 78, 80], ["SP", "TEST", 90, 92], ["shaking", "PROBLEM", 130, 137]]], ["After a 2-h incubation, the mixtures were added to wells, which were coated with 1 ng of ACE2, and incubated at 37 \u2022 C for 1 h.", [["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["ACE2", "PROTEIN", 89, 93], ["a 2-h incubation", "TREATMENT", 6, 22], ["the mixtures", "TREATMENT", 24, 36], ["1 ng of ACE2", "TREATMENT", 81, 93]]], ["Following three washes, peroxidase-conjugated avidin and chromatic substrate were sequentially added.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 24, 34], ["conjugated avidin", "SIMPLE_CHEMICAL", 35, 52], ["peroxidase", "PROTEIN", 24, 34], ["three washes", "TREATMENT", 10, 22], ["peroxidase-conjugated avidin", "TREATMENT", 24, 52], ["chromatic substrate", "TREATMENT", 57, 76]]], ["The absorbance was read at 405 nm in an ELISA plate reader.", [["The absorbance", "TEST", 0, 14]]], ["Values are mean \u00b1 standard error of six independent assays.SP-10 blocks both the binding of S protein and the infectivity of S-protein-pseudotyped retrovirus to Vero E6 cellsIn addition to IFA, Vero E6 cells transfected with the plasmid encoding human ACE2 were infected with vectorpseudotyped retrovirus, S-protein-pseudotyped retrovirus, or SP-10/S-protein-pseudotyped retrovirus mixture.", [["Vero E6 cells", "ANATOMY", 161, 174], ["Vero E6 cells", "ANATOMY", 194, 207], ["plasmid", "ANATOMY", 229, 236], ["SP-10", "CHEMICAL", 59, 64], ["SP-10", "GENE_OR_GENE_PRODUCT", 59, 64], ["S protein", "GENE_OR_GENE_PRODUCT", 92, 101], ["S-protein", "GENE_OR_GENE_PRODUCT", 125, 134], ["pseudotyped", "ORGANISM", 135, 146], ["retrovirus", "ORGANISM", 147, 157], ["Vero E6 cells", "CELL", 161, 174], ["Vero E6 cells", "CELL", 194, 207], ["human", "ORGANISM", 246, 251], ["ACE2", "GENE_OR_GENE_PRODUCT", 252, 256], ["vectorpseudotyped retrovirus", "ORGANISM", 276, 304], ["S-protein-pseudotyped retrovirus", "ORGANISM", 306, 338], ["SP-10", "GENE_OR_GENE_PRODUCT", 343, 348], ["pseudotyped", "ORGANISM", 359, 370], ["retrovirus", "ORGANISM", 371, 381], ["SP", "PROTEIN", 59, 61], ["S protein", "PROTEIN", 92, 101], ["S-protein", "PROTEIN", 125, 134], ["Vero E6 cells", "CELL_LINE", 161, 174], ["Vero E6 cells", "CELL_LINE", 194, 207], ["plasmid", "DNA", 229, 236], ["human ACE2", "PROTEIN", 246, 256], ["SP-10/S-protein", "PROTEIN", 343, 358], ["human", "SPECIES", 246, 251], ["Vero E6", "SPECIES", 161, 168], ["Vero E6", "SPECIES", 194, 201], ["human", "SPECIES", 246, 251], ["Values", "TEST", 0, 6], ["mean", "TEST", 11, 15], ["S protein", "TEST", 92, 101], ["S-protein", "TEST", 125, 134], ["pseudotyped retrovirus", "PROBLEM", 135, 157], ["Vero E6 cells", "TREATMENT", 161, 174], ["IFA", "TEST", 189, 192], ["Vero E6 cells", "TREATMENT", 194, 207], ["the plasmid encoding human ACE2", "TREATMENT", 225, 256], ["vectorpseudotyped retrovirus", "PROBLEM", 276, 304], ["S-protein", "TEST", 306, 315], ["pseudotyped retrovirus", "PROBLEM", 316, 338], ["SP", "TEST", 343, 345], ["pseudotyped retrovirus mixture", "PROBLEM", 359, 389], ["E6 cells", "OBSERVATION", 166, 174], ["pseudotyped retrovirus", "OBSERVATION", 359, 381]]], ["The luciferase activity was assayed 48 h postinfection.", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["luciferase", "PROTEIN", 4, 14], ["luciferase activity", "OBSERVATION", 4, 23]]], ["SP-10 inhibited the Sprotein-pseudotyped retrovirus infectivity in a dose-dependent manner (Fig. 5) .", [["SP-10", "CHEMICAL", 0, 5], ["SP-10", "CHEMICAL", 0, 5], ["SP-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["Sprotein", "GENE_OR_GENE_PRODUCT", 20, 28], ["retrovirus", "ORGANISM", 41, 51], ["Sprotein", "PROTEIN", 20, 28], ["SP", "TEST", 0, 2], ["the Sprotein-pseudotyped retrovirus infectivity", "PROBLEM", 16, 63], ["pseudotyped retrovirus infectivity", "OBSERVATION", 29, 63]]], ["These results indicated that SP-10 was a novel anti-SARS-CoV peptide that was able to block the SARS-CoV S protein binding to Vero E6 cells.DiscussionIn this study, we analyzed peptide mimics of the S protein to block its interaction with Vero E6 cells by biotinylated ELISA, IFA, and S-protein-pseudotyped retrovirus infectivity.", [["Vero E6 cells", "ANATOMY", 126, 139], ["Vero E6 cells", "ANATOMY", 239, 252], ["SP-10", "CHEMICAL", 29, 34], ["SP-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 47, 60], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 96, 106], ["Vero E6 cells", "CELL", 126, 139], ["Vero E6 cells", "CELL", 239, 252], ["IFA", "GENE_OR_GENE_PRODUCT", 276, 279], ["S-protein", "GENE_OR_GENE_PRODUCT", 285, 294], ["pseudotyped retrovirus", "ORGANISM", 295, 317], ["SP", "PROTEIN", 29, 31], ["SARS-CoV S protein", "PROTEIN", 96, 114], ["Vero E6 cells", "CELL_LINE", 126, 139], ["S protein", "PROTEIN", 199, 208], ["Vero E6 cells", "CELL_LINE", 239, 252], ["S-protein", "PROTEIN", 285, 294], ["SARS-CoV", "SPECIES", 96, 104], ["Vero E6", "SPECIES", 126, 133], ["Vero E6", "SPECIES", 239, 246], ["SP", "TEST", 29, 31], ["a novel anti-SARS-CoV peptide", "TREATMENT", 39, 68], ["the SARS", "PROBLEM", 92, 100], ["CoV S protein binding", "PROBLEM", 101, 122], ["this study", "TEST", 153, 163], ["the S protein", "TREATMENT", 195, 208], ["Vero E6 cells", "TREATMENT", 239, 252], ["biotinylated ELISA", "TEST", 256, 274], ["IFA", "TEST", 276, 279], ["S-protein", "TEST", 285, 294], ["pseudotyped retrovirus infectivity", "PROBLEM", 295, 329], ["E6 cells", "OBSERVATION", 131, 139], ["pseudotyped retrovirus infectivity", "OBSERVATION", 295, 329]]], ["SP-4 (residues 192-203), SP-8 (residues 483-494), and SP-10 (residues 660-683) exhibited the inhibitory potentials.", [["SP-4", "CHEMICAL", 0, 4], ["SP-10 (residues 660-683", "CHEMICAL", 54, 77], ["SP-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["SP-8", "GENE_OR_GENE_PRODUCT", 25, 29], ["SP-10", "GENE_OR_GENE_PRODUCT", 54, 59], ["SP", "PROTEIN", 0, 2], ["SP", "PROTEIN", 54, 56], ["SP", "TEST", 0, 2], ["SP", "TEST", 25, 27], ["SP", "TEST", 54, 56], ["the inhibitory potentials", "PROBLEM", 89, 114]]], ["Additional mapping showed that SP-10-2 (residues 660-671), SP-10-3 (residues 664-675), and SP-10-4 (residues 672-683) had inhibitory activities.", [["SP-10-4 (residues 672-683", "CHEMICAL", 91, 116], ["SP-10-2", "GENE_OR_GENE_PRODUCT", 31, 38], ["SP-10-3", "GENE_OR_GENE_PRODUCT", 59, 66], ["SP", "PROTEIN", 31, 33], ["SP-10-4", "DNA", 91, 98], ["Additional mapping", "TEST", 0, 18], ["SP", "TEST", 31, 33], ["SP", "TEST", 59, 61], ["SP", "TEST", 91, 93]]], ["The receptor-binding regions of SARS-CoV S protein have been defined in several reports.", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 32, 42], ["receptor-binding regions", "PROTEIN", 4, 28], ["SARS-CoV S protein", "PROTEIN", 32, 50], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV S protein", "TEST", 37, 50], ["SARS", "OBSERVATION", 32, 36]]], ["For examples, Xiao et al. (2003) identified that the receptor-binding site of S protein is localized between amino acid residues 203 and 537.", [["amino acid", "CHEMICAL", 109, 119], ["amino acid", "CHEMICAL", 109, 119], ["amino acid", "AMINO_ACID", 109, 119], ["S protein", "PROTEIN", 78, 87], ["amino acid residues", "TEST", 109, 128]]], ["Wong et al. (2004) indicated that the 193-amino acid fragment of S protein (residues 318-510) binds ACE2 efficiently.", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["amino acid", "AMINO_ACID", 42, 52], ["318-510", "AMINO_ACID", 85, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 100, 104], ["193-amino acid fragment", "PROTEIN", 38, 61], ["S protein", "PROTEIN", 65, 74], ["residues 318-510", "PROTEIN", 76, 92], ["ACE2", "PROTEIN", 100, 104], ["S protein", "TEST", 65, 74]]], ["Babcock et al. (2004) suggested that amino acids 270-510 of S protein are required for interaction with receptor.", [["amino acids 270-510", "CHEMICAL", 37, 56], ["amino acids", "CHEMICAL", 37, 48], ["amino acids", "AMINO_ACID", 37, 48], ["270-510", "AMINO_ACID", 49, 56], ["S protein", "GENE_OR_GENE_PRODUCT", 60, 69], ["S protein", "PROTEIN", 60, 69], ["amino acids", "TEST", 37, 48], ["S protein", "TREATMENT", 60, 69], ["receptor", "TREATMENT", 104, 112]]], ["By analyzing a series of peptides derived from S protein, we identified that peptides spanning residues 192-203, 483-494, and 660-683 of S protein efficiently blocked the binding of S protein to ACE2.", [["S protein", "GENE_OR_GENE_PRODUCT", 137, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 195, 199], ["S protein", "PROTEIN", 47, 56], ["S protein", "PROTEIN", 137, 146], ["S protein", "PROTEIN", 182, 191], ["ACE2", "PROTEIN", 195, 199], ["S protein", "TEST", 47, 56], ["ACE2", "TEST", 195, 199]]], ["Therefore, our findings refined and extended the possible domains involved in receptor interaction.DiscussionVirus entry process is an attractive drug target for blocking infection.", [["infection", "DISEASE", 171, 180], ["blocking infection", "PROBLEM", 162, 180], ["infection", "OBSERVATION", 171, 180]]], ["Virus envelope protein initially binds to cell surface receptor, leading to its global conformational changes.", [["cell surface", "ANATOMY", 42, 54], ["cell surface receptor", "GENE_OR_GENE_PRODUCT", 42, 63], ["Virus envelope protein", "PROTEIN", 0, 22], ["cell surface receptor", "PROTEIN", 42, 63], ["Virus envelope protein", "PROBLEM", 0, 22], ["its global conformational changes", "PROBLEM", 76, 109], ["cell", "OBSERVATION", 42, 46], ["surface", "OBSERVATION_MODIFIER", 47, 54], ["global", "OBSERVATION_MODIFIER", 80, 86], ["conformational changes", "OBSERVATION", 87, 109]]], ["Subsequently, the fusion peptide is exposed to insert into the target cell membrane, resulting in fusion between the cell membrane and viral envelope, which allow the virus genome to enter the target cells .", [["cell membrane", "ANATOMY", 70, 83], ["cell membrane", "ANATOMY", 117, 130], ["cells", "ANATOMY", 200, 205], ["cell membrane", "CELLULAR_COMPONENT", 70, 83], ["cell membrane", "CELLULAR_COMPONENT", 117, 130], ["cells", "CELL", 200, 205], ["target cells", "CELL_TYPE", 193, 205], ["the fusion peptide", "TREATMENT", 14, 32], ["fusion", "TREATMENT", 98, 104], ["the cell membrane", "TREATMENT", 113, 130], ["viral envelope", "PROBLEM", 135, 149], ["the virus genome", "TREATMENT", 163, 179], ["fusion", "OBSERVATION", 18, 24], ["target cell membrane", "OBSERVATION", 63, 83], ["fusion", "OBSERVATION", 98, 104], ["cell membrane", "OBSERVATION", 117, 130], ["viral envelope", "OBSERVATION", 135, 149], ["target cells", "OBSERVATION", 193, 205]]], ["Based on this process, fusioninhibitory peptides have been successfully developed, or under advance clinical trial for various viruses, such as T-20 for HIV-1, C-peptides (P-400 and P cr -400) for human T-cell leukemia virus, and D4E1 for feline immunodeficiency virus (Kilby et al., 1998; Ma et al., 2002; Pinon et al., 2003) .", [["T-cell leukemia virus", "DISEASE", 203, 224], ["feline immunodeficiency virus", "DISEASE", 239, 268], ["T-20", "GENE_OR_GENE_PRODUCT", 144, 148], ["HIV-1", "ORGANISM", 153, 158], ["C-peptides", "SIMPLE_CHEMICAL", 160, 170], ["human T-cell leukemia virus", "ORGANISM", 197, 224], ["D4E1", "ORGANISM", 230, 234], ["feline immunodeficiency virus", "ORGANISM", 239, 268], ["T-20", "SPECIES", 144, 148], ["HIV-1", "SPECIES", 153, 158], ["human", "SPECIES", 197, 202], ["feline immunodeficiency virus", "SPECIES", 239, 268], ["T-20", "SPECIES", 144, 148], ["HIV-1", "SPECIES", 153, 158], ["human T-cell leukemia virus", "SPECIES", 197, 224], ["feline immunodeficiency virus", "SPECIES", 239, 268], ["fusioninhibitory peptides", "PROBLEM", 23, 48], ["various viruses", "PROBLEM", 119, 134], ["T", "TEST", 144, 145], ["HIV", "TEST", 153, 156], ["C-peptides", "TEST", 160, 170], ["P", "TEST", 172, 173], ["P cr", "TEST", 182, 186], ["human T-cell leukemia virus", "PROBLEM", 197, 224], ["feline immunodeficiency virus", "PROBLEM", 239, 268], ["cell leukemia virus", "OBSERVATION", 205, 224]]], ["Recently, this strategy of utilizing peptides that block membrane fusion has been applied in SARS-CoV.", [["membrane", "ANATOMY", 57, 65], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["SARS-CoV", "ORGANISM", 93, 101], ["SARS-CoV", "SPECIES", 93, 101], ["peptides", "TREATMENT", 37, 45], ["block membrane fusion", "TREATMENT", 51, 72]]], ["For examples, HR2-peptide of S protein has been shown to interfere with S protein conformational changes, resulting in inhibition of SARS-CoV fusion with target cells Ni et al., 2005; Zhu et al., 2004; Yuan et al., 2004) .", [["cells", "ANATOMY", 161, 166], ["HR2-peptide", "GENE_OR_GENE_PRODUCT", 14, 25], ["S protein", "GENE_OR_GENE_PRODUCT", 29, 38], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 133, 141], ["HR2", "PROTEIN", 14, 17], ["S protein", "PROTEIN", 29, 38], ["S protein", "PROTEIN", 72, 81], ["SARS-CoV", "SPECIES", 133, 141], ["examples", "TEST", 4, 12], ["HR2", "TEST", 14, 17], ["S protein", "TEST", 29, 38], ["S protein conformational changes", "PROBLEM", 72, 104], ["SARS", "PROBLEM", 133, 137], ["CoV fusion", "TREATMENT", 138, 148]]], ["Peptides derived from HR1 region of S protein have also been identified as potential inhibitors for virus entry (Ni et al., 2005; Yuan et al., 2004) .", [["HR1 region of S protein", "GENE_OR_GENE_PRODUCT", 22, 45], ["HR1 region", "PROTEIN", 22, 32], ["S protein", "PROTEIN", 36, 45], ["S protein", "PROBLEM", 36, 45], ["S protein", "OBSERVATION", 36, 45]]], ["In this study, we designed small peptides derived from S protein to evaluate their inhibitions of S protein binding to ACE2 and Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 128, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["Vero E6 cells", "CELL", 128, 141], ["S protein", "PROTEIN", 55, 64], ["S protein", "PROTEIN", 98, 107], ["ACE2", "PROTEIN", 119, 123], ["Vero E6 cells", "CELL_LINE", 128, 141], ["Vero E6", "SPECIES", 128, 135], ["this study", "TEST", 3, 13], ["small peptides", "PROBLEM", 27, 41], ["S protein", "TEST", 55, 64], ["S protein binding", "PROBLEM", 98, 115], ["ACE2", "TEST", 119, 123], ["Vero E6 cells", "TREATMENT", 128, 141], ["E6 cells", "OBSERVATION", 133, 141]]], ["This approach of utilizing compounds that block receptor interaction has proven useful in other viral systems, including HIV-1 and hepatitis C virus, where compounds designed to inhibit viral entry through blockade of the viral receptors are finding success in vitro and in clinical trials (DeClercq, 2001; van Compernolle et al., 2003) .", [["HIV-1 and hepatitis C", "DISEASE", 121, 142], ["HIV-1", "ORGANISM", 121, 126], ["hepatitis C virus", "ORGANISM", 131, 148], ["viral receptors", "PROTEIN", 222, 237], ["HIV-1", "SPECIES", 121, 126], ["hepatitis C virus", "SPECIES", 131, 148], ["HIV-1", "SPECIES", 121, 126], ["hepatitis C virus", "SPECIES", 131, 148], ["block receptor interaction", "PROBLEM", 42, 68], ["other viral systems", "PROBLEM", 90, 109], ["HIV", "PROBLEM", 121, 124], ["hepatitis C virus", "PROBLEM", 131, 148], ["the viral receptors", "TREATMENT", 218, 237]]], ["Because RNA viruses are capable of being randomly and selectively altered due to high replication numbers and the infidelity of the viral RNA polymerase, it is possible that virus would adapt resistance to inhibitors.", [["viral RNA polymerase", "PROTEIN", 132, 152], ["RNA viruses", "PROBLEM", 8, 19], ["high replication numbers", "PROBLEM", 81, 105], ["the viral RNA polymerase", "PROBLEM", 128, 152], ["virus", "PROBLEM", 174, 179], ["inhibitors", "TREATMENT", 206, 216], ["viruses", "OBSERVATION", 12, 19], ["viral RNA polymerase", "OBSERVATION", 132, 152]]], ["However, Chakraborti et al. (2005) showed that most of the natural or artificial mutations on S protein did not affect the binding of S protein to ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 147, 151], ["S protein", "PROTEIN", 94, 103], ["S protein", "PROTEIN", 134, 143], ["ACE2", "PROTEIN", 147, 151], ["artificial mutations", "PROBLEM", 70, 90]]], ["These findings suggested that the viruses could easily mutate and escape antibodies that do not exhibit the same energy profile of binding to S as ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 147, 151], ["antibodies", "PROTEIN", 73, 83], ["ACE2", "PROTEIN", 147, 151], ["the viruses", "PROBLEM", 30, 41], ["escape antibodies", "PROBLEM", 66, 83], ["viruses", "OBSERVATION", 34, 41]]], ["Therefore, our finding suggested that SP-10 was a potent inhibitor for the inhibition of S protein binding to Vero E6 cells, the first step in viral infection.DiscussionIn conclusion, this is the first report of small peptides designed to disrupt the interaction of SARS-CoV S protein and ACE2.", [["Vero E6 cells", "ANATOMY", 110, 123], ["SP-10", "CHEMICAL", 38, 43], ["viral infection", "DISEASE", 143, 158], ["SARS", "DISEASE", 266, 270], ["SP-10", "GENE_OR_GENE_PRODUCT", 38, 43], ["Vero E6 cells", "CELL", 110, 123], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 266, 276], ["ACE2", "GENE_OR_GENE_PRODUCT", 289, 293], ["SP", "PROTEIN", 38, 40], ["S protein", "PROTEIN", 89, 98], ["Vero E6 cells", "CELL_LINE", 110, 123], ["SARS-CoV S protein", "PROTEIN", 266, 284], ["ACE2", "PROTEIN", 289, 293], ["Vero E6", "SPECIES", 110, 117], ["SARS-CoV", "SPECIES", 266, 274], ["SP", "TEST", 38, 40], ["a potent inhibitor", "TREATMENT", 48, 66], ["S protein binding", "PROBLEM", 89, 106], ["Vero E6 cells", "PROBLEM", 110, 123], ["viral infection", "PROBLEM", 143, 158], ["small peptides", "PROBLEM", 212, 226], ["SARS", "TEST", 266, 270], ["CoV S protein", "TEST", 271, 284], ["ACE2", "TEST", 289, 293], ["E6 cells", "OBSERVATION", 115, 123], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["infection", "OBSERVATION", 149, 158]]], ["By analyzing a series of peptides derived from S protein, we Fig. 4 .", [["S protein", "GENE_OR_GENE_PRODUCT", 47, 56], ["S protein", "PROTEIN", 47, 56]]], ["Inhibitory effect of SP-10 on the SARS-CoV S protein and Vero E6 cell interaction by IFA.", [["cell", "ANATOMY", 65, 69], ["SP-10", "CHEMICAL", 21, 26], ["SP-10", "GENE_OR_GENE_PRODUCT", 21, 26], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 34, 44], ["Vero E6 cell", "CELL", 57, 69], ["IFA", "GENE_OR_GENE_PRODUCT", 85, 88], ["SP", "PROTEIN", 21, 23], ["SARS-CoV S protein", "PROTEIN", 34, 52], ["SARS-CoV", "SPECIES", 34, 42], ["SP", "TEST", 21, 23], ["the SARS", "TEST", 30, 38], ["CoV S protein", "TEST", 39, 52], ["Vero E6 cell interaction", "PROBLEM", 57, 81], ["Vero E6 cell interaction", "OBSERVATION", 57, 81]]], ["Vero E6 cells were cultured on glass coverslips and incubated with 20 g/ml BSA, 20 g/ml biotin-labeled S protein, 0.5 nmol SP-10/20 g/ml biotin-labeled S protein mixture, 2.5 nmol SP-10/20 g/ml biotin-labeled S protein mixture, or 5 nmol SP-10/20 g/ml biotin-labeled S protein mixture.", [["Vero E6 cells", "ANATOMY", 0, 13], ["biotin", "CHEMICAL", 88, 94], ["biotin", "CHEMICAL", 252, 258], ["biotin", "CHEMICAL", 88, 94], ["biotin", "CHEMICAL", 137, 143], ["biotin", "CHEMICAL", 194, 200], ["biotin", "CHEMICAL", 252, 258], ["Vero E6 cells", "CELL", 0, 13], ["BSA", "SIMPLE_CHEMICAL", 75, 78], ["biotin", "SIMPLE_CHEMICAL", 88, 94], ["biotin", "SIMPLE_CHEMICAL", 137, 143], ["biotin", "SIMPLE_CHEMICAL", 194, 200], ["biotin", "SIMPLE_CHEMICAL", 252, 258], ["Vero E6 cells", "CELL_LINE", 0, 13], ["S protein", "PROTEIN", 103, 112], ["SP", "PROTEIN", 123, 125], ["SP", "PROTEIN", 180, 182], ["SP", "PROTEIN", 238, 240], ["Vero E6", "SPECIES", 0, 7], ["Vero E6 cells", "PROBLEM", 0, 13], ["glass coverslips", "TREATMENT", 31, 47], ["BSA", "TEST", 75, 78], ["biotin", "TEST", 88, 94], ["protein", "TEST", 105, 112], ["SP", "TEST", 123, 125], ["biotin", "TEST", 137, 143], ["protein mixture", "TEST", 154, 169], ["SP", "TEST", 180, 182], ["biotin", "TEST", 194, 200], ["labeled S protein mixture", "TEST", 201, 226], ["SP", "TEST", 238, 240], ["biotin", "TEST", 252, 258], ["E6 cells", "OBSERVATION", 5, 13]]], ["Recombinant S protein was purified from E. coli (A) or baculovirus (B).", [["Recombinant S protein", "GENE_OR_GENE_PRODUCT", 0, 21], ["E. coli", "ORGANISM", 40, 47], ["(A)", "ORGANISM", 48, 51], ["baculovirus", "ORGANISM", 55, 66], ["B", "CELL", 68, 69], ["Recombinant S protein", "PROTEIN", 0, 21], ["E. coli", "SPECIES", 40, 47], ["E. coli", "SPECIES", 40, 47], ["baculovirus", "SPECIES", 55, 66], ["Recombinant S protein", "TEST", 0, 21], ["E. coli", "PROBLEM", 40, 47], ["baculovirus", "PROBLEM", 55, 66], ["E. coli", "OBSERVATION_MODIFIER", 40, 47]]], ["After a 16 h-incubation at 4 \u2022 C, cells were stained with fluorescence-conjugated streptavidin and evaluated under a confocal microscope.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["streptavidin", "SIMPLE_CHEMICAL", 82, 94], ["fluorescence-conjugated streptavidin", "TREATMENT", 58, 94], ["a confocal microscope", "TEST", 115, 136]]], ["Magnification, 400\u00d7.", [["Magnification", "TEST", 0, 13]]], ["Inhibitory effect of SP-10 on the SARS-CoV S-protein-pseudotyped retrovirus infectivity.", [["SP-10", "CHEMICAL", 21, 26], ["SP-10", "GENE_OR_GENE_PRODUCT", 21, 26], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["pseudotyped retrovirus", "ORGANISM", 53, 75], ["SP", "PROTEIN", 21, 23], ["SARS-CoV", "SPECIES", 34, 42], ["SP", "TEST", 21, 23], ["the SARS", "TEST", 30, 38], ["CoV S-protein", "TEST", 39, 52], ["pseudotyped retrovirus infectivity", "PROBLEM", 53, 87], ["pseudotyped retrovirus infectivity", "OBSERVATION", 53, 87]]], ["S-protein-pseudotyped retroviruses were mixed with various amounts of SP-10 and incubated at 37 \u2022 C with shaking.", [["SP-10", "CHEMICAL", 70, 75], ["retroviruses", "ORGANISM", 22, 34], ["SP", "PROTEIN", 70, 72], ["pseudotyped retroviruses", "PROBLEM", 10, 34], ["SP", "TEST", 70, 72], ["shaking", "PROBLEM", 105, 112], ["pseudotyped retroviruses", "OBSERVATION", 10, 34]]], ["After a 2-h incubation, the mixtures were inoculated with Vero E6 cells transfected with the plasmid encoding human ACE2.", [["cells", "ANATOMY", 66, 71], ["plasmid", "ANATOMY", 93, 100], ["Vero E6 cells", "CELL", 58, 71], ["human", "ORGANISM", 110, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["Vero E6 cells", "CELL_LINE", 58, 71], ["plasmid", "DNA", 93, 100], ["human ACE2", "PROTEIN", 110, 120], ["human", "SPECIES", 110, 115], ["Vero E6", "SPECIES", 58, 65], ["human", "SPECIES", 110, 115], ["a 2-h incubation", "TREATMENT", 6, 22], ["the mixtures", "TREATMENT", 24, 36], ["Vero E6 cells", "TREATMENT", 58, 71], ["the plasmid encoding human ACE2", "TREATMENT", 89, 120]]], ["The luciferase activity of cell lysate was assayed 2 days postinfection.", [["cell lysate", "ANATOMY", 27, 38], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["cell", "CELL", 27, 31], ["luciferase", "PROTEIN", 4, 14], ["cell lysate", "TREATMENT", 27, 38], ["cell lysate", "OBSERVATION", 27, 38]]], ["Relative infectivity is presented as comparison with the RLU relative to untreated cells.", [["cells", "ANATOMY", 83, 88], ["cells", "CELL", 83, 88], ["RLU", "PROTEIN", 57, 60], ["untreated cells", "CELL_TYPE", 73, 88], ["Relative infectivity", "PROBLEM", 0, 20], ["the RLU", "TEST", 53, 60], ["infectivity", "OBSERVATION", 9, 20]]], ["Values are mean \u00b1 standard error of four independent assays.Discussionidentified that peptides spanning residues 192-203, 483-494, and 660-683 of S protein efficiently blocked the binding of S protein to ACE2.", [["S protein", "GENE_OR_GENE_PRODUCT", 146, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["S protein", "PROTEIN", 146, 155], ["S protein", "PROTEIN", 191, 200], ["ACE2", "PROTEIN", 204, 208], ["Values", "TEST", 0, 6], ["mean", "TEST", 11, 15], ["peptides spanning residues", "TEST", 86, 112], ["ACE2", "TEST", 204, 208]]], ["A novel putative receptor-binding region of S protein was defined by a peptide-scanning method.", [["putative receptor-binding region", "PROTEIN", 8, 40], ["S protein", "PROTEIN", 44, 53], ["S protein", "PROBLEM", 44, 53], ["a peptide-scanning method", "TEST", 69, 94]]], ["Furthermore, SP-10 has been identified as a potent inhibitor for the inhibition of S protein binding to Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 104, 117], ["SP-10", "CHEMICAL", 13, 18], ["SP-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["Vero E6 cells", "CELL", 104, 117], ["SP", "PROTEIN", 13, 15], ["S protein", "PROTEIN", 83, 92], ["Vero E6 cells", "CELL_LINE", 104, 117], ["Vero E6", "SPECIES", 104, 111], ["SP", "TEST", 13, 15], ["a potent inhibitor", "TREATMENT", 42, 60], ["S protein binding", "PROBLEM", 83, 100], ["Vero E6 cells", "TREATMENT", 104, 117], ["E6 cells", "OBSERVATION", 109, 117]]], ["Therefore, SP-10 can be used as a candidate in designing more potent anti-SARS-CoV peptides for drug development in the future.", [["SP-10", "CHEMICAL", 11, 16], ["SP-10", "GENE_OR_GENE_PRODUCT", 11, 16], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 69, 82], ["SP", "PROTEIN", 11, 13], ["CoV peptides", "TREATMENT", 79, 91]]]], "PMC7252051": [["Ethics statement/confirmation of patients\u2019 permissionNot requiredConflict of interestWe have no conflicts of interest.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]]]}